{"PMC7370867": [["IntroductionThe stunning diffusion of COVID-19 from our region placed at the epicentre of the Italian epidemic at the end of February 2020 brought us to stop any elective medical activities except for those related to emergency [1].", [["COVID-19", "CHEMICAL", 38, 46], ["COVID", "TEST", 38, 43], ["any elective medical activities", "TREATMENT", 158, 189]]], ["Periodic outpatient assessment of otitis-prone children (OPC) (i.e. with a history of recurrent acute otitis media\u2014RAOM\u2014defined as \u2265 3 distinct episodes in a 6 months, or \u2265 4 in 12 months) [2] who were regularly followed at our tertiary outpatient clinic of upper respiratory tract infections (CURTI) was discontinued since 9 March.IntroductionIn order to avoid leaving the patients to themselves just during the winter months, which are the most critical ones for OPC, we kept in touch with their families and compensated with telemedicine assessment.", [["upper respiratory tract", "ANATOMY", 258, 281], ["otitis", "DISEASE", 34, 40], ["OPC", "DISEASE", 57, 60], ["otitis", "DISEASE", 102, 108], ["upper respiratory tract infections", "DISEASE", 258, 292], ["CURTI", "DISEASE", 294, 299], ["children", "ORGANISM", 47, 55], ["upper respiratory", "ORGANISM_SUBDIVISION", 258, 275], ["tract", "ORGANISM_SUBDIVISION", 276, 281], ["patients", "ORGANISM", 374, 382], ["children", "SPECIES", 47, 55], ["patients", "SPECIES", 374, 382], ["Periodic outpatient assessment", "TEST", 0, 30], ["otitis", "PROBLEM", 34, 40], ["recurrent acute otitis media", "PROBLEM", 86, 114], ["upper respiratory tract infections", "PROBLEM", 258, 292], ["telemedicine assessment", "TEST", 528, 551], ["otitis", "OBSERVATION", 34, 40], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["otitis", "OBSERVATION", 102, 108], ["upper", "ANATOMY_MODIFIER", 258, 263], ["respiratory tract", "ANATOMY", 264, 281]]], ["This incidentally leads to unexpected but not at all negative findings.Material and methodsFamily of OPC scheduled for periodic evaluation between 9 March and 17 May were reached by a telephone call performed by resident physicians on 12\u201319 May.", [["periodic evaluation", "TEST", 119, 138], ["negative", "OBSERVATION", 53, 61]]], ["In some children a complete paediatric evaluation with pneumatic otoscopy [3] was executed on 18\u201319 May.", [["children", "ORGANISM", 8, 16], ["children", "SPECIES", 8, 16], ["a complete paediatric evaluation", "TEST", 17, 49], ["pneumatic otoscopy", "TREATMENT", 55, 73]]], ["The mean number of episodes of acute otitis media without spontaneous tympanic membrane perforation (AOMsTMP) and otorrhea episodes [4], as well as the number of systemic antibiotic treatments administered in the February\u2013April 2020 period was recorded and compared with the corresponding ones in the February\u2013April 2019 period (data available from children\u2019s medical records).Material and methodsParents were asked to give a subjective opinion about children\u2019s clinical conditions (improved, stable, got worse) during the lockdown.", [["tympanic membrane", "ANATOMY", 70, 87], ["otitis", "DISEASE", 37, 43], ["tympanic membrane perforation", "DISEASE", 70, 99], ["otorrhea", "DISEASE", 114, 122], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 70, 87], ["children", "ORGANISM", 349, 357], ["children", "ORGANISM", 451, 459], ["children", "SPECIES", 349, 357], ["children", "SPECIES", 451, 459], ["acute otitis media", "PROBLEM", 31, 49], ["spontaneous tympanic membrane perforation", "PROBLEM", 58, 99], ["otorrhea episodes", "PROBLEM", 114, 131], ["systemic antibiotic treatments", "TREATMENT", 162, 192], ["mean number", "OBSERVATION_MODIFIER", 4, 15], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["otitis", "OBSERVATION", 37, 43], ["tympanic membrane", "ANATOMY", 70, 87], ["perforation", "OBSERVATION", 88, 99], ["stable", "OBSERVATION_MODIFIER", 493, 499]]], ["On the basis of information achieved, resident physicians gave indication to perform an urgent visit just at the end of the lockdown, a programmable visit, a visit only in case of needing.Material and methodsThe statistical analysis was mainly designed to detect any possible difference in the number of documented infectious recurrences (number of AOMsTMP and otorrhea episodes and number of systemic antibiotic treatments) between the two periods.", [["AOMsTMP", "DISEASE", 349, 356], ["otorrhea", "DISEASE", 361, 369], ["The statistical analysis", "TEST", 208, 232], ["documented infectious recurrences", "PROBLEM", 304, 337], ["AOMsTMP", "PROBLEM", 349, 356], ["otorrhea episodes", "PROBLEM", 361, 378], ["systemic antibiotic treatments", "TREATMENT", 393, 423], ["infectious", "OBSERVATION_MODIFIER", 315, 325], ["recurrences", "OBSERVATION", 326, 337]]], ["The results are given as absolute numbers and percentages, or arithmetical mean values \u00b1 standard deviation.", [["absolute numbers", "TEST", 25, 41], ["percentages", "TEST", 46, 57], ["arithmetical mean values", "TEST", 62, 86]]], ["The data were analysed using STATA 10.0 software (StataCorp, College Station, TX, USA); a p < 0.05 was considered statistically significant.Material and methodsThe protocol was approved by our local Ethics Committee of our hospital and was conducted in accordance with the principles of good clinical practice.", [["The data", "TEST", 0, 8], ["STATA", "TEST", 29, 34]]], ["Written informed consent was achieved by the children\u2019s parents.ResultsAmong 102 children (50% males; mean age 41.4 \u00b1 14.0 months) scheduled for a follow-up visit during the lockdown 30.4% had a history of RAOM without spontaneous tympanic membrane perforation, and 69.6% of RAOM with spontaneous tympanic membrane perforations occurring in \u2265 two thirds of the episodes [4] (Table 1).ResultsMost of parents (82.3%) declared that children had improved during the lockdown, and 16.7% that children were stable; only in one case (1%) parents considered clinical conditions of the child getting worse.", [["tympanic membrane", "ANATOMY", 231, 248], ["RAOM", "ANATOMY", 275, 279], ["tympanic membrane", "ANATOMY", 297, 314], ["RAOM", "DISEASE", 206, 210], ["tympanic membrane perforation", "DISEASE", 231, 260], ["RAOM", "DISEASE", 275, 279], ["tympanic membrane perforations", "DISEASE", 297, 327], ["children", "ORGANISM", 45, 53], ["children", "ORGANISM", 81, 89], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 231, 248], ["tympanic membrane", "MULTI-TISSUE_STRUCTURE", 297, 314], ["children", "ORGANISM", 429, 437], ["children", "ORGANISM", 487, 495], ["children", "SPECIES", 45, 53], ["children", "SPECIES", 81, 89], ["children", "SPECIES", 429, 437], ["children", "SPECIES", 487, 495], ["spontaneous tympanic membrane perforation", "PROBLEM", 219, 260], ["spontaneous tympanic membrane perforations", "PROBLEM", 285, 327], ["tympanic membrane", "ANATOMY", 231, 248], ["perforation", "OBSERVATION", 249, 260], ["tympanic membrane", "ANATOMY", 297, 314], ["perforations", "OBSERVATION", 315, 327], ["stable", "OBSERVATION_MODIFIER", 501, 507]]], ["We documented a statistically significant reduction in the mean number of: episodes of AOMsTMP, otorrhea episodes, and systemic antibiotic treatments during the February\u2013April 2020 period compared with February\u2013April 2019 (Table 1).ResultsClinical evaluation performed in 27.4% cases revealed normal middle ear findings in all but three (89.3%) children; middle ear effusion as previously defined [5] was detected in the remaining children (10.7%).ResultsResident physicians gave indication to non-urgent programmable clinical evaluation in 86.3% cases and clinical evaluation to be perform only in case of needing in the remaining children (13.7%).DiscussionOur data document a global improvement of OPC in Milan during the Italian lockdown, attested by a significant reduction in the mean number of episodes of AOMsTMP, otorrhea episodes, and number of antibiotic treatments.", [["ear", "ANATOMY", 307, 310], ["ear", "ANATOMY", 362, 365], ["AOMsTMP", "DISEASE", 87, 94], ["otorrhea", "DISEASE", 96, 104], ["ear effusion", "DISEASE", 362, 374], ["OPC", "DISEASE", 701, 704], ["AOMsTMP", "DISEASE", 813, 820], ["otorrhea", "DISEASE", 822, 830], ["ear", "ORGAN", 307, 310], ["children", "ORGANISM", 345, 353], ["ear", "ORGAN", 362, 365], ["children", "ORGANISM", 431, 439], ["children", "ORGANISM", 632, 640], ["children", "SPECIES", 345, 353], ["children", "SPECIES", 431, 439], ["children", "SPECIES", 632, 640], ["a statistically significant reduction", "PROBLEM", 14, 51], ["AOMsTMP", "PROBLEM", 87, 94], ["otorrhea episodes", "PROBLEM", 96, 113], ["systemic antibiotic treatments", "TREATMENT", 119, 149], ["ResultsClinical evaluation", "TEST", 232, 258], ["middle ear effusion", "PROBLEM", 355, 374], ["non-urgent programmable clinical evaluation", "TEST", 494, 537], ["clinical evaluation", "TEST", 557, 576], ["AOMsTMP", "PROBLEM", 813, 820], ["otorrhea episodes", "PROBLEM", 822, 839], ["antibiotic treatments", "TREATMENT", 855, 876], ["statistically", "OBSERVATION_MODIFIER", 16, 29], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["reduction", "OBSERVATION_MODIFIER", 42, 51], ["otorrhea", "OBSERVATION", 96, 104], ["normal", "OBSERVATION", 293, 299], ["middle ear", "ANATOMY", 300, 310], ["middle", "ANATOMY_MODIFIER", 355, 361], ["ear", "ANATOMY", 362, 365], ["effusion", "OBSERVATION", 366, 374], ["global", "OBSERVATION_MODIFIER", 679, 685], ["improvement", "OBSERVATION_MODIFIER", 686, 697], ["significant", "OBSERVATION_MODIFIER", 757, 768], ["reduction", "OBSERVATION_MODIFIER", 769, 778], ["otorrhea", "OBSERVATION", 822, 830]]], ["Among 28 children who were evaluated just at the end of the lockdown, a complete recovery with normal otoscopic findings was detected in about 90% of cases.", [["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17]]], ["AOM is a widespread and multi-factorial disease, with RAOM mainly affecting males attending day-care, expose to second/third-hand smoke, having older siblings and a positive familiar history of allergy [6\u201311].", [["AOM", "DISEASE", 0, 3], ["allergy", "DISEASE", 194, 201], ["AOM", "PROBLEM", 0, 3], ["multi-factorial disease", "PROBLEM", 24, 47], ["allergy", "PROBLEM", 194, 201], ["widespread", "OBSERVATION_MODIFIER", 9, 19], ["multi-factorial", "OBSERVATION_MODIFIER", 24, 39], ["disease", "OBSERVATION", 40, 47]]], ["Brief or no breast-feeding, prematurity, the use of pacifier and push-and-pull bottles, air pollution are other predisposing factors [7\u201311].DiscussionDespite temporary restriction in day-care attendance has been proven to partially reduce the number of acute exacerbations [9, 10], this alone cannot completely change the natural history of disease.DiscussionIt is well known that RAOM has a natural tendency to improve with increasing age of the child [12\u201317].", [["breast", "ANATOMY", 12, 18], ["prematurity", "DISEASE", 28, 39], ["breast", "ORGANISM_SUBDIVISION", 12, 18], ["prematurity", "PROBLEM", 28, 39], ["pacifier", "TREATMENT", 52, 60], ["push-and-pull bottles", "TREATMENT", 65, 86], ["air pollution", "PROBLEM", 88, 101], ["acute exacerbations", "PROBLEM", 253, 272], ["disease", "PROBLEM", 341, 348], ["no", "UNCERTAINTY", 9, 11], ["breast", "ANATOMY", 12, 18], ["prematurity", "OBSERVATION", 28, 39], ["acute", "OBSERVATION_MODIFIER", 253, 258], ["exacerbations", "OBSERVATION", 259, 272], ["disease", "OBSERVATION", 341, 348]]], ["As a fact, Rosenfeld et al. [13] in their systematic literature review and metanalisis attested that only 17% of OPC remained classified like this and even that 41% did not experience any further AOM episode during a median observation period of 6 months (range 10 weeks to 2 years).", [["OPC", "DISEASE", 113, 116], ["AOM", "DISEASE", 196, 199], ["OPC", "CANCER", 113, 116], ["any further AOM episode", "PROBLEM", 184, 207]]], ["The authors [13] also reported that the mean baseline rate of AOM recurrence was at least 0.46 episodes per patient/month with a cumulative recurrence rate of 0.23 (95% CI 0.18-0.28) AOM episodes per patient/month during the study period.DiscussionEven if our study has some limitations (i.e. the retrospective nature and the lack of a control group) mainly due to the fact that it was performed during the Italia lockdown for the COVID-19 pandemic, even considering that the natural history of RAOM tends to spontaneous resolution, the reduction in the mean number of AOM episodes per patient/month here documented appears to be more consistent than that generally reported by literature [12, 13, 15\u201317].DiscussionUnder these circumstances, the significant improvement here attested could be considered an incidental positive effect of the national lockdown: exceptional circumstances during COVID-19 pandemic totally modified not only OPC way of living, but subvert social habits at their foundation with confinement of people in their own home.", [["AOM", "DISEASE", 62, 65], ["AOM", "DISEASE", 183, 186], ["RAOM", "DISEASE", 495, 499], ["AOM", "DISEASE", 569, 572], ["AOM", "PATHOLOGICAL_FORMATION", 62, 65], ["patient", "ORGANISM", 108, 115], ["patient", "ORGANISM", 200, 207], ["patient", "ORGANISM", 586, 593], ["people", "ORGANISM", 1022, 1028], ["patient", "SPECIES", 108, 115], ["patient", "SPECIES", 200, 207], ["patient", "SPECIES", 586, 593], ["people", "SPECIES", 1022, 1028], ["AOM recurrence", "PROBLEM", 62, 76], ["a cumulative recurrence rate", "TEST", 127, 155], ["CI", "TEST", 169, 171], ["AOM episodes", "PROBLEM", 183, 195], ["our study", "TEST", 256, 265], ["the COVID", "TEST", 427, 436], ["the reduction", "TREATMENT", 533, 546], ["AOM episodes", "PROBLEM", 569, 581], ["recurrence", "OBSERVATION", 66, 76], ["reduction", "OBSERVATION_MODIFIER", 537, 546]]], ["Abolition of any contact of OPC with environment and people other than the ones strictly belonging to the domestic setting, rather than avoidance of the sole inter-personal contacts between children at day-care could be responsible for this result; reduction in air pollution in our metropolitan city during the lockdown could also partially account for it.DiscussionReassessment of the patients during the next winter season would be useful to verify this supposition.", [["children", "ORGANISM", 190, 198], ["patients", "ORGANISM", 387, 395], ["people", "SPECIES", 53, 59], ["children", "SPECIES", 190, 198], ["patients", "SPECIES", 387, 395], ["air pollution", "PROBLEM", 262, 275], ["air pollution", "OBSERVATION", 262, 275]]]], "PMC7135573": [["Once upon a time, in a not-so-far-away land, a man went to the hospital to get better.", [["man", "ORGANISM", 47, 50], ["man", "SPECIES", 47, 50]]], ["Instead, he caught an infection, and he died.", [["infection", "DISEASE", 22, 31], ["an infection", "PROBLEM", 19, 31], ["infection", "OBSERVATION", 22, 31]]]], "0f208bebd18b4f14be62fd1f072b76804dfd45ec": [["Firstly, question-answering (QA) communities are inherently time-evolving [21] , with new users (both askers and answerers) joining daily and the existing users changing their interests and behavior (such as, e.g., long-term inactive users, who turn into active participants).", [["participants", "SPECIES", 262, 274]]], ["This is a severe limitation, that lowers the effectiveness of expert recommendation, since the recommended experts may no more reply to questions matching initially-relevant and already-outdated interests.", [["a severe limitation", "PROBLEM", 8, 27], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["limitation", "OBSERVATION", 17, 27]]], ["In addition, short-term answerers would likely not be recommended at all, being their expertise gained in a far too short time period for such users to build a solid reputation as actual experts.", [["a solid reputation", "TREATMENT", 158, 176]]], ["Secondly, there is no common agreement on the choice of the discriminative content features to capture answerers' expertise.", [["no common", "UNCERTAINTY", 19, 28]]], ["However, tags are more insightful, concise and explicit user-generated explanations of both post meaning and topical expertise, with respect to the general topics inferrable from the textual post contents [19] .", [["topical expertise", "TREATMENT", 109, 126]]], ["Thirdly, supplementing content features with further auxiliary data (e.g., networks of user interactions) for more effective expert recommendation involves devising a plausible joint processing of such information.", [["joint", "ANATOMY", 177, 182]]], ["Under such a model, Bayesian probabilistic matrix factorization [15] and the statistical formalization of asking-answering are seamlessly integrated.", [["Bayesian probabilistic matrix factorization", "TREATMENT", 20, 63]]], ["This allows for explaining both the expertise of users and their behavioral patterns as the result of a generative process, that is governed by a certain number of latent factors.", [["latent factors", "PROTEIN", 164, 178]]], ["These are estimated via a MCMC algorithm, that implements the derived mathematical details of Gibbs sampling inference under the devised model.IntroductionExtensive tests over real-world CQA data show that our approach overcomes several state-of-the-art competitors in recommendation effectiveness.", [["a MCMC algorithm", "TEST", 24, 40], ["Extensive tests over real", "TEST", 155, 180]]], ["Expertise prediction for recommendation and posterior inference are covered in Sect.", [["posterior", "ANATOMY_MODIFIER", 44, 53]]], ["The experimental evaluation of our approach is presented in Sect.", [["The experimental evaluation", "TEST", 0, 27]]], ["For any two answers a u,hi , a u,hj \u2208 a u , h i < h j iff ts u,hi < ts u,hj .", [["ts u", "TEST", 58, 62], ["hj", "PROBLEM", 73, 75], ["hj", "ANATOMY", 73, 75]]], ["For this reason, the wording of a u,h is disregarded and, consequently, the computational burden of processing very large amounts of raw text is avoided. s u,h indicates the acknowledged degree of expertise gained by u with regard to the question answered through a u,h and, by extension, under each tag within t u,h .PreliminariesAt the current timestamp now , the expertise of all users in U under the tags of T is summarized by matrix E (now ) .", [["matrix E", "GENE_OR_GENE_PRODUCT", 431, 439]]], ["Its generic entry E (now ) ut quantifies the expertise of user u under tag t at time now as the below weighted averagePreliminariesis assumed to be 0, which corresponds to an unknown or missing value.", [["missing value", "PROBLEM", 186, 199], ["entry", "OBSERVATION_MODIFIER", 12, 17]]], ["Essentially, larger values of \u03bb imply a faster decay of earlier answers.PreliminariesAs a supplement to the information from the answering history of users, their asking-answering interactions are also captured as edges of G. More precisely, an edge u i \u2192 u j from a responder u i to an asker u j belongs to A, if u i answered at least one question posted by u j .", [["larger", "OBSERVATION_MODIFIER", 13, 19]]], ["By an abuse of notation, we also write G to denote the adjacency matrix associated with the asking-answering graph.", [["matrix", "CELLULAR_COMPONENT", 65, 71], ["the adjacency matrix", "PROBLEM", 51, 71]]], ["The generic entry G ij is 1 iff u i \u2192 u j \u2208 A and 0 otherwise.Problem StatementGiven a question q, let t q be the set of tags attached to q by the asker.", [["t q", "DNA", 103, 106], ["q", "DNA", 138, 139], ["ij", "ANATOMY", 20, 22]]], ["We aim to recommend q to targeted users, with the highest acknowledged expertise in the tags of t q at time now , who are most likely to reply with high-quality answers.Problem StatementUnfortunately, in the context of the generic QA community D, E (now ) and G are generally very sparse.", [["D", "SIMPLE_CHEMICAL", 244, 245]]], ["Consequently, the expertise of users under specific tags within t q may not be known.", [["t q", "DNA", 64, 67]]], ["Thus, experts can be simply recommended from a list of answerers, ranked by their average expertise under the tags attached to q.Problem StatementHereinafter, to avoid cluttering notation, we will write E to mean E (now ) .The ENGAGE ModelENGAGE (timE-evolviNG tAG-based Expertise) is a Bayesian generative latentfactor model of temporally-discounted expertise and asking-answering behavior in QA communities.", [["ENGAGE ModelENGAGE", "DNA", 227, 245], ["timE", "DNA", 247, 251]]], ["Under ENGAGE, the matrices E and G of a QA community D are the result of a probabilistic generative process, that is ruled by K latent factors.", [["K latent factors", "GENE_OR_GENE_PRODUCT", 126, 142], ["K latent factors", "PROTEIN", 126, 142], ["a probabilistic generative process", "PROBLEM", 73, 107], ["probabilistic generative process", "OBSERVATION", 75, 107]]], ["These are captured by embedding users and tags in a K-dimensional latent space, through the seamless integration of Bayesian probabilistic matrix factorization [15] and the statistical modeling of the asking-answering behavior.", [["a K-dimensional latent space", "PROBLEM", 50, 78], ["Bayesian probabilistic matrix factorization", "TREATMENT", 116, 159]]], ["Formally, each user u \u2208 U is associated with a column vector L u \u2208 R K The k-th entry of L u (with k = 1, . . . , K) is a random variable representing the unknown degree to which the k-th latent factor explains the expertise of u.", [["k-th latent factor", "PROTEIN", 183, 201], ["a column vector", "TREATMENT", 45, 60], ["k", "TEST", 99, 100], ["unknown degree", "OBSERVATION_MODIFIER", 155, 169]]], ["Analogously, each tag t \u2208 T is associated with a column vector H t \u2208 R K .", [["tag t \u2208 T", "DNA", 18, 27], ["H t \u2208 R K", "CELL_LINE", 63, 72]]], ["The k-th entry of H t (with k = 1, . . . , K) is a random variable representing the unknown extent to which the k-th latent factor is inherently characteristic of t.", [["k-th latent factor", "PROTEIN", 112, 130], ["k", "TEST", 28, 29], ["unknown extent", "OBSERVATION_MODIFIER", 84, 98]]], ["The latent-factor representation of all users and tags is collectively denoted as L \u2208 R K\u00d7N and H \u2208 R K\u00d7M , respectively.", [["L \u2208 R K\u00d7N", "TEST", 82, 91], ["latent", "OBSERVATION_MODIFIER", 4, 10]]], ["This provides a valuable contribution to the identification of experts, since those users, who answer questions from other users with a high expertise, are also likely to have gained a high expertise.The ENGAGE ModelThe latent-factor representations of users and tags stem from multivariate Gaussian prior distributions parameterized, respectively, by \u0398 L = {\u03bc L , \u039b L } and \u0398 H = {\u03bc H , \u039b H }.", [["H , \u039b H", "CHEMICAL", 384, 391], ["\u0398 H = {\u03bc", "SIMPLE_CHEMICAL", 375, 383], ["users and tags stem", "TREATMENT", 253, 272], ["L", "TEST", 361, 362], ["latent", "OBSERVATION_MODIFIER", 220, 226]]], ["In turn, such parameters are drawn from the below Gaussian-Wishart prior distributions (hereinafter indicated as N W) [2] PrThe ENGAGE Modelwhere X \u2208 {L, H}, W (\u039b X ; \u03bd 0 , W 0 ) denotes the Wishart distribution [2] and \u0398 0 = {\u03bc 0 , \u03b2 0 , \u03bd 0 , W 0 } is a set of hyperparameters.The ENGAGE ModelThe conditional (in)dependencies among the random variables under ENGAGE are shown by means of plate notation in Fig. 1a .", [["ENGAGE", "DNA", 361, 367], ["ENGAGE", "TEST", 128, 134], ["Modelwhere", "TEST", 135, 145], ["H}", "TEST", 154, 156], ["\u03bd", "TEST", 167, 168], ["denotes", "TEST", 179, 186], ["distribution", "TEST", 199, 211], ["\u0398", "TEST", 220, 221], ["\u03b2", "TEST", 233, 234], ["hyperparameters", "TEST", 263, 278], ["The conditional (in)dependencies", "PROBLEM", 295, 327]]], ["Notice that unshaded nodes correspond to latent factors, whereas shaded nodes correspond to observed magnitudes.", [["nodes", "ANATOMY", 21, 26], ["unshaded nodes", "MULTI-TISSUE_STRUCTURE", 12, 26], ["nodes", "MULTI-TISSUE_STRUCTURE", 72, 77], ["latent factors", "PROTEIN", 41, 55], ["unshaded nodes", "PROBLEM", 12, 26], ["latent factors", "PROBLEM", 41, 55], ["shaded nodes", "PROBLEM", 65, 77], ["nodes", "OBSERVATION", 21, 26], ["latent", "OBSERVATION_MODIFIER", 41, 47], ["nodes", "OBSERVATION", 72, 77], ["magnitudes", "OBSERVATION_MODIFIER", 101, 111]]], ["The generative process modeled by ENGAGE performs the realization of the observed random variables (i.e., the individual entries of E and G) according to the conditional (in)dependencies of Fig. 1a as detailed in Fig. 1b.Model InferenceUnder ENGAGE, the experts for a given question q are found by ranking users based on a recommendation score, that involves the latent-factor representations of users and tags.", [["ENGAGE", "PROTEIN", 34, 40]]], ["The inference of the latent-factor representations is discussed in Sect.", [["latent", "OBSERVATION_MODIFIER", 21, 27]]], ["P uq is computed by averaging the current expertise of u under the individual tags of t q .", [["P uq", "DNA", 0, 4], ["t q", "DNA", 86, 89]]], ["Let t be an adopted tag of t q .", [["t q", "DNA", 27, 30]]], ["If the expertise of u under t is acknowledged, E ut can be directly used in the definition of P uq .", [["P uq", "DNA", 94, 98]]], ["Otherwise, if the expertise of u under t is an unknown entry of E, then E ut is suitably predicted by resorting to the latent-factor representations of u and t under ENGAGE.", [["E", "DNA", 64, 65], ["E ut", "DNA", 72, 76]]], ["4, S is the number of samples of both L u and H t , which are respectively referred to as L (s) (\u0398|E, G, \u03b1, \u03b2, \u0398 0 ) .", [["E", "TEST", 99, 100], ["G", "TEST", 102, 103], ["\u03b1", "TEST", 105, 106]]], ["However, the latter is analytically intractable.", [["analytically intractable", "PROBLEM", 23, 47], ["analytically", "OBSERVATION_MODIFIER", 23, 35], ["intractable", "OBSERVATION", 36, 47]]], ["Therefore, the generic L (s) u and H (s) t are drawn through approximate posterior inference, as described in Sect.", [["posterior", "ANATOMY_MODIFIER", 73, 82]]], ["4.2.Approximate Posterior InferenceA well-known technique for approximate stochastic inference [14] is Gibbs sampling.", [["Approximate Posterior InferenceA well-known technique", "TREATMENT", 4, 57], ["Gibbs sampling", "TEST", 103, 117], ["Posterior", "ANATOMY_MODIFIER", 16, 25]]], ["The latter defines a (first-order) Markov chain, whose stationary distribution eventually approaches the true posterior distribution Pr (\u0398|E, G, \u03b1, \u03b2, \u0398 0 ).", [["Markov chain", "PROTEIN", 35, 47], ["Markov chain", "PROBLEM", 35, 47], ["E", "TEST", 139, 140], ["G", "TEST", 142, 143], ["posterior", "ANATOMY_MODIFIER", 110, 119]]], ["More precisely, at the generic transition, each parameter \u03b8 \u2208 \u0398 is sequentially sampled from the respective full conditional Pr(\u03b8|\u0398 \u2212 \u03b8, E, G, \u03b1, \u03b2, \u0398 0 ) .", [["Pr", "PROTEIN", 125, 127], ["\u03b8", "PROTEIN", 134, 135], ["\u03b1", "PROTEIN", 143, 144], ["\u03b2", "CELL_LINE", 146, 147], ["\u03b8", "TEST", 134, 135], ["E", "TEST", 137, 138], ["G", "TEST", 140, 141], ["\u03b1", "TEST", 143, 144]]], ["This is the conditional distribution over \u03b8, given all other parameters \u0398 \u2212 \u03b8, the (hyper)parameters \u0398 0 as well as the observations E and G.Approximate Posterior InferenceThe derived full conditional distributions over the individual parameters of ENGAGE are reported next, along with the algorithm designed to perform Gibbs sampling inference.Approximate Posterior InferenceParameters L u and H t .", [["ENGAGE", "DNA", 249, 255], ["Posterior", "ANATOMY_MODIFIER", 153, 162], ["Posterior", "ANATOMY_MODIFIER", 357, 366]]], ["Due to the conjugacy between the multivariate Gaussian distribution on L u (with unknown parameters \u0398 L ) and the Gaussian-Wishart prior on \u0398 L , the full conditional on L u is a multivariate Guassian distribution, i.e.,Approximate Posterior InferenceLikewise, because of the conjugacy between the multivariate Gaussian distribution on H t (with unknown parameters \u0398 H ) and the Gaussian-Wishart prior on \u0398 H , the full conditional on H t is a multivariate Guassian distribution, i.e.,Approximate Posterior Inferencewith \u039b * (t)Approximate Posterior Inferencewhere c is the number of columns within matrix X and Gibbs Sampling.", [["\u0398 L", "CELL_LINE", 140, 143], ["L u", "CELL_LINE", 170, 173], ["\u0398 H", "CELL_LINE", 405, 408], ["the Gaussian", "TEST", 110, 122], ["Gibbs Sampling", "TEST", 612, 626], ["Posterior", "ANATOMY_MODIFIER", 232, 241], ["Posterior", "ANATOMY_MODIFIER", 497, 506], ["Posterior", "ANATOMY_MODIFIER", 540, 549]]], ["Algorithm 1 sketches the pseudo code of the sampler, designed to implement approximate posterior inference under ENGAGE.", [["posterior", "ANATOMY_MODIFIER", 87, 96]]], ["After a preliminary initialization (line 1), the sampler enters a loop (lines 2-11), whose generic iteration h embraces two steps.", [["the sampler", "TREATMENT", 45, 56], ["a loop (lines", "TREATMENT", 64, 77], ["loop", "OBSERVATION", 66, 70]]], ["The maximum number H of iterations is established, by following the widelyadopted convergence-criterion in [12] .", [["maximum", "OBSERVATION_MODIFIER", 4, 11]]], ["As a consequence, the S samples used in Eq.", [["the S samples", "TEST", 18, 31]]], ["4, can be drawn when convergence is met (i.e., after the burn-in period, in which samples are instead still sensible to the preliminary initialization).Experimental EvaluationWe comparatively investigated the recommendation effectiveness of ENGAGE.Data SetAll experiments were conducted on Stack Overflow 2 [1, 16] , i.e., a real-world QA community for sharing knowledge on computer programming.", [["samples", "ANATOMY", 82, 89]]], ["More precisely, we formed our training and test sets from an anonymized and quarterly dump 3 of all Stack Overflow data, produced by its users within a time interval ranging from Jan 1, 2015 to July 31, 2015.", [["test sets", "TEST", 43, 52], ["all Stack Overflow data", "TEST", 96, 119]]], ["We chose such users, their answers to the questions of Q, the respective timestamps and votes as the test set.", [["the test set", "TEST", 97, 109]]], ["The state-of-the art model in [19] , hereinafter called TER (Tag-based Expert Recommendation), infers user expertise from the factorization of the user-tag matrix.", [["matrix", "CELLULAR_COMPONENT", 156, 162], ["Tag", "PROTEIN", 61, 64]]], ["Unlike ENGAGE, TER ignores both the drift of users' interests over time and their asking-answering behavior.CompetitorsTEM [20] is a state-of-the art joint model of topics and expertise.", [["joint", "ANATOMY", 150, 155]]], ["The specific expertise of users under the different topics is explicitly captured.CompetitorsCQARank [20] combines the user topical interests and expertise under TEM with the link analysis of the asking-answering interaction graph, in order to enhance the inference of user topical expertise.CompetitorsBoth TEM and CQARank disregard the drift of users' interests over time.Recommendation EffectivenessWe comparatively assessed the recommendation performance of ENGAGE through several evaluation metrics.", [["several evaluation metrics", "TEST", 477, 503]]], ["Let q \u2208 Q be a generic question of the test set.", [["the test set", "TEST", 35, 47]]], ["Assume that R (q) and R (q) are, respectively, the ground-truth and the recommended list of experts for q.", [["R (q)", "GENE_OR_GENE_PRODUCT", 12, 17]]], ["The adopted evaluation metrics are enumerated next.Recommendation Effectiveness-Precision at top R (q) (Precision (q) (q) ) [9] is the correctness of R (q) , i.e., the fraction of top-R (q) recommended experts, who are ground-truth answerers.", [["The adopted evaluation metrics", "TEST", 0, 30], ["Precision at top R", "TREATMENT", 80, 98]]], ["Formally, nDCG(q) = DCG(q) IDCG(q) , whereRecommendation EffectivenessIn the above equation, s (q) i represents the relevance of R (q) i to q (according to thumbs-up/down).", [["nDCG", "TEST", 10, 14], ["DCG", "TEST", 20, 23], ["thumbs", "TEST", 156, 162]]], ["IDCG(q) is the DCG(q) value of the ideal ranking.Recommendation Effectiveness-Accuracy (Acc (q) ) [22] measures the quality of the best-answer's rank, i.e.,Recommendation EffectivenessLarger values of the above measures denote a higher recommendation effectiveness.", [["the above measures", "TREATMENT", 201, 219]]], ["In all tests, the time decay factor \u03bb was fixed to 0.2.", [["all tests", "TEST", 3, 12]]], ["The number K of latent factors was set to 15.", [["latent factors", "PROTEIN", 16, 30], ["latent factors", "TEST", 16, 30]]], ["The number S of samples used in Eq.", [["samples", "ANATOMY", 16, 23]]], ["The overall number H of iterations for Algorithm 1 was fixed to 1, 000, in compliance with the convergence-criterion in [12] .", [["Algorithm", "TEST", 39, 48]]], ["In particular, the lower effectiveness of Votes and InDegree is due to the fact that both focus only on the importance of users, without accounting for their specific discounted expertise.", [["lower", "OBSERVATION_MODIFIER", 19, 24]]], ["TEM and CQARank are two state-of-the-art competitors, that use tags to capture topical expertise.", [["TEM", "TEST", 0, 3]]], ["However, their effectiveness is penalized with respect to ENGAGE, since tags are mixed up with the textual content of posts, rather then being used as user-generated explanations of their topical expertise.", [["ENGAGE", "DNA", 58, 64]]], ["A thorough experimentation on real-world CQA data showed the overcoming recommendation effectiveness of our approach with respect to several state-of-the-art competitors.Conclusions and Further ResearchIt is interesting to explore the impact of alternative implementations of gradual forgetting on recommendation effectiveness.", [["A thorough experimentation", "TEST", 0, 26], ["our approach", "TREATMENT", 104, 116], ["alternative implementations", "TREATMENT", 245, 272]]], ["In this regard, temporal hyperbolic discounting [21] is a viable choice.", [["temporal hyperbolic discounting", "PROBLEM", 16, 47]]], ["Finally, three further lines of innovative research involve studying the incorporation of, respectively, user roles [5, 7, 13, 18] , exposure [11] to posted questions as well as the recent generative models of text corpora (such as, e.g., [4] ) for more effective expert recommendation.", [["corpora", "MULTI-TISSUE_STRUCTURE", 215, 222], ["innovative research", "TREATMENT", 32, 51]]]], "51c09cc0639636a74aee49204811510a369fe7ba": [["TO THE EDITOR: It has been argued that reduced levels of bulk billing have resulted in emergency department (ED) overcrowding due to an increase in nonemergency, primary care ED presentations.", [["increase", "OBSERVATION_MODIFIER", 136, 144]]], ["During the same period, there was a 1.5% decline in the proportion of general practice services bulk billed in Queensland.", [["a 1.5% decline", "PROBLEM", 34, 48]]]], "2c26e3b68282e7ecbe5777718996af9e32bbe667": [], "a89de2302bef8efe03fb937119e00142397a2083": [["IntroductionAnimal hoarding is a complex human and animal welfare issue that exists in almost every community.", [["hoarding", "DISEASE", 19, 27], ["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46]]], ["Suspected hoarding cases frequently come to public attention when individuals amass large numbers of animals with good intentions, but lack capacity for providing minimal standards of care (Lockwood, 1994) .IntroductionWhile the true prevalence of hoarding is unknown due to the social isolation of hoarders, dismissive responses by potential reporters, and a lack of legal investigative authority or motivation to pursue hoarding cases, an estimated 700-2000 new cases are re-ported per year (Patronek, 1999) .", [["hoarding", "DISEASE", 10, 18], ["hoarding", "DISEASE", 248, 256], ["hoarding", "DISEASE", 422, 430], ["hoarding", "PROBLEM", 248, 256]]], ["Hoarding occurs among individuals as well as those operating animal shelters, sanctuaries, and rescue groups (Miller and Zawistowski, 2012) .IntroductionHoarding conditions are often characterized by an accumulation of animal waste, carcasses, elevated ammonia levels, and garbage, leading to compromised animal welfare and health (Campbell and Robinson, 2001) .", [["ammonia", "CHEMICAL", 253, 260], ["ammonia", "CHEMICAL", 253, 260], ["ammonia", "SIMPLE_CHEMICAL", 253, 260], ["an accumulation of animal waste", "PROBLEM", 200, 231], ["elevated ammonia levels", "PROBLEM", 244, 267], ["accumulation", "OBSERVATION_MODIFIER", 203, 215], ["animal waste", "OBSERVATION", 219, 231], ["elevated", "OBSERVATION_MODIFIER", 244, 252], ["ammonia levels", "OBSERVATION", 253, 267]]], ["Animals can be found in overcrowded conditions without provision for adequate food, water, sanitation and veterinary care.", [["Animals", "ORGANISM", 0, 7], ["veterinary care", "TREATMENT", 106, 121]]], ["As a result, animals seized from hoarding situations frequently suffer from a variety of medical conditions including respiratory infections, diarrhea, parasitism, and skin diseases (Patronek, 2008; Reinisch, 2009) .IntroductionLegal and humane interventions in large-scale cases can be procedurally cumbersome and costly, often requiring a multi-faceted response involving representatives from animal control, humane societies, veterinary medicine, public health, code enforcement, social services, and law enforcement (Patronek, 2001) .", [["respiratory", "ANATOMY", 118, 129], ["skin", "ANATOMY", 168, 172], ["hoarding", "DISEASE", 33, 41], ["respiratory infections", "DISEASE", 118, 140], ["diarrhea", "DISEASE", 142, 150], ["parasitism", "DISEASE", 152, 162], ["skin diseases", "DISEASE", 168, 181], ["skin", "ORGAN", 168, 172], ["hoarding situations", "PROBLEM", 33, 52], ["medical conditions", "PROBLEM", 89, 107], ["respiratory infections", "PROBLEM", 118, 140], ["diarrhea", "PROBLEM", 142, 150], ["parasitism", "PROBLEM", 152, 162], ["skin diseases", "PROBLEM", 168, 181], ["IntroductionLegal", "TREATMENT", 216, 233], ["humane interventions", "TREATMENT", 238, 258], ["large-scale cases", "TREATMENT", 262, 279], ["respiratory", "ANATOMY", 118, 129], ["infections", "OBSERVATION", 130, 140], ["diarrhea", "OBSERVATION", 142, 150], ["parasitism", "OBSERVATION", 152, 162], ["skin", "ANATOMY", 168, 172], ["diseases", "OBSERVATION", 173, 181]]], ["When the number of animals and the severity of conditions exceed the response capacity of local agencies, a collaborative effort between local and national agencies is often required (Lockwood, 1994) .IntroductionResponses to suspected large-scale cruelty cases often consist of both forensic and animal rescue components.", [["large-scale cruelty cases", "PROBLEM", 236, 261], ["large", "OBSERVATION_MODIFIER", 236, 241], ["-scale", "OBSERVATION_MODIFIER", 241, 247]]], ["Historically, the high prevalence of infectious diseases and lack of socialization of cats seized in largescale cases often resulted in mass euthanasia in shelters already crowded by pet overpopulation.", [["infectious diseases", "DISEASE", 37, 56], ["cats", "ORGANISM", 86, 90], ["cats", "SPECIES", 86, 90], ["infectious diseases", "PROBLEM", 37, 56], ["mass euthanasia in shelters", "PROBLEM", 136, 163], ["high prevalence", "OBSERVATION_MODIFIER", 18, 33], ["infectious", "OBSERVATION", 37, 47], ["mass euthanasia", "OBSERVATION", 136, 151], ["pet overpopulation", "OBSERVATION", 183, 201]]], ["1,2 In recent years, responding agencies have invested in the physical and behavioral rehabilitation of seized animals to reduce their euthanasia.", [["1,2", "CHEMICAL", 0, 3], ["behavioral rehabilitation", "TREATMENT", 75, 100], ["euthanasia", "OBSERVATION", 135, 145]]], ["3 This has increased the number of animals eventually placed in homes and the cost of intervening in suspected cruelty cases.", [["increased", "OBSERVATION_MODIFIER", 11, 20], ["number", "OBSERVATION_MODIFIER", 25, 31]]], ["The costs have exceeded $1-2 million 4 in the largest cases.", [["largest", "OBSERVATION_MODIFIER", 46, 53]]], ["Infectious diseases pose a risk to other animals in the shelter and potentially to pets in the community.", [["Infectious diseases", "DISEASE", 0, 19]]], ["Some infections could have zoonotic risk to both shelter staff and potential adopters.", [["infections", "DISEASE", 5, 15], ["Some infections", "PROBLEM", 0, 15], ["infections", "OBSERVATION", 5, 15]]], ["Knowledge of conditions commonly present in large-scale cruelty investigations would assist with planning for the care of seized animals, including ordering of medical supplies, preparation of shelter protocols, and eventual placement of the animals.", [["medical supplies", "TREATMENT", 160, 176], ["shelter protocols", "TREATMENT", 193, 210], ["eventual placement of the animals", "TREATMENT", 216, 249]]], ["Although media reports frequently cite high disease rates from such cases, there are no detailed descriptions of diseases diagnosed in cats seized in cruelty investigations.", [["cats", "ORGANISM", 135, 139], ["cats", "SPECIES", 135, 139], ["high disease rates", "PROBLEM", 39, 57], ["diseases", "PROBLEM", 113, 121], ["cruelty investigations", "TEST", 150, 172]]], ["5, 7 From November 2009 through March 2012, more than 2000 cats were removed from four cat sanctuaries following reports consistent with animal hoarding.", [["hoarding", "DISEASE", 144, 152], ["cats", "ORGANISM", 59, 63], ["cat", "ORGANISM", 87, 90], ["cats", "SPECIES", 59, 63], ["animal hoarding", "PROBLEM", 137, 152], ["consistent with", "UNCERTAINTY", 121, 136], ["animal hoarding", "OBSERVATION", 137, 152]]], ["In each case, veterinarians performed intake examinations and screened for infectious diseases as needed to guide treatment decisions for ill cats and to segregate infectious cats housed in temporary shelters.", [["infectious diseases", "DISEASE", 75, 94], ["cats", "ORGANISM", 142, 146], ["cats", "ORGANISM", 175, 179], ["cats", "SPECIES", 142, 146], ["cats", "SPECIES", 175, 179], ["intake examinations", "TEST", 38, 57], ["infectious diseases", "PROBLEM", 75, 94], ["treatment decisions", "TREATMENT", 114, 133], ["ill cats", "TREATMENT", 138, 146]]], ["The purpose of this study was to examine the available records of cats removed during the four large-scale cruelty investigations to characterize the infectious diseases of cats with respiratory and gastrointestinal signs and to determine the prevalence of retroviral infections.Case 1In November 2009, 594 cats were relinquished from a cat sanctuary in Florida following a site assessment that revealed high rates of disease and mortality.", [["respiratory", "ANATOMY", 183, 194], ["gastrointestinal", "ANATOMY", 199, 215], ["infectious diseases", "DISEASE", 150, 169], ["respiratory and gastrointestinal signs", "DISEASE", 183, 221], ["retroviral infections", "DISEASE", 257, 278], ["cats", "ORGANISM", 66, 70], ["cats", "ORGANISM", 173, 177], ["gastrointestinal", "ORGAN", 199, 215], ["retroviral", "ORGANISM", 257, 267], ["cats", "ORGANISM", 307, 311], ["cat", "ORGANISM", 337, 340], ["cats", "SPECIES", 66, 70], ["cats", "SPECIES", 173, 177], ["cats", "SPECIES", 307, 311], ["retroviral", "SPECIES", 257, 267], ["this study", "TEST", 15, 25], ["cruelty investigations", "TEST", 107, 129], ["the infectious diseases of cats", "PROBLEM", 146, 177], ["respiratory and gastrointestinal signs", "PROBLEM", 183, 221], ["retroviral infections", "PROBLEM", 257, 278], ["a site assessment", "TEST", 372, 389], ["high rates of disease", "PROBLEM", 404, 425], ["infectious", "OBSERVATION_MODIFIER", 150, 160], ["gastrointestinal", "ANATOMY", 199, 215], ["retroviral infections", "OBSERVATION", 257, 278], ["high", "OBSERVATION_MODIFIER", 404, 408], ["disease", "OBSERVATION", 418, 425]]], ["The majority of cats were group-housed in indoor/outdoor wire mesh pens.", [["cats", "ORGANISM", 16, 20], ["cats", "SPECIES", 16, 20], ["outdoor wire mesh pens", "TREATMENT", 49, 71], ["mesh pens", "OBSERVATION", 62, 71]]], ["Cats under treatment were housed in a barn in plastic airline carriers.", [["treatment", "TREATMENT", 11, 20]]], ["Following relinquishment, cats were examined and sheltered on-site for several weeks pending disposition.Case 2In June 2010, 387 cats were relinquished from a Pennsylvania cat sanctuary after an inspection revealed the cats to be housed in overcrowded and unsanitary conditions on the first floor of a two-story commercial building.", [["cats", "ORGANISM", 26, 30], ["cats", "ORGANISM", 129, 133], ["cat", "ORGANISM", 172, 175], ["cats", "ORGANISM", 219, 223], ["cats", "SPECIES", 26, 30], ["cats", "SPECIES", 129, 133], ["cats", "SPECIES", 219, 223], ["an inspection", "TEST", 192, 205]]], ["The majority of cats were group-housed indoors.", [["cats", "ORGANISM", 16, 20], ["cats", "SPECIES", 16, 20]]], ["Following relinquishment, cats were transported to a temporary shelter established at a nearby fairground for intake examinations.", [["cats", "ORGANISM", 26, 30], ["cats", "SPECIES", 26, 30], ["intake examinations", "TEST", 110, 129]]], ["There they were housed in stacked wire crates for several weeks pending disposition.Case 3In June 2011, 697 cats were seized from a cat sanctuary in Florida.", [["cats", "ORGANISM", 108, 112], ["cat", "ORGANISM", 132, 135], ["cats", "SPECIES", 108, 112], ["stacked wire crates", "TREATMENT", 26, 45]]], ["Cats were grouphoused in outdoor community pens, barn pens, travel trailers, or indoor wire crates.", [["barn pens", "TREATMENT", 49, 58], ["travel trailers", "TREATMENT", 60, 75], ["indoor wire crates", "TREATMENT", 80, 98]]], ["Cats were transported to several air-conditioned warehouses where intake examinations were performed.", [["Cats", "ORGANISM", 0, 4], ["intake examinations", "TEST", 66, 85]]], ["Cats were housed in stacked wire cages in the temporary shelter for approximately 3 months until disposition.Case 4In February 2012, 696 cats were seized from a Florida cat sanctuary.", [["cats", "ORGANISM", 137, 141], ["cat", "ORGANISM", 169, 172], ["cats", "SPECIES", 137, 141], ["stacked wire cages", "TREATMENT", 20, 38]]], ["The majority of cats roamed freely outdoors, with a few dozen housed in pens or trailers designated for diseased animals.", [["cats", "ORGANISM", 16, 20], ["cats", "SPECIES", 16, 20]]], ["Movement of cats among the various housing areas was unrestricted.", [["cats", "ORGANISM", 12, 16], ["cats", "SPECIES", 12, 16]]], ["Cats healthy enough for transport were relocated to a vacant animal shelter where they received intake examinations.", [["intake examinations", "TEST", 96, 115]]], ["The cats were then group-housed two to four per indoor/outdoor run or in individual cages until disposition approximately 6 months post-seizure.Intake examinationsIntake examinations were performed on all cats on-site at the sanctuary (case 1) or upon arrival at the temporary shelters (cases 2-4).", [["cats", "ORGANISM", 4, 8], ["cats", "ORGANISM", 205, 209], ["cats", "SPECIES", 4, 8], ["Intake examinations", "TEST", 144, 163], ["Intake examinations", "TEST", 163, 182]]], ["Intake protocols varied between the four cases but all included a physical examination that documented each cat's estimated age, breed, sex, weight, and body condition score.", [["body", "ANATOMY", 153, 157], ["cat", "ORGANISM", 108, 111], ["body", "ORGANISM_SUBDIVISION", 153, 157], ["Intake protocols", "TREATMENT", 0, 16], ["a physical examination", "TEST", 64, 86]]], ["The presence of illness or injuries was recorded.Intake examinationsCats were photographed, vaccinated, treated for internal and external parasites, and blood was collected for retroviral testing.", [["blood", "ANATOMY", 153, 158], ["illness", "DISEASE", 16, 23], ["injuries", "DISEASE", 27, 35], ["blood", "ORGANISM_SUBSTANCE", 153, 158], ["retroviral", "ORGANISM", 177, 187], ["illness", "PROBLEM", 16, 23], ["injuries", "PROBLEM", 27, 35], ["Intake examinations", "TEST", 49, 68], ["internal and external parasites", "PROBLEM", 116, 147], ["retroviral testing", "TEST", 177, 195], ["illness", "OBSERVATION", 16, 23], ["injuries", "OBSERVATION", 27, 35], ["external parasites", "ANATOMY", 129, 147]]], ["Specimens were collected from a subset of the cats exhibiting signs of respiratory (ocular or nasal discharge, sneezing, coughing, conjunctivitis, or blepharospasm) or gastrointestinal (diarrhea) disease.", [["Specimens", "ANATOMY", 0, 9], ["respiratory", "ANATOMY", 71, 82], ["ocular", "ANATOMY", 84, 90], ["nasal", "ANATOMY", 94, 99], ["gastrointestinal", "ANATOMY", 168, 184], ["respiratory (ocular or nasal discharge", "DISEASE", 71, 109], ["sneezing", "DISEASE", 111, 119], ["coughing", "DISEASE", 121, 129], ["conjunctivitis", "DISEASE", 131, 145], ["blepharospasm", "DISEASE", 150, 163], ["gastrointestinal (diarrhea) disease", "DISEASE", 168, 203], ["cats", "ORGANISM", 46, 50], ["nasal", "ORGANISM_SUBDIVISION", 94, 99], ["gastrointestinal", "ORGANISM_SUBDIVISION", 168, 184], ["cats", "SPECIES", 46, 50], ["Specimens", "TEST", 0, 9], ["respiratory (ocular or nasal discharge", "PROBLEM", 71, 109], ["sneezing", "PROBLEM", 111, 119], ["coughing", "PROBLEM", 121, 129], ["conjunctivitis", "PROBLEM", 131, 145], ["blepharospasm", "PROBLEM", 150, 163], ["gastrointestinal (diarrhea) disease", "PROBLEM", 168, 203], ["respiratory", "ANATOMY", 71, 82], ["ocular", "ANATOMY", 84, 90], ["nasal", "ANATOMY", 94, 99], ["gastrointestinal", "ANATOMY", 168, 184]]], ["The criteria for performing diagnostic testing varied between cases and were based on the participating agency's medical protocols and the decisions made by the supervising veterinarians.Intake examinationsRespiratory specimens were collected at the time of intake examination.", [["Respiratory specimens", "ANATOMY", 206, 227], ["Respiratory specimens", "CANCER", 206, 227], ["performing diagnostic testing", "TEST", 17, 46], ["Intake examinations", "TEST", 187, 206], ["Respiratory specimens", "TEST", 206, 227], ["intake examination", "TEST", 258, 276]]], ["Fecal specimens were usually collected during the first 5 days of housing at the temporary shelters when diarrhea was observed.", [["Fecal specimens", "ANATOMY", 0, 15], ["diarrhea", "DISEASE", 105, 113], ["Fecal specimens", "ORGANISM_SUBSTANCE", 0, 15], ["Fecal specimens", "TEST", 0, 15], ["diarrhea", "PROBLEM", 105, 113]]], ["A small subset of 15 cats from case 4 were sampled 14 days post-intake to the temporary shelter due to persistence of diarrhea despite anti-parasite treatments (pyrantel pamoate, praziquantel, ponazuril) administered during the intake examination.Serological testingIn all cases, cats were tested for feline leukemia virus (FeLV) antigen and feline immunodeficiency virus (FIV) antibody with a commercially available ELISA (SNAP Feline Triple Test or SNAP Combo Test, IDEXX Laboratories) using whole blood.", [["whole blood", "ANATOMY", 494, 505], ["diarrhea", "DISEASE", 118, 126], ["pyrantel pamoate", "CHEMICAL", 161, 177], ["praziquantel", "CHEMICAL", 179, 191], ["ponazuril", "CHEMICAL", 193, 202], ["feline leukemia virus", "DISEASE", 301, 322], ["feline immunodeficiency virus", "DISEASE", 342, 371], ["pyrantel pamoate", "CHEMICAL", 161, 177], ["praziquantel", "CHEMICAL", 179, 191], ["ponazuril", "CHEMICAL", 193, 202], ["cats", "ORGANISM", 21, 25], ["pyrantel pamoate", "SIMPLE_CHEMICAL", 161, 177], ["praziquantel", "SIMPLE_CHEMICAL", 179, 191], ["ponazuril", "SIMPLE_CHEMICAL", 193, 202], ["cats", "ORGANISM", 280, 284], ["feline leukemia virus", "ORGANISM", 301, 322], ["FeLV", "ORGANISM", 324, 328], ["feline immunodeficiency virus", "ORGANISM", 342, 371], ["FIV", "ORGANISM", 373, 376], ["blood", "ORGANISM_SUBSTANCE", 500, 505], ["feline leukemia virus (FeLV) antigen", "PROTEIN", 301, 337], ["cats", "SPECIES", 21, 25], ["cats", "SPECIES", 280, 284], ["feline leukemia virus", "SPECIES", 301, 322], ["feline immunodeficiency virus", "SPECIES", 342, 371], ["feline leukemia virus", "SPECIES", 301, 322], ["FeLV", "SPECIES", 324, 328], ["feline immunodeficiency virus", "SPECIES", 342, 371], ["FIV", "SPECIES", 373, 376], ["diarrhea", "PROBLEM", 118, 126], ["anti-parasite treatments", "TREATMENT", 135, 159], ["pyrantel pamoate", "TREATMENT", 161, 177], ["praziquantel", "TREATMENT", 179, 191], ["ponazuril)", "TREATMENT", 193, 203], ["the intake examination", "TEST", 224, 246], ["Serological testingIn", "TEST", 247, 268], ["cats", "TEST", 280, 284], ["feline leukemia virus", "PROBLEM", 301, 322], ["FeLV) antigen", "TEST", 324, 337], ["feline immunodeficiency virus", "PROBLEM", 342, 371], ["FIV) antibody", "TEST", 373, 386], ["ELISA", "TEST", 417, 422], ["Triple Test", "TEST", 436, 447], ["SNAP Combo Test", "TEST", 451, 466], ["whole blood", "TEST", 494, 505], ["small", "OBSERVATION_MODIFIER", 2, 7], ["subset", "OBSERVATION_MODIFIER", 8, 14], ["diarrhea", "OBSERVATION", 118, 126]]], ["Testing for D. immitis antigen (SNAP Feline Triple Test, IDEXX Laboratories) was performed in the majority of cats 7 months and older in two of the four cases.Testing of cats with respiratory diseaseDiagnostic specimens from cats with signs of respiratory disease were collected by swabbing the conjunctiva for PCR detection of pathogens.", [["respiratory diseaseDiagnostic specimens", "ANATOMY", 180, 219], ["respiratory", "ANATOMY", 244, 255], ["conjunctiva", "ANATOMY", 295, 306], ["respiratory disease", "DISEASE", 244, 263], ["D. immitis antigen", "GENE_OR_GENE_PRODUCT", 12, 30], ["cats", "ORGANISM", 110, 114], ["cats", "ORGANISM", 170, 174], ["cats", "ORGANISM", 225, 229], ["conjunctiva", "ORGAN", 295, 306], ["D. immitis antigen", "PROTEIN", 12, 30], ["D. immitis", "SPECIES", 12, 22], ["cats", "SPECIES", 170, 174], ["cats", "SPECIES", 225, 229], ["D. immitis", "SPECIES", 12, 22], ["Testing", "TEST", 0, 7], ["D. immitis antigen", "TEST", 12, 30], ["Testing of cats", "TEST", 159, 174], ["respiratory diseaseDiagnostic specimens", "PROBLEM", 180, 219], ["respiratory disease", "PROBLEM", 244, 263], ["PCR detection", "TEST", 311, 324], ["pathogens", "PROBLEM", 328, 337], ["respiratory disease", "OBSERVATION", 244, 263], ["conjunctiva", "ANATOMY", 295, 306]]], ["One specimen was collected by rolling a dry polyester swab (Fisherbrand, Thermo Fischer Scientific) in the ventral conjunctival sac and a second swab was collected by rubbing a dry swab around the oropharynx.", [["specimen", "ANATOMY", 4, 12], ["ventral conjunctival sac", "ANATOMY", 107, 131], ["swab", "ANATOMY", 145, 149], ["swab", "ANATOMY", 181, 185], ["oropharynx", "ANATOMY", 197, 207], ["polyester", "CHEMICAL", 44, 53], ["ventral conjunctival sac", "TISSUE", 107, 131], ["oropharynx", "ORGAN", 197, 207], ["a dry polyester swab", "TREATMENT", 38, 58], ["a second swab", "TREATMENT", 136, 149], ["a dry swab around the oropharynx", "PROBLEM", 175, 207], ["ventral", "ANATOMY_MODIFIER", 107, 114], ["conjunctival sac", "ANATOMY", 115, 131], ["oropharynx", "ANATOMY", 197, 207]]], ["The paired swabs from each cat were placed together in a sterile dry polystyrene vial for pooled analysis and labeled with pertinent specimen identification information such as specimen collection date, animal identification, and agency name.", [["swabs", "ANATOMY", 11, 16], ["specimen", "ANATOMY", 133, 141], ["specimen", "ANATOMY", 177, 185], ["polystyrene", "CHEMICAL", 69, 80], ["cat", "ORGANISM", 27, 30], ["cat", "SPECIES", 27, 30], ["The paired swabs", "TEST", 0, 16], ["a sterile dry polystyrene vial", "TREATMENT", 55, 85], ["pooled analysis", "TEST", 90, 105], ["pertinent specimen identification", "TEST", 123, 156], ["specimen collection", "TEST", 177, 196]]], ["Fresh latex gloves were worn during specimen collection for each cat and the vial containing the paired swabs was placed in an individual plastic self-sealing bag to reduce cross-contamination prior to testing.", [["specimen", "ANATOMY", 36, 44], ["swabs", "ANATOMY", 104, 109], ["cat", "ORGANISM", 65, 68], ["Fresh latex gloves", "TREATMENT", 0, 18], ["specimen collection", "TEST", 36, 55], ["each cat", "TREATMENT", 60, 68], ["the vial", "TREATMENT", 73, 81], ["the paired swabs", "PROBLEM", 93, 109], ["an individual plastic self-sealing bag", "TREATMENT", 124, 162], ["testing", "TEST", 202, 209], ["latex gloves", "OBSERVATION", 6, 18], ["sealing bag", "OBSERVATION", 151, 162]]], ["The specimens were stored at 4\u00b0C pending analysis within 72 h of collection by a commercial reference laboratory (Feline Upper Respiratory Disease RealPCR Panel, IDEXX Laboratories).Testing of cats with respiratory diseaseRespiratory specimens were tested by real-time PCR for feline herpesvirus type 1 (FHV) glycoprotein B (gB) gene, S66371; feline calicivirus (FCV) ORF 1 gene, AF109465; influenza virus H1N1 type A influenza hemagglutin HA gene, GQ229373; Streptococcus equi subspecies zooepidemicus (SEZ) AroA, 3-phosphoshikimate 1-carboxyvinyltransferase gene, FM204884; Bordetella bronchiseptica hemagglutinin fusion protein gene (FhaB), AF140678; Mycoplasma felis single-stranded rRNAinternal transcribed region 1 (ITS-1) gene, AF443608; and Chlamydophila felis outer membrane protein A (OmpA) gene, AP00686.", [["specimens", "ANATOMY", 4, 13], ["respiratory diseaseRespiratory specimens", "ANATOMY", 203, 243], ["feline calicivirus", "DISEASE", 343, 361], ["specimens", "CANCER", 4, 13], ["cats", "ORGANISM", 193, 197], ["feline herpesvirus type 1", "ORGANISM", 277, 302], ["FHV", "GENE_OR_GENE_PRODUCT", 304, 307], ["glycoprotein B", "GENE_OR_GENE_PRODUCT", 309, 323], ["gB", "GENE_OR_GENE_PRODUCT", 325, 327], ["feline calicivirus", "ORGANISM", 343, 361], ["FCV) ORF 1", "ORGANISM", 363, 373], ["AF109465;", "ORGANISM", 380, 389], ["influenza virus H1N1 type A influenza", "ORGANISM", 390, 427], ["hemagglutin HA", "ORGANISM", 428, 442], ["Streptococcus equi subspecies zooepidemicus", "ORGANISM", 459, 502], ["3-phosphoshikimate 1-carboxyvinyltransferase", "GENE_OR_GENE_PRODUCT", 515, 559], ["Bordetella bronchiseptica", "ORGANISM", 576, 601], ["hemagglutinin fusion protein", "GENE_OR_GENE_PRODUCT", 602, 630], ["Mycoplasma felis", "ORGANISM", 654, 670], ["single-stranded rRNAinternal transcribed region 1", "GENE_OR_GENE_PRODUCT", 671, 720], ["ITS-1", "GENE_OR_GENE_PRODUCT", 722, 727], ["AF443608", "GENE_OR_GENE_PRODUCT", 735, 743], ["Chlamydophila felis", "ORGANISM", 749, 768], ["outer membrane protein A", "GENE_OR_GENE_PRODUCT", 769, 793], ["OmpA", "GENE_OR_GENE_PRODUCT", 795, 799], ["feline herpesvirus type 1 (FHV) glycoprotein B (gB) gene", "DNA", 277, 333], ["feline calicivirus (FCV) ORF 1 gene", "DNA", 343, 378], ["AF109465", "DNA", 380, 388], ["influenza virus H1N1 type A influenza hemagglutin HA gene", "DNA", 390, 447], ["Streptococcus equi subspecies zooepidemicus (SEZ) AroA, 3-phosphoshikimate 1-carboxyvinyltransferase gene", "DNA", 459, 564], ["FM204884", "DNA", 566, 574], ["Bordetella bronchiseptica hemagglutinin fusion protein gene", "DNA", 576, 635], ["FhaB", "DNA", 637, 641], ["AF140678", "DNA", 644, 652], ["Mycoplasma felis single-stranded rRNAinternal transcribed region 1", "DNA", 654, 720], ["ITS-1) gene", "DNA", 722, 733], ["AF443608", "DNA", 735, 743], ["Chlamydophila felis outer membrane protein A (OmpA) gene", "DNA", 749, 805], ["AP00686", "DNA", 807, 814], ["cats", "SPECIES", 193, 197], ["feline herpesvirus", "SPECIES", 277, 295], ["feline calicivirus", "SPECIES", 343, 361], ["influenza virus H1N1", "SPECIES", 390, 410], ["A influenza hemagglutin", "SPECIES", 416, 439], ["Streptococcus equi", "SPECIES", 459, 477], ["subspecies zooepidemicus", "SPECIES", 478, 502], ["Bordetella bronchiseptica hemagglutinin", "SPECIES", 576, 615], ["Mycoplasma felis", "SPECIES", 654, 670], ["Chlamydophila felis", "SPECIES", 749, 768], ["feline herpesvirus type 1", "SPECIES", 277, 302], ["FHV", "SPECIES", 304, 307], ["feline calicivirus", "SPECIES", 343, 361], ["FCV", "SPECIES", 363, 366], ["Streptococcus equi subspecies zooepidemicus", "SPECIES", 459, 502], ["Bordetella bronchiseptica", "SPECIES", 576, 601], ["Mycoplasma felis", "SPECIES", 654, 670], ["Chlamydophila felis", "SPECIES", 749, 768], ["The specimens", "TEST", 0, 13], ["C pending analysis", "TEST", 31, 49], ["Testing of cats", "TEST", 182, 197], ["respiratory diseaseRespiratory specimens", "TEST", 203, 243], ["PCR", "TEST", 269, 272], ["feline herpesvirus type", "TEST", 277, 300], ["glycoprotein B (gB) gene", "TEST", 309, 333], ["feline calicivirus", "TEST", 343, 361], ["AF", "TEST", 380, 382], ["influenza virus H1N1 type A influenza hemagglutin HA gene", "PROBLEM", 390, 447], ["Streptococcus equi subspecies zooepidemicus", "TEST", 459, 502], ["AroA", "TEST", 509, 513], ["phosphoshikimate", "TREATMENT", 517, 533], ["Bordetella bronchiseptica hemagglutinin fusion protein gene", "TEST", 576, 635], ["FhaB", "TEST", 637, 641], ["AF", "TEST", 644, 646], ["Mycoplasma felis", "TEST", 654, 670], ["ITS", "TEST", 722, 725], ["AF443608", "TEST", 735, 743], ["Chlamydophila", "TEST", 749, 762]]], ["Real-time PCR was performed with seven quality controls, including PCR-positive controls, PCR-negative controls, negative extraction controls, DNA pre-analytic quality control targeting the host 18S rRNA gene complex, RNA pre-analytic quality control targeting the host 18S rRNA gene complex, an internal positive control spiked into the lysis solution, and an environmental contamination monitoring control.Testing of cats with diarrheaFecal specimens were collected from the litter box, cage floor, or by rectal swab from cats with diarrhea.", [["diarrheaFecal specimens", "ANATOMY", 429, 452], ["rectal swab", "ANATOMY", 507, 518], ["diarrhea", "DISEASE", 534, 542], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["cats", "ORGANISM", 419, 423], ["diarrheaFecal specimens", "CANCER", 429, 452], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 507, 518], ["cats", "ORGANISM", 524, 528], ["host 18S rRNA gene complex", "DNA", 190, 216], ["host 18S rRNA gene complex", "PROTEIN", 265, 291], ["cats", "SPECIES", 419, 423], ["cats", "SPECIES", 524, 528], ["Real-time PCR", "TEST", 0, 13], ["PCR", "TEST", 67, 70], ["PCR", "TEST", 90, 93], ["DNA pre-analytic quality control", "TREATMENT", 143, 175], ["the host 18S rRNA gene complex", "PROBLEM", 186, 216], ["RNA pre-analytic quality control", "TREATMENT", 218, 250], ["the host 18S rRNA gene complex", "PROBLEM", 261, 291], ["an internal positive control", "TREATMENT", 293, 321], ["the lysis solution", "TREATMENT", 334, 352], ["an environmental contamination monitoring control", "TREATMENT", 358, 407], ["diarrheaFecal specimens", "TEST", 429, 452], ["diarrhea", "PROBLEM", 534, 542], ["rectal", "ANATOMY", 507, 513]]], ["To avoid cross-contamination of specimens, each fecal specimen was collected using fresh gloves and assisted by a fresh wooden tongue depressor or fresh syringe depending on the consistency of the specimen.", [["specimens", "ANATOMY", 32, 41], ["fecal specimen", "ANATOMY", 48, 62], ["tongue", "ANATOMY", 127, 133], ["specimen", "ANATOMY", 197, 205], ["fecal specimen", "ORGANISM_SUBSTANCE", 48, 62], ["tongue", "ORGANISM_SUBDIVISION", 127, 133], ["cross-contamination of specimens", "TEST", 9, 41], ["each fecal specimen", "TEST", 43, 62], ["fresh gloves", "TREATMENT", 83, 95], ["a fresh wooden tongue depressor", "TREATMENT", 112, 143], ["fresh syringe", "TREATMENT", 147, 160]]], ["Fecal aliquots were split into two fresh plastic screw-top jars.", [["Fecal", "ANATOMY", 0, 5], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["Fecal aliquots", "TREATMENT", 0, 14], ["two fresh plastic screw-top jars", "TREATMENT", 31, 63], ["fresh", "OBSERVATION_MODIFIER", 35, 40], ["plastic screw", "OBSERVATION", 41, 54], ["top jars", "OBSERVATION", 55, 63]]], ["One jar from each specimen was selected for PCR assay and was individually placed into its own plastic self-sealing bag to further reduce the chance of cross-contamination.", [["specimen", "ANATOMY", 18, 26], ["PCR assay", "TEST", 44, 53], ["plastic self-sealing bag", "TREATMENT", 95, 119], ["cross-contamination", "PROBLEM", 152, 171], ["sealing bag", "OBSERVATION", 108, 119], ["cross-contamination", "OBSERVATION", 152, 171]]], ["The second jar was designated for fecal flotation.", [["fecal", "ANATOMY", 34, 39], ["fecal", "ORGANISM_SUBSTANCE", 34, 39], ["fecal flotation", "TREATMENT", 34, 49]]], ["All supplies were disposed of after each specimen and were not re-used.", [["specimen", "ANATOMY", 41, 49]]], ["Specimens were stored at 4\u00b0C pending analysis within 72 h of collection at the reference laboratory (IDEXX Feline Diarrhea RealPCR Panel, IDEXX Laboratories).Testing of cats with diarrheaFecal specimens were tested by real-time PCR for a panel of potential enteropathogens, including feline panleukopenia virus (FPV) VP2 gene, EU252145; feline coronavirus (FCoV) 7b gene, DQ010921.1; Campylobacter jejuni UDP-Nacetylglucosamine acyltransferase gene lpxA, AL111168; Clostridium perfringens alpha toxin (CPA) gene, phospholipase C, L43545; Campylobacter coli UDP-Nacetylglucosamine acyltransferase lpxA gene, AY531496; Salmonella spp. invasion A gene, EU348366; Tritrichomonas foetus 5.8S rRNA gene, AF339736; Cryptosporidium spp. small-subunit rRNA gene, A093489; Giardia spp. small-subunit rRNA gene, DQ836339; and Toxoplasma gondii internal transcribed spacer-1 gene, L49390.", [["Specimens", "ANATOMY", 0, 9], ["diarrheaFecal specimens", "ANATOMY", 179, 202], ["Diarrhea", "DISEASE", 114, 122], ["feline panleukopenia", "DISEASE", 284, 304], ["feline coronavirus", "DISEASE", 337, 355], ["UDP", "CHEMICAL", 405, 408], ["AL111168", "CHEMICAL", 455, 463], ["CPA", "CHEMICAL", 502, 505], ["UDP", "CHEMICAL", 557, 560], ["AY531496", "CHEMICAL", 607, 615], ["Cryptosporidium spp", "DISEASE", 708, 727], ["UDP", "CHEMICAL", 405, 408], ["Nacetylglucosamine", "CHEMICAL", 409, 427], ["UDP", "CHEMICAL", 557, 560], ["Nacetylglucosamine", "CHEMICAL", 561, 579], ["cats", "ORGANISM", 169, 173], ["diarrheaFecal specimens", "CANCER", 179, 202], ["feline panleukopenia virus", "ORGANISM", 284, 310], ["FPV", "ORGANISM", 312, 315], ["VP2", "GENE_OR_GENE_PRODUCT", 317, 320], ["feline coronavirus", "ORGANISM", 337, 355], ["FCoV) 7b", "GENE_OR_GENE_PRODUCT", 357, 365], ["Campylobacter jejuni", "ORGANISM", 384, 404], ["UDP-Nacetylglucosamine acyltransferase", "GENE_OR_GENE_PRODUCT", 405, 443], ["Clostridium perfringens alpha toxin", "GENE_OR_GENE_PRODUCT", 465, 500], ["CPA", "SIMPLE_CHEMICAL", 502, 505], ["phospholipase C", "GENE_OR_GENE_PRODUCT", 513, 528], ["Campylobacter coli", "ORGANISM", 538, 556], ["UDP-Nacetylglucosamine acyltransferase lpxA", "GENE_OR_GENE_PRODUCT", 557, 600], ["Salmonella spp", "ORGANISM", 617, 631], ["Cryptosporidium spp", "ORGANISM", 708, 727], ["Giardia spp", "ORGANISM", 763, 774], ["Toxoplasma gondii internal transcribed spacer-1", "GENE_OR_GENE_PRODUCT", 815, 862], ["feline panleukopenia virus (FPV) VP2 gene", "DNA", 284, 325], ["feline coronavirus (FCoV) 7b gene", "DNA", 337, 370], ["DQ010921.1", "DNA", 372, 382], ["Campylobacter jejuni UDP-Nacetylglucosamine acyltransferase gene", "DNA", 384, 448], ["lpxA", "DNA", 449, 453], ["AL111168", "DNA", 455, 463], ["Clostridium perfringens alpha toxin (CPA) gene", "DNA", 465, 511], ["phospholipase C, L43545; Campylobacter coli UDP-Nacetylglucosamine acyltransferase lpxA gene", "DNA", 513, 605], ["Tritrichomonas foetus 5.8S rRNA gene", "DNA", 660, 696], ["small-subunit rRNA gene", "DNA", 729, 752], ["small-subunit rRNA gene", "DNA", 776, 799], ["DQ836339", "DNA", 801, 809], ["Toxoplasma gondii internal transcribed spacer-1 gene", "DNA", 815, 867], ["L49390", "DNA", 869, 875], ["cats", "SPECIES", 169, 173], ["feline panleukopenia virus", "SPECIES", 284, 310], ["feline coronavirus", "SPECIES", 337, 355], ["Campylobacter jejuni", "SPECIES", 384, 404], ["Clostridium perfringens", "SPECIES", 465, 488], ["Campylobacter coli", "SPECIES", 538, 556], ["Tritrichomonas foetus", "SPECIES", 660, 681], ["Toxoplasma gondii", "SPECIES", 815, 832], ["feline panleukopenia virus", "SPECIES", 284, 310], ["FPV", "SPECIES", 312, 315], ["feline coronavirus", "SPECIES", 337, 355], ["FCoV", "SPECIES", 357, 361], ["Campylobacter jejuni", "SPECIES", 384, 404], ["Clostridium perfringens", "SPECIES", 465, 488], ["Campylobacter coli", "SPECIES", 538, 556], ["Toxoplasma gondii", "SPECIES", 815, 832], ["Specimens", "TEST", 0, 9], ["C pending analysis", "TEST", 27, 45], ["collection", "PROBLEM", 61, 71], ["Diarrhea", "PROBLEM", 114, 122], ["diarrheaFecal specimens", "TEST", 179, 202], ["a panel", "TEST", 236, 243], ["potential enteropathogens", "PROBLEM", 247, 272], ["feline panleukopenia virus", "PROBLEM", 284, 310], ["Campylobacter jejuni UDP", "TEST", 384, 408], ["lpxA", "TEST", 449, 453], ["Clostridium perfringens alpha toxin (CPA", "TEST", 465, 505], ["phospholipase C", "TEST", 513, 528], ["Campylobacter coli UDP", "TEST", 538, 560], ["Salmonella spp", "PROBLEM", 617, 631], ["EU", "TEST", 650, 652], ["Tritrichomonas foetus", "TEST", 660, 681], ["S rRNA gene", "TEST", 685, 696], ["AF", "PROBLEM", 698, 700], ["Cryptosporidium spp", "PROBLEM", 708, 727], ["small-subunit rRNA gene", "PROBLEM", 729, 752], ["Giardia spp", "PROBLEM", 763, 774], ["small-subunit rRNA gene", "PROBLEM", 776, 799], ["Toxoplasma gondii internal transcribed spacer", "TREATMENT", 815, 860], ["Campylobacter coli", "ANATOMY", 538, 556], ["Giardia spp", "OBSERVATION", 763, 774], ["spacer", "OBSERVATION_MODIFIER", 854, 860]]], ["The same quality controls were performed as the respiratory PCR.", [["the respiratory PCR", "TEST", 44, 63]]], ["Fecal specimens were also tested by zinc sulfate centrifugation to detect parasite cysts, oocytes, and larvae at a reference laboratory (IDEXX Reference Laboratories).Dermatophyte screeningUndercover investigators suspected dermatophytosis to be widespread in case 4 prior to seizure of the cats, so the cats were screened for clinically obvious signs of infection at the time of the intake examination at the temporary shelter.", [["Fecal specimens", "ANATOMY", 0, 15], ["cysts", "ANATOMY", 83, 88], ["oocytes", "ANATOMY", 90, 97], ["zinc sulfate", "CHEMICAL", 36, 48], ["dermatophytosis", "DISEASE", 224, 239], ["seizure", "DISEASE", 276, 283], ["infection", "DISEASE", 355, 364], ["zinc sulfate", "CHEMICAL", 36, 48], ["Fecal specimens", "ORGANISM_SUBSTANCE", 0, 15], ["zinc sulfate", "SIMPLE_CHEMICAL", 36, 48], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 90, 97], ["cats", "ORGANISM", 291, 295], ["cats", "ORGANISM", 304, 308], ["cats", "SPECIES", 291, 295], ["cats", "SPECIES", 304, 308], ["Fecal specimens", "TEST", 0, 15], ["zinc sulfate centrifugation", "TREATMENT", 36, 63], ["parasite cysts", "PROBLEM", 74, 88], ["Dermatophyte screening", "TEST", 167, 189], ["dermatophytosis", "PROBLEM", 224, 239], ["seizure of the cats", "PROBLEM", 276, 295], ["the cats", "TEST", 300, 308], ["infection", "PROBLEM", 355, 364], ["the intake examination", "TEST", 380, 402], ["parasite", "OBSERVATION_MODIFIER", 74, 82], ["cysts", "OBSERVATION", 83, 88], ["infection", "OBSERVATION", 355, 364]]], ["Each cat was assessed in room light for skin lesions and in a dark room with a Wood's lamp to screen for fluorescing hairs.", [["skin lesions", "ANATOMY", 40, 52], ["hairs", "ANATOMY", 117, 122], ["cat", "ORGANISM", 5, 8], ["skin lesions", "CANCER", 40, 52], ["hairs", "MULTI-TISSUE_STRUCTURE", 117, 122], ["skin lesions", "PROBLEM", 40, 52], ["fluorescing hairs", "PROBLEM", 105, 122], ["skin", "ANATOMY", 40, 44], ["lesions", "OBSERVATION", 45, 52]]], ["Specimens were collected using a freshly unsealed toothbrush from all cats with skin lesions or cats that had fluorescing hairs on Wood's lamp examination.", [["Specimens", "ANATOMY", 0, 9], ["skin lesions", "ANATOMY", 80, 92], ["hairs", "ANATOMY", 122, 127], ["skin lesions", "DISEASE", 80, 92], ["cats", "ORGANISM", 70, 74], ["skin lesions", "CANCER", 80, 92], ["cats", "ORGANISM", 96, 100], ["hairs", "MULTI-TISSUE_STRUCTURE", 122, 127], ["cats", "SPECIES", 70, 74], ["cats", "SPECIES", 96, 100], ["Specimens", "TEST", 0, 9], ["a freshly unsealed toothbrush", "TREATMENT", 31, 60], ["skin lesions", "PROBLEM", 80, 92], ["Wood's lamp examination", "TEST", 131, 154], ["skin", "ANATOMY", 80, 84], ["lesions", "OBSERVATION", 85, 92]]], ["Suspicious areas were brushed at least 30 times.", [["Suspicious areas", "PROBLEM", 0, 16]]], ["Specimens were transported via overnight courier with ice packs to a university laboratory (University of Wisconsin, School of Veterinary Medicine, Dermatology Research Laboratory) for testing.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9], ["ice packs", "TREATMENT", 54, 63], ["testing", "TEST", 185, 192]]], ["The specimens were plated onto dermatophyte culture media in Petri dish plates (90 \u00d7 15 mm) within 72 h of collection (Mycosel agar modified with phenol red as a color indicator, Becton Dickinson), incubated at 27-30\u00b0C for 21 days, and examined daily for growth.CatsNo original records from the cat sanctuaries were available, so information for this report was collected retrospectively from the examination records completed at the time cats were relinquished or seized.", [["specimens", "ANATOMY", 4, 13], ["phenol", "CHEMICAL", 146, 152], ["phenol red", "CHEMICAL", 146, 156], ["specimens", "CELL", 4, 13], ["cat", "ORGANISM", 295, 298], ["cats", "ORGANISM", 439, 443], ["The specimens", "TEST", 0, 13], ["dermatophyte culture media", "TEST", 31, 57], ["Petri dish plates", "TEST", 61, 78], ["collection (Mycosel agar", "TREATMENT", 107, 131], ["phenol red", "TREATMENT", 146, 156], ["the cat sanctuaries", "TEST", 291, 310], ["the examination", "TEST", 393, 408]]], ["The vast majority of cats in each case were adults.", [["cats", "ORGANISM", 21, 25], ["cats", "SPECIES", 21, 25]]], ["Of cats for which estimated ages were available, 98% (1956/1989) were estimated to be >6 months of age.", [["cats", "ORGANISM", 3, 7], ["cats", "SPECIES", 3, 7]]], ["Of cats for which gender information was available, 52% were female (939/1790).Respiratory infectionsSigns of upper respiratory infection (URI) were observed during intake examinations in 27% (366/1368) of cats for which records of physical findings were available.", [["Respiratory", "ANATOMY", 79, 90], ["respiratory", "ANATOMY", 116, 127], ["upper respiratory infection", "DISEASE", 110, 137], ["URI", "DISEASE", 139, 142], ["cats", "ORGANISM", 3, 7], ["upper respiratory", "ORGANISM_SUBDIVISION", 110, 127], ["cats", "ORGANISM", 206, 210], ["cats", "SPECIES", 3, 7], ["cats", "SPECIES", 206, 210], ["Respiratory infectionsSigns", "PROBLEM", 79, 106], ["upper respiratory infection", "PROBLEM", 110, 137], ["URI", "PROBLEM", 139, 142], ["intake examinations", "TEST", 165, 184], ["physical findings", "TEST", 232, 249], ["upper", "ANATOMY_MODIFIER", 110, 115], ["respiratory", "ANATOMY", 116, 127], ["infection", "OBSERVATION", 128, 137]]], ["The proportion of cats in each case with signs of URI ranged from 16% to 38%.Respiratory infectionsA subset of 81 cats with respiratory signs was tested for respiratory infections (Table 1) .", [["Respiratory", "ANATOMY", 77, 88], ["respiratory", "ANATOMY", 124, 135], ["respiratory", "ANATOMY", 157, 168], ["URI", "DISEASE", 50, 53], ["Respiratory infectionsA", "DISEASE", 77, 100], ["respiratory signs", "DISEASE", 124, 141], ["respiratory infections", "DISEASE", 157, 179], ["cats", "ORGANISM", 18, 22], ["cats", "ORGANISM", 114, 118], ["cats", "SPECIES", 18, 22], ["cats", "SPECIES", 114, 118], ["URI", "PROBLEM", 50, 53], ["respiratory signs", "TEST", 124, 141], ["respiratory infections", "PROBLEM", 157, 179], ["URI", "OBSERVATION", 50, 53], ["infections", "OBSERVATION", 169, 179]]], ["FCV (78%), M. felis (78%), and SEZ (55%) were the most prevalent infectious agents, followed by FHV (33%), C. felis (26%), and B. bronchiseptica (17%).", [["M. felis", "DISEASE", 11, 19], ["C. felis", "DISEASE", 107, 115], ["B. bronchiseptica", "DISEASE", 127, 144], ["FCV", "ORGANISM", 0, 3], ["M. felis", "ORGANISM", 11, 19], ["SEZ", "GENE_OR_GENE_PRODUCT", 31, 34], ["C. felis", "ORGANISM", 107, 115], ["B. bronchiseptica", "ORGANISM", 127, 144], ["M. felis", "SPECIES", 11, 19], ["C. felis", "SPECIES", 107, 115], ["B. bronchiseptica", "SPECIES", 127, 144], ["FCV", "SPECIES", 0, 3], ["M. felis", "SPECIES", 11, 19], ["FHV", "SPECIES", 96, 99], ["C. felis", "SPECIES", 107, 115], ["B. bronchiseptica", "SPECIES", 127, 144], ["FCV", "TEST", 0, 3], ["M. felis", "TEST", 11, 19], ["SEZ", "TEST", 31, 34], ["C. felis", "TEST", 107, 115], ["B. bronchiseptica", "PROBLEM", 127, 144]]], ["H1N1 influenza was not identified in any cat.", [["influenza", "DISEASE", 5, 14], ["H1N1 influenza", "ORGANISM", 0, 14], ["cat", "ORGANISM", 41, 44], ["H1N1 influenza", "SPECIES", 0, 14], ["cat", "SPECIES", 41, 44], ["H1N1 influenza", "PROBLEM", 0, 14]]], ["The majority of tested cats were infected with multiple pathogens (Table 4 ).", [["cats", "ORGANISM", 23, 27], ["cats", "SPECIES", 23, 27], ["multiple", "OBSERVATION_MODIFIER", 47, 55], ["pathogens", "OBSERVATION", 56, 65]]], ["In cats in which SEZ was identified, 88% (45/51) and 78% (40/51) of cats were co-infected with FCV and M. felis, respectively.Enteric infectionsA total of 68 diarrheic fecal specimens were submitted for PCR testing ( Table 2 ).", [["fecal specimens", "ANATOMY", 168, 183], ["cats", "ORGANISM", 3, 7], ["SEZ", "GENE_OR_GENE_PRODUCT", 17, 20], ["cats", "ORGANISM", 68, 72], ["FCV", "ORGANISM", 95, 98], ["M. felis", "ORGANISM", 103, 111], ["cats", "SPECIES", 3, 7], ["cats", "SPECIES", 68, 72], ["FCV", "SPECIES", 95, 98], ["M. felis", "SPECIES", 103, 111], ["FCV", "SPECIES", 95, 98], ["M. felis", "SPECIES", 103, 111], ["cats", "TEST", 68, 72], ["diarrheic fecal specimens", "TEST", 158, 183], ["PCR testing", "TEST", 203, 214]]], ["The most commonly identified enteropathogens included FCoV (88%), Giardia spp.", [["Giardia spp", "DISEASE", 66, 77], ["Giardia spp", "ORGANISM", 66, 77], ["enteropathogens", "PROBLEM", 29, 44], ["FCoV", "TEST", 54, 58], ["Giardia spp", "PROBLEM", 66, 77], ["enteropathogens", "OBSERVATION", 29, 44], ["Giardia spp", "OBSERVATION", 66, 77]]], ["(56%), C. perfringens (49%), C. jejuni (50%) and T. foetus (39%).", [["C. perfringens", "DISEASE", 7, 21], ["C. jejuni", "DISEASE", 29, 38], ["C. perfringens", "ORGANISM", 7, 21], ["C. jejuni", "ORGANISM", 29, 38], ["T. foetus", "ORGANISM", 49, 58], ["C. perfringens", "SPECIES", 7, 21], ["C. jejuni", "SPECIES", 29, 38], ["T. foetus", "SPECIES", 49, 58], ["C. perfringens", "SPECIES", 7, 21], ["C. jejuni", "SPECIES", 29, 38], ["T. foetus", "SPECIES", 49, 58], ["C. perfringens", "PROBLEM", 7, 21], ["C. jejuni", "TEST", 29, 38], ["T. foetus", "TEST", 49, 58], ["perfringens", "OBSERVATION_MODIFIER", 10, 21], ["jejuni", "ANATOMY", 32, 38]]], ["FPV, Salmonella spp., and T. gondii were not detected in any specimens.", [["specimens", "ANATOMY", 61, 70], ["FPV", "ORGANISM", 0, 3], ["Salmonella spp.", "ORGANISM", 5, 20], ["T. gondii", "ORGANISM", 26, 35], ["Salmonella spp.", "SPECIES", 5, 20], ["T. gondii", "SPECIES", 26, 35], ["FPV", "SPECIES", 0, 3], ["Salmonella spp.", "SPECIES", 5, 20], ["T. gondii", "SPECIES", 26, 35], ["FPV", "TEST", 0, 3], ["Salmonella spp.", "TEST", 5, 20], ["T. gondii", "TEST", 26, 35]]], ["A total of 95 fecal specimens were tested for parasites using zinc sulfate centrifugation (Table 3) .", [["fecal specimens", "ANATOMY", 14, 29], ["zinc sulfate", "CHEMICAL", 62, 74], ["zinc sulfate", "CHEMICAL", 62, 74], ["fecal specimens", "CANCER", 14, 29], ["zinc sulfate", "SIMPLE_CHEMICAL", 62, 74], ["fecal specimens", "TEST", 14, 29], ["parasites", "PROBLEM", 46, 55], ["zinc sulfate centrifugation", "TREATMENT", 62, 89]]], ["Hookworms were identified in the sanctuaries in which cats had contact with earth (cases 3 and 4), whereas ascarids were identified in all four cases.", [["Hookworms", "ANATOMY", 0, 9], ["cats", "ORGANISM", 54, 58], ["ascarids", "CANCER", 107, 115], ["cats", "SPECIES", 54, 58], ["Hookworms", "PROBLEM", 0, 9]]], ["Most tested specimens harbored multiple enteropathogens (Table 4 ).", [["specimens", "ANATOMY", 12, 21], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["enteropathogens", "OBSERVATION", 40, 55]]], ["In cats infected with T. foetus, 67% were co-infected with Giardia spp.FeLV and FIV infectionsIn the three sanctuaries from which results from FeLV/FIV testing were available for review (cases 1, 3 and 4), the overall seroprevalences of FeLV and FIV were 8% and 8%, respectively (Table 5) .", [["Giardia spp", "DISEASE", 59, 70], ["FIV infections", "DISEASE", 80, 94], ["cats", "ORGANISM", 3, 7], ["T. foetus", "ORGANISM", 22, 31], ["Giardia spp", "ORGANISM", 59, 70], ["FeLV", "ORGANISM", 71, 75], ["FIV", "ORGANISM", 80, 83], ["FeLV", "ORGANISM", 143, 147], ["FIV", "ORGANISM", 148, 151], ["FeLV", "ORGANISM", 237, 241], ["FIV", "ORGANISM", 246, 249], ["cats", "SPECIES", 3, 7], ["T. foetus", "SPECIES", 22, 31], ["T. foetus", "SPECIES", 22, 31], ["FIV", "SPECIES", 80, 83], ["FIV", "SPECIES", 148, 151], ["FeLV", "SPECIES", 237, 241], ["FIV", "SPECIES", 246, 249], ["T. foetus", "PROBLEM", 22, 31], ["Giardia spp", "PROBLEM", 59, 70], ["FeLV", "PROBLEM", 71, 75], ["FIV infections", "PROBLEM", 80, 94], ["FeLV/FIV testing", "TEST", 143, 159], ["FeLV and FIV", "TREATMENT", 237, 249], ["Giardia spp", "OBSERVATION", 59, 70], ["FIV infections", "OBSERVATION", 80, 94]]], ["A total of 1% of cats were positive for both FeLV and FIV.", [["cats", "ORGANISM", 17, 21], ["FeLV", "ORGANISM", 45, 49], ["FIV", "ORGANISM", 54, 57], ["cats", "SPECIES", 17, 21], ["FeLV", "SPECIES", 45, 49], ["FIV", "SPECIES", 54, 57]]], ["In all four cases, retroviral-infected cats were found to be roaming freely with uninfected cats and were not restricted to areas formally designated for segregating infected cats.Heartworm infectionOnly 1/1048 cats tested for Dirofilaria immitis antigen had a positive test.Dermatophyte infectionsFinances did not allow for fungal culture of all of the cats in case 4 and culturing was limited to cats with a high degree of suspicion for dermatophytosis based on the presence of suspect skin lesions and/or Wood's lamp examination.", [["skin lesions", "ANATOMY", 488, 500], ["Dirofilaria immitis", "DISEASE", 227, 246], ["Dermatophyte infections", "DISEASE", 275, 298], ["dermatophytosis", "DISEASE", 439, 454], ["retroviral", "ORGANISM", 19, 29], ["cats", "ORGANISM", 39, 43], ["cats", "ORGANISM", 92, 96], ["cats", "ORGANISM", 175, 179], ["cats", "ORGANISM", 211, 215], ["Dirofilaria immitis antigen", "GENE_OR_GENE_PRODUCT", 227, 254], ["cats", "ORGANISM", 354, 358], ["cats", "ORGANISM", 398, 402], ["skin lesions", "CANCER", 488, 500], ["Dirofilaria immitis antigen", "PROTEIN", 227, 254], ["cats", "SPECIES", 39, 43], ["cats", "SPECIES", 92, 96], ["cats", "SPECIES", 175, 179], ["cats", "SPECIES", 211, 215], ["Dirofilaria immitis", "SPECIES", 227, 246], ["Dirofilaria immitis", "SPECIES", 227, 246], ["retroviral-infected cats", "PROBLEM", 19, 43], ["uninfected cats", "TREATMENT", 81, 96], ["segregating infected cats", "PROBLEM", 154, 179], ["Heartworm infectionOnly", "TEST", 180, 203], ["cats", "TEST", 211, 215], ["Dirofilaria immitis antigen", "TEST", 227, 254], ["Dermatophyte infections", "PROBLEM", 275, 298], ["fungal culture", "TEST", 325, 339], ["culturing", "TEST", 373, 382], ["dermatophytosis", "PROBLEM", 439, 454], ["skin lesions", "PROBLEM", 488, 500], ["Wood's lamp examination", "TEST", 508, 531], ["retroviral", "ANATOMY", 19, 29], ["infected cats", "OBSERVATION", 166, 179], ["infections", "OBSERVATION", 288, 298], ["high degree", "OBSERVATION_MODIFIER", 410, 421], ["dermatophytosis", "OBSERVATION", 439, 454], ["skin", "ANATOMY", 488, 492], ["lesions", "OBSERVATION", 493, 500]]], ["All cats received one lime sulfur dip at intake pending fungal culture results.Dermatophyte infectionsOf the total population of 696 cats, it was suspected that 76 cats were infected; of these, 69 (91%) were culture-positive for M. canis.", [["sulfur dip", "CHEMICAL", 27, 37], ["M. canis", "DISEASE", 229, 237], ["sulfur", "CHEMICAL", 27, 33], ["cats", "ORGANISM", 4, 8], ["cats", "ORGANISM", 133, 137], ["cats", "ORGANISM", 164, 168], ["M. canis", "ORGANISM", 229, 237], ["cats", "SPECIES", 4, 8], ["cats", "SPECIES", 133, 137], ["cats", "SPECIES", 164, 168], ["M. canis", "SPECIES", 229, 237], ["M. canis", "SPECIES", 229, 237], ["All cats", "TREATMENT", 0, 8], ["fungal culture", "TEST", 56, 70], ["Dermatophyte infectionsOf", "PROBLEM", 79, 104], ["culture", "TEST", 208, 215], ["M. canis", "PROBLEM", 229, 237], ["total", "OBSERVATION_MODIFIER", 109, 114], ["M. canis", "OBSERVATION", 229, 237]]], ["A total of 14/69 culture-positive cats had <9 colony forming units per plate (cfu/plate); of these, all had skin lesions but only one had a positive Wood's lamp examination.", [["skin lesions", "ANATOMY", 108, 120], ["cats", "ORGANISM", 34, 38], ["skin lesions", "CANCER", 108, 120], ["cats", "SPECIES", 34, 38], ["culture", "TEST", 17, 24], ["positive cats", "PROBLEM", 25, 38], ["plate (cfu/plate", "TEST", 71, 87], ["skin lesions", "PROBLEM", 108, 120], ["Wood's lamp examination", "TEST", 149, 172], ["skin", "ANATOMY", 108, 112], ["lesions", "OBSERVATION", 113, 120]]], ["All cats with confirmed dermatophyte infections were treated with twice weekly lime-sulfur dips at a 1:16 dilution and oral terbinafine at 35 mg/kg once daily until they had two consecutive negative weekly fungal cultures.DiscussionSymptomatic cats from all four large-scale cruelty investigations were found to carry a variety of infectious diseases.", [["oral", "ANATOMY", 119, 123], ["dermatophyte infections", "DISEASE", 24, 47], ["lime-sulfur dips", "CHEMICAL", 79, 95], ["terbinafine", "CHEMICAL", 124, 135], ["infectious diseases", "DISEASE", 331, 350], ["sulfur", "CHEMICAL", 84, 90], ["terbinafine", "CHEMICAL", 124, 135], ["cats", "ORGANISM", 4, 8], ["oral", "ORGANISM_SUBDIVISION", 119, 123], ["terbinafine", "SIMPLE_CHEMICAL", 124, 135], ["cats", "ORGANISM", 244, 248], ["cats", "SPECIES", 4, 8], ["cats", "SPECIES", 244, 248], ["dermatophyte infections", "PROBLEM", 24, 47], ["lime-sulfur dips", "TREATMENT", 79, 95], ["oral terbinafine", "TREATMENT", 119, 135], ["fungal cultures", "TEST", 206, 221], ["DiscussionSymptomatic cats", "PROBLEM", 222, 248], ["infectious diseases", "PROBLEM", 331, 350], ["dermatophyte", "OBSERVATION_MODIFIER", 24, 36], ["infections", "OBSERVATION", 37, 47], ["infectious", "OBSERVATION", 331, 341]]], ["This was not unexpected given the large number of cats confined in crowded conditions and the failure to isolate diseased cats from clinically normal cats.DiscussionClinical signs of respiratory disease were observed in cats rescued from all four cases.", [["respiratory", "ANATOMY", 183, 194], ["respiratory disease", "DISEASE", 183, 202], ["cats", "ORGANISM", 50, 54], ["cats", "ORGANISM", 122, 126], ["cats", "ORGANISM", 150, 154], ["cats", "ORGANISM", 220, 224], ["cats", "SPECIES", 122, 126], ["cats", "SPECIES", 150, 154], ["cats", "SPECIES", 220, 224], ["crowded conditions", "PROBLEM", 67, 85], ["the failure to isolate diseased cats", "PROBLEM", 90, 126], ["respiratory disease", "PROBLEM", 183, 202], ["not unexpected", "UNCERTAINTY", 9, 23], ["large", "OBSERVATION_MODIFIER", 34, 39], ["number", "OBSERVATION_MODIFIER", 40, 46], ["cats", "OBSERVATION", 50, 54], ["crowded conditions", "OBSERVATION", 67, 85], ["failure", "OBSERVATION", 94, 101], ["respiratory disease", "OBSERVATION", 183, 202]]], ["In this study, the most prevalent respiratory pathogens were M. felis, FCV, and SEZ.", [["M. felis", "ORGANISM", 61, 69], ["FCV", "ORGANISM", 71, 74], ["M. felis", "SPECIES", 61, 69], ["M. felis", "SPECIES", 61, 69], ["FCV", "SPECIES", 71, 74], ["this study", "TEST", 3, 13], ["the most prevalent respiratory pathogens", "PROBLEM", 15, 55], ["FCV", "TEST", 71, 74]]], ["All three pathogens have been reported in cats both with and without clinical signs of disease, making segregation of populations based on clinical signs alone an ineffective biosecurity strategy (McManus et al., 2014) .", [["cats", "ORGANISM", 42, 46], ["cats", "SPECIES", 42, 46], ["All three pathogens", "PROBLEM", 0, 19], ["disease", "PROBLEM", 87, 94], ["segregation of populations", "PROBLEM", 103, 129], ["clinical signs", "TEST", 139, 153], ["disease", "OBSERVATION", 87, 94]]], ["The role that M. felis and SEZ play in feline respiratory disease is currently poorly defined.", [["respiratory", "ANATOMY", 46, 57], ["SEZ", "CHEMICAL", 27, 30], ["feline respiratory disease", "DISEASE", 39, 65], ["M. felis", "ORGANISM", 14, 22], ["SEZ", "GENE_OR_GENE_PRODUCT", 27, 30], ["feline", "ORGANISM", 39, 45], ["M. felis", "SPECIES", 14, 22], ["feline", "SPECIES", 39, 45], ["M. felis", "SPECIES", 14, 22], ["feline respiratory disease", "PROBLEM", 39, 65], ["respiratory disease", "OBSERVATION", 46, 65]]], ["They may act as primary pathogens or exert their effects only in combination with other infectious co-factors (Randolph et al., 1993) .", [["primary pathogens", "PROBLEM", 16, 33]]], ["Mycoplasma infection has been signifi-cantly associated with feline URI in animal shelters, but most affected cats also carried co-infections such as FHV (Bannasch and Foley, 2005; Veir et al., 2008; Hartmann et al., 2010; Holst et al., 2010; Burns et al., 2011; Litster et al., 2012) .", [["Mycoplasma infection", "DISEASE", 0, 20], ["co-infections", "DISEASE", 128, 141], ["Mycoplasma", "ORGANISM", 0, 10], ["feline", "ORGANISM", 61, 67], ["cats", "ORGANISM", 110, 114], ["feline", "SPECIES", 61, 67], ["cats", "SPECIES", 110, 114], ["FHV", "SPECIES", 150, 153], ["Mycoplasma infection", "PROBLEM", 0, 20], ["feline URI", "PROBLEM", 61, 71], ["Foley", "TREATMENT", 168, 173], ["infection", "OBSERVATION", 11, 20], ["Foley", "ANATOMY", 168, 173]]], ["M. felis-infected shelter cats treated with a 14-day course of oral doxycycline had clinical improvement, although clearance of the organism was not demonstrated (Kompare et al., 2012) .DiscussionFCV was the most common viral respiratory pathogen detected (78%), surpassing the prevalence rate of FHV (33%).", [["oral", "ANATOMY", 63, 67], ["doxycycline", "CHEMICAL", 68, 79], ["viral respiratory pathogen", "DISEASE", 220, 246], ["FHV", "DISEASE", 297, 300], ["doxycycline", "CHEMICAL", 68, 79], ["M. felis", "ORGANISM", 0, 8], ["cats", "ORGANISM", 26, 30], ["oral", "ORGANISM_SUBDIVISION", 63, 67], ["doxycycline", "SIMPLE_CHEMICAL", 68, 79], ["M. felis", "SPECIES", 0, 8], ["cats", "SPECIES", 26, 30], ["M. felis", "SPECIES", 0, 8], ["FHV", "SPECIES", 297, 300], ["oral doxycycline", "TREATMENT", 63, 79], ["the organism", "PROBLEM", 128, 140], ["the most common viral respiratory pathogen", "PROBLEM", 204, 246], ["infected", "OBSERVATION_MODIFIER", 9, 17]]], ["FHV persists as a latent infection in cats and can recrudesce during periods of stress .", [["FHV", "CHEMICAL", 0, 3], ["infection", "DISEASE", 25, 34], ["cats", "ORGANISM", 38, 42], ["cats", "SPECIES", 38, 42], ["FHV", "SPECIES", 0, 3], ["FHV", "PROBLEM", 0, 3], ["a latent infection in cats", "PROBLEM", 16, 42], ["stress", "PROBLEM", 80, 86], ["latent", "OBSERVATION_MODIFIER", 18, 24], ["infection", "OBSERVATION", 25, 34]]], ["As a consequence of stress and crosscontamination, FHV is the most prevalent viral pathogen in cats with acute URI in traditional short-term shelter housing (Bannasch and Foley, 2005; Veir et al., 2008; McManus et al., 2014) .", [["FHV", "CHEMICAL", 51, 54], ["FHV", "GENE_OR_GENE_PRODUCT", 51, 54], ["cats", "ORGANISM", 95, 99], ["cats", "SPECIES", 95, 99], ["FHV", "SPECIES", 51, 54], ["stress and crosscontamination", "PROBLEM", 20, 49], ["acute URI", "PROBLEM", 105, 114], ["Foley", "TREATMENT", 171, 176], ["most prevalent", "OBSERVATION_MODIFIER", 62, 76], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["URI", "OBSERVATION", 111, 114], ["Foley", "ANATOMY", 171, 176]]], ["In contrast to cats in short-term shelters, foster programs, or trap-neuterreturn programs, cats housed long-term in sanctuaries are more likely to be infected with FCV than FHV, similar to the findings of cats from the cases in this report (McManus et al., 2014) .", [["FCV", "DISEASE", 165, 168], ["cats", "ORGANISM", 15, 19], ["FCV", "ORGANISM", 165, 168], ["cats", "ORGANISM", 206, 210], ["cats", "SPECIES", 15, 19], ["FCV", "SPECIES", 165, 168], ["FHV", "SPECIES", 174, 177], ["trap-neuterreturn programs", "TREATMENT", 64, 90], ["more likely to be", "UNCERTAINTY", 133, 150], ["infected", "OBSERVATION", 151, 159]]], ["The high prevalence of FCV among cats with URI is concerning because of considerable strain variability in its pathogenicity, transmissibility, and environmental stability and its association with a wide array of clinical signs including fever, conjunctivitis, oral ulceration, limping, ocular and nasal discharge, and gingivostomatitis (Reubel et al., 1992; Dawson et al., 1994; Pedersen et al., 2000; Radford et al., 2007; Gerriets et al., 2012) .", [["oral", "ANATOMY", 261, 265], ["ocular", "ANATOMY", 287, 293], ["nasal", "ANATOMY", 298, 303], ["FCV", "DISEASE", 23, 26], ["URI", "DISEASE", 43, 46], ["fever", "DISEASE", 238, 243], ["conjunctivitis", "DISEASE", 245, 259], ["oral ulceration", "DISEASE", 261, 276], ["limping", "DISEASE", 278, 285], ["ocular and nasal discharge", "DISEASE", 287, 313], ["gingivostomatitis", "DISEASE", 319, 336], ["FCV", "ORGANISM", 23, 26], ["cats", "ORGANISM", 33, 37], ["oral", "ORGANISM_SUBDIVISION", 261, 265], ["nasal", "ORGAN", 298, 303], ["cats", "SPECIES", 33, 37], ["FCV", "SPECIES", 23, 26], ["URI", "PROBLEM", 43, 46], ["considerable strain variability", "PROBLEM", 72, 103], ["its pathogenicity", "PROBLEM", 107, 124], ["clinical signs", "PROBLEM", 213, 227], ["fever", "PROBLEM", 238, 243], ["conjunctivitis", "PROBLEM", 245, 259], ["oral ulceration", "PROBLEM", 261, 276], ["limping", "PROBLEM", 278, 285], ["ocular and nasal discharge", "PROBLEM", 287, 313], ["gingivostomatitis", "PROBLEM", 319, 336], ["high prevalence", "OBSERVATION_MODIFIER", 4, 19], ["considerable", "OBSERVATION_MODIFIER", 72, 84], ["strain", "OBSERVATION_MODIFIER", 85, 91], ["variability", "OBSERVATION_MODIFIER", 92, 103], ["conjunctivitis", "OBSERVATION", 245, 259], ["oral", "ANATOMY", 261, 265], ["ulceration", "OBSERVATION", 266, 276], ["ocular", "ANATOMY", 287, 293], ["nasal", "ANATOMY", 298, 303]]], ["The reason for the shift from high prevalence of FHV in cats in short-term shelter housing to high prevalence of FCV in cats in long-term group-housed confinement is unknown (Reubel et al., 1992; Lommer and Verstraete, 2003; Dowers et al., 2010) .DiscussionSEZ was detected with high frequency in cats with respiratory disease.", [["respiratory", "ANATOMY", 307, 318], ["FHV", "DISEASE", 49, 52], ["FCV", "DISEASE", 113, 116], ["respiratory disease", "DISEASE", 307, 326], ["FHV", "CANCER", 49, 52], ["cats", "ORGANISM", 56, 60], ["FCV", "ORGANISM", 113, 116], ["cats", "ORGANISM", 120, 124], ["cats", "ORGANISM", 297, 301], ["cats", "SPECIES", 56, 60], ["cats", "SPECIES", 120, 124], ["cats", "SPECIES", 297, 301], ["FCV", "SPECIES", 113, 116], ["respiratory disease", "PROBLEM", 307, 326], ["respiratory disease", "OBSERVATION", 307, 326]]], ["SEZ is considered to be an emerging pathogen in animal shelters and has been reported as the causative agent of several outbreaks of fatal hemorrhagic pneumonia disease in dogs (Garnett et al., 1982; Chalker et al., 2003; Kim et al., 2007; Pesavento et al., 2008; Byun et al., 2009; Priestnall and Erles, 2011) .", [["SEZ", "CHEMICAL", 0, 3], ["hemorrhagic pneumonia disease", "DISEASE", 139, 168], ["SEZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["dogs", "ORGANISM", 172, 176], ["dogs", "SPECIES", 172, 176], ["fatal hemorrhagic pneumonia disease in dogs", "PROBLEM", 133, 176], ["considered to be", "UNCERTAINTY", 7, 23], ["fatal", "OBSERVATION_MODIFIER", 133, 138], ["hemorrhagic", "OBSERVATION_MODIFIER", 139, 150], ["pneumonia", "OBSERVATION", 151, 160]]], ["SEZ can also be found in asymptomatic dogs, and it is possible that infectious co-factors such as canine distemper virus, canine influenza virus, or canine pneumovirus are required for maximum virulence (Byun et al., 2009; Larson et al., 2011) .DiscussionIn cats, SEZ infections are associated with purulent nasal discharge, dyspnea, coughing, pneumonia, rhinitis, meningoencephalitis, and death, but the overall prevalence of SEZ in sheltered cats has yet to be determined (Britton and Davies, 2010; Martin-Vaquero et al., 2011) .", [["nasal", "ANATOMY", 308, 313], ["SEZ", "CHEMICAL", 0, 3], ["canine distemper virus", "DISEASE", 98, 120], ["influenza virus", "DISEASE", 129, 144], ["SEZ infections", "DISEASE", 264, 278], ["dyspnea", "DISEASE", 325, 332], ["coughing", "DISEASE", 334, 342], ["pneumonia", "DISEASE", 344, 353], ["rhinitis", "DISEASE", 355, 363], ["meningoencephalitis", "DISEASE", 365, 384], ["death", "DISEASE", 390, 395], ["SEZ", "DISEASE", 427, 430], ["SEZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["dogs", "ORGANISM", 38, 42], ["canine distemper virus", "ORGANISM", 98, 120], ["canine influenza virus", "ORGANISM", 122, 144], ["canine pneumovirus", "ORGANISM", 149, 167], ["cats", "ORGANISM", 258, 262], ["nasal", "ORGANISM_SUBDIVISION", 308, 313], ["SEZ", "SIMPLE_CHEMICAL", 427, 430], ["cats", "ORGANISM", 444, 448], ["SEZ", "PROTEIN", 0, 3], ["dogs", "SPECIES", 38, 42], ["canine distemper virus", "SPECIES", 98, 120], ["canine influenza virus", "SPECIES", 122, 144], ["canine pneumovirus", "SPECIES", 149, 167], ["cats", "SPECIES", 258, 262], ["cats", "SPECIES", 444, 448], ["canine distemper virus", "SPECIES", 98, 120], ["canine influenza virus", "SPECIES", 122, 144], ["canine", "SPECIES", 149, 155], ["infectious co-factors", "PROBLEM", 68, 89], ["canine distemper virus", "PROBLEM", 98, 120], ["canine influenza virus", "PROBLEM", 122, 144], ["canine pneumovirus", "PROBLEM", 149, 167], ["SEZ infections", "PROBLEM", 264, 278], ["purulent nasal discharge", "PROBLEM", 299, 323], ["dyspnea", "PROBLEM", 325, 332], ["coughing", "PROBLEM", 334, 342], ["pneumonia", "PROBLEM", 344, 353], ["rhinitis", "PROBLEM", 355, 363], ["meningoencephalitis", "PROBLEM", 365, 384], ["death", "PROBLEM", 390, 395], ["infectious", "OBSERVATION", 68, 78], ["purulent", "OBSERVATION_MODIFIER", 299, 307], ["dyspnea", "OBSERVATION", 325, 332], ["coughing", "OBSERVATION", 334, 342], ["pneumonia", "OBSERVATION", 344, 353], ["rhinitis", "OBSERVATION", 355, 363], ["meningoencephalitis", "OBSERVATION", 365, 384]]], ["SEZ was reported as the causative agent of death in 78 cats from June 2006 to January 2008 in an Israeli cattery (Blum et al., 2010) .", [["SEZ", "CHEMICAL", 0, 3], ["death", "DISEASE", 43, 48], ["SEZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["cats", "ORGANISM", 55, 59], ["death", "PROBLEM", 43, 48]]], ["The common finding of SEZ in cats in large-scale cases could explain in part why URI appears to be more severe and even deadly in such circumstances, in contrast to the milder and self-limiting URI commonly associated with cats in short-term shelters in which SEZ does not appear to be commonly involved.", [["SEZ", "CHEMICAL", 22, 25], ["SEZ", "GENE_OR_GENE_PRODUCT", 22, 25], ["cats", "ORGANISM", 29, 33], ["cats", "ORGANISM", 223, 227], ["cats", "SPECIES", 29, 33], ["cats", "SPECIES", 223, 227], ["URI", "PROBLEM", 81, 84], ["self-limiting URI", "PROBLEM", 180, 197], ["common", "OBSERVATION_MODIFIER", 4, 10], ["large", "OBSERVATION_MODIFIER", 37, 42], ["appears to be", "UNCERTAINTY", 85, 98], ["more severe", "OBSERVATION_MODIFIER", 99, 110]]], ["SEZ is likely an underrecognized cause of severe disease in cats since screening is not currently included in routine laboratory test panels, and the clinical presentation is different to the dramatic hemorrhagic respiratory disease observed in dogs.", [["respiratory", "ANATOMY", 213, 224], ["SEZ", "CHEMICAL", 0, 3], ["hemorrhagic respiratory disease", "DISEASE", 201, 232], ["SEZ", "GENE_OR_GENE_PRODUCT", 0, 3], ["cats", "ORGANISM", 60, 64], ["dogs", "ORGANISM", 245, 249], ["cats", "SPECIES", 60, 64], ["dogs", "SPECIES", 245, 249], ["severe disease in cats", "PROBLEM", 42, 64], ["screening", "TEST", 71, 80], ["routine laboratory test panels", "TEST", 110, 140], ["the dramatic hemorrhagic respiratory disease", "PROBLEM", 188, 232], ["likely an underrecognized", "UNCERTAINTY", 7, 32], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["disease", "OBSERVATION", 49, 56], ["dramatic", "OBSERVATION_MODIFIER", 192, 200], ["hemorrhagic", "OBSERVATION_MODIFIER", 201, 212], ["respiratory disease", "OBSERVATION", 213, 232]]], ["B. bronchiseptica is a Gram-negative bacterium considered to be a primary respiratory pathogen of cats found most commonly in high-density housing environments such as shelters or sanctuaries (Helps et al., 2005; Egberink et al., 2009) .", [["B. bronchiseptica", "ORGANISM", 0, 17], ["Gram", "GENE_OR_GENE_PRODUCT", 23, 27], ["cats", "ORGANISM", 98, 102], ["B. bronchiseptica", "SPECIES", 0, 17], ["cats", "SPECIES", 98, 102], ["B. bronchiseptica", "SPECIES", 0, 17], ["B. bronchiseptica", "PROBLEM", 0, 17], ["a Gram", "TEST", 21, 27], ["negative bacterium", "PROBLEM", 28, 46], ["a primary respiratory pathogen of cats", "PROBLEM", 64, 102], ["bronchiseptica", "OBSERVATION", 3, 17], ["density", "OBSERVATION", 131, 138]]], ["Clinical signs vary in severity from mild sneezing and ocular discharge to pneumonia and death (Willoughby et al., 1991; Welsh, 1996; Speakman et al., 1999) .", [["ocular", "ANATOMY", 55, 61], ["sneezing", "DISEASE", 42, 50], ["pneumonia", "DISEASE", 75, 84], ["death", "DISEASE", 89, 94], ["Clinical signs", "PROBLEM", 0, 14], ["severity", "PROBLEM", 23, 31], ["mild sneezing", "PROBLEM", 37, 50], ["ocular discharge", "PROBLEM", 55, 71], ["pneumonia", "PROBLEM", 75, 84], ["death", "PROBLEM", 89, 94], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["sneezing", "OBSERVATION", 42, 50], ["ocular", "ANATOMY", 55, 61], ["pneumonia", "OBSERVATION", 75, 84]]], ["C. felis is currently recognized as primarily an ocular pathogen causing conjunctivitis but continues to be isolated from cats with respiratory tract disease.", [["ocular", "ANATOMY", 49, 55], ["respiratory tract", "ANATOMY", 132, 149], ["C. felis", "DISEASE", 0, 8], ["conjunctivitis", "DISEASE", 73, 87], ["respiratory tract disease", "DISEASE", 132, 157], ["C. felis", "ORGANISM", 0, 8], ["cats", "ORGANISM", 122, 126], ["respiratory tract", "ORGANISM_SUBDIVISION", 132, 149], ["C. felis", "SPECIES", 0, 8], ["cats", "SPECIES", 122, 126], ["C. felis", "SPECIES", 0, 8], ["C. felis", "PROBLEM", 0, 8], ["an ocular pathogen", "PROBLEM", 46, 64], ["conjunctivitis", "PROBLEM", 73, 87], ["respiratory tract disease", "PROBLEM", 132, 157], ["felis", "OBSERVATION", 3, 8], ["ocular", "ANATOMY", 49, 55], ["pathogen", "OBSERVATION", 56, 64], ["conjunctivitis", "OBSERVATION", 73, 87], ["respiratory tract disease", "OBSERVATION", 132, 157]]], ["Reported infection rates range from 1% to 5% of cats without signs of URI to 10-30% of cats with conjunctivitis or URI (Wills et al., 1988; Gruffydd-Jones et al., 1995; Sykes et al., 1999; Low et al., 2007; McManus et al., 2014) .DiscussionA total of 14 different potential enteropathogens were identified in cats with diarrhea, including four protozoan pathogens.", [["infection", "DISEASE", 9, 18], ["conjunctivitis", "DISEASE", 97, 111], ["URI", "DISEASE", 115, 118], ["diarrhea", "DISEASE", 319, 327], ["protozoan pathogens", "DISEASE", 344, 363], ["cats", "ORGANISM", 48, 52], ["cats", "ORGANISM", 87, 91], ["enteropathogens", "ORGANISM", 274, 289], ["cats", "ORGANISM", 309, 313], ["cats", "SPECIES", 48, 52], ["cats", "SPECIES", 309, 313], ["infection rates", "PROBLEM", 9, 24], ["URI", "PROBLEM", 70, 73], ["conjunctivitis", "PROBLEM", 97, 111], ["URI", "PROBLEM", 115, 118], ["14 different potential enteropathogens", "PROBLEM", 251, 289], ["diarrhea", "PROBLEM", 319, 327], ["four protozoan pathogens", "PROBLEM", 339, 363], ["infection", "OBSERVATION", 9, 18], ["conjunctivitis", "OBSERVATION", 97, 111], ["enteropathogens", "OBSERVATION", 274, 289], ["protozoan", "OBSERVATION_MODIFIER", 344, 353], ["pathogens", "OBSERVATION", 354, 363]]], ["T. foetus was detected with high frequency in cats from all four cases, with prevalences ranging from 29% to 50% of cats tested.", [["T. foetus", "ORGANISM", 0, 9], ["cats", "ORGANISM", 46, 50], ["cats", "ORGANISM", 116, 120], ["T. foetus", "SPECIES", 0, 9], ["cats", "SPECIES", 46, 50], ["cats", "SPECIES", 116, 120], ["T. foetus", "SPECIES", 0, 9], ["T. foetus", "PROBLEM", 0, 9], ["prevalences", "TEST", 77, 88]]], ["T. foetus is a highly contagious causative agent of intermittent large bowel diarrhea in cats, particularly when cats are confined in grouphousing (Gookin et al., 1999 Foster et al., 2004; Holliday et al., 2009; Tolbert and Gookin, 2009 ).", [["bowel", "ANATOMY", 71, 76], ["bowel diarrhea", "DISEASE", 71, 85], ["T. foetus", "ORGANISM", 0, 9], ["bowel", "ORGAN", 71, 76], ["cats", "ORGANISM", 89, 93], ["cats", "ORGANISM", 113, 117], ["T. foetus", "SPECIES", 0, 9], ["cats", "SPECIES", 89, 93], ["cats", "SPECIES", 113, 117], ["T. foetus", "SPECIES", 0, 9], ["intermittent large bowel diarrhea in cats", "PROBLEM", 52, 93], ["highly", "OBSERVATION_MODIFIER", 15, 21], ["contagious", "OBSERVATION_MODIFIER", 22, 32], ["intermittent", "OBSERVATION_MODIFIER", 52, 64], ["large", "OBSERVATION_MODIFIER", 65, 70], ["bowel", "ANATOMY", 71, 76], ["diarrhea", "OBSERVATION", 77, 85]]], ["The diagnosis, management, and adoption of cats infected with T. foetus can be difficult in a shelter setting.", [["cats", "ORGANISM", 43, 47], ["T. foetus", "ORGANISM", 62, 71], ["cats", "SPECIES", 43, 47], ["T. foetus", "SPECIES", 62, 71], ["management", "TREATMENT", 15, 25]]], ["T. foetus is often not identified, or misdiagnosed as Giardia spp. on fecal flotation, which is an important consideration because 67% of cats infected with T. foetus in this study were co-infected with Giardia spp.DiscussionCurrently there is no approved treatment for feline tritrichomoniasis, and response to therapy is variable.", [["fecal", "ANATOMY", 70, 75], ["Giardia spp", "DISEASE", 54, 65], ["Giardia spp", "DISEASE", 203, 214], ["feline tritrichomoniasis", "DISEASE", 270, 294], ["T. foetus", "ORGANISM", 0, 9], ["Giardia spp", "ORGANISM", 54, 65], ["fecal", "ORGANISM_SUBSTANCE", 70, 75], ["cats", "ORGANISM", 138, 142], ["T. foetus", "ORGANISM", 157, 166], ["Giardia spp", "ORGANISM", 203, 214], ["feline", "ORGANISM", 270, 276], ["T. foetus", "SPECIES", 0, 9], ["cats", "SPECIES", 138, 142], ["T. foetus", "SPECIES", 157, 166], ["feline", "SPECIES", 270, 276], ["T. foetus", "SPECIES", 0, 9], ["T. foetus", "SPECIES", 157, 166], ["Giardia spp", "PROBLEM", 54, 65], ["fecal flotation", "TREATMENT", 70, 85], ["T. foetus", "PROBLEM", 157, 166], ["this study", "TEST", 170, 180], ["Giardia spp", "PROBLEM", 203, 214], ["feline tritrichomoniasis", "PROBLEM", 270, 294], ["therapy", "TREATMENT", 312, 319], ["Giardia spp", "OBSERVATION", 54, 65], ["fecal", "ANATOMY", 70, 75], ["flotation", "OBSERVATION", 76, 85], ["Giardia spp", "OBSERVATION", 203, 214], ["no", "UNCERTAINTY", 244, 246]]], ["The antiprotozoal drug ronidazole is frequently used but can cause reversible neurotoxicosis (Gookin et al., 2006) .", [["ronidazole", "CHEMICAL", 23, 33], ["neurotoxicosis", "DISEASE", 78, 92], ["ronidazole", "CHEMICAL", 23, 33], ["ronidazole", "SIMPLE_CHEMICAL", 23, 33], ["The antiprotozoal drug ronidazole", "TREATMENT", 0, 33], ["reversible neurotoxicosis", "PROBLEM", 67, 92], ["reversible", "OBSERVATION_MODIFIER", 67, 77], ["neurotoxicosis", "OBSERVATION", 78, 92]]], ["Due to the high potential for transmission, infected cats should be immediately isolated and treated with ronidazole administered at the recommended dose of 30 mg/kg daily for 14 days.", [["ronidazole", "CHEMICAL", 106, 116], ["ronidazole", "CHEMICAL", 106, 116], ["cats", "ORGANISM", 53, 57], ["ronidazole", "SIMPLE_CHEMICAL", 106, 116], ["cats", "SPECIES", 53, 57], ["infected cats", "TREATMENT", 44, 57], ["ronidazole", "TREATMENT", 106, 116]]], ["PCR testing should be repeated after treatment is finished to assure treatment success.", [["PCR testing", "TEST", 0, 11], ["treatment", "TREATMENT", 37, 46], ["treatment success", "TREATMENT", 69, 86]]], ["Regardless of testing results, however, cats should be kept isolated until after their adoption to minimize spread to other cats as relapse of infection can occur as long as 20 weeks post-treatment.DiscussionGiardia spp. was identified in 56% of fecal specimens tested.", [["fecal specimens", "ANATOMY", 246, 261], ["infection", "DISEASE", 143, 152], ["cats", "ORGANISM", 40, 44], ["cats", "ORGANISM", 124, 128], ["Giardia spp.", "ORGANISM", 208, 220], ["fecal specimens", "CANCER", 246, 261], ["cats", "SPECIES", 40, 44], ["Giardia spp.", "SPECIES", 208, 220], ["testing results", "TEST", 14, 29], ["infection", "PROBLEM", 143, 152], ["fecal specimens", "TEST", 246, 261], ["infection", "OBSERVATION", 143, 152]]], ["This exceeds prevalences previously reported in sheltered cats both with and without diarrhea in New York (8%), California (10%), or Florida (20%; Spain et al., 2001; Mekaru et al., 2007; Sabshin et al., 2012; McManus et al., 2014) .", [["diarrhea", "DISEASE", 85, 93], ["cats", "ORGANISM", 58, 62], ["cats", "SPECIES", 58, 62], ["diarrhea", "PROBLEM", 85, 93]]], ["Cryptosporidium spp. was detected in all four cases at higher prevalences than previously reported in sheltered cats both with and without diarrhea from Colorado (8%), New York (5%), Florida (20%; Hill et al., 2000; Spain et al., 2001; Sabshin et al., 2012; McManus et al., 2014) .", [["Cryptosporidium spp", "DISEASE", 0, 19], ["diarrhea", "DISEASE", 139, 147], ["Cryptosporidium spp", "ORGANISM", 0, 19], ["cats", "ORGANISM", 112, 116], ["cats", "SPECIES", 112, 116], ["Cryptosporidium spp", "PROBLEM", 0, 19], ["diarrhea", "PROBLEM", 139, 147], ["spp", "OBSERVATION_MODIFIER", 16, 19]]], ["Cystoisopora spp. was infrequently detected, which is most likely because of the low proportions of kittens present in all cases (Gates and Nolan, 2009 ).", [["Cystoisopora spp.", "ORGANISM", 0, 17], ["kittens", "ORGANISM", 100, 107], ["Cystoisopora spp.", "SPECIES", 0, 17], ["Cystoisopora spp.", "SPECIES", 0, 17], ["Cystoisopora spp.", "PROBLEM", 0, 17], ["most likely", "UNCERTAINTY", 54, 65]]], ["The high prevalence of Giardia and Cryptosporidium spp. can be attributed to the increased population density and continuous reinfection of cats from accumulated feces found in hoarding cases.", [["feces", "ANATOMY", 162, 167], ["Cryptosporidium spp", "DISEASE", 35, 54], ["hoarding", "DISEASE", 177, 185], ["Giardia", "ORGANISM_SUBSTANCE", 23, 30], ["Cryptosporidium spp", "ORGANISM", 35, 54], ["cats", "ORGANISM", 140, 144], ["feces", "ORGANISM_SUBDIVISION", 162, 167], ["cats", "SPECIES", 140, 144], ["Giardia", "PROBLEM", 23, 30], ["Cryptosporidium spp", "PROBLEM", 35, 54], ["the increased population density", "PROBLEM", 77, 109], ["continuous reinfection of cats", "PROBLEM", 114, 144], ["accumulated feces", "PROBLEM", 150, 167], ["high prevalence", "OBSERVATION_MODIFIER", 4, 19], ["Giardia", "OBSERVATION", 23, 30], ["Cryptosporidium spp", "OBSERVATION", 35, 54], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["population", "OBSERVATION_MODIFIER", 91, 101], ["density", "OBSERVATION", 102, 109], ["reinfection", "OBSERVATION_MODIFIER", 125, 136], ["feces", "OBSERVATION", 162, 167]]], ["Both pathogens create management challenges due to their environmental durability, potential for misdiagnosis, and lack of practical curative treatment options.DiscussionNematodes with zoonotic potential, ascarids and hookworms, were identified in 14% and 9% of symptomatic cats tested, respectively.", [["zoonotic potential, ascarids and hookworms", "DISEASE", 185, 227], ["cats", "ORGANISM", 274, 278], ["cats", "SPECIES", 274, 278], ["management challenges", "TREATMENT", 22, 43], ["misdiagnosis", "PROBLEM", 97, 109], ["practical curative treatment options", "TREATMENT", 123, 159], ["symptomatic cats", "TREATMENT", 262, 278]]], ["Previous studies have identified the prevalence of hookworms in outdoor-dwelling feral cats in Florida (75%), cats housed in a Florida shelter (14%), and in pet cats in Pennsylvania (8%; Anderson et al., 2003; Gates and Nolan, 2009; Sabshin et al., 2012) .", [["cats", "ORGANISM", 87, 91], ["cats", "SPECIES", 87, 91], ["cats", "SPECIES", 110, 114], ["cats", "SPECIES", 161, 165], ["Previous studies", "TEST", 0, 16], ["hookworms", "PROBLEM", 51, 60]]], ["The collection of fecal specimens after intake parasite treatments were administered might explain why the prevalence of ascarids detected in this study was much lower than prevalence rates reported in northern, mid-Atlantic and central states (Spain et al., 2001; Vasilopulos et al., 2006) .DiscussionOne or more potentially pathogenic bacteria including C. jejuni, C. coli, and C. perfringens were detected in the majority of cats.", [["fecal specimens", "ANATOMY", 18, 33], ["ascarids", "DISEASE", 121, 129], ["C. jejuni", "DISEASE", 356, 365], ["fecal specimens", "ORGANISM_SUBSTANCE", 18, 33], ["ascarids", "CANCER", 121, 129], ["C. jejuni", "ORGANISM", 356, 365], ["C. coli", "ORGANISM", 367, 374], ["C. perfringens", "ORGANISM", 380, 394], ["cats", "ORGANISM", 428, 432], ["C. jejuni", "SPECIES", 356, 365], ["C. coli", "SPECIES", 367, 374], ["C. perfringens", "SPECIES", 380, 394], ["cats", "SPECIES", 428, 432], ["C. jejuni", "SPECIES", 356, 365], ["C. coli", "SPECIES", 367, 374], ["C. perfringens", "SPECIES", 380, 394], ["fecal specimens", "TEST", 18, 33], ["intake parasite treatments", "TREATMENT", 40, 66], ["ascarids", "PROBLEM", 121, 129], ["this study", "TEST", 142, 152], ["pathogenic bacteria", "PROBLEM", 326, 345], ["C. jejuni", "PROBLEM", 356, 365], ["C. coli", "PROBLEM", 367, 374], ["C. perfringens", "PROBLEM", 380, 394], ["collection", "OBSERVATION_MODIFIER", 4, 14], ["fecal", "ANATOMY", 18, 23], ["central", "ANATOMY_MODIFIER", 229, 236], ["jejuni", "ANATOMY", 359, 365]]], ["However, the clinical significance of this is unclear, as C. perfringens has been identified in cats both with and without diarrhea (Sabshin et al., 2012) .", [["diarrhea", "DISEASE", 123, 131], ["C. perfringens", "ORGANISM", 58, 72], ["cats", "ORGANISM", 96, 100], ["C. perfringens", "SPECIES", 58, 72], ["cats", "SPECIES", 96, 100], ["C. perfringens", "SPECIES", 58, 72], ["C. perfringens", "PROBLEM", 58, 72], ["diarrhea", "PROBLEM", 123, 131]]], ["The quantity of CPA detected in feces might better correlate with diarrhea than its mere presence .DiscussionThe finding of FCoV in most cats is consistent with previous reports that documented higher seropositivity rates for FCoV antibodies in confined cats than in free-roaming stray and feral cats, presumably due to shared litter boxes (Pedersen, 2009) .", [["feces", "ANATOMY", 32, 37], ["CPA", "CHEMICAL", 16, 19], ["diarrhea", "DISEASE", 66, 74], ["CPA", "CHEMICAL", 16, 19], ["CPA", "SIMPLE_CHEMICAL", 16, 19], ["feces", "ORGANISM_SUBSTANCE", 32, 37], ["FCoV", "GENE_OR_GENE_PRODUCT", 124, 128], ["cats", "ORGANISM", 137, 141], ["FCoV antibodies", "GENE_OR_GENE_PRODUCT", 226, 241], ["cats", "ORGANISM", 254, 258], ["cats", "ORGANISM", 296, 300], ["FCoV antibodies", "PROTEIN", 226, 241], ["cats", "SPECIES", 254, 258], ["cats", "SPECIES", 296, 300], ["FCoV", "SPECIES", 226, 230], ["CPA", "PROBLEM", 16, 19], ["diarrhea", "PROBLEM", 66, 74], ["FCoV", "PROBLEM", 124, 128], ["higher seropositivity rates", "PROBLEM", 194, 221], ["FCoV antibodies", "TEST", 226, 241], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["CPA", "OBSERVATION", 16, 19], ["feces", "OBSERVATION", 32, 37], ["FCoV", "OBSERVATION", 124, 128], ["consistent with", "UNCERTAINTY", 145, 160]]], ["Infection with FCoV usually causes only a transient, mild diarrhea.", [["FCoV", "DISEASE", 15, 19], ["diarrhea", "DISEASE", 58, 66], ["FCoV", "SPECIES", 15, 19], ["Infection", "PROBLEM", 0, 9], ["FCoV", "PROBLEM", 15, 19], ["a transient, mild diarrhea", "PROBLEM", 40, 66], ["FCoV", "OBSERVATION", 15, 19], ["transient", "OBSERVATION_MODIFIER", 42, 51], ["mild", "OBSERVATION_MODIFIER", 53, 57], ["diarrhea", "OBSERVATION", 58, 66]]], ["Viral mutations can lead to fatal feline infectious peritonitis, which is anecdotally reported to be relatively common in hoarded cats (Pedersen, 2009) .DiscussionSanctuary managers in all four cases in this report described policies for all cats to be tested for FeLV and FIV and then segregated based on serological results.", [["feline infectious peritonitis", "DISEASE", 34, 63], ["feline", "ORGANISM", 34, 40], ["cats", "ORGANISM", 130, 134], ["cats", "ORGANISM", 242, 246], ["FeLV", "ORGANISM", 264, 268], ["FIV", "ORGANISM", 273, 276], ["feline", "SPECIES", 34, 40], ["cats", "SPECIES", 130, 134], ["FeLV", "SPECIES", 264, 268], ["FIV", "SPECIES", 273, 276], ["Viral mutations", "PROBLEM", 0, 15], ["fatal feline infectious peritonitis", "PROBLEM", 28, 63], ["all cats", "TREATMENT", 238, 246], ["FeLV and FIV", "TREATMENT", 264, 276], ["serological results", "TEST", 306, 325], ["fatal", "OBSERVATION_MODIFIER", 28, 33], ["feline", "OBSERVATION_MODIFIER", 34, 40], ["infectious", "OBSERVATION_MODIFIER", 41, 51], ["peritonitis", "OBSERVATION", 52, 63]]], ["However, retroviral-infected cats were identified in each of the facilities, often group-housed with uninfected cats.", [["retroviral", "ORGANISM", 9, 19], ["cats", "ORGANISM", 29, 33], ["cats", "ORGANISM", 112, 116], ["cats", "SPECIES", 29, 33], ["cats", "SPECIES", 112, 116], ["infected", "OBSERVATION", 20, 28]]], ["The retroviral prevalence of cats from these cases surpasses infection rates reported for both pet and feral cats (Luria et al., 2004; Levy et al., 2006) .", [["infection", "DISEASE", 61, 70], ["retroviral", "ORGANISM", 4, 14], ["cats", "ORGANISM", 29, 33], ["cats", "ORGANISM", 109, 113], ["cats", "SPECIES", 29, 33], ["cats", "SPECIES", 109, 113], ["infection rates", "PROBLEM", 61, 76], ["retroviral prevalence", "OBSERVATION", 4, 25]]], ["This can be attributed to the increased physical contact, stress, and agonistic interactions between cats living in densely populated confinement.", [["cats", "ORGANISM", 101, 105], ["cats", "SPECIES", 101, 105], ["the increased physical contact", "PROBLEM", 26, 56], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["physical contact", "OBSERVATION", 40, 56], ["densely", "OBSERVATION_MODIFIER", 116, 123], ["populated confinement", "OBSERVATION", 124, 145]]], ["All cats should be tested for retroviruses at the time of seizure from hoarding cases as the retroviral status of cats will influence housing decisions, medical care, and adoption options.", [["seizure", "DISEASE", 58, 65], ["hoarding", "DISEASE", 71, 79], ["cats", "ORGANISM", 4, 8], ["retroviruses", "ORGANISM", 30, 42], ["retroviral", "ORGANISM", 93, 103], ["cats", "ORGANISM", 114, 118], ["cats", "SPECIES", 4, 8], ["cats", "SPECIES", 114, 118], ["All cats", "TREATMENT", 0, 8], ["retroviruses", "PROBLEM", 30, 42], ["seizure", "PROBLEM", 58, 65]]], ["Cats should also be retested 2 months after the initial testing to identify early infections that escaped detection at the time of intake.DiscussionDermatophytosis is an important consideration when sheltering cats from any source because it is highly contagious, has zoonotic potential, and can be difficult to diagnose and to treat (Carlotti et al., 2010) .", [["infections", "DISEASE", 82, 92], ["Dermatophytosis", "DISEASE", 148, 163], ["cats", "ORGANISM", 210, 214], ["the initial testing", "TEST", 44, 63], ["early infections", "PROBLEM", 76, 92], ["Dermatophytosis", "PROBLEM", 148, 163], ["sheltering cats", "PROBLEM", 199, 214], ["infections", "OBSERVATION", 82, 92]]], ["Its management is particularly challenging when sheltering large numbers of seized cats, because of the potential transmission of Microsporum canis in temporary shelters to both cats and to humans.", [["Microsporum canis", "DISEASE", 130, 147], ["cats", "ORGANISM", 83, 87], ["Microsporum canis", "ORGANISM", 130, 147], ["cats", "ORGANISM", 178, 182], ["humans", "ORGANISM", 190, 196], ["Microsporum canis", "SPECIES", 130, 147], ["cats", "SPECIES", 178, 182], ["humans", "SPECIES", 190, 196], ["Microsporum canis", "SPECIES", 130, 147], ["humans", "SPECIES", 190, 196], ["Its management", "TREATMENT", 0, 14], ["Microsporum canis", "PROBLEM", 130, 147]]], ["Due to prior difficulties in managing dermatophytosis cases in temporary shelters, in case 4 all cats were dipped in limesulfur at intake to decrease the overall spore burden in the shelter and to reduce in-shelter transmission of disease.", [["spore", "ANATOMY", 162, 167], ["dermatophytosis", "DISEASE", 38, 53], ["limesulfur", "CHEMICAL", 117, 127], ["cats", "ORGANISM", 97, 101], ["cats", "SPECIES", 97, 101], ["prior difficulties in managing dermatophytosis", "PROBLEM", 7, 53], ["disease", "PROBLEM", 231, 238], ["overall", "OBSERVATION_MODIFIER", 154, 161], ["spore", "OBSERVATION_MODIFIER", 162, 167], ["burden", "OBSERVATION", 168, 174], ["disease", "OBSERVATION", 231, 238]]], ["Cats that exhibited lesions suspected to be dermatophytosis were immediately segregated.", [["lesions", "ANATOMY", 20, 27], ["dermatophytosis", "DISEASE", 44, 59], ["Cats", "ORGANISM", 0, 4], ["lesions", "PATHOLOGICAL_FORMATION", 20, 27], ["lesions", "PROBLEM", 20, 27], ["dermatophytosis", "PROBLEM", 44, 59], ["lesions", "OBSERVATION", 20, 27], ["dermatophytosis", "OBSERVATION", 44, 59]]], ["Cats with skin lesions, Wood's lamp positive examinations, or culture-confirmed dermatophytosis were treated with terbinafine and lime-sulfur dips.", [["skin lesions", "ANATOMY", 10, 22], ["skin lesions", "DISEASE", 10, 22], ["dermatophytosis", "DISEASE", 80, 95], ["terbinafine", "CHEMICAL", 114, 125], ["lime-sulfur", "CHEMICAL", 130, 141], ["terbinafine", "CHEMICAL", 114, 125], ["sulfur", "CHEMICAL", 135, 141], ["skin lesions", "PATHOLOGICAL_FORMATION", 10, 22], ["terbinafine", "SIMPLE_CHEMICAL", 114, 125], ["lime-sulfur dips", "SIMPLE_CHEMICAL", 130, 146], ["skin lesions", "PROBLEM", 10, 22], ["Wood's lamp positive examinations", "TEST", 24, 57], ["culture", "TEST", 62, 69], ["dermatophytosis", "PROBLEM", 80, 95], ["terbinafine", "TREATMENT", 114, 125], ["lime-sulfur dips", "TREATMENT", 130, 146], ["skin", "ANATOMY", 10, 14], ["lesions", "OBSERVATION", 15, 22], ["dermatophytosis", "OBSERVATION", 80, 95]]], ["This protocol was effective in eliminating infections in all treated cats.DiscussionIn cruelty cases involving a limited number of cats, it is often practical to perform comprehensive diagnostic testing of each cat for infectious diseases and to develop individualized treatment plans based on test results.", [["infections", "DISEASE", 43, 53], ["infectious diseases", "DISEASE", 219, 238], ["cats", "ORGANISM", 69, 73], ["cats", "ORGANISM", 131, 135], ["cat", "ORGANISM", 211, 214], ["cats", "SPECIES", 69, 73], ["This protocol", "TREATMENT", 0, 13], ["infections", "PROBLEM", 43, 53], ["comprehensive diagnostic testing", "TEST", 170, 202], ["infectious diseases", "PROBLEM", 219, 238], ["individualized treatment plans", "TREATMENT", 254, 284], ["test results", "TEST", 294, 306], ["infections", "OBSERVATION", 43, 53]]], ["In contrast, large-scale cases involving hundreds of cats taken in and housed in makeshift quarters by emergency responders require population-level management.", [["cats", "ORGANISM", 53, 57], ["cats", "SPECIES", 53, 57], ["population-level management", "TREATMENT", 132, 159], ["large", "OBSERVATION_MODIFIER", 13, 18]]], ["Medical protocols for both healthy and diseased cats must be developed prior to the seizure so they can be implemented at the time of first contact with the cats.", [["seizure", "DISEASE", 84, 91], ["cats", "ORGANISM", 48, 52], ["cats", "ORGANISM", 157, 161], ["cats", "SPECIES", 48, 52], ["cats", "SPECIES", 157, 161], ["Medical protocols", "TREATMENT", 0, 17], ["both healthy and diseased cats", "PROBLEM", 22, 52], ["the seizure", "PROBLEM", 80, 91]]], ["Protocols used to date have been based primarily on the anecdotal experience of responding agencies.DiscussionWhile the actual proportion of cats tested in this retrospective study was low, the results provide useful information regarding the potential identity and prevalence of pathogens for which protocols can be tailored.", [["cats", "ORGANISM", 141, 145], ["this retrospective study", "TEST", 156, 180], ["pathogens", "PROBLEM", 280, 289]]], ["The results reported in this study might not be representative of all cat hoarding cases, due to differences in geographical location, housing type, and level of care provided.DiscussionSimilar to traditional animal shelters, at the time of intake examination pyrantel pamoate, ponazuril, praziquantal, and a topical treatment effective against fleas and mites should be adminis-tered to all cats.", [["hoarding", "DISEASE", 74, 82], ["pyrantel pamoate", "CHEMICAL", 260, 276], ["ponazuril", "CHEMICAL", 278, 287], ["praziquantal", "CHEMICAL", 289, 301], ["ponazuril", "CHEMICAL", 278, 287], ["cat", "ORGANISM", 70, 73], ["pyrantel pamoate", "SIMPLE_CHEMICAL", 260, 276], ["ponazuril", "SIMPLE_CHEMICAL", 278, 287], ["praziquantal", "SIMPLE_CHEMICAL", 289, 301], ["cats", "ORGANISM", 392, 396], ["this study", "TEST", 24, 34], ["examination", "TEST", 248, 259], ["pyrantel pamoate", "TREATMENT", 260, 276], ["ponazuril", "TREATMENT", 278, 287], ["praziquantal", "TREATMENT", 289, 301], ["a topical treatment", "TREATMENT", 307, 326]]], ["All cats 4 weeks of age or older should be vaccinated against FPV, FCV, and FHV with a modified-live vaccine.", [["cats", "ORGANISM", 4, 8], ["FPV", "ORGANISM", 62, 65], ["FCV", "ORGANISM", 67, 70], ["cats", "SPECIES", 4, 8], ["FPV", "SPECIES", 62, 65], ["FCV", "SPECIES", 67, 70], ["FHV", "SPECIES", 76, 79], ["a modified-live vaccine", "TREATMENT", 85, 108]]], ["If cats are to be co-housed, which is usually the case in large-scale operations, vaccination against FeLV should be initiated at intake to reduce the risk of continued transmission from cats that have infections that are not detected immediately (Levy et al., 2008) .", [["FeLV", "DISEASE", 102, 106], ["infections", "DISEASE", 202, 212], ["cats", "ORGANISM", 3, 7], ["FeLV", "ORGANISM", 102, 106], ["cats", "ORGANISM", 187, 191], ["cats", "SPECIES", 3, 7], ["cats", "SPECIES", 187, 191], ["FeLV", "SPECIES", 102, 106], ["large-scale operations", "TREATMENT", 58, 80], ["vaccination", "TREATMENT", 82, 93], ["FeLV", "TREATMENT", 102, 106], ["continued transmission from cats", "PROBLEM", 159, 191], ["infections", "PROBLEM", 202, 212], ["infections", "OBSERVATION", 202, 212]]], ["Cats 12 weeks of age or older should be vaccinated against rabies.DiscussionWhile antibiotic therapy should always be used judiciously to avoid the development of drug resistance, consideration should be given to the inclusion of antibiotics in the intake protocol due to the high prevalence and morbidity of SEZ in cats from large-scale cases.", [["rabies", "DISEASE", 59, 65], ["SEZ", "CHEMICAL", 309, 312], ["rabies", "ORGANISM", 59, 65], ["SEZ", "SIMPLE_CHEMICAL", 309, 312], ["cats", "ORGANISM", 316, 320], ["rabies", "SPECIES", 59, 65], ["antibiotic therapy", "TREATMENT", 82, 100], ["drug resistance", "PROBLEM", 163, 178], ["antibiotics", "TREATMENT", 230, 241], ["the intake protocol", "TREATMENT", 245, 264], ["morbidity of SEZ in cats", "PROBLEM", 296, 320], ["drug resistance", "OBSERVATION", 163, 178], ["large", "OBSERVATION_MODIFIER", 326, 331]]], ["Cefovecin has been used effectively in the control of fatal SEZ outbreaks in shelter dogs in which a single dose provides broadspectrum long-lasting activity and reduces handling stress, crosscontamination between animals, and labor costs.", [["Cefovecin", "CHEMICAL", 0, 9], ["SEZ", "DISEASE", 60, 63], ["Cefovecin", "CHEMICAL", 0, 9], ["Cefovecin", "SIMPLE_CHEMICAL", 0, 9], ["dogs", "SPECIES", 85, 89], ["Cefovecin", "TREATMENT", 0, 9], ["handling stress", "PROBLEM", 170, 185], ["labor costs", "PROBLEM", 227, 238]]], ["It is also an ideal empirical treatment for many commonly encountered conditions in cats seized from hoarding cases, including wounds, pyoderma, and otitis.", [["wounds", "ANATOMY", 127, 133], ["pyoderma", "ANATOMY", 135, 143], ["hoarding", "DISEASE", 101, 109], ["wounds", "DISEASE", 127, 133], ["pyoderma", "DISEASE", 135, 143], ["otitis", "DISEASE", 149, 155], ["cats", "ORGANISM", 84, 88], ["wounds", "PATHOLOGICAL_FORMATION", 127, 133], ["cats", "SPECIES", 84, 88], ["an ideal empirical treatment", "TREATMENT", 11, 39], ["hoarding cases", "PROBLEM", 101, 115], ["wounds", "PROBLEM", 127, 133], ["pyoderma", "PROBLEM", 135, 143], ["otitis", "PROBLEM", 149, 155], ["wounds", "ANATOMY", 127, 133], ["pyoderma", "OBSERVATION", 135, 143], ["otitis", "OBSERVATION", 149, 155]]], ["Unfortunately, cefovecin is ineffective against other common bacterial pathogens encountered in cats with URI, such as M. felis, B. bronchiseptica, and C. felis.", [["cefovecin", "CHEMICAL", 15, 24], ["URI", "DISEASE", 106, 109], ["M. felis", "DISEASE", 119, 127], ["C. felis", "DISEASE", 152, 160], ["cefovecin", "CHEMICAL", 15, 24], ["cefovecin", "SIMPLE_CHEMICAL", 15, 24], ["cats", "ORGANISM", 96, 100], ["M. felis", "ORGANISM", 119, 127], ["B. bronchiseptica", "ORGANISM", 129, 146], ["C. felis", "ORGANISM", 152, 160], ["cats", "SPECIES", 96, 100], ["M. felis", "SPECIES", 119, 127], ["B. bronchiseptica", "SPECIES", 129, 146], ["C. felis", "SPECIES", 152, 160], ["M. felis", "SPECIES", 119, 127], ["B. bronchiseptica", "SPECIES", 129, 146], ["C. felis", "SPECIES", 152, 160], ["cefovecin", "TREATMENT", 15, 24], ["other common bacterial pathogens", "PROBLEM", 48, 80], ["URI", "PROBLEM", 106, 109], ["bronchiseptica", "PROBLEM", 132, 146]]], ["This means that effective treatment of cats with URI often requires combination therapy with other antibiotics such as doxycycline.", [["URI", "DISEASE", 49, 52], ["doxycycline", "CHEMICAL", 119, 130], ["doxycycline", "CHEMICAL", 119, 130], ["cats", "ORGANISM", 39, 43], ["doxycycline", "SIMPLE_CHEMICAL", 119, 130], ["effective treatment of cats", "TREATMENT", 16, 43], ["URI", "PROBLEM", 49, 52], ["combination therapy", "TREATMENT", 68, 87], ["other antibiotics", "TREATMENT", 93, 110], ["doxycycline", "TREATMENT", 119, 130]]], ["Doxycycline should not be used alone for therapy however, as SEZ isolates are frequently resistant to doxycycline (Chalker et al., 2012) .DiscussionThe effort and expense of such broad-spectrum preventive healthcare delivered concurrent with the physical examinations and forensic documentation should not be underestimated.", [["Doxycycline", "CHEMICAL", 0, 11], ["doxycycline", "CHEMICAL", 102, 113], ["Doxycycline", "CHEMICAL", 0, 11], ["doxycycline", "CHEMICAL", 102, 113], ["Doxycycline", "SIMPLE_CHEMICAL", 0, 11], ["SEZ isolates", "ORGANISM", 61, 73], ["doxycycline", "SIMPLE_CHEMICAL", 102, 113], ["Doxycycline", "TREATMENT", 0, 11], ["therapy", "TREATMENT", 41, 48], ["SEZ isolates", "PROBLEM", 61, 73], ["doxycycline", "TREATMENT", 102, 113], ["the physical examinations", "TEST", 242, 267], ["forensic documentation", "TEST", 272, 294]]], ["However, it has been our experience that a well-planned and resourced intake procedure is more likely to result in comprehensive and consistent care than a less thorough protocol that relies on routine treatments to be provided at a later time.DiscussionProtocols should be in place for assessment of sick cats, including those identified at the time of intake as well as those that develop disease while in the temporary shelter.", [["cats", "ORGANISM", 306, 310], ["resourced intake procedure", "TREATMENT", 60, 86], ["a less thorough protocol", "TREATMENT", 154, 178], ["routine treatments", "TREATMENT", 194, 212], ["DiscussionProtocols", "TREATMENT", 244, 263], ["disease", "PROBLEM", 391, 398], ["disease", "OBSERVATION", 391, 398]]], ["Diagnostic panels should include testing for bacterial, viral, and parasitic infections and include screening for pathogens unique to large-scale cases, such as SEZ.", [["bacterial, viral, and parasitic infections", "DISEASE", 45, 87], ["SEZ", "CHEMICAL", 161, 164], ["Diagnostic panels", "TEST", 0, 17], ["testing", "TEST", 33, 40], ["bacterial", "PROBLEM", 45, 54], ["viral", "PROBLEM", 56, 61], ["parasitic infections", "PROBLEM", 67, 87], ["screening", "TEST", 100, 109], ["pathogens", "PROBLEM", 114, 123], ["viral", "OBSERVATION", 56, 61], ["parasitic", "OBSERVATION_MODIFIER", 67, 76], ["infections", "OBSERVATION", 77, 87]]], ["The diagnostic value of necropsy of cats found dead or euthanased should not be overlooked as a useful disease management tool.", [["cats", "ORGANISM", 36, 40], ["cats", "SPECIES", 36, 40], ["dead", "PROBLEM", 47, 51], ["a useful disease management tool", "PROBLEM", 94, 126]]], ["Diagnostic laboratories should be notified of the need for timely result reporting, particularly if highly pathogenic or unusual infections are detected.DiscussionTreatment protocols must be developed to ensure that cats receive consistent care, regardless of the personnel involved.", [["infections", "DISEASE", 129, 139], ["cats", "ORGANISM", 216, 220], ["Diagnostic laboratories", "TEST", 0, 23], ["unusual infections", "PROBLEM", 121, 139], ["Treatment protocols", "TREATMENT", 163, 182], ["unusual", "OBSERVATION_MODIFIER", 121, 128], ["infections", "OBSERVATION", 129, 139]]], ["Treatments must be practical and affordable within the context of large-scale cases, which are often staffed by rotating teams of emergency responders and volunteers.", [["volunteers", "ORGANISM", 155, 165], ["Treatments", "TREATMENT", 0, 10]]], ["For example, mild to moderate URIs could be treated empirically with once daily doxycycline, whereas severe respiratory infections warrant diagnostic testing and more broadspectrum coverage pending the results of testing.DiscussionWhether cats are discharged from temporary shelters directly to new adoptive homes or to another shelter for eventual placement, complete records of examination findings, diagnostic results, and treatments administered should be transmitted with each cat.", [["respiratory", "ANATOMY", 108, 119], ["URIs", "DISEASE", 30, 34], ["doxycycline", "CHEMICAL", 80, 91], ["respiratory infections", "DISEASE", 108, 130], ["doxycycline", "CHEMICAL", 80, 91], ["doxycycline", "SIMPLE_CHEMICAL", 80, 91], ["cats", "ORGANISM", 239, 243], ["cat", "ORGANISM", 482, 485], ["mild to moderate URIs", "PROBLEM", 13, 34], ["doxycycline", "TREATMENT", 80, 91], ["severe respiratory infections", "PROBLEM", 101, 130], ["diagnostic testing", "TEST", 139, 157], ["more broadspectrum coverage", "TREATMENT", 162, 189], ["testing", "TEST", 213, 220], ["eventual placement", "TREATMENT", 340, 358], ["examination findings", "TEST", 380, 400], ["treatments", "TREATMENT", 426, 436], ["mild", "OBSERVATION_MODIFIER", 13, 17], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["URIs", "OBSERVATION", 30, 34], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["respiratory", "ANATOMY", 108, 119], ["infections", "OBSERVATION", 120, 130]]], ["The high carriage rate of persistent infections that are difficult to diagnose and to eliminate means that these cats pose a risk for transmission of new pathogens into any other facility they are transferred to.", [["infections", "DISEASE", 37, 47], ["cats", "ORGANISM", 113, 117], ["cats", "SPECIES", 113, 117], ["persistent infections", "PROBLEM", 26, 47], ["new pathogens", "PROBLEM", 150, 163], ["high", "OBSERVATION_MODIFIER", 4, 8], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["infections", "OBSERVATION", 37, 47]]], ["Therefore, cats rescued from hoarding cases should be segregated from any pre-existing cat shelter populations until they are rehomed.ConclusionsThis report is the first to describe infectious diseases detected in cats at the time of intervention in large-scale hoarding investigations.", [["hoarding", "DISEASE", 29, 37], ["infectious diseases", "DISEASE", 182, 201], ["hoarding", "DISEASE", 262, 270], ["cats", "ORGANISM", 11, 15], ["cat", "ORGANISM", 87, 90], ["cats", "ORGANISM", 214, 218], ["cats", "SPECIES", 11, 15], ["cats", "SPECIES", 214, 218], ["infectious diseases", "PROBLEM", 182, 201], ["intervention", "TREATMENT", 234, 246], ["hoarding investigations", "TEST", 262, 285], ["infectious", "OBSERVATION", 182, 192]]], ["Most symptomatic cats harbored multiple respiratory and enteric pathogens, and the prevalence of retroviral infections was higher than typically found in animal shelters.", [["respiratory", "ANATOMY", 40, 51], ["respiratory and enteric pathogens", "DISEASE", 40, 73], ["retroviral infections", "DISEASE", 97, 118], ["cats", "ORGANISM", 17, 21], ["retroviral", "ORGANISM", 97, 107], ["cats", "SPECIES", 17, 21], ["retroviral", "SPECIES", 97, 107], ["Most symptomatic cats", "PROBLEM", 0, 21], ["multiple respiratory and enteric pathogens", "PROBLEM", 31, 73], ["retroviral infections", "PROBLEM", 97, 118], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["respiratory", "ANATOMY", 40, 51], ["enteric", "OBSERVATION_MODIFIER", 56, 63], ["pathogens", "OBSERVATION", 64, 73], ["retroviral infections", "OBSERVATION", 97, 118]]], ["These findings can be used to guide preventive care protocols, but much more knowledge is needed to inform comprehensive management tactics for such cases, especially since hoarding is being reported with increasing frequency.", [["hoarding", "DISEASE", 173, 181], ["preventive care protocols", "TREATMENT", 36, 61], ["comprehensive management", "TREATMENT", 107, 131], ["hoarding", "PROBLEM", 173, 181], ["increasing frequency", "PROBLEM", 205, 225]]], ["Currently, intervention strategies tend to center on emergency management of individual situations, and there is little follow-up or transparency regarding case outcomes.", [["intervention strategies", "TREATMENT", 11, 34], ["emergency management", "TREATMENT", 53, 73]]], ["Prospective research is needed to more fully characterize the infectious diseases present in both symptomatic and asymptomatic cats and the effectiveness of preventive care and treatment protocols.", [["cats", "ORGANISM", 127, 131], ["cats", "SPECIES", 127, 131], ["the infectious diseases", "PROBLEM", 58, 81], ["asymptomatic cats", "PROBLEM", 114, 131], ["preventive care", "TREATMENT", 157, 172], ["treatment protocols", "TREATMENT", 177, 196], ["infectious", "OBSERVATION", 62, 72], ["symptomatic", "OBSERVATION_MODIFIER", 98, 109]]], ["Additional topics deserving attention include the management of stress and pain in seized cats, the characterization and management of common noninfectious conditions, and the long-term outcomes of the cats.", [["pain", "DISEASE", 75, 79], ["cats", "ORGANISM", 90, 94], ["cats", "ORGANISM", 202, 206], ["cats", "SPECIES", 90, 94], ["cats", "SPECIES", 202, 206], ["the management", "TREATMENT", 46, 60], ["stress", "PROBLEM", 64, 70], ["pain", "PROBLEM", 75, 79], ["the characterization", "TEST", 96, 116], ["management", "TREATMENT", 121, 131], ["common noninfectious conditions", "PROBLEM", 135, 166]]], ["This will enable the development of best-practice guidelines and cost:benefit analyses to guide responders across the industry and to continuously improve outcomes for rescued cats.Conflict of interest statementDr.", [["cats", "ORGANISM", 176, 180], ["cats", "SPECIES", 176, 180], ["rescued cats", "TREATMENT", 168, 180]]], ["Christian Leutenegger is the Head of PCR at IDEXX Laboratories.", [["Head", "ANATOMY", 29, 33]]]], "084f9322e99b14b595ef428445829904f4a0c17b": [["IntroductionIschemic stroke occurs in the brain when blood flow is restricted, causing brain cells to die rapidly.", [["brain", "ANATOMY", 42, 47], ["blood", "ANATOMY", 53, 58], ["brain cells", "ANATOMY", 87, 98], ["stroke", "DISEASE", 21, 27], ["brain", "ORGAN", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["brain cells", "CELL", 87, 98], ["brain cells", "CELL_TYPE", 87, 98], ["IntroductionIschemic stroke", "PROBLEM", 0, 27], ["blood flow", "TEST", 53, 63], ["brain cells", "PROBLEM", 87, 98], ["stroke", "OBSERVATION", 21, 27], ["brain", "ANATOMY", 42, 47], ["brain cells", "OBSERVATION", 87, 98]]], ["Movements on the opposite side of the body are frequently affected 1 .", [["body", "ANATOMY", 38, 42], ["body", "ORGANISM_SUBDIVISION", 38, 42], ["opposite", "ANATOMY_MODIFIER", 17, 25], ["body", "ANATOMY", 38, 42]]], ["Stroke victims also often exhibit lack of responsiveness to stimuli on their affected side.", [["Stroke", "DISEASE", 0, 6], ["Stroke victims", "PROBLEM", 0, 14], ["lack of responsiveness", "PROBLEM", 34, 56]]], ["The W.H.O. estimates that, worldwide, there are 31 million stroke survivors, with another 9 million new strokes annually.", [["stroke", "DISEASE", 59, 65], ["strokes", "DISEASE", 104, 111], ["another 9 million new strokes", "PROBLEM", 82, 111], ["new", "OBSERVATION_MODIFIER", 100, 103], ["strokes", "OBSERVATION", 104, 111]]], ["The vast majority of stroke victims are not eligible for the few therapies that improve outcome because they arrive in hospital too late for reperfusion to be effective 2 .", [["stroke", "DISEASE", 21, 27], ["stroke victims", "PROBLEM", 21, 35], ["reperfusion", "TREATMENT", 141, 152], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17], ["stroke", "OBSERVATION", 21, 27]]], ["Treatment six hours or more after ischemic stroke is usually limited to rehabilitation: therapies that reverse sensory impairments and locomotor disability are urgently needed, and these must work when initiated many hours after stroke.IntroductionNeurotrophin-3 is a growth factor which plays a key role in the development, and function of locomotor circuits that express NT3 receptors, including descending serotonergic 3 and corticospinal tract (CST) axons 4 and afferents from muscle and skin that mediate proprioception and tactile sensation [5] [6] [7] .", [["corticospinal tract (CST) axons 4", "ANATOMY", 428, 461], ["afferents", "ANATOMY", 466, 475], ["muscle", "ANATOMY", 481, 487], ["skin", "ANATOMY", 492, 496], ["ischemic stroke", "DISEASE", 34, 49], ["sensory impairments", "DISEASE", 111, 130], ["locomotor disability", "DISEASE", 135, 155], ["stroke", "DISEASE", 229, 235], ["Neurotrophin-3", "GENE_OR_GENE_PRODUCT", 248, 262], ["NT3", "GENE_OR_GENE_PRODUCT", 373, 376], ["descending serotonergic 3", "GENE_OR_GENE_PRODUCT", 398, 423], ["corticospinal tract (CST) axons 4", "GENE_OR_GENE_PRODUCT", 428, 461], ["afferents", "TISSUE", 466, 475], ["muscle", "ORGAN", 481, 487], ["skin", "ORGAN", 492, 496], ["Neurotrophin-3", "PROTEIN", 248, 262], ["growth factor", "PROTEIN", 268, 281], ["NT3 receptors", "PROTEIN", 373, 386], ["ischemic stroke", "PROBLEM", 34, 49], ["therapies", "TREATMENT", 88, 97], ["reverse sensory impairments", "PROBLEM", 103, 130], ["locomotor disability", "PROBLEM", 135, 155], ["stroke", "PROBLEM", 229, 235], ["IntroductionNeurotrophin", "TREATMENT", 236, 260], ["a growth factor", "PROBLEM", 266, 281], ["locomotor circuits", "TREATMENT", 341, 359], ["NT3 receptors", "TREATMENT", 373, 386], ["tactile sensation", "TEST", 529, 546], ["ischemic", "OBSERVATION_MODIFIER", 34, 42], ["stroke", "OBSERVATION", 43, 49], ["descending", "ANATOMY_MODIFIER", 398, 408], ["corticospinal tract", "ANATOMY", 428, 447], ["muscle", "ANATOMY", 481, 487], ["skin", "ANATOMY", 492, 496]]], ["However, peripheral levels of NT3 drop in the postnatal period 8 .", [["NT3", "GENE_OR_GENE_PRODUCT", 30, 33], ["NT3", "PROTEIN", 30, 33], ["peripheral levels", "TEST", 9, 26], ["NT3 drop", "PROBLEM", 30, 38], ["peripheral", "ANATOMY_MODIFIER", 9, 19], ["NT3 drop", "OBSERVATION", 30, 38]]], ["We and others had shown that delivery of NT3 into the CNS promotes recovery in rodent models of spinal cord injury [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] but this involved invasive routes of delivery (e.g., intraspinal injection or intrathecal infusion) or gene therapy.", [["CNS", "ANATOMY", 54, 57], ["spinal cord", "ANATOMY", 96, 107], ["intraspinal", "ANATOMY", 217, 228], ["intrathecal", "ANATOMY", 242, 253], ["cord injury", "DISEASE", 103, 114], ["9] [10] [11] [12] [13] [14] [15] [16] [17] [18]", "CHEMICAL", 116, 163], ["NT3", "GENE_OR_GENE_PRODUCT", 41, 44], ["CNS", "ANATOMICAL_SYSTEM", 54, 57], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 96, 107], ["[9] [10] [11] [12] [13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 115, 163], ["intraspinal", "IMMATERIAL_ANATOMICAL_ENTITY", 217, 228], ["NT3", "PROTEIN", 41, 44], ["delivery of NT3", "TREATMENT", 29, 44], ["spinal cord injury", "PROBLEM", 96, 114], ["delivery", "TREATMENT", 201, 209], ["intraspinal injection", "TREATMENT", 217, 238], ["intrathecal infusion", "TREATMENT", 242, 262], ["gene therapy", "TREATMENT", 267, 279], ["CNS", "ANATOMY", 54, 57], ["spinal cord", "ANATOMY", 96, 107], ["intraspinal", "ANATOMY", 217, 228]]], ["We also recently showed that injection of an adeno-associated viral vector (AAV) encoding full-length human NT3 (preproNT3, 30kDa) into forelimb muscles 24 hours after stroke in adult or elderly rats improved sensorimotor recovery 19 .", [["forelimb muscles", "ANATOMY", 136, 152], ["stroke", "DISEASE", 168, 174], ["adeno-associated viral", "ORGANISM", 45, 67], ["AAV", "ORGANISM", 76, 79], ["human", "ORGANISM", 102, 107], ["NT3", "GENE_OR_GENE_PRODUCT", 108, 111], ["preproNT3, 30kDa", "GENE_OR_GENE_PRODUCT", 113, 129], ["forelimb muscles", "ORGANISM", 136, 152], ["rats", "ORGANISM", 195, 199], ["adeno-associated viral vector", "DNA", 45, 74], ["full-length human NT3", "PROTEIN", 90, 111], ["preproNT3", "PROTEIN", 113, 122], ["30kDa", "PROTEIN", 124, 129], ["human", "SPECIES", 102, 107], ["rats", "SPECIES", 195, 199], ["human", "SPECIES", 102, 107], ["an adeno-associated viral vector (AAV", "TREATMENT", 42, 79], ["full-length human NT3", "TREATMENT", 90, 111], ["stroke", "PROBLEM", 168, 174], ["forelimb muscles", "ANATOMY", 136, 152]]], ["We had originally expected that AAV1 would be trafficked from muscle to the spinal cord retrogradely in axons 20 and that this would enhance secretion of NT3 by motor neurons, leading to sprouting of the spared CST 11, 21, 22 and sensorimotor recovery.", [["muscle", "ANATOMY", 62, 68], ["spinal cord", "ANATOMY", 76, 87], ["axons", "ANATOMY", 104, 109], ["motor neurons", "ANATOMY", 161, 174], ["AAV1", "GENE_OR_GENE_PRODUCT", 32, 36], ["muscle", "ORGAN", 62, 68], ["spinal cord", "ORGAN", 76, 87], ["NT3", "GENE_OR_GENE_PRODUCT", 154, 157], ["motor neurons", "CELL", 161, 174], ["AAV1", "PROTEIN", 32, 36], ["NT3", "PROTEIN", 154, 157], ["motor neurons", "CELL_TYPE", 161, 174], ["AAV1", "TREATMENT", 32, 36], ["secretion of NT3 by motor neurons", "PROBLEM", 141, 174], ["muscle", "ANATOMY", 62, 68], ["spinal cord", "ANATOMY", 76, 87], ["motor neurons", "ANATOMY", 161, 174]]], ["Although NT3 protein was overexpressed in injected muscles, to our surprise we found little evidence for expression of the human NT3 transgene in the spinal cord or cervical DRGs 17, 19 using this dose and preparation of AAV.", [["muscles", "ANATOMY", 51, 58], ["spinal cord", "ANATOMY", 150, 161], ["cervical DRGs", "ANATOMY", 165, 178], ["NT3", "GENE_OR_GENE_PRODUCT", 9, 12], ["muscles", "ORGAN", 51, 58], ["human", "ORGANISM", 123, 128], ["NT3", "GENE_OR_GENE_PRODUCT", 129, 132], ["spinal cord", "ORGAN", 150, 161], ["AAV", "ORGANISM", 221, 224], ["NT3 protein", "PROTEIN", 9, 20], ["human NT3 transgene", "DNA", 123, 142], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["NT3 protein", "TEST", 9, 20], ["the human NT3 transgene in the spinal cord", "PROBLEM", 119, 161], ["cervical DRGs", "TEST", 165, 178], ["preparation of AAV", "TREATMENT", 206, 224], ["muscles", "ANATOMY", 51, 58], ["little evidence for", "UNCERTAINTY", 85, 104], ["NT3 transgene", "OBSERVATION", 129, 142], ["spinal cord", "ANATOMY", 150, 161], ["cervical DRGs", "ANATOMY", 165, 178], ["AAV", "OBSERVATION", 221, 224]]], ["This serendipitous result led us to reject our original assumption that sensorimotor recovery required expression of the human NT3 transgene in the spinal cord and to wonder whether peripheral infusion of NT3 protein would suffice.IntroductionAccordingly, here, we test the hypothesis that infusion of the mature form of the NT3 protein (14 kDa) into disabled forelimb muscles improves sensorimotor recovery.", [["spinal cord", "ANATOMY", 148, 159], ["forelimb muscles", "ANATOMY", 360, 376], ["sensorimotor", "ANATOMY", 386, 398], ["human", "ORGANISM", 121, 126], ["NT3", "GENE_OR_GENE_PRODUCT", 127, 130], ["spinal cord", "ORGAN", 148, 159], ["NT3", "GENE_OR_GENE_PRODUCT", 205, 208], ["NT3", "GENE_OR_GENE_PRODUCT", 325, 328], ["forelimb muscles", "ORGAN", 360, 376], ["human NT3 transgene", "DNA", 121, 140], ["NT3 protein", "PROTEIN", 205, 216], ["NT3 protein", "PROTEIN", 325, 336], ["14 kDa", "PROTEIN", 338, 344], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["sensorimotor recovery", "PROBLEM", 72, 93], ["the human NT3 transgene in the spinal cord", "TREATMENT", 117, 159], ["peripheral infusion of NT3 protein", "TREATMENT", 182, 216], ["the NT3 protein", "TEST", 321, 336], ["spinal cord", "ANATOMY", 148, 159], ["forelimb muscles", "ANATOMY", 360, 376], ["sensorimotor recovery", "OBSERVATION", 386, 407]]], ["This is consistent with work by others 23 including a study showing that a signal from muscle spindles can improve neuroplasticity of descending pathways and can enhance recovery after CNS injury 24 .", [["muscle spindles", "ANATOMY", 87, 102], ["CNS", "ANATOMY", 185, 188], ["muscle spindles", "DISEASE", 87, 102], ["muscle spindles", "MULTI-TISSUE_STRUCTURE", 87, 102], ["CNS", "ANATOMICAL_SYSTEM", 185, 188], ["a study", "TEST", 52, 59], ["a signal from muscle spindles", "PROBLEM", 73, 102], ["CNS injury", "PROBLEM", 185, 195], ["consistent with", "UNCERTAINTY", 8, 23], ["muscle", "ANATOMY", 87, 93], ["descending", "ANATOMY_MODIFIER", 134, 144]]], ["Notably, NT3 protein is synthesised by muscle spindles 25 and can be transported from muscle to sensory ganglia and spinal motor neurons in nerves 7, 17, 19 and from the bloodstream to the CNS [26] [27] [28] .", [["muscle spindles", "ANATOMY", 39, 54], ["muscle", "ANATOMY", 86, 92], ["sensory ganglia", "ANATOMY", 96, 111], ["spinal motor neurons", "ANATOMY", 116, 136], ["nerves", "ANATOMY", 140, 146], ["bloodstream", "ANATOMY", 170, 181], ["CNS", "ANATOMY", 189, 192], ["NT3", "GENE_OR_GENE_PRODUCT", 9, 12], ["muscle spindles 25", "CELL", 39, 57], ["muscle", "ORGAN", 86, 92], ["sensory ganglia", "MULTI-TISSUE_STRUCTURE", 96, 111], ["spinal motor neurons", "CELL", 116, 136], ["nerves", "MULTI-TISSUE_STRUCTURE", 140, 146], ["NT3 protein", "PROTEIN", 9, 20], ["spinal motor neurons", "CELL_TYPE", 116, 136], ["NT3 protein", "TEST", 9, 20], ["NT3 protein", "OBSERVATION", 9, 20], ["muscle", "ANATOMY", 39, 45], ["muscle", "ANATOMY", 86, 92], ["sensory ganglia", "ANATOMY", 96, 111], ["spinal motor", "ANATOMY", 116, 128], ["nerves", "ANATOMY", 140, 146]]], ["This route of administration and time frame is clinically feasible so to take this potential therapy one step nearer the clinic, we next set out to determine whether intramuscular infusion of human NT3 protein (mature form, 14kDa) would improve outcome after stroke (i.e., bypassing the use of gene therapy and spinal surgery).IntroductionImportantly, the mature form of the NT3 protein has excellent translational potential: Phase I and II clinical trials have shown that repeated, systemic, high doses of NT3 protein are well-tolerated, safe and effective in more than 200 humans with sensory and motor neuropathy (Charcot-Marie-Tooth Type 1A) 29 or constipation including in people with spinal cord injury [29] [30] [31] [32] [33] .", [["intramuscular", "ANATOMY", 166, 179], ["spinal", "ANATOMY", 311, 317], ["spinal cord", "ANATOMY", 690, 701], ["stroke", "DISEASE", 259, 265], ["sensory and motor neuropathy", "DISEASE", 587, 615], ["constipation", "DISEASE", 652, 664], ["cord injury", "DISEASE", 697, 708], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 166, 179], ["human", "ORGANISM", 192, 197], ["NT3", "GENE_OR_GENE_PRODUCT", 198, 201], ["NT3", "GENE_OR_GENE_PRODUCT", 375, 378], ["NT3", "GENE_OR_GENE_PRODUCT", 507, 510], ["humans", "ORGANISM", 575, 581], ["people", "ORGANISM", 678, 684], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 690, 701], ["30] [31] [32", "SIMPLE_CHEMICAL", 715, 727], ["human NT3 protein", "PROTEIN", 192, 209], ["NT3 protein", "PROTEIN", 375, 386], ["NT3 protein", "PROTEIN", 507, 518], ["human", "SPECIES", 192, 197], ["humans", "SPECIES", 575, 581], ["people", "SPECIES", 678, 684], ["human", "SPECIES", 192, 197], ["humans", "SPECIES", 575, 581], ["this potential therapy", "TREATMENT", 78, 100], ["intramuscular infusion of human NT3 protein", "TREATMENT", 166, 209], ["stroke", "PROBLEM", 259, 265], ["gene therapy", "TREATMENT", 294, 306], ["spinal surgery", "TREATMENT", 311, 325], ["NT3 protein", "TREATMENT", 507, 518], ["sensory and motor neuropathy", "PROBLEM", 587, 615], ["constipation", "PROBLEM", 652, 664], ["spinal cord injury", "PROBLEM", 690, 708], ["spinal", "ANATOMY", 311, 317], ["motor neuropathy", "OBSERVATION", 599, 615], ["spinal cord", "ANATOMY", 690, 701]]], ["In contrast to other neurotrophins, NT3 does not cause any serious adverse effects such as pain 34 probably because its principal high affinity receptor TrkC is not expressed on adult nociceptors 6, 35 .", [["adult nociceptors", "ANATOMY", 178, 195], ["pain", "DISEASE", 91, 95], ["neurotrophins", "GENE_OR_GENE_PRODUCT", 21, 34], ["NT3", "GENE_OR_GENE_PRODUCT", 36, 39], ["TrkC", "GENE_OR_GENE_PRODUCT", 153, 157], ["neurotrophins", "PROTEIN", 21, 34], ["NT3", "PROTEIN", 36, 39], ["TrkC", "PROTEIN", 153, 157], ["NT3", "TREATMENT", 36, 39], ["any serious adverse effects", "PROBLEM", 55, 82], ["pain", "PROBLEM", 91, 95]]], ["These studies pave the way for NT3 as a therapy for stroke in humans.", [["stroke", "DISEASE", 52, 58], ["NT3", "GENE_OR_GENE_PRODUCT", 31, 34], ["humans", "ORGANISM", 62, 68], ["NT3", "PROTEIN", 31, 34], ["humans", "SPECIES", 62, 68], ["humans", "SPECIES", 62, 68], ["These studies", "TEST", 0, 13], ["NT3", "TREATMENT", 31, 34], ["a therapy", "TREATMENT", 38, 47], ["stroke in humans", "PROBLEM", 52, 68], ["stroke", "OBSERVATION", 52, 58]]], ["We now show in a blinded, randomized preclinical trial that treatment of disabled upper arm muscles with human NT3 protein reverses sensory and motor disability in rats when treatment is initiated in a clinically-feasible timeframe (24 hours after stroke).Experimental designRats received unilateral focal cortical stroke or underwent sham surgery 19, 36 (Fig. 1a,b) .", [["upper arm muscles", "ANATOMY", 82, 99], ["focal cortical", "ANATOMY", 300, 314], ["sensory and motor disability", "DISEASE", 132, 160], ["stroke", "DISEASE", 248, 254], ["cortical stroke", "DISEASE", 306, 321], ["upper arm", "ORGANISM_SUBDIVISION", 82, 91], ["muscles", "ORGANISM_SUBDIVISION", 92, 99], ["human", "ORGANISM", 105, 110], ["NT3", "GENE_OR_GENE_PRODUCT", 111, 114], ["rats", "ORGANISM", 164, 168], ["cortical", "MULTI-TISSUE_STRUCTURE", 306, 314], ["human NT3 protein", "PROTEIN", 105, 122], ["human", "SPECIES", 105, 110], ["rats", "SPECIES", 164, 168], ["human", "SPECIES", 105, 110], ["disabled upper arm muscles", "TREATMENT", 73, 99], ["human NT3 protein", "TREATMENT", 105, 122], ["treatment", "TREATMENT", 174, 183], ["stroke", "PROBLEM", 248, 254], ["Experimental designRats", "PROBLEM", 256, 279], ["unilateral focal cortical stroke", "PROBLEM", 289, 321], ["sham surgery", "TREATMENT", 335, 347], ["upper", "ANATOMY_MODIFIER", 82, 87], ["arm muscles", "ANATOMY", 88, 99], ["unilateral", "OBSERVATION_MODIFIER", 289, 299], ["focal", "OBSERVATION_MODIFIER", 300, 305], ["cortical stroke", "OBSERVATION", 306, 321]]], ["Twentyfour hours after stroke, rats were allocated to treatment using NT3 or vehicle, infused into affected triceps brachii muscles for one month via implanted catheters and subcutaneous osmotic minipumps.", [["triceps brachii muscles", "ANATOMY", 108, 131], ["subcutaneous", "ANATOMY", 174, 186], ["stroke", "DISEASE", 23, 29], ["NT3", "CHEMICAL", 70, 73], ["rats", "ORGANISM", 31, 35], ["NT3", "GENE_OR_GENE_PRODUCT", 70, 73], ["triceps brachii muscles", "TISSUE", 108, 131], ["NT3", "PROTEIN", 70, 73], ["rats", "SPECIES", 31, 35], ["stroke", "PROBLEM", 23, 29], ["treatment", "TREATMENT", 54, 63], ["NT3 or vehicle", "TREATMENT", 70, 84], ["implanted catheters", "TREATMENT", 150, 169], ["subcutaneous osmotic minipumps", "TREATMENT", 174, 204], ["triceps", "ANATOMY", 108, 115], ["brachii muscles", "ANATOMY", 116, 131], ["catheters", "OBSERVATION", 160, 169]]], ["Experiments were performed in accordance with guidelines from the Stroke Therapy Academic Industry Roundtable (STAIR) and others and our findings were reported in accordance with the ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines.", [["Stroke", "DISEASE", 66, 72]]], ["All surgical procedures, behavioural testing and analysis were performed using a randomised block design.", [["All surgical procedures", "TEST", 0, 23], ["behavioural testing", "TEST", 25, 44], ["analysis", "TEST", 49, 57], ["a randomised block design", "TREATMENT", 79, 104]]], ["All surgeries, behavioural testing and analysis were performed with investigators blinded to treatment groups.", [["All surgeries", "TREATMENT", 0, 13], ["behavioural testing", "TEST", 15, 34], ["analysis", "TEST", 39, 47]]], ["Rats were randomised to surgery by drawing a rat identity number from an envelope and then a stroke/sham allocation from an envelope.", [["stroke", "DISEASE", 93, 99], ["Rats", "ORGANISM", 0, 4], ["rat", "ORGANISM", 45, 48], ["Rats", "SPECIES", 0, 4], ["rat", "SPECIES", 45, 48], ["surgery", "TREATMENT", 24, 31], ["a stroke/sham allocation", "TREATMENT", 91, 115]]], ["Allocation concealment was performed by having NT3 and vehicle stocks coded by an independent person prior to loading pumps.", [["NT3", "GENE_OR_GENE_PRODUCT", 47, 50], ["NT3", "PROTEIN", 47, 50], ["person", "SPECIES", 94, 100], ["Allocation concealment", "TEST", 0, 22], ["NT3", "TREATMENT", 47, 50], ["loading pumps", "TREATMENT", 110, 123]]], ["Behavioural testing was conducted blind and codes were only broken after behavioural analyses were complete.", [["Behavioural testing", "TEST", 0, 19], ["behavioural analyses", "TEST", 73, 93]]], ["65 Lister hooded (~4 months; 200-300 g) outbred female rats (Charles River, UK) and 95 adult C57Bl/6 mice (7-8 weeks) were used.", [["rats", "ORGANISM", 55, 59], ["Charles River", "ORGANISM", 61, 74], ["UK", "ORGANISM", 76, 78], ["C57Bl/6 mice", "ORGANISM", 93, 105], ["rats", "SPECIES", 55, 59], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105]]], ["All procedures were in accordance with the UK Home Office guidelines and Animals (Scientific Procedures) Act of 1986.Stroke or sham lesionsRats were maintained (Specific Pathogen Free) in groups of 2 to 4 in Plexiglas housing with tunnels and bedding on a 12:12 hour light/dark cycle with food and water ad libitum.", [["sham lesions", "ANATOMY", 127, 139], ["Stroke", "DISEASE", 117, 123], ["lesions", "PATHOLOGICAL_FORMATION", 132, 139], ["Rats", "ORGANISM", 139, 143], ["Rats", "SPECIES", 139, 143], ["Stroke", "PROBLEM", 117, 123], ["sham lesions", "PROBLEM", 127, 139], ["sham", "ANATOMY", 127, 131], ["lesions", "OBSERVATION", 132, 139]]], ["Focal ischemic stroke was induced in the hemisphere representing the dominant forelimb ( Supplementary Fig. 1 ), as determined by the cylinder behavioural test.", [["hemisphere", "ANATOMY", 41, 51], ["forelimb", "ANATOMY", 78, 86], ["ischemic stroke", "DISEASE", 6, 21], ["forelimb", "ORGANISM_SUBDIVISION", 78, 86], ["Focal ischemic stroke", "PROBLEM", 0, 21], ["the cylinder behavioural test", "TEST", 130, 159], ["ischemic", "OBSERVATION_MODIFIER", 6, 14], ["stroke", "OBSERVATION", 15, 21], ["hemisphere", "ANATOMY_MODIFIER", 41, 51], ["dominant", "OBSERVATION_MODIFIER", 69, 77], ["forelimb", "OBSERVATION_MODIFIER", 78, 86]]], ["Stroke lesions (n = 60) were performed as previously described 19 .", [["Stroke lesions", "ANATOMY", 0, 14], ["Stroke", "DISEASE", 0, 6], ["Stroke lesions", "PATHOLOGICAL_FORMATION", 0, 14], ["Stroke lesions", "PROBLEM", 0, 14]]], ["Briefly, animals were transferred to a stereotaxic frame (David Kopf Instruments, USA) where a midline incision was made, the cortex was then exposed via craniotomy using the following co-ordinates [defined as anterioposterior (AP), mediolateral (ML)]: AP 4 mm to \u2212 2 mm, ML 2 mm to 4 mm, relative to bregma.", [["cortex", "ANATOMY", 126, 132], ["animals", "ORGANISM", 9, 16], ["cortex", "CANCER", 126, 132], ["a midline incision", "TREATMENT", 93, 111], ["craniotomy", "TREATMENT", 154, 164], ["anterioposterior (AP), mediolateral (ML)", "TEST", 210, 250], ["AP", "TEST", 253, 255], ["midline", "ANATOMY", 95, 102], ["incision", "OBSERVATION", 103, 111], ["cortex", "ANATOMY", 126, 132], ["craniotomy", "OBSERVATION", 154, 164]]], ["Endothelin-1 (ET-1, 400 pmol/\u00b5L in sterile saline; CalBioChem) was applied using a glass micropipette attached to a Hamilton syringe.", [["Endothelin-1", "CHEMICAL", 0, 12], ["Endothelin-1", "GENE_OR_GENE_PRODUCT", 0, 12], ["ET-1", "GENE_OR_GENE_PRODUCT", 14, 18], ["saline", "SIMPLE_CHEMICAL", 43, 49], ["CalBioChem", "SIMPLE_CHEMICAL", 51, 61], ["Endothelin-1 (ET", "TREATMENT", 0, 16], ["sterile saline", "TREATMENT", 35, 49], ["CalBioChem)", "TREATMENT", 51, 62], ["a glass micropipette", "TREATMENT", 81, 101], ["a Hamilton syringe", "TREATMENT", 114, 132]]], ["1 \u00b5l of ET-1 to was applied to the overlying dura to reduce bleeding, and immediately thereafter, the dura mater was incised and reflected.", [["dura", "ANATOMY", 45, 49], ["dura mater", "ANATOMY", 102, 112], ["ET-1", "CHEMICAL", 8, 12], ["bleeding", "DISEASE", 60, 68], ["ET-1", "GENE_OR_GENE_PRODUCT", 8, 12], ["dura", "TISSUE", 45, 49], ["dura mater", "MULTI-TISSUE_STRUCTURE", 102, 112], ["ET-1", "TREATMENT", 8, 12], ["the overlying dura", "PROBLEM", 31, 49], ["bleeding", "PROBLEM", 60, 68], ["the dura mater", "TREATMENT", 98, 112], ["overlying", "ANATOMY_MODIFIER", 35, 44], ["dura", "ANATOMY", 45, 49], ["bleeding", "OBSERVATION", 60, 68], ["dura mater", "ANATOMY", 102, 112]]], ["Four 1 \u03bcl volumes of ET-1 were administered topically and four 1 \u00b5l volumes were microinjected intracortically (at a depth of 1 mm from the brain surface) at the following co-ordinates (from bregma and midline, respectively): AP + 3.5 mm, ML 2.8 mm AP + 2.0 mm, ML 2.8 mm AP + 0.5 mm, ML 2.8 mm AP -1.0 mm, ML 2.8 mm Temperature was maintained using a rectal probe connected to a homeothermic blanket (Harvard Apparatus, USA) placed under the animal which maintained rectal temperature at 36 \u00b1 1\u00b0C. Prior to suturing, the animal was left undisturbed for 5 minutes.", [["brain surface", "ANATOMY", 140, 153], ["midline", "ANATOMY", 202, 209], ["rectal", "ANATOMY", 352, 358], ["rectal", "ANATOMY", 467, 473], ["ET-1", "CHEMICAL", 21, 25], ["ET-1", "GENE_OR_GENE_PRODUCT", 21, 25], ["brain surface", "MULTI-TISSUE_STRUCTURE", 140, 153], ["rectal", "ORGAN", 467, 473], ["ET-1", "TREATMENT", 21, 25], ["AP", "TEST", 226, 228], ["ML", "TEST", 239, 241], ["AP", "TEST", 249, 251], ["ML", "TEST", 262, 264], ["AP", "TEST", 272, 274], ["ML", "TEST", 285, 287], ["AP", "TEST", 295, 297], ["Temperature", "TEST", 317, 328], ["a rectal probe", "TREATMENT", 350, 364], ["a homeothermic blanket", "TREATMENT", 378, 400], ["rectal temperature", "TEST", 467, 485], ["suturing", "TREATMENT", 508, 516], ["brain", "ANATOMY", 140, 145], ["surface", "ANATOMY_MODIFIER", 146, 153], ["midline", "ANATOMY_MODIFIER", 202, 209], ["rectal", "ANATOMY", 352, 358], ["rectal", "ANATOMY", 467, 473], ["suturing", "OBSERVATION", 508, 516], ["left", "ANATOMY_MODIFIER", 533, 537]]], ["Modifying previous work 36 , the skull fragment was then replaced and sealed using bone wax (Covidien, UK).", [["skull fragment", "ANATOMY", 33, 47], ["bone", "ANATOMY", 83, 87], ["skull fragment", "MULTI-TISSUE_STRUCTURE", 33, 47], ["bone", "TISSUE", 83, 87], ["the skull fragment", "PROBLEM", 29, 47], ["skull", "ANATOMY", 33, 38], ["fragment", "OBSERVATION", 39, 47], ["bone", "ANATOMY", 83, 87]]], ["100% (60/60) of rats survived this stroke surgery.", [["stroke", "DISEASE", 35, 41], ["rats", "ORGANISM", 16, 20], ["rats", "SPECIES", 16, 20], ["this stroke surgery", "TREATMENT", 30, 49]]], ["Sham-operated (n = 5) rats received all procedures up to, but not including, craniotomy or endothelin-1 injection.", [["endothelin-1", "CHEMICAL", 91, 103], ["rats", "ORGANISM", 22, 26], ["endothelin-1", "GENE_OR_GENE_PRODUCT", 91, 103], ["rats", "SPECIES", 22, 26], ["all procedures", "TREATMENT", 36, 50], ["craniotomy", "TREATMENT", 77, 87], ["endothelin", "TREATMENT", 91, 101], ["craniotomy", "OBSERVATION", 77, 87]]], ["Animals were given buprenorphine (0.01 mg/kg, subcutaneously) for postoperative pain relief.Stroke or sham lesionsOur method of inducing stroke with ET-1 is advantageous for evaluating regenerative stroke therapies for four reasons: 1) our model produces ischemic lesions that model small focal human strokes rather than larger \"malignant\" strokes that tend to be fatal in humans 37 ; 2) our model targets sensorimotor cortex; 3) our stroke model involves only low mortality rates and has reasonable reproducibility 36 with a proven ability to detect therapies that induce neuroplasticity and functional recovery 19, 38 ; 4) our model causes sustained sensorimotor deficits (e.g., impaired use of limbs) which are common neurological symptoms of human stroke.Magnetic resonance imagingStructural images were obtained prior to stroke, 24 hours after stroke and at one and eight weeks after stroke.", [["subcutaneously", "ANATOMY", 46, 60], ["sham lesions", "ANATOMY", 102, 114], ["lesions", "ANATOMY", 264, 271], ["sensorimotor cortex", "ANATOMY", 406, 425], ["limbs", "ANATOMY", 697, 702], ["neurological", "ANATOMY", 721, 733], ["buprenorphine", "CHEMICAL", 19, 32], ["postoperative pain", "DISEASE", 66, 84], ["Stroke", "DISEASE", 92, 98], ["stroke", "DISEASE", 137, 143], ["stroke", "DISEASE", 198, 204], ["strokes", "DISEASE", 301, 308], ["strokes", "DISEASE", 340, 347], ["stroke", "DISEASE", 434, 440], ["sensorimotor deficits", "DISEASE", 652, 673], ["stroke", "DISEASE", 752, 758], ["stroke", "DISEASE", 826, 832], ["stroke", "DISEASE", 849, 855], ["stroke", "DISEASE", 889, 895], ["buprenorphine", "CHEMICAL", 19, 32], ["Animals", "ORGANISM", 0, 7], ["buprenorphine", "SIMPLE_CHEMICAL", 19, 32], ["lesions", "PATHOLOGICAL_FORMATION", 107, 114], ["ET-1", "GENE_OR_GENE_PRODUCT", 149, 153], ["lesions", "PATHOLOGICAL_FORMATION", 264, 271], ["human", "ORGANISM", 295, 300], ["humans", "ORGANISM", 373, 379], ["sensorimotor cortex", "MULTI-TISSUE_STRUCTURE", 406, 425], ["limbs", "ORGANISM_SUBDIVISION", 697, 702], ["human", "ORGANISM", 746, 751], ["human", "SPECIES", 295, 300], ["humans", "SPECIES", 373, 379], ["human", "SPECIES", 746, 751], ["human", "SPECIES", 295, 300], ["humans", "SPECIES", 373, 379], ["human", "SPECIES", 746, 751], ["buprenorphine", "TREATMENT", 19, 32], ["postoperative pain relief", "PROBLEM", 66, 91], ["Stroke", "PROBLEM", 92, 98], ["sham lesions", "PROBLEM", 102, 114], ["inducing stroke", "PROBLEM", 128, 143], ["regenerative stroke therapies", "TREATMENT", 185, 214], ["ischemic lesions", "PROBLEM", 255, 271], ["model small focal human strokes", "PROBLEM", 277, 308], ["larger \"malignant\" strokes", "PROBLEM", 321, 347], ["our stroke model", "PROBLEM", 430, 446], ["low mortality rates", "PROBLEM", 461, 480], ["therapies", "TREATMENT", 551, 560], ["sustained sensorimotor deficits", "PROBLEM", 642, 673], ["common neurological symptoms", "PROBLEM", 714, 742], ["human stroke", "PROBLEM", 746, 758], ["Magnetic resonance imaging", "TEST", 759, 785], ["Structural images", "TEST", 785, 802], ["stroke", "PROBLEM", 826, 832], ["stroke", "PROBLEM", 849, 855], ["stroke", "PROBLEM", 889, 895], ["sham", "ANATOMY", 102, 106], ["lesions", "OBSERVATION", 107, 114], ["ischemic", "OBSERVATION_MODIFIER", 255, 263], ["lesions", "OBSERVATION", 264, 271], ["small", "OBSERVATION_MODIFIER", 283, 288], ["focal", "OBSERVATION_MODIFIER", 289, 294], ["human strokes", "OBSERVATION", 295, 308], ["larger", "OBSERVATION_MODIFIER", 321, 327], ["\"", "OBSERVATION_MODIFIER", 328, 329], ["malignant", "OBSERVATION_MODIFIER", 329, 338], ["sensorimotor deficits", "OBSERVATION", 652, 673], ["limbs", "ANATOMY", 697, 702], ["stroke", "OBSERVATION", 752, 758]]], ["MR imaging was conducted on a 7 Tesla (T) horizontal bore VMRIS scanner (Varian, Palo Alto, CA, USA).", [["MR", "PROTEIN", 0, 2], ["MR imaging", "TEST", 0, 10]]], ["Animals were anaesthetised using 3.5% isoflurane, in 0.8 L/min medical air and 0.2 L/min medical oxygen in an induction chamber.", [["isoflurane", "CHEMICAL", 38, 48], ["oxygen", "CHEMICAL", 97, 103], ["isoflurane", "CHEMICAL", 38, 48], ["oxygen", "CHEMICAL", 97, 103], ["Animals", "ORGANISM", 0, 7], ["isoflurane", "SIMPLE_CHEMICAL", 38, 48], ["oxygen", "SIMPLE_CHEMICAL", 97, 103], ["3.5% isoflurane", "TREATMENT", 33, 48], ["medical oxygen", "TREATMENT", 89, 103], ["an induction chamber", "TREATMENT", 107, 127]]], ["Once anaesthetised they were secured in a stereotaxic head frame inside the quadrature birdcage MR coil (43 mm internal diameter, ID) and placed into the scanner.", [["head", "ANATOMY", 54, 58], ["head", "ORGANISM_SUBDIVISION", 54, 58], ["stereotaxic head frame", "DNA", 42, 64], ["the quadrature birdcage MR coil", "TREATMENT", 72, 103]]], ["Each animal's physiology was supervised throughout the procedure using a respiration monitor (BIOPAC, USA) and a pulse oximetry sensor (Nonin, USA) that interfaced with a PC running Biopac.", [["the procedure", "TREATMENT", 51, 64], ["a respiration monitor", "TEST", 71, 92], ["a pulse oximetry sensor", "TEST", 111, 134], ["a PC running Biopac", "TREATMENT", 169, 188]]], ["Additionally, an MRI compatible homeothermic blanket (Harvard Apparatus, USA) placed over the animal responded to any alterations in the body temperature identified by the rectal probe, and maintained temperature at 37 \u00b1 1\u00b0C. The T2 weighted MR images were acquired using a fast spin-echo sequence: effective echo time (TE) 60 ms, repetition time (TR) 4000 ms, field of view (FOV) 40 mm x 40 mm and an acquisition matrix 128 x 128, acquiring 20 x 1 mm thick slices in approximately 8 minutes.", [["body", "ANATOMY", 137, 141], ["rectal", "ANATOMY", 172, 178], ["slices", "ANATOMY", 458, 464], ["body", "ORGANISM_SUBDIVISION", 137, 141], ["rectal", "ORGAN", 172, 178], ["MR", "PROTEIN", 242, 244], ["an MRI", "TEST", 14, 20], ["homeothermic blanket", "TREATMENT", 32, 52], ["the body temperature", "TEST", 133, 153], ["the rectal probe", "TREATMENT", 168, 184], ["The T2 weighted MR images", "TEST", 226, 251], ["a fast spin-echo sequence", "TEST", 272, 297], ["an acquisition matrix", "TEST", 399, 420], ["thick slices", "TEST", 452, 464], ["rectal", "ANATOMY", 172, 178]]], ["At the end of the study (to avoid affecting blinding or randomization), lesion volumes at the 24 hour time point were measured using a semi-automatic contour method in Jim software under blinded conditions (Xinapse systems Ltd).Functional magnetic resonance imaging (fMRI)Functional magnetic resonance imaging (fMRI) was performed in a subset of rats that did not receive intracortical injections of BDA tracer (n = 10/group).", [["lesion", "ANATOMY", 72, 78], ["intracortical", "ANATOMY", 372, 385], ["BDA", "CHEMICAL", 400, 403], ["BDA", "CHEMICAL", 400, 403], ["rats", "ORGANISM", 346, 350], ["BDA tracer", "SIMPLE_CHEMICAL", 400, 410], ["rats", "SPECIES", 346, 350], ["the study", "TEST", 14, 23], ["blinding", "PROBLEM", 44, 52], ["lesion volumes", "PROBLEM", 72, 86], ["Functional magnetic resonance imaging", "TEST", 228, 265], ["MRI", "TEST", 268, 271], ["Functional magnetic resonance imaging (fMRI", "TEST", 272, 315], ["intracortical injections", "TREATMENT", 372, 396], ["BDA tracer", "TEST", 400, 410], ["lesion", "OBSERVATION", 72, 78]]], ["Images were acquired prior to stroke and at one and eight weeks after stroke during non-noxious somatosensory stimulation of the affected or less-affected wrist 19 .", [["wrist", "ANATOMY", 155, 160], ["stroke", "DISEASE", 30, 36], ["stroke", "DISEASE", 70, 76], ["wrist", "ORGANISM_SUBDIVISION", 155, 160], ["Images", "TEST", 0, 6], ["stroke", "PROBLEM", 30, 36], ["stroke", "PROBLEM", 70, 76], ["non-noxious somatosensory stimulation", "TREATMENT", 84, 121], ["wrist", "ANATOMY", 155, 160]]], ["This involves delivery of small electrical currents to a wrist whilst the subjects were kept anaesthetised using medium dose Alpha-Chloralose suitable for recovery and longitudinal (repeated) imaging 39 .", [["wrist", "ANATOMY", 57, 62], ["Alpha-Chloralose", "CHEMICAL", 125, 141], ["Alpha-Chloralose", "CHEMICAL", 125, 141], ["wrist", "ORGANISM_SUBDIVISION", 57, 62], ["Alpha-Chloralose", "SIMPLE_CHEMICAL", 125, 141], ["small electrical currents", "PROBLEM", 26, 51], ["medium dose Alpha-Chloralose", "TREATMENT", 113, 141], ["longitudinal (repeated) imaging", "TEST", 168, 199], ["small", "OBSERVATION_MODIFIER", 26, 31], ["wrist", "ANATOMY", 57, 62]]], ["Alpha chloralose anesthesia was prepared by mixing equal amounts of Borax Decahydrate (Sigma) and alpha chloralose-Pestanal (analytical standard, <8% beta isoform, 45373, Sigma, UK) in physiological saline each at a concentration of 40 mg/ml in a glass beaker at 52\u00b0C prior to filtering using a 0.22 \u00b5m filter.Functional magnetic resonance imaging (fMRI)Rats were first anaesthetised using 4% isoflurane, 0.8 L/min medical air and 0.2 L/min oxygen.", [["chloralose", "CHEMICAL", 6, 16], ["Borax Decahydrate", "CHEMICAL", 68, 85], ["alpha chloralose-Pestanal", "CHEMICAL", 98, 123], ["isoflurane", "CHEMICAL", 393, 403], ["oxygen", "CHEMICAL", 441, 447], ["Alpha chloralose", "CHEMICAL", 0, 16], ["Borax Decahydrate", "CHEMICAL", 68, 85], ["alpha chloralose", "CHEMICAL", 98, 114], ["Pestanal", "CHEMICAL", 115, 123], ["isoflurane", "CHEMICAL", 393, 403], ["oxygen", "CHEMICAL", 441, 447], ["Alpha chloralose", "SIMPLE_CHEMICAL", 0, 16], ["Borax", "SIMPLE_CHEMICAL", 68, 73], ["Decahydrate", "SIMPLE_CHEMICAL", 74, 85], ["Sigma", "SIMPLE_CHEMICAL", 87, 92], ["alpha chloralose-Pestanal", "SIMPLE_CHEMICAL", 98, 123], ["isoflurane", "SIMPLE_CHEMICAL", 393, 403], ["oxygen", "SIMPLE_CHEMICAL", 441, 447], ["Rats", "SPECIES", 354, 358], ["Alpha chloralose anesthesia", "TREATMENT", 0, 27], ["alpha chloralose", "TEST", 98, 114], ["physiological saline", "TREATMENT", 185, 205], ["a 0.22 \u00b5m filter", "TREATMENT", 293, 309], ["Functional magnetic resonance imaging", "TEST", 310, 347], ["MRI", "TEST", 350, 353], ["4% isoflurane", "TREATMENT", 390, 403], ["oxygen", "TREATMENT", 441, 447], ["chloralose anesthesia", "OBSERVATION", 6, 27]]], ["A tail cannulation was performed and the animal was transferred to the MRI machine.", [["tail", "ANATOMY", 2, 6], ["tail", "MULTI-TISSUE_STRUCTURE", 2, 6], ["A tail cannulation", "TEST", 0, 18], ["tail", "OBSERVATION_MODIFIER", 2, 6], ["cannulation", "OBSERVATION", 7, 18]]], ["A bolus of 40 mg/kg alpha chloralose-Pestanal was injected intravenously and then the isoflurane was switched off after 5 minutes.", [["intravenously", "ANATOMY", 59, 72], ["alpha chloralose-Pestanal", "CHEMICAL", 20, 45], ["isoflurane", "CHEMICAL", 86, 96], ["Pestanal", "CHEMICAL", 37, 45], ["isoflurane", "CHEMICAL", 86, 96], ["alpha chloralose-Pestanal", "SIMPLE_CHEMICAL", 20, 45], ["isoflurane", "SIMPLE_CHEMICAL", 86, 96], ["A bolus", "TREATMENT", 0, 7], ["alpha chloralose", "TREATMENT", 20, 36], ["Pestanal", "TREATMENT", 37, 45], ["the isoflurane", "TREATMENT", 82, 96]]], ["An infusion line for continuous application of alpha chloralose was then attached to the cannula at 10 mg/kg/h over the experimental time.", [["alpha chloralose", "CHEMICAL", 47, 63], ["alpha chloralose", "CHEMICAL", 47, 63], ["alpha chloralose", "SIMPLE_CHEMICAL", 47, 63], ["An infusion line", "TREATMENT", 0, 16], ["continuous application of alpha chloralose", "TREATMENT", 21, 63], ["the cannula", "TREATMENT", 85, 96], ["infusion line", "OBSERVATION", 3, 16]]], ["Medical air (0.8 L/min) and oxygen (0.2 L/min) was continuously delivered throughout the scanning period .", [["oxygen", "CHEMICAL", 28, 34], ["oxygen", "CHEMICAL", 28, 34], ["oxygen", "SIMPLE_CHEMICAL", 28, 34], ["Medical air", "TREATMENT", 0, 11], ["oxygen", "TREATMENT", 28, 34]]], ["MR images were obtained using a 7 Tesla scanner (Varian, Agilent).", [["MR", "PROTEIN", 0, 2], ["MR images", "TEST", 0, 9], ["a 7 Tesla scanner (Varian, Agilent)", "TREATMENT", 30, 65]]], ["Initially, a T2-weighted structural scan was acquired, using a fast spin echo (FSE) sequence with repetition time (TR) = 4000 ms, echo time (TE) = 60 ms and field of view (FOV) of 40 x 40 mm, yielding 20 slices with voxel size of 0.3215 x 0.3125 x 1 mm in approximately 8 min. fMRI scans were acquired using a Multi-Gradient-Multi-Echo sequence (TR = 360 ms, TEs = 5, 10, 15 ms, voxel size 0.5 mm x 0.5 mm x 1 mm, resolution 64 x 64 x 20, scan time 23 s).", [["slices", "ANATOMY", 204, 210], ["T2", "DNA", 13, 15], ["Multi-Gradient-Multi-Echo sequence", "DNA", 310, 344], ["a T2-weighted structural scan", "TEST", 11, 40], ["a fast spin echo", "TEST", 61, 77], ["echo time", "TEST", 130, 139], ["field of view (FOV)", "TEST", 157, 176], ["voxel size", "TEST", 216, 226], ["fMRI scans", "TEST", 277, 287], ["Echo sequence", "TEST", 331, 344], ["TR", "TEST", 346, 348], ["ms", "TEST", 355, 357], ["TEs", "TEST", 359, 362], ["voxel size", "TEST", 379, 389], ["resolution", "TEST", 414, 424], ["scan time", "TEST", 439, 448], ["size", "OBSERVATION_MODIFIER", 222, 226]]], ["100 volumes were acquired with a pseudo-random onoff stimulation of the forepaw at 3 Hz (400 \u03bcs, 2 mA pulse) using a platinum subdermal needle electrode (F-E2, Grass Technologies, USA) and a TENS (Transcutaneous Electrical Nerve Stimulation) pad.", [["platinum", "CHEMICAL", 117, 125], ["F-E2", "CHEMICAL", 154, 158], ["platinum", "CHEMICAL", 117, 125], ["a pseudo", "TEST", 31, 39], ["a platinum subdermal needle electrode", "TREATMENT", 115, 152], ["a TENS (Transcutaneous Electrical Nerve Stimulation) pad", "TREATMENT", 189, 245]]], ["It has previously been shown that the use of a TENS pad results in this intensity of stimulation being innocuous rather than noxious: whereas blood pressure is not altered at 2 mA stimulation, it is increased with 3.8 mA stimulation (see references in 19 ).", [["blood", "ANATOMY", 142, 147], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["a TENS pad", "TREATMENT", 45, 55], ["blood pressure", "TEST", 142, 156], ["3.8 mA stimulation", "TREATMENT", 214, 232], ["increased", "OBSERVATION_MODIFIER", 199, 208]]], ["The order of paw stimulation was also randomised.", [["paw", "ORGANISM_SUBDIVISION", 13, 16], ["paw stimulation", "TREATMENT", 13, 28]]], ["Animals were closely monitored following the end of the scanning, given 5 ml of saline (subcutaneous, room temperature) and were kept in a warmed incubator (31 deg C) until fully conscious: this takes 2 to 3 hours due to slow pharmacokinetics of alpha chloralose.", [["subcutaneous", "ANATOMY", 88, 100], ["alpha chloralose", "CHEMICAL", 246, 262], ["alpha chloralose", "CHEMICAL", 246, 262], ["Animals", "ORGANISM", 0, 7], ["saline", "SIMPLE_CHEMICAL", 80, 86], ["alpha chloralose", "SIMPLE_CHEMICAL", 246, 262], ["the scanning", "TEST", 52, 64], ["saline (subcutaneous, room temperature", "TREATMENT", 80, 118], ["a warmed incubator", "TREATMENT", 137, 155], ["alpha chloralose", "TREATMENT", 246, 262]]], ["Two animals died following alpha chloralose anaesthesia due to breathing difficulties in recovery.", [["alpha chloralose", "CHEMICAL", 27, 43], ["breathing difficulties", "DISEASE", 63, 85], ["alpha chloralose", "CHEMICAL", 27, 43], ["alpha chloralose", "GENE_OR_GENE_PRODUCT", 27, 43], ["alpha chloralose anaesthesia", "TREATMENT", 27, 55], ["breathing difficulties", "PROBLEM", 63, 85]]], ["Scans with obvious imaging artefacts were discarded, leaving final group numbers of n=7, 9, 7 and n=9, 8, 4 at weeks 0, 1 and 8 for NT3 and vehicle treated groups respectively.", [["NT3", "GENE_OR_GENE_PRODUCT", 132, 135], ["NT3", "PROTEIN", 132, 135], ["Scans", "TEST", 0, 5], ["obvious imaging artefacts", "TEST", 11, 36], ["NT3 and vehicle treated groups", "TREATMENT", 132, 162]]], ["The resulting images were analyzed with SPM-8 (Statistical Parametric Mapping, FIL, UCL).", [["The resulting images", "TEST", 0, 20], ["SPM", "TEST", 40, 43], ["Statistical Parametric Mapping", "TEST", 47, 77]]], ["In order to make sure all lesions were in the same side of the brain, images with righthand side strokes were rotated about the sagittal mid-plane, so that the lesioned hemisphere always appeared on the left.", [["lesions", "ANATOMY", 26, 33], ["brain", "ANATOMY", 63, 68], ["hemisphere", "ANATOMY", 169, 179], ["left", "ANATOMY", 203, 207], ["strokes", "DISEASE", 97, 104], ["lesions", "CANCER", 26, 33], ["brain", "ORGAN", 63, 68], ["all lesions", "PROBLEM", 22, 33], ["images", "TEST", 70, 76], ["righthand side strokes", "PROBLEM", 82, 104], ["lesions", "OBSERVATION", 26, 33], ["brain", "ANATOMY", 63, 68], ["lesioned", "OBSERVATION", 160, 168], ["left", "ANATOMY_MODIFIER", 203, 207]]], ["Functional scans were initially realigned to the first image in the timeseries in order to correct for movements of the head.", [["head", "ANATOMY", 120, 124], ["head", "ORGANISM_SUBDIVISION", 120, 124], ["Functional scans", "TEST", 0, 16], ["movements of the head", "TEST", 103, 124], ["head", "ANATOMY", 120, 124]]], ["The first volume of the functional scan was then spatially registered to the structural image, which was, in turn, linearly warped to a template brain.", [["brain", "ANATOMY", 145, 150], ["brain", "ORGAN", 145, 150], ["the functional scan", "TEST", 20, 39], ["the structural image", "TEST", 73, 93], ["brain", "ANATOMY", 145, 150]]], ["Linear warping was used in this step in order to avoid deforming the lesion region.", [["lesion", "ANATOMY", 69, 75], ["Linear warping", "TREATMENT", 0, 14], ["deforming the lesion region", "PROBLEM", 55, 82], ["warping", "OBSERVATION", 7, 14], ["lesion", "OBSERVATION", 69, 75]]], ["Warping parameters obtained during registration of structural image to template were applied to the realigned functional time-series, resulting in structural and functional images that are all in a standard space.", [["Warping parameters", "TEST", 0, 18], ["structural image", "TEST", 51, 67], ["structural and functional images", "TEST", 147, 179]]], ["Finally, functional images were smoothed using a Gaussian kernel with Full Width Half Maximum of 1.0 x 1.0 x 2 mm (twice the voxel size).", [["functional images", "TEST", 9, 26], ["a Gaussian kernel", "TEST", 47, 64], ["1.0 x 1.0 x 2 mm", "OBSERVATION_MODIFIER", 97, 113], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["Because of the relatively long effective TR of the functional images, a PET basic model (one-sample t-test) was used for firstlevel analyses with covariates consisting of the pseudo-random stimulation pattern (paradigm), and the estimated movement parameters of each individual rat.", [["rat", "ORGANISM", 278, 281], ["TR", "PROTEIN", 41, 43], ["rat", "SPECIES", 278, 281], ["a PET basic model", "TEST", 70, 87], ["sample t-test", "TEST", 93, 106], ["firstlevel analyses", "TEST", 121, 140], ["the pseudo", "TEST", 171, 181], ["the estimated movement parameters", "TEST", 225, 258]]], ["Volumes signal intensity was globally scaled and individual masks, generated from the fast spin echo (FSE) structural scan for each rat brain at each time-point using a 3D Pulse-Coupled Neural Network 40 (also registered to the template), were used as explicit masks for the first-level statistical analysis.", [["brain", "ANATOMY", 136, 141], ["rat", "ORGANISM", 132, 135], ["brain", "ORGAN", 136, 141], ["rat", "SPECIES", 132, 135], ["Volumes signal intensity", "TEST", 0, 24], ["individual masks", "TEST", 49, 65], ["the fast spin echo", "TEST", 82, 100], ["structural scan", "TEST", 107, 122], ["a 3D Pulse", "TEST", 167, 177], ["the first-level statistical analysis", "TEST", 271, 307], ["intensity", "OBSERVATION_MODIFIER", 15, 24], ["globally", "OBSERVATION_MODIFIER", 29, 37], ["scaled", "OBSERVATION_MODIFIER", 38, 44], ["brain", "ANATOMY", 136, 141]]], ["Contrast images from the First-level analysis were then carried onto a Second-level (random effects) group analysis.", [["Contrast images", "TEST", 0, 15], ["group analysis", "TEST", 101, 115]]], ["Effects of group (i.e. NT3 or vehicle treated) and stimulated paw (i.e. affected or lessaffected) were used to create statistical comparisons.", [["NT3", "GENE_OR_GENE_PRODUCT", 23, 26], ["paw", "ORGANISM_SUBDIVISION", 62, 65], ["NT3", "PROTEIN", 23, 26], ["NT3 or vehicle", "TREATMENT", 23, 37]]], ["A flexible factorial analysis was used to compare the difference between the NT3 and vehicle treated groups in the change from baseline to 8 weeks 41 .", [["NT3", "GENE_OR_GENE_PRODUCT", 77, 80], ["NT3", "PROTEIN", 77, 80], ["A flexible factorial analysis", "TEST", 0, 29], ["the NT3 and vehicle treated groups", "TREATMENT", 73, 107]]], ["Statistical parametric maps were generated using an uncorrected threshold of p < 0.05; images show group mean activations and T values are given.NT3 or vehicle treatment24 hours after stroke (immediately after MRI), rats were allocated to treatment using a randomized block design.", [["NT3", "CHEMICAL", 145, 148], ["stroke", "DISEASE", 184, 190], ["NT3", "GENE_OR_GENE_PRODUCT", 145, 148], ["rats", "ORGANISM", 216, 220], ["NT3", "PROTEIN", 145, 148], ["rats", "SPECIES", 216, 220], ["Statistical parametric maps", "TEST", 0, 27], ["images", "TEST", 87, 93], ["group mean activations", "TEST", 99, 121], ["T values", "TEST", 126, 134], ["NT3", "TREATMENT", 145, 148], ["stroke", "PROBLEM", 184, 190], ["MRI", "TEST", 210, 213], ["treatment", "TREATMENT", 239, 248], ["a randomized block design", "TREATMENT", 255, 280]]], ["Allocation concealment was performed by having NT3 and vehicle stocks coded by a third party.", [["NT3", "GENE_OR_GENE_PRODUCT", 47, 50], ["NT3", "PROTEIN", 47, 50], ["Allocation concealment", "TEST", 0, 22], ["NT3", "TREATMENT", 47, 50]]], ["Rats were anaesthetised as above and a small incision was made between elbow and axilla, and a small subcutaneous space was formed to the lower back.", [["elbow", "ANATOMY", 71, 76], ["axilla", "ANATOMY", 81, 87], ["subcutaneous space", "ANATOMY", 101, 119], ["lower back", "ANATOMY", 138, 148], ["Rats", "ORGANISM", 0, 4], ["elbow", "ORGANISM_SUBDIVISION", 71, 76], ["axilla", "ORGAN", 81, 87], ["Rats", "SPECIES", 0, 4], ["a small incision", "PROBLEM", 37, 53], ["a small subcutaneous space", "TREATMENT", 93, 119], ["small", "OBSERVATION_MODIFIER", 39, 44], ["incision", "OBSERVATION", 45, 53], ["elbow", "ANATOMY", 71, 76], ["axilla", "ANATOMY", 81, 87], ["small", "OBSERVATION_MODIFIER", 95, 100], ["subcutaneous space", "ANATOMY", 101, 119], ["lower", "ANATOMY_MODIFIER", 138, 143], ["back", "ANATOMY", 144, 148]]], ["The osmotic pump with the catheter attached was positioned in this subcutaneous space and then an ultrafine, flexible catheter was implanted approximately 15 millimetres into the proximal end of the long head of the triceps brachii muscle on the disabled side and this was sutured in place (Prolene 5/0, Ethicon, UK).", [["subcutaneous space", "ANATOMY", 67, 85], ["head", "ANATOMY", 204, 208], ["triceps brachii muscle", "ANATOMY", 216, 238], ["head", "ORGANISM_SUBDIVISION", 204, 208], ["triceps brachii muscle", "TISSUE", 216, 238], ["The osmotic pump", "TREATMENT", 0, 16], ["the catheter", "TREATMENT", 22, 34], ["an ultrafine, flexible catheter", "TREATMENT", 95, 126], ["Prolene", "TREATMENT", 291, 298], ["osmotic pump", "OBSERVATION", 4, 16], ["catheter", "OBSERVATION", 26, 34], ["subcutaneous space", "ANATOMY", 67, 85], ["flexible", "OBSERVATION_MODIFIER", 109, 117], ["catheter", "OBSERVATION", 118, 126], ["proximal", "ANATOMY_MODIFIER", 179, 187], ["end", "ANATOMY_MODIFIER", 188, 191], ["long", "ANATOMY_MODIFIER", 199, 203], ["head", "ANATOMY_MODIFIER", 204, 208], ["triceps", "ANATOMY_MODIFIER", 216, 223], ["brachii muscle", "ANATOMY", 224, 238], ["sutured", "OBSERVATION", 273, 280]]], ["Triceps brachii was selected as the site for infusion because this large muscle is involved in forelimb extension during walking and for postural support during rearing) rearing.", [["Triceps brachii", "ANATOMY", 0, 15], ["site", "ANATOMY", 36, 40], ["muscle", "ANATOMY", 73, 79], ["forelimb", "ANATOMY", 95, 103], ["Triceps brachii", "ORGAN", 0, 15], ["muscle", "ORGAN", 73, 79], ["forelimb", "ORGANISM_SUBDIVISION", 95, 103], ["infusion", "TREATMENT", 45, 53], ["postural support", "TREATMENT", 137, 153], ["brachii", "ANATOMY", 8, 15], ["muscle", "ANATOMY", 73, 79]]], ["Note that in the triceps brachii, the end plates are located in the belly of the muscle 42 .", [["triceps brachii", "ANATOMY", 17, 32], ["muscle", "ANATOMY", 81, 87], ["triceps brachii", "ORGAN", 17, 32], ["belly", "ORGANISM_SUBDIVISION", 68, 73], ["muscle", "ORGAN", 81, 87], ["the end plates", "TREATMENT", 34, 48], ["triceps brachii", "ANATOMY", 17, 32], ["end", "OBSERVATION_MODIFIER", 38, 41], ["plates", "OBSERVATION_MODIFIER", 42, 48], ["belly", "ANATOMY", 68, 73], ["muscle", "ANATOMY", 81, 87]]], ["The catheter was made from stretchable and flexible silicone tubing (ID = 0.012 inches, wall thickness = 0.007 inches, Trelleberg, SF Medical, UK, SFM1-1050) attached to the osmotic pump via larger gluedon tubing (ID 0.76 mm, VWR International).", [["wall", "ANATOMY", 88, 92], ["SFM1-1050", "CHEMICAL", 147, 156], ["The catheter", "TREATMENT", 0, 12], ["stretchable and flexible silicone tubing", "TREATMENT", 27, 67], ["wall thickness", "TEST", 88, 102], ["SFM1", "TEST", 147, 151], ["the osmotic pump", "TREATMENT", 170, 186], ["larger gluedon tubing", "TREATMENT", 191, 212], ["catheter", "OBSERVATION", 4, 12], ["silicone tubing", "OBSERVATION", 52, 67], ["wall", "ANATOMY_MODIFIER", 88, 92], ["osmotic pump", "OBSERVATION", 174, 186], ["larger", "OBSERVATION_MODIFIER", 191, 197], ["gluedon tubing", "OBSERVATION", 198, 212]]], ["A second section of this stiff tubing (10 millimetres long) was inserted to guide the flexible catheter into the triceps; the guide was slid back after the silicone tube was implanted.", [["triceps", "ANATOMY", 113, 120], ["triceps", "ORGANISM_SUBDIVISION", 113, 120], ["silicone tube", "TISSUE", 156, 169], ["A second section of this stiff tubing (10 millimetres long)", "TREATMENT", 0, 59], ["the flexible catheter into the triceps", "TREATMENT", 82, 120], ["the silicone tube", "TREATMENT", 152, 169], ["stiff tubing", "OBSERVATION", 25, 37], ["flexible", "OBSERVATION_MODIFIER", 86, 94], ["catheter", "OBSERVATION", 95, 103], ["triceps", "ANATOMY", 113, 120], ["silicone tube", "OBSERVATION", 156, 169]]], ["Catheters were connected to subcutaneous osmotic minipumps (2ML2, Alzet) containing either vehicle (0.9% saline containing 0.1% bovine serum albumin; Sigma; A3059; 9048-46-8) or vehicle containing recombinant human NT3 (kind gift of Genentech Inc., USA).", [["subcutaneous", "ANATOMY", 28, 40], ["serum", "ANATOMY", 135, 140], ["A3059; 9048-46-8", "CHEMICAL", 157, 173], ["saline", "SIMPLE_CHEMICAL", 105, 111], ["bovine", "ORGANISM", 128, 134], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["albumin", "GENE_OR_GENE_PRODUCT", 141, 148], ["9048-46-8", "SIMPLE_CHEMICAL", 164, 173], ["human", "ORGANISM", 209, 214], ["NT3", "GENE_OR_GENE_PRODUCT", 215, 218], ["recombinant human NT3", "PROTEIN", 197, 218], ["bovine", "SPECIES", 128, 134], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 209, 214], ["Catheters", "TREATMENT", 0, 9], ["subcutaneous osmotic minipumps", "TREATMENT", 28, 58], ["vehicle (0.9% saline", "TREATMENT", 91, 111], ["% bovine serum albumin", "TREATMENT", 126, 148]]], ["Pump flow moderators were MR-compatible (PEEK micro medical tubing, Durect, #0002511).", [["MR", "PROTEIN", 26, 28], ["Pump flow moderators", "TEST", 0, 20], ["MR", "TEST", 26, 28], ["PEEK micro medical tubing", "TREATMENT", 41, 66]]], ["The original vials contained 0.586 mg/ml recombinant human (\"rhu\") NT3 in 20 mM acetate, 140 mM NaCl, pH 5.0.", [["acetate", "CHEMICAL", 80, 87], ["NaCl", "CHEMICAL", 96, 100], ["acetate", "CHEMICAL", 80, 87], ["NaCl", "CHEMICAL", 96, 100], ["human", "ORGANISM", 53, 58], ["NT3", "GENE_OR_GENE_PRODUCT", 67, 70], ["acetate", "SIMPLE_CHEMICAL", 80, 87], ["NT3", "PROTEIN", 67, 70], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["The original vials", "TREATMENT", 0, 18], ["0.586 mg/ml recombinant human (\"rhu\"", "TREATMENT", 29, 65], ["NT3 in 20 mM acetate", "TREATMENT", 67, 87], ["pH", "TEST", 102, 104]]], ["SDS PAGE and proteomic analysis indicates that this is the 119 amino acid mature NT3 protein obtained after proteolytic cleavage of the 258 amino acid proneurotrophin-3 (Uniprot P20873) ( Supplementary Figures 7 and 8 ).", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "AMINO_ACID", 63, 73], ["NT3", "GENE_OR_GENE_PRODUCT", 81, 84], ["proneurotrophin-3", "GENE_OR_GENE_PRODUCT", 151, 168], ["NT3 protein", "PROTEIN", 81, 92], ["proteomic analysis", "TEST", 13, 31], ["amino acid", "TEST", 63, 73], ["NT3 protein", "TEST", 81, 92], ["proteolytic cleavage", "TREATMENT", 108, 128], ["the 258 amino acid proneurotrophin", "TREATMENT", 132, 166]]], ["The NT3 dose (12 \u00b5g/24 hours) was selected based on previous experiments 9 .", [["NT3", "GENE_OR_GENE_PRODUCT", 4, 7], ["NT3", "PROTEIN", 4, 7], ["The NT3 dose", "TREATMENT", 0, 12]]], ["Pumps were replaced after two weeks and removed after four weeks.", [["Pumps", "TREATMENT", 0, 5]]], ["Skin was sutured and analgesic administered as above.", [["Skin", "ANATOMY", 0, 4], ["Skin", "ORGAN", 0, 4], ["analgesic", "TREATMENT", 21, 30], ["sutured", "OBSERVATION", 9, 16]]], ["All rats survived this surgery.", [["rats", "ORGANISM", 4, 8], ["rats", "SPECIES", 4, 8], ["this surgery", "TREATMENT", 18, 30]]], ["Sham rats did not undergo this surgery.", [["Sham rats", "ORGANISM", 0, 9], ["rats", "SPECIES", 5, 9], ["this surgery", "TREATMENT", 26, 38]]], ["Pilot experiments showed that the pump flow rate (5 \u00b5l/hour) was sufficient to deliver substances (0.9% saline containing 1% Fast Green, Sigma) to the entire volume of the triceps muscles.Enzyme Linked Immunosorbent Assay (ELISAs)Rats (n = 5/group) were terminally anesthetised (4 weeks following stroke, before pumps were removed) and triceps brachii and C7 spinal cord were rapidly dissected and snap frozen in liquid nitrogen prior to storage at -80\u00b0C. Tissue was homogenised in ice cold lysis buffer containing 137 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1% NP40, 10% glycerol, 1 mM phenylmethanesulfonylfluoride, 10 \u03bcg/ml aprotinin, 1 \u03bcg/ml leupeptin and 0.5 mM sodium vanadate, using approximately 10 times the volume of buffer to the wet weight of tissue (10 \u00b5l/mg tissue).", [["triceps muscles", "ANATOMY", 172, 187], ["triceps brachii", "ANATOMY", 336, 351], ["C7 spinal cord", "ANATOMY", 356, 370], ["Tissue", "ANATOMY", 456, 462], ["tissue", "ANATOMY", 749, 755], ["tissue", "ANATOMY", 766, 772], ["stroke", "DISEASE", 297, 303], ["NaCl", "CHEMICAL", 522, 526], ["Tris-HCl", "CHEMICAL", 534, 542], ["glycerol", "CHEMICAL", 566, 574], ["phenylmethanesulfonylfluoride", "CHEMICAL", 581, 610], ["sodium vanadate", "CHEMICAL", 661, 676], ["nitrogen", "CHEMICAL", 420, 428], ["NaCl", "CHEMICAL", 522, 526], ["Tris-HCl", "CHEMICAL", 534, 542], ["NP40", "CHEMICAL", 556, 560], ["glycerol", "CHEMICAL", 566, 574], ["phenylmethanesulfonylfluoride", "CHEMICAL", 581, 610], ["aprotinin", "CHEMICAL", 621, 630], ["leupeptin", "CHEMICAL", 640, 649], ["sodium vanadate", "CHEMICAL", 661, 676], ["saline", "SIMPLE_CHEMICAL", 104, 110], ["triceps muscles", "TISSUE", 172, 187], ["triceps brachii", "ORGAN", 336, 351], ["spinal cord", "ORGAN", 359, 370], ["Tissue", "TISSUE", 456, 462], ["Tris-HCl", "SIMPLE_CHEMICAL", 534, 542], ["NP40", "SIMPLE_CHEMICAL", 556, 560], ["glycerol", "SIMPLE_CHEMICAL", 566, 574], ["phenylmethanesulfonylfluoride", "SIMPLE_CHEMICAL", 581, 610], ["aprotinin", "SIMPLE_CHEMICAL", 621, 630], ["leupeptin", "SIMPLE_CHEMICAL", 640, 649], ["sodium vanadate", "SIMPLE_CHEMICAL", 661, 676], ["tissue", "TISSUE", 749, 755], ["tissue", "TISSUE", 766, 772], ["Rats", "SPECIES", 230, 234], ["Pilot experiments", "TEST", 0, 17], ["the pump flow rate", "TREATMENT", 30, 48], ["0.9% saline", "TREATMENT", 99, 110], ["Enzyme", "TEST", 188, 194], ["Immunosorbent Assay", "TEST", 202, 221], ["ELISAs", "TEST", 223, 229], ["Rats", "TEST", 230, 234], ["stroke", "PROBLEM", 297, 303], ["pumps", "TREATMENT", 312, 317], ["liquid nitrogen", "TREATMENT", 413, 428], ["ice cold lysis buffer", "TREATMENT", 482, 503], ["NaCl", "TEST", 522, 526], ["pH", "TEST", 544, 546], ["glycerol", "TREATMENT", 566, 574], ["1 mM phenylmethanesulfonylfluoride", "TREATMENT", 576, 610], ["aprotinin", "TREATMENT", 621, 630], ["leupeptin", "TREATMENT", 640, 649], ["0.5 mM sodium vanadate", "TREATMENT", 654, 676], ["buffer", "TREATMENT", 721, 727], ["triceps muscles", "ANATOMY", 172, 187], ["triceps brachii", "ANATOMY", 336, 351], ["C7", "ANATOMY_MODIFIER", 356, 358], ["spinal cord", "ANATOMY", 359, 370]]], ["Protein content was measured and NT3 ELISA was carried out according to manufacturer's instructions (Emax, Promega).Enzyme Linked Immunosorbent Assay (ELISAs)n.b., Promega NT3 ELISA kits are no longer available.", [["NT3", "GENE_OR_GENE_PRODUCT", 33, 36], ["Promega", "ORGANISM", 164, 171], ["NT3", "GENE_OR_GENE_PRODUCT", 172, 175], ["NT3", "PROTEIN", 33, 36], ["Protein content", "TEST", 0, 15], ["NT3 ELISA", "TEST", 33, 42], ["Enzyme", "TEST", 116, 122], ["Immunosorbent Assay", "TEST", 130, 149], ["ELISAs", "TEST", 151, 157], ["Promega NT3 ELISA kits", "TREATMENT", 164, 186]]], ["However, it was recently discovered that when performing ELISA using other NT3 kits (R&D using \"Reagent Diluent\" and Abcam using diluent A), measurements of NT3 from skeletal muscle lysates do not provide reliable quantitative data.", [["skeletal muscle lysates", "ANATOMY", 166, 189], ["NT3", "GENE_OR_GENE_PRODUCT", 75, 78], ["Abcam", "GENE_OR_GENE_PRODUCT", 117, 122], ["NT3", "GENE_OR_GENE_PRODUCT", 157, 160], ["skeletal muscle", "ORGAN", 166, 181], ["lysates", "ORGANISM_SUBSTANCE", 182, 189], ["NT3 kits", "PROTEIN", 75, 83], ["Abcam", "PROTEIN", 117, 122], ["NT3", "PROTEIN", 157, 160], ["other NT3 kits", "TREATMENT", 69, 83], ["Reagent Diluent\"", "TREATMENT", 96, 112], ["measurements of NT3 from skeletal muscle lysates", "TEST", 141, 189], ["skeletal muscle", "ANATOMY", 166, 181]]], ["This is due to so-called \"matrix effects\" as shown by poor recovery of spiked-in NT3 (<80% or >120%) and non-linear relationship between concentration of input material and estimated NT3 concentration based on a dilution series of muscle homogenate.", [["matrix", "ANATOMY", 26, 32], ["muscle homogenate", "ANATOMY", 231, 248], ["matrix", "CELLULAR_COMPONENT", 26, 32], ["NT3", "GENE_OR_GENE_PRODUCT", 81, 84], ["NT3", "GENE_OR_GENE_PRODUCT", 183, 186], ["muscle homogenate", "TISSUE", 231, 248], ["NT3", "PROTEIN", 183, 186], ["so-called \"matrix effects", "PROBLEM", 15, 40], ["NT3", "TEST", 81, 84], ["concentration of input material", "TREATMENT", 137, 168], ["estimated NT3 concentration", "TREATMENT", 173, 200], ["a dilution series of muscle homogenate", "TREATMENT", 210, 248], ["muscle", "ANATOMY", 231, 237]]], ["To overcome the effect of interfering substances, samples should be diluted and appropriate diluents to prepare standards and diluted samples must be used.", [["samples", "ANATOMY", 50, 57], ["samples", "ANATOMY", 134, 141], ["interfering substances", "TREATMENT", 26, 48], ["samples", "TREATMENT", 50, 57], ["appropriate diluents", "TREATMENT", 80, 100], ["standards and diluted samples", "TREATMENT", 112, 141]]], ["The Abcam kit used with diluent B (not A), however, provided reliable quantitative results (Dr. Aline Barroso Spejo, unpublished results).Behavioural testingWe assessed sensory and motor deficits after stroke using the cylinder test (to assess postural support by forelimbs during rearing), adhesive patch test (to assess responsiveness to tactile stimuli), horizontal ladder (to assess forelimb and hindlimb skilled locomotion), a grip strength test and a test used to monitor unusual responses to cold stimuli (cold allodynia) 19, 38 .", [["forelimbs", "ANATOMY", 264, 273], ["forelimb", "ANATOMY", 387, 395], ["hindlimb", "ANATOMY", 400, 408], ["sensory and motor deficits", "DISEASE", 169, 195], ["stroke", "DISEASE", 202, 208], ["allodynia", "DISEASE", 518, 527], ["Abcam", "GENE_OR_GENE_PRODUCT", 4, 9], ["diluent B", "SIMPLE_CHEMICAL", 24, 33], ["forelimbs", "ORGANISM_SUBDIVISION", 264, 273], ["forelimb", "ORGANISM_SUBDIVISION", 387, 395], ["hindlimb", "ORGANISM_SUBDIVISION", 400, 408], ["Abcam kit", "PROTEIN", 4, 13], ["The Abcam kit", "TEST", 0, 13], ["Behavioural testingWe", "TEST", 138, 159], ["motor deficits", "PROBLEM", 181, 195], ["stroke", "PROBLEM", 202, 208], ["the cylinder test", "TEST", 215, 232], ["postural support", "TREATMENT", 244, 260], ["adhesive patch test", "TEST", 291, 310], ["tactile stimuli", "TEST", 340, 355], ["horizontal ladder", "TREATMENT", 358, 375], ["forelimb and hindlimb skilled locomotion", "TEST", 387, 427], ["a grip strength test", "TEST", 430, 450], ["a test", "TEST", 455, 461], ["cold stimuli", "TEST", 499, 511], ["cold allodynia", "TEST", 513, 527], ["hindlimb", "ANATOMY", 400, 408]]], ["All behavioural testing was carried out by an experimenter blinded to surgery and treatment groups.", [["All behavioural testing", "TEST", 0, 23], ["surgery", "TREATMENT", 70, 77], ["treatment groups", "TREATMENT", 82, 98]]], ["Rats were handled and trained for three weeks on the horizontal ladder before the study began.", [["Rats", "ORGANISM", 0, 4], ["Rats", "SPECIES", 0, 4], ["the study", "TEST", 78, 87]]], ["Preoperative baseline scores for the horizontal ladder, the vertical cylinder and the grip strength test were collected one week before surgery.Assessment of somatosensory responsiveness:The \"adhesive patch\" test was used to measure 1) the time taken to contact stimuli on the wrists, 2) the time taken to remove stimuli from the wrists, and 3) the magnitude of lack of responsiveness to stimuli on the affected wrist 32, 34, 46, 47 .", [["somatosensory", "ANATOMY", 158, 171], ["wrists", "ANATOMY", 277, 283], ["wrists", "ANATOMY", 330, 336], ["wrist", "ANATOMY", 412, 417], ["wrists", "ORGANISM_SUBDIVISION", 277, 283], ["wrists", "ORGANISM_SUBDIVISION", 330, 336], ["wrist", "ORGANISM_SUBDIVISION", 412, 417], ["Preoperative baseline scores", "TEST", 0, 28], ["the horizontal ladder", "TREATMENT", 33, 54], ["the vertical cylinder", "TREATMENT", 56, 77], ["the grip strength test", "TEST", 82, 104], ["surgery", "TREATMENT", 136, 143], ["The \"adhesive patch\" test", "TREATMENT", 187, 212], ["wrists", "ANATOMY", 277, 283], ["wrists", "ANATOMY", 330, 336], ["wrist", "ANATOMY", 412, 417]]], ["For each trial, a round adhesive patch (13 mm diameter, Ryman) was applied to each wrist on the dorsal side and the animal was returned to its home cage.", [["wrist", "ANATOMY", 83, 88], ["dorsal", "ANATOMY", 96, 102], ["wrist", "ORGANISM_SUBDIVISION", 83, 88], ["dorsal side", "MULTI-TISSUE_STRUCTURE", 96, 107], ["a round adhesive patch (13 mm diameter, Ryman)", "TREATMENT", 16, 62], ["wrist", "ANATOMY", 83, 88], ["dorsal", "ANATOMY_MODIFIER", 96, 102]]], ["Two times were recorded for both forepaws: (1) contact and (2) remove; where \"contact\" represents the time taken for the animal to contact an adhesive patch with its mouth, and \"remove\" represents the time taken for the animal to remove the first adhesive patch from its wrist.", [["mouth", "ANATOMY", 166, 171], ["wrist", "ANATOMY", 271, 276], ["mouth", "ORGANISM_SUBDIVISION", 166, 171], ["wrist", "ORGANISM_SUBDIVISION", 271, 276], ["an adhesive patch", "TREATMENT", 139, 156], ["the first adhesive patch", "TREATMENT", 237, 261], ["wrist", "ANATOMY", 271, 276]]], ["To determine whether the rats preferentially removed a sticker from their less-affected wrist before their more-affected wrist, the order and side of label removal was recorded.", [["wrist", "ANATOMY", 88, 93], ["wrist", "ANATOMY", 121, 126], ["rats", "ORGANISM", 25, 29], ["wrist", "ORGANISM_SUBDIVISION", 88, 93], ["wrist", "ORGANISM_SUBDIVISION", 121, 126], ["rats", "SPECIES", 25, 29], ["label removal", "TREATMENT", 150, 163], ["wrist", "ANATOMY", 88, 93], ["wrist", "ANATOMY", 121, 126]]], ["The magnitude of asymmetry was established using the seven levels of stimulus pairs on both wrists as previously described (Figure 2a) .", [["wrists", "ANATOMY", 92, 98], ["wrists", "ORGANISM_SUBDIVISION", 92, 98], ["asymmetry", "PROBLEM", 17, 26], ["magnitude", "OBSERVATION_MODIFIER", 4, 13], ["asymmetry", "OBSERVATION", 17, 26], ["wrists", "ANATOMY", 92, 98]]], ["From trial to trial, the size of the stimulus was progressively increased on the affected wrist and decreased on the less affected wrist by an equal amount (14.1 mm 2 ), until the rat removed the stimulus on the affected wrist first (reversal of original bias).", [["wrist", "ANATOMY", 90, 95], ["wrist", "ANATOMY", 131, 136], ["wrist", "ANATOMY", 221, 226], ["wrist", "ORGANISM_SUBDIVISION", 90, 95], ["wrist", "ORGANISM_SUBDIVISION", 131, 136], ["rat", "ORGANISM", 180, 183], ["wrist", "ORGANISM_SUBDIVISION", 221, 226], ["rat", "SPECIES", 180, 183], ["trial", "TREATMENT", 14, 19], ["the stimulus", "PROBLEM", 33, 45], ["size", "OBSERVATION_MODIFIER", 25, 29], ["progressively", "OBSERVATION_MODIFIER", 50, 63], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["wrist", "ANATOMY", 90, 95], ["decreased", "OBSERVATION_MODIFIER", 100, 109], ["wrist", "ANATOMY", 131, 136], ["wrist", "ANATOMY", 221, 226]]], ["The higher the score, the greater the degree of somatosensory impairment.Assessment of somatosensory responsiveness:Walking: To assess impairments in forelimb and hindlimb function after stroke, rats were videotaped as they walked along a horizontal ladder.", [["somatosensory", "ANATOMY", 87, 100], ["forelimb", "ANATOMY", 150, 158], ["hindlimb", "ANATOMY", 163, 171], ["somatosensory impairment", "DISEASE", 48, 72], ["impairments in forelimb and hindlimb function", "DISEASE", 135, 180], ["stroke", "DISEASE", 187, 193], ["forelimb", "ORGANISM_SUBDIVISION", 150, 158], ["hindlimb", "ORGANISM_SUBDIVISION", 163, 171], ["rats", "ORGANISM", 195, 199], ["rats", "SPECIES", 195, 199], ["The higher the score", "PROBLEM", 0, 20], ["somatosensory impairment", "PROBLEM", 48, 72], ["impairments in forelimb and hindlimb function", "PROBLEM", 135, 180], ["stroke", "PROBLEM", 187, 193], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["greater", "OBSERVATION_MODIFIER", 26, 33], ["somatosensory impairment", "OBSERVATION", 48, 72], ["forelimb", "ANATOMY", 150, 158], ["hindlimb", "ANATOMY", 163, 171]]], ["Rats were videotaped crossing a horizontal ladder (1 m) with irregularly spaced rungs (1 to 4 cm spacing changed weekly) weekly, 3 times per session.", [["rungs", "ANATOMY", 80, 85], ["Rats", "ORGANISM", 0, 4], ["Rats", "SPECIES", 0, 4], ["irregularly spaced rungs", "PROBLEM", 61, 85]]], ["Any slight paw slips, deep paw slips and complete misses were scored as errors.Assessment of somatosensory responsiveness:The mean number of errors per step was calculated for each limb for each week (Foot faults are routinely normalized \"per step\" after stroke although analysis of foot fault data with or without normalization led to the same conclusions being drawn).Assessment of forelimb use during rearing:The cylinder test was used to assess asymmetries in forelimb use for postural support during rearing within a transparent 20 cm diameter and 30 cm high cylinder 19 .", [["paw", "ANATOMY", 11, 14], ["somatosensory", "ANATOMY", 93, 106], ["limb", "ANATOMY", 181, 185], ["forelimb", "ANATOMY", 384, 392], ["forelimb", "ANATOMY", 464, 472], ["stroke", "DISEASE", 255, 261], ["limb", "ORGANISM_SUBDIVISION", 181, 185], ["forelimb", "ORGANISM_SUBDIVISION", 384, 392], ["forelimb", "ORGANISM_SUBDIVISION", 464, 472], ["Any slight paw slips", "PROBLEM", 0, 20], ["deep paw slips", "PROBLEM", 22, 36], ["stroke", "PROBLEM", 255, 261], ["analysis of foot fault data", "TEST", 271, 298], ["The cylinder test", "TEST", 412, 429], ["postural support", "TREATMENT", 481, 497], ["a transparent 20 cm diameter", "TREATMENT", 520, 548], ["slight", "OBSERVATION_MODIFIER", 4, 10], ["paw slips", "OBSERVATION", 11, 20], ["deep", "ANATOMY_MODIFIER", 22, 26], ["paw", "ANATOMY", 27, 30], ["mean", "OBSERVATION_MODIFIER", 126, 130], ["number", "OBSERVATION_MODIFIER", 131, 137], ["Foot", "ANATOMY", 201, 205], ["foot", "ANATOMY", 283, 287], ["forelimb", "ANATOMY", 384, 392], ["forelimb", "ANATOMY", 464, 472], ["20 cm diameter", "OBSERVATION_MODIFIER", 534, 548], ["30 cm", "OBSERVATION_MODIFIER", 553, 558]]], ["An angled mirror was placed behind the cylinder to allow movements to be recorded when the animal turned away from the camera.", [["An angled mirror", "TREATMENT", 0, 16], ["angled", "OBSERVATION_MODIFIER", 3, 9]]], ["During exploration, rats rear against the vertical surface of the cylinder.", [["surface", "ANATOMY", 51, 58], ["rats", "ORGANISM", 20, 24], ["rats", "SPECIES", 20, 24], ["exploration", "TEST", 7, 18]]], ["The first forelimb to touch the wall was scored as an independent placement for that forelimb.", [["forelimb", "ANATOMY", 10, 18], ["wall", "ANATOMY", 32, 36], ["forelimb", "ANATOMY", 85, 93], ["forelimb", "ORGANISM_SUBDIVISION", 10, 18], ["wall", "TISSUE", 32, 36], ["forelimb", "ORGANISM_SUBDIVISION", 85, 93], ["an independent placement", "TREATMENT", 51, 75], ["wall", "ANATOMY_MODIFIER", 32, 36]]], ["Subsequent placement of the other forelimb against the wall to maintain balance was scored as \"both.\"", [["forelimb", "ANATOMY", 34, 42], ["wall", "ANATOMY", 55, 59], ["forelimb", "ORGANISM_SUBDIVISION", 34, 42], ["wall", "TISSUE", 55, 59], ["wall", "ANATOMY_MODIFIER", 55, 59], ["balance", "OBSERVATION", 72, 79]]], ["If both forelimbs were simultaneously placed against the wall during rearing this was scored as \"both.\"", [["forelimbs", "ANATOMY", 8, 17], ["wall", "ANATOMY", 57, 61], ["forelimbs", "ORGANISM_SUBDIVISION", 8, 17], ["wall", "TISSUE", 57, 61], ["forelimbs", "ANATOMY", 8, 17], ["wall", "ANATOMY_MODIFIER", 57, 61]]], ["A lateral movement along the wall using both forelimbs alternately was also scored as \"both.\"", [["wall", "ANATOMY", 29, 33], ["forelimbs", "ANATOMY", 45, 54], ["wall", "TISSUE", 29, 33], ["forelimbs", "ORGANISM_SUBDIVISION", 45, 54], ["A lateral movement", "PROBLEM", 0, 18], ["lateral", "OBSERVATION_MODIFIER", 2, 9], ["movement", "OBSERVATION", 10, 18], ["wall", "ANATOMY_MODIFIER", 29, 33], ["both forelimbs", "ANATOMY", 40, 54]]], ["Scores were obtained from a total number of 10 full rears to control for differences in rearing between animals.", [["Scores", "TEST", 0, 6]]], ["Once scores had been acquired, forelimb asymmetry was calculated using the formula: 100 \u00d7 (ipsilateral forelimb use + 1/2 bilateral forelimb use)/total forelimb use observations (Hsu and Jones 2005).", [["forelimb", "ANATOMY", 31, 39], ["forelimb", "ANATOMY", 103, 111], ["forelimb", "ANATOMY", 132, 140], ["forelimb", "ANATOMY", 152, 160], ["forelimb", "ORGANISM_SUBDIVISION", 31, 39], ["forelimb", "ORGANISM_SUBDIVISION", 103, 111], ["forelimb", "ORGANISM_SUBDIVISION", 132, 140], ["forelimb", "ORGANISM_SUBDIVISION", 152, 160], ["forelimb asymmetry", "PROBLEM", 31, 49], ["1/2 bilateral forelimb use", "TREATMENT", 118, 144]]], ["Both the affected and less affected forelimb strength were each measured (simultaneously) at baseline, week 1, week 4 and week 8 following stroke.", [["forelimb", "ANATOMY", 36, 44], ["stroke", "DISEASE", 139, 145], ["forelimb", "ORGANISM_SUBDIVISION", 36, 44], ["stroke", "PROBLEM", 139, 145], ["affected", "OBSERVATION_MODIFIER", 9, 17], ["less", "OBSERVATION_MODIFIER", 22, 26], ["stroke", "OBSERVATION", 139, 145]]], ["A pair of force transducers were used in parallel to measure the peak force achieved by a rat's forelimbs as its bilateral grip was broken by the experimenter gently pulling the rat by the base of the tail horizontally away from the transducer.", [["forelimbs", "ANATOMY", 96, 105], ["tail", "ANATOMY", 201, 205], ["rat", "ORGANISM", 90, 93], ["forelimbs", "ORGANISM_SUBDIVISION", 96, 105], ["grip", "ORGANISM_SUBDIVISION", 123, 127], ["rat", "ORGANISM", 178, 181], ["tail", "ORGANISM_SUBDIVISION", 201, 205], ["rat", "SPECIES", 90, 93], ["rat", "SPECIES", 178, 181], ["rat", "SPECIES", 90, 93], ["A pair of force transducers", "TREATMENT", 0, 27], ["a rat's forelimbs", "TREATMENT", 88, 105], ["peak force", "OBSERVATION", 65, 75], ["bilateral", "ANATOMY_MODIFIER", 113, 122], ["base", "ANATOMY_MODIFIER", 189, 193], ["tail", "ANATOMY_MODIFIER", 201, 205]]], ["The average of three strength readings was noted down per session and an average taken for both arms.", [["average", "OBSERVATION_MODIFIER", 4, 11], ["arms", "ANATOMY", 96, 100]]], ["The difference in grip strength was taken by subtracting the affected forepaw grip strength from the less affected grip strength.Assessment of cold allodynia:The presence or absence of cold allodynia was assessed using standard methods 43 .", [["allodynia", "DISEASE", 148, 157], ["allodynia", "DISEASE", 190, 199], ["grip", "ORGANISM_SUBDIVISION", 18, 22], ["grip", "ORGANISM_SUBDIVISION", 115, 119], ["The difference in grip strength", "PROBLEM", 0, 31], ["cold allodynia", "PROBLEM", 143, 157], ["cold allodynia", "PROBLEM", 185, 199], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["grip strength", "OBSERVATION", 18, 31]]], ["Rats were placed in a transparent cylinder (20 cm diameter, 30 cm height) atop a mesh wire floor.", [["Rats", "ORGANISM", 0, 4], ["Rats", "SPECIES", 0, 4], ["a transparent cylinder (20 cm diameter", "TREATMENT", 20, 58], ["a mesh wire floor", "TREATMENT", 79, 96]]], ["A drop (50 \u00b5l) of acetone was placed against the centre of the forepaw.", [["acetone", "CHEMICAL", 18, 25], ["acetone", "CHEMICAL", 18, 25], ["acetone", "SIMPLE_CHEMICAL", 18, 25], ["forepaw", "ORGANISM_SUBDIVISION", 63, 70], ["A drop", "PROBLEM", 0, 6], ["acetone", "TREATMENT", 18, 25], ["drop", "OBSERVATION_MODIFIER", 2, 6], ["forepaw", "ANATOMY", 63, 70]]], ["In the following 20 s after acetone application the rat's response was monitored.", [["acetone", "CHEMICAL", 28, 35], ["acetone", "CHEMICAL", 28, 35], ["acetone", "SIMPLE_CHEMICAL", 28, 35], ["rat", "ORGANISM", 52, 55], ["rat", "SPECIES", 52, 55], ["acetone application", "TREATMENT", 28, 47], ["the rat's response", "TEST", 48, 66]]], ["If the rat did not withdraw, flick or lick its paw within this 20 s period then no response was recorded for that trial (0, see below).", [["rat", "ORGANISM", 7, 10], ["paw", "ORGANISM_SUBDIVISION", 47, 50], ["rat", "SPECIES", 7, 10], ["flick or lick its paw", "PROBLEM", 29, 50]]], ["However, if within this 20 s period the animal responded to the cooling effect of the acetone, then the animal's response was assessed for an additional 20 s, a total of 40 s from initial application.", [["acetone", "CHEMICAL", 86, 93], ["acetone", "CHEMICAL", 86, 93], ["acetone", "SIMPLE_CHEMICAL", 86, 93], ["the acetone", "TREATMENT", 82, 93]]], ["The reasons for taking a longer period of time to assess the evoked behaviour were to measure only pain-related behaviour evoked by cooling and not startle responses that can occur following the initial application of acetone 43 .", [["pain", "DISEASE", 99, 103], ["acetone", "CHEMICAL", 218, 225], ["acetone", "CHEMICAL", 218, 225], ["pain", "PROBLEM", 99, 103], ["acetone", "TREATMENT", 218, 225]]], ["Moreover, the behaviour evoked by acetone is often an interrupted series of behaviours, thus it is important to give enough time to see all pain-related behaviours.", [["acetone", "CHEMICAL", 34, 41], ["pain", "DISEASE", 140, 144], ["acetone", "CHEMICAL", 34, 41], ["acetone", "SIMPLE_CHEMICAL", 34, 41], ["all pain", "PROBLEM", 136, 144]]], ["Responses to acetone were graded to the following 4-point scale: 0, no response; 1, quick withdrawal, flick or stamp of the paw; 2, prolonged withdrawal or repeated flicking of the paw; 3, repeated flicking of the paw with licking directed at the ventral side of the paw.", [["paw", "ANATOMY", 124, 127], ["paw", "ANATOMY", 181, 184], ["paw", "ANATOMY", 214, 217], ["ventral", "ANATOMY", 247, 254], ["paw", "ANATOMY", 267, 270], ["acetone", "CHEMICAL", 13, 20], ["acetone", "CHEMICAL", 13, 20], ["acetone", "SIMPLE_CHEMICAL", 13, 20], ["paw", "ORGANISM_SUBDIVISION", 124, 127], ["paw", "ORGANISM_SUBDIVISION", 181, 184], ["paw", "ORGANISM_SUBDIVISION", 214, 217], ["ventral side", "ORGANISM_SUBDIVISION", 247, 259], ["paw", "ORGANISM_SUBDIVISION", 267, 270], ["acetone", "TEST", 13, 20], ["quick withdrawal", "PROBLEM", 84, 100], ["prolonged withdrawal", "PROBLEM", 132, 152], ["paw", "ANATOMY", 124, 127], ["paw", "ANATOMY", 181, 184], ["paw", "ANATOMY", 214, 217], ["ventral", "ANATOMY_MODIFIER", 247, 254], ["paw", "ANATOMY", 267, 270]]], ["Acetone was applied alternately three times to each paw and the responses scored categorically.", [["Acetone", "CHEMICAL", 0, 7], ["Acetone", "CHEMICAL", 0, 7], ["Acetone", "SIMPLE_CHEMICAL", 0, 7], ["paw", "ORGANISM_SUBDIVISION", 52, 55], ["Acetone", "TREATMENT", 0, 7]]], ["Cumulative scores were then generated by adding the scores for each rat together, the minimum score being 0 (no response to any of the six trials) and the maximum possible score being 9 per forepaw.Anatomical tracingTo visualize uninjured CST axons, six weeks after stroke, 10% biotinylated dextran amine (BDA; 10,000 MW, Invitrogen) in PBS (pH 7.4) was microinjected unilaterally into the uninjured sensorimotor cortex.", [["CST axons", "ANATOMY", 239, 248], ["sensorimotor cortex", "ANATOMY", 400, 419], ["stroke", "DISEASE", 266, 272], ["dextran amine", "CHEMICAL", 291, 304], ["BDA", "CHEMICAL", 306, 309], ["amine", "CHEMICAL", 299, 304], ["BDA", "CHEMICAL", 306, 309], ["rat", "ORGANISM", 68, 71], ["CST axons", "MULTI-TISSUE_STRUCTURE", 239, 248], ["dextran amine", "SIMPLE_CHEMICAL", 291, 304], ["BDA", "SIMPLE_CHEMICAL", 306, 309], ["PBS", "SIMPLE_CHEMICAL", 337, 340], ["sensorimotor cortex", "MULTI-TISSUE_STRUCTURE", 400, 419], ["rat", "SPECIES", 68, 71], ["Cumulative scores", "TEST", 0, 17], ["stroke", "PROBLEM", 266, 272], ["10% biotinylated dextran amine", "TREATMENT", 274, 304], ["Invitrogen", "TEST", 322, 332], ["PBS", "TEST", 337, 340], ["pH", "TEST", 342, 344], ["uninjured", "ANATOMY_MODIFIER", 390, 399], ["sensorimotor cortex", "ANATOMY", 400, 419]]], ["Animals were placed in a stereotaxic frame and six burr holes were made into the skull at the following coordinates (defined as anterioposterior (AP), mediolateral (ML): 1) AP: +1 mm, ML: 1.5 mm; 2) AP: +0.5 mm, ML: 2.5 mm; 3) AP: +1.5 mm, ML: 2.5 mm; 4) AP: +0.5 mm, ML: 3.5 mm; 5) AP: +2.0 mm, ML: 3.5 mm; 6) AP: -0.5 mm, ML: 3.5 mm, relative to bregma.", [["skull", "ANATOMY", 81, 86], ["anterioposterior", "ANATOMY", 128, 144], ["Animals", "ORGANISM", 0, 7], ["skull", "ORGAN", 81, 86], ["six burr holes", "TREATMENT", 47, 61], ["AP", "TEST", 199, 201], ["AP", "TEST", 227, 229], ["AP", "TEST", 255, 257], ["AP", "TEST", 283, 285], ["AP", "TEST", 311, 313], ["burr holes", "OBSERVATION", 51, 61], ["skull", "ANATOMY", 81, 86], ["mediolateral", "ANATOMY_MODIFIER", 151, 163], ["3.5 mm", "OBSERVATION_MODIFIER", 328, 334], ["bregma", "OBSERVATION", 348, 354]]], ["At each site, 0.5 \u03bcl injections of BDA (10% in PBS) were delivered using a glass micropipette attached to a Hamilton syringe inserted 2 mm from the skull surface and delivered at a rate of 0.25 \u03bcl/min.", [["skull surface", "ANATOMY", 148, 161], ["BDA", "CHEMICAL", 35, 38], ["BDA", "CHEMICAL", 35, 38], ["BDA", "SIMPLE_CHEMICAL", 35, 38], ["skull surface", "MULTI-TISSUE_STRUCTURE", 148, 161], ["0.5 \u03bcl injections of BDA", "TREATMENT", 14, 38], ["a glass micropipette", "TREATMENT", 73, 93], ["a Hamilton syringe", "TREATMENT", 106, 124], ["skull", "ANATOMY", 148, 153], ["surface", "ANATOMY_MODIFIER", 154, 161]]], ["Animals were subsequently left for 2 weeks before being perfused.", [["Animals", "ORGANISM", 0, 7], ["left", "ANATOMY_MODIFIER", 26, 30]]], ["Tract tracing was not performed in rats that were to undergo functional MRI or neurophysiology.NeurophysiologyAs described below, we recorded from the ulnar nerve on the affected side and stimulated the ipsilateral median nerve 44 or, in the pyramids, the corticospinal tract corresponding to the affected or less-affected hemisphere.", [["ulnar nerve", "ANATOMY", 151, 162], ["ipsilateral median nerve", "ANATOMY", 203, 227], ["pyramids", "ANATOMY", 242, 250], ["corticospinal tract", "ANATOMY", 256, 275], ["hemisphere", "ANATOMY", 323, 333], ["rats", "ORGANISM", 35, 39], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 151, 162], ["corticospinal tract", "ORGAN", 256, 275], ["hemisphere", "CANCER", 323, 333], ["rats", "SPECIES", 35, 39], ["Tract tracing", "TEST", 0, 13], ["functional MRI", "TEST", 61, 75], ["ulnar nerve", "ANATOMY", 151, 162], ["ipsilateral", "ANATOMY_MODIFIER", 203, 214], ["median nerve", "ANATOMY", 215, 227], ["pyramids", "ANATOMY_MODIFIER", 242, 250], ["corticospinal tract", "ANATOMY", 256, 275], ["affected", "OBSERVATION", 297, 305], ["less", "OBSERVATION_MODIFIER", 309, 313]]], ["At the end of the study, 18 rats (6 rats per group) were anaesthetised with an intraperitoneal injection of 1.25g/kg urethane (Sigma-Aldrich).", [["intraperitoneal", "ANATOMY", 79, 94], ["urethane", "CHEMICAL", 117, 125], ["urethane", "CHEMICAL", 117, 125], ["rats", "ORGANISM", 28, 32], ["rats", "ORGANISM", 36, 40], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 94], ["urethane", "SIMPLE_CHEMICAL", 117, 125], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 127, 140], ["rats", "SPECIES", 28, 32], ["rats", "SPECIES", 36, 40], ["the study", "TEST", 14, 23], ["an intraperitoneal injection", "TREATMENT", 76, 104]]], ["The rat was kept at 37\u00b0C with a homeothermic blanket system and rectal thermometer probe.", [["rectal", "ANATOMY", 64, 70], ["rat", "ORGANISM", 4, 7], ["rectal", "ORGANISM_SUBDIVISION", 64, 70], ["rat", "SPECIES", 4, 7], ["rat", "SPECIES", 4, 7], ["a homeothermic blanket system", "TREATMENT", 30, 59], ["rectal thermometer probe", "TREATMENT", 64, 88], ["rectal", "ANATOMY", 64, 70]]], ["Tracheotomy was performed and a tracheal cannula inserted.", [["tracheal", "ANATOMY", 32, 40], ["tracheal cannula", "MULTI-TISSUE_STRUCTURE", 32, 48], ["Tracheotomy", "TREATMENT", 0, 11], ["a tracheal cannula", "TREATMENT", 30, 48], ["tracheal", "ANATOMY", 32, 40], ["cannula", "OBSERVATION", 41, 48]]], ["The pyramids were then exposed ventrally by blunt dissection and removal of a small area of bone.", [["pyramids", "ANATOMY", 4, 12], ["area", "ANATOMY", 84, 88], ["bone", "ANATOMY", 92, 96], ["bone", "TISSUE", 92, 96], ["blunt dissection", "TREATMENT", 44, 60], ["removal", "TREATMENT", 65, 72], ["a small area of bone", "PROBLEM", 76, 96], ["pyramids", "ANATOMY_MODIFIER", 4, 12], ["blunt", "OBSERVATION_MODIFIER", 44, 49], ["dissection", "OBSERVATION", 50, 60], ["removal", "OBSERVATION_MODIFIER", 65, 72], ["small", "OBSERVATION_MODIFIER", 78, 83], ["area", "OBSERVATION_MODIFIER", 84, 88], ["bone", "ANATOMY", 92, 96]]], ["The brachial plexus of the affected forelimb was exposed from a ventral approach by dissecting the pectoralis major.", [["brachial plexus", "ANATOMY", 4, 19], ["forelimb", "ANATOMY", 36, 44], ["ventral", "ANATOMY", 64, 71], ["pectoralis major", "ANATOMY", 99, 115], ["brachial plexus", "MULTI-TISSUE_STRUCTURE", 4, 19], ["forelimb", "ORGAN", 36, 44], ["pectoralis", "ORGAN", 99, 109], ["a ventral approach", "TREATMENT", 62, 80], ["brachial plexus", "ANATOMY", 4, 19], ["affected forelimb", "ANATOMY", 27, 44], ["ventral", "ANATOMY_MODIFIER", 64, 71], ["pectoralis", "ANATOMY", 99, 109]]], ["The ulnar and median nerves were dissected free from surrounding connective tissue and cut distally (to prevent twitches of target muscles).", [["ulnar", "ANATOMY", 4, 9], ["nerves", "ANATOMY", 21, 27], ["connective tissue", "ANATOMY", 65, 82], ["muscles", "ANATOMY", 131, 138], ["ulnar", "MULTI-TISSUE_STRUCTURE", 4, 9], ["nerves", "MULTI-TISSUE_STRUCTURE", 21, 27], ["connective tissue", "TISSUE", 65, 82], ["muscles", "ORGAN", 131, 138], ["twitches of target muscles", "PROBLEM", 112, 138], ["ulnar", "ANATOMY", 4, 9], ["median nerves", "ANATOMY", 14, 27], ["connective tissue", "OBSERVATION", 65, 82], ["cut", "OBSERVATION_MODIFIER", 87, 90], ["distally", "OBSERVATION_MODIFIER", 91, 99], ["muscles", "ANATOMY", 131, 138]]], ["Skin flaps from the incision formed a pool, which was filled with paraffin oil.Spinal reflexes:The median and ulnar nerves supply flexor muscles in the forearm, wrist and hand.", [["Skin", "ANATOMY", 0, 4], ["oil", "ANATOMY", 75, 78], ["Spinal", "ANATOMY", 79, 85], ["ulnar nerves", "ANATOMY", 110, 122], ["flexor muscles", "ANATOMY", 130, 144], ["forearm", "ANATOMY", 152, 159], ["wrist", "ANATOMY", 161, 166], ["hand", "ANATOMY", 171, 175], ["Skin", "ORGAN", 0, 4], ["ulnar nerves", "MULTI-TISSUE_STRUCTURE", 110, 122], ["flexor muscles", "TISSUE", 130, 144], ["forearm", "ORGANISM_SUBDIVISION", 152, 159], ["wrist", "ORGANISM_SUBDIVISION", 161, 166], ["hand", "ORGANISM_SUBDIVISION", 171, 175], ["Skin flaps", "TREATMENT", 0, 10], ["the incision", "PROBLEM", 16, 28], ["paraffin oil", "TREATMENT", 66, 78], ["Spinal reflexes", "TEST", 79, 94], ["flaps", "OBSERVATION", 5, 10], ["incision", "OBSERVATION", 20, 28], ["median", "ANATOMY_MODIFIER", 99, 105], ["ulnar nerves", "ANATOMY", 110, 122], ["flexor muscles", "ANATOMY", 130, 144], ["forearm", "ANATOMY", 152, 159], ["wrist", "ANATOMY", 161, 166], ["hand", "ANATOMY", 171, 175]]], ["Stimulation of afferents in the median nerve can generate responses in the ulnar nerve motor neurons.", [["afferents", "ANATOMY", 15, 24], ["nerve", "ANATOMY", 39, 44], ["ulnar nerve motor neurons", "ANATOMY", 75, 100], ["afferents", "MULTI-TISSUE_STRUCTURE", 15, 24], ["nerve", "MULTI-TISSUE_STRUCTURE", 39, 44], ["ulnar nerve motor neurons", "CELL", 75, 100], ["ulnar nerve motor neurons", "CELL_TYPE", 75, 100], ["afferents", "OBSERVATION_MODIFIER", 15, 24], ["median nerve", "ANATOMY", 32, 44], ["ulnar nerve", "ANATOMY", 75, 86]]], ["The proximal segment of each nerve was mounted on a pair of silver wire hook electrodes (with >1 cm separation).", [["nerve", "ANATOMY", 29, 34], ["silver", "CHEMICAL", 60, 66], ["proximal segment", "MULTI-TISSUE_STRUCTURE", 4, 20], ["nerve", "MULTI-TISSUE_STRUCTURE", 29, 34], ["a pair of silver wire hook electrodes", "TREATMENT", 50, 87], ["proximal", "ANATOMY_MODIFIER", 4, 12], ["segment", "ANATOMY_MODIFIER", 13, 20], ["each nerve", "ANATOMY", 24, 34], ["silver wire", "OBSERVATION", 60, 71], ["hook electrodes", "OBSERVATION", 72, 87]]], ["Electrical stimuli of increasing amplitude from 50 \u00b5A to 500 \u00b5A, in 50 \u03bcA steps, (single 100 \u00b5s square wave pulse at 0.5 Hz) were delivered from a constant current stimulator (NL800A Neurolog, Digitimer) to the proximal segment of the cut median nerve.", [["nerve", "ANATOMY", 246, 251], ["nerve", "MULTI-TISSUE_STRUCTURE", 246, 251], ["Electrical stimuli", "TEST", 0, 18], ["increasing amplitude", "PROBLEM", 22, 42], ["a constant current stimulator", "TREATMENT", 145, 174], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["amplitude", "OBSERVATION_MODIFIER", 33, 42], ["proximal", "ANATOMY_MODIFIER", 211, 219], ["segment", "ANATOMY_MODIFIER", 220, 227], ["cut", "ANATOMY_MODIFIER", 235, 238], ["median nerve", "ANATOMY", 239, 251]]], ["Ulnar nerve responses to each stimulus were recorded from the pair of silver wire hook electrodes connected to a differential pre-amplifier and amplifier (Digitimer) coupled via a PowerLab (AD Instruments) interface to a personal computer running LabChart and Scope software (AD Instruments).", [["Ulnar nerve", "ANATOMY", 0, 11], ["silver", "CHEMICAL", 70, 76], ["Ulnar nerve", "MULTI-TISSUE_STRUCTURE", 0, 11], ["each stimulus", "TEST", 25, 38], ["the pair of silver wire hook electrodes", "TREATMENT", 58, 97], ["amplifier (Digitimer)", "TREATMENT", 144, 165], ["a PowerLab (AD Instruments", "TREATMENT", 178, 204], ["nerve", "ANATOMY", 6, 11]]], ["An average of 64 sweeps at 400 \u00b5A was calculated online for each nerve and used to find the difference in amplitudes of monosynaptic reflexes evoked by median nerve stimulation.Spinal reflexes:This was achieved using software to calculate the absolute integral of any response between 1.5 ms and 3 ms, regardless of whether a response was observed qualitatively.Spinal reflexes:CST stimulation experiment with ulnar recordings: Ulnar nerve recordings were obtained during stimulation of each pyramid in turn.", [["nerve", "ANATOMY", 65, 70], ["nerve", "ANATOMY", 159, 164], ["Spinal", "ANATOMY", 177, 183], ["Spinal", "ANATOMY", 362, 368], ["ulnar", "ANATOMY", 410, 415], ["Ulnar nerve", "ANATOMY", 428, 439], ["nerve", "MULTI-TISSUE_STRUCTURE", 65, 70], ["nerve", "MULTI-TISSUE_STRUCTURE", 159, 164], ["Ulnar nerve", "MULTI-TISSUE_STRUCTURE", 428, 439], ["monosynaptic reflexes", "TEST", 120, 141], ["software", "TEST", 217, 225], ["Spinal reflexes", "TEST", 362, 377], ["CST stimulation experiment", "TEST", 378, 404], ["Ulnar nerve recordings", "TEST", 428, 450], ["average", "OBSERVATION_MODIFIER", 3, 10], ["nerve", "ANATOMY", 159, 164], ["ulnar", "ANATOMY", 410, 415], ["nerve", "ANATOMY", 434, 439]]], ["The concentric bipolar stimulation electrode (FHC CBBPC75) was located 1 mm lateral to the midline and gently lowered through the pyramid up to a maximum depth of 1.5 mm while stimulating at 300 \u03bcA (4 pulses, pulse width 100 \u00b5s; frequency 500 Hz).", [["midline", "ANATOMY", 91, 98], ["bipolar", "DISEASE", 15, 22], ["The concentric bipolar stimulation electrode (FHC CBBPC75)", "TREATMENT", 0, 58], ["4 pulses", "TEST", 199, 207], ["pulse width", "TEST", 209, 220], ["concentric", "OBSERVATION_MODIFIER", 4, 14], ["bipolar", "OBSERVATION_MODIFIER", 15, 22], ["stimulation electrode", "OBSERVATION", 23, 44], ["midline", "ANATOMY_MODIFIER", 91, 98], ["maximum", "OBSERVATION_MODIFIER", 146, 153], ["depth", "OBSERVATION_MODIFIER", 154, 159], ["1.5 mm", "OBSERVATION_MODIFIER", 163, 169]]], ["At the electrode location providing maximal ulnar nerve response, stimuli of increasing intensity were applied in the range of 50 \u00b5A to 400 \u00b5A, in 50 \u00b5A increments.", [["ulnar nerve", "ANATOMY", 44, 55], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 44, 55], ["increasing intensity", "PROBLEM", 77, 97], ["maximal", "ANATOMY_MODIFIER", 36, 43], ["ulnar nerve", "ANATOMY", 44, 55], ["increasing", "OBSERVATION_MODIFIER", 77, 87], ["intensity", "OBSERVATION_MODIFIER", 88, 97]]], ["The number of spikes 50% greater than the noise, and falling between 17 and 45 ms, was calculated for each sweep.", [["spikes", "TEST", 14, 20], ["number", "OBSERVATION_MODIFIER", 4, 10], ["spikes", "OBSERVATION_MODIFIER", 14, 20]]], ["The average number of spikes for 5 sweeps at each amplitude was calculated and the difference in the number of spikes elicited by stimulation of the pyramids from the lesioned or contralesional hemisphere.", [["contralesional hemisphere", "ANATOMY", 179, 204], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["spikes", "OBSERVATION_MODIFIER", 22, 28], ["difference", "OBSERVATION_MODIFIER", 83, 93], ["contralesional hemisphere", "ANATOMY", 179, 204]]], ["Furthermore, the signal was rectified and the area under the curve was measured between 17 and 45 ms for each sweep and averaged for the 5 sweeps at each intensity.", [["the curve", "TEST", 57, 66]]], ["Each parameter was analysed using twoway repeated measures ANOVA.", [["twoway repeated measures ANOVA", "TREATMENT", 34, 64]]], ["Graphs show mean and standard error of the mean for the area under the curve for stimuli given at 400 \u00b5A.HistologyEight weeks after stroke surgery and two weeks after injection of BDA, rats were terminally anesthetized with sodium pentobarbital (80 mg/kg; i.p.) and perfused transcardially with PBS for 5 minutes, followed by 500 ml of 4% paraformaldehyde in PBS for 15 minutes.", [["stroke", "DISEASE", 132, 138], ["BDA", "CHEMICAL", 180, 183], ["sodium pentobarbital", "CHEMICAL", 224, 244], ["paraformaldehyde", "CHEMICAL", 339, 355], ["sodium pentobarbital", "CHEMICAL", 224, 244], ["paraformaldehyde", "CHEMICAL", 339, 355], ["BDA", "SIMPLE_CHEMICAL", 180, 183], ["rats", "ORGANISM", 185, 189], ["sodium", "SIMPLE_CHEMICAL", 224, 230], ["pentobarbital", "SIMPLE_CHEMICAL", 231, 244], ["paraformaldehyde", "SIMPLE_CHEMICAL", 339, 355], ["rats", "SPECIES", 185, 189], ["Graphs", "TEST", 0, 6], ["mean", "TEST", 12, 16], ["Histology", "TEST", 105, 114], ["stroke surgery", "TREATMENT", 132, 146], ["injection of BDA", "TREATMENT", 167, 183], ["sodium pentobarbital", "TREATMENT", 224, 244], ["PBS", "TREATMENT", 295, 298], ["4% paraformaldehyde in PBS", "TREATMENT", 336, 362], ["mean", "OBSERVATION_MODIFIER", 12, 16]]], ["The brain, C6-C8 spinal cord, C7 and C8 DRGs and both arms were carefully dissected and stored in 4% paraformaldehyde in PBS for 2 hours and then transferred to 30% sucrose in PBS and stored at 2-5\u00b0C. Spinal cord segments C1 and C7 was embedded in OCT and 40 \u03bcm transverse slices were cut using a freezing stage microtome (Kryomat; Leitz, Germany).", [["brain", "ANATOMY", 4, 9], ["C6-C8 spinal cord", "ANATOMY", 11, 28], ["C8 DRGs", "ANATOMY", 37, 44], ["Spinal cord", "ANATOMY", 201, 212], ["slices", "ANATOMY", 273, 279], ["sucrose", "CHEMICAL", 165, 172], ["paraformaldehyde", "CHEMICAL", 101, 117], ["sucrose", "CHEMICAL", 165, 172], ["brain", "ORGAN", 4, 9], ["C6-C8 spinal cord", "CANCER", 11, 28], ["C7", "CELL", 30, 32], ["C8 DRGs", "CELL", 37, 44], ["paraformaldehyde", "SIMPLE_CHEMICAL", 101, 117], ["sucrose", "SIMPLE_CHEMICAL", 165, 172], ["C7", "DNA", 229, 231], ["4% paraformaldehyde in PBS", "TREATMENT", 98, 124], ["30% sucrose in PBS", "TREATMENT", 161, 179], ["OCT", "TEST", 248, 251], ["a freezing stage microtome", "TREATMENT", 295, 321], ["brain", "ANATOMY", 4, 9], ["C6", "ANATOMY_MODIFIER", 11, 13], ["C8", "ANATOMY_MODIFIER", 14, 16], ["spinal cord", "ANATOMY", 17, 28], ["C7", "ANATOMY_MODIFIER", 30, 32], ["C8", "ANATOMY_MODIFIER", 37, 39], ["both", "ANATOMY_MODIFIER", 49, 53], ["arms", "ANATOMY", 54, 58], ["cord", "ANATOMY", 208, 212], ["segments", "ANATOMY_MODIFIER", 213, 221], ["C1", "ANATOMY", 222, 224], ["C7", "ANATOMY", 229, 231]]], ["Ten series of sections were collected and stored in TBS/0.03% azide (100mM Tris, 15 mM NaCl, 0.5mM NaN3, pH 7.4) at 4\u00b0C. CST axons were counted that crossed the midline, at two more lateral planes and at an oblique plane (Figure 3a ) at C7 and C1.", [["sections", "ANATOMY", 14, 22], ["CST axons", "ANATOMY", 121, 130], ["midline", "ANATOMY", 161, 168], ["lateral planes", "ANATOMY", 182, 196], ["azide", "CHEMICAL", 62, 67], ["NaCl", "CHEMICAL", 87, 91], ["azide", "CHEMICAL", 62, 67], ["Tris", "CHEMICAL", 75, 79], ["NaCl", "CHEMICAL", 87, 91], ["NaN3", "CHEMICAL", 99, 103], ["sections", "MULTI-TISSUE_STRUCTURE", 14, 22], ["azide", "SIMPLE_CHEMICAL", 62, 67], ["NaN3", "SIMPLE_CHEMICAL", 99, 103], ["CST axons", "MULTI-TISSUE_STRUCTURE", 121, 130], ["midline", "ORGAN", 161, 168], ["TBS", "TEST", 52, 55], ["NaCl", "TEST", 87, 91], ["pH", "TEST", 105, 107], ["CST axons", "TEST", 121, 130], ["midline", "ANATOMY_MODIFIER", 161, 168], ["C7", "ANATOMY", 237, 239], ["C1", "ANATOMY", 244, 246]]], ["For each rat, we estimated the number of CST axons per cord segment by calculating the average number of CST axons per section and then multiplying by a scaling factor (number of sections cut per segment).HistologyThe total length of serotonergic processes was measured using a standard method designed specifically to measure serotonergic sprouting after neurotrophin treatment (see refs in 17 ) and which is well suited for quantification of dense terminal arbors (e.g., in the dorsal horn of the spinal cord).", [["CST axons", "ANATOMY", 41, 50], ["cord", "ANATOMY", 55, 59], ["CST axons", "ANATOMY", 105, 114], ["sections", "ANATOMY", 179, 187], ["dense terminal arbors", "ANATOMY", 444, 465], ["dorsal horn", "ANATOMY", 480, 491], ["spinal cord", "ANATOMY", 499, 510], ["rat", "ORGANISM", 9, 12], ["CST axons", "TISSUE", 41, 50], ["cord segment", "MULTI-TISSUE_STRUCTURE", 55, 67], ["CST axons", "TISSUE", 105, 114], ["neurotrophin", "GENE_OR_GENE_PRODUCT", 356, 368], ["terminal arbors", "MULTI-TISSUE_STRUCTURE", 450, 465], ["dorsal horn", "MULTI-TISSUE_STRUCTURE", 480, 491], ["spinal cord", "ORGAN", 499, 510], ["scaling factor", "PROTEIN", 153, 167], ["neurotrophin", "PROTEIN", 356, 368], ["rat", "SPECIES", 9, 12], ["a scaling factor", "TREATMENT", 151, 167], ["Histology", "TEST", 205, 214], ["a standard method", "TREATMENT", 276, 293], ["neurotrophin treatment", "TREATMENT", 356, 378], ["dense terminal arbors", "PROBLEM", 444, 465], ["cord", "ANATOMY", 55, 59], ["segment", "ANATOMY_MODIFIER", 60, 67], ["total", "OBSERVATION_MODIFIER", 218, 223], ["length", "OBSERVATION_MODIFIER", 224, 230], ["dense", "OBSERVATION_MODIFIER", 444, 449], ["terminal", "OBSERVATION_MODIFIER", 450, 458], ["arbors", "OBSERVATION_MODIFIER", 459, 465], ["dorsal", "ANATOMY_MODIFIER", 480, 486], ["horn", "ANATOMY_MODIFIER", 487, 491], ["spinal cord", "ANATOMY", 499, 510]]], ["Processes were identified using the \"adjust threshold\" function in ImageJ and fiber lengths were measured in three areas: the dorsal horn, intermediate grey and ventral horn (Fig. 4a ) in 3 sections per rat.", [["fiber", "ANATOMY", 78, 83], ["dorsal horn", "ANATOMY", 126, 137], ["ventral horn", "ANATOMY", 161, 173], ["sections", "ANATOMY", 190, 198], ["dorsal horn", "MULTI-TISSUE_STRUCTURE", 126, 137], ["ventral horn", "TISSUE", 161, 173], ["rat", "ORGANISM", 203, 206], ["rat", "SPECIES", 203, 206], ["ImageJ and fiber lengths", "TEST", 67, 91], ["dorsal horn", "ANATOMY", 126, 137], ["intermediate grey", "OBSERVATION", 139, 156], ["ventral horn", "ANATOMY", 161, 173]]], ["We calculated the ratio of the sides ipsilateral and contralateral to NT3 treatment for the three areas separately.HistologyImmunofluorescence was visualized under a Zeiss Imager.Z1 microscope or a confocal Zeiss LSM 700 laser scanning microscope.", [["NT3", "GENE_OR_GENE_PRODUCT", 70, 73], ["NT3", "PROTEIN", 70, 73], ["NT3 treatment", "TREATMENT", 70, 83], ["HistologyImmunofluorescence", "TEST", 115, 142], ["a Zeiss Imager", "TREATMENT", 164, 178], ["laser scanning microscope", "TEST", 221, 246]]], ["Photographs were taken using the Axio Cam and AxioVision LE Rel.", [["AxioVision LE Rel", "DNA", 46, 63], ["Photographs", "TEST", 0, 11], ["the Axio Cam", "TREATMENT", 29, 41], ["AxioVision LE Rel", "TREATMENT", 46, 63]]], ["4.2 or the LSM Image Browser software for image analysis.Radiolabelling of NT3NT3 protein was radiolabelled with 50 \u00b5Ci (1.85 MBq) N-succinimidyl [2,3-3 H]propionate ( 3 H-NSP) and separated from unbound 3 H-NSP using an \u00c4KTAprime purification system using a modification of a previous method 45 The same treatment was repeated for mice 24 h after stroke, with an incubation period of 40 mins (n = 6).", [["N-succinimidyl [2,3-3 H]propionate", "CHEMICAL", 131, 165], ["3 H-NSP", "CHEMICAL", 168, 175], ["stroke", "DISEASE", 348, 354], ["N-succinimidyl [2,3-3 H]propionate", "CHEMICAL", 131, 165], ["3 H-NSP", "CHEMICAL", 168, 175], ["NT3NT3", "GENE_OR_GENE_PRODUCT", 75, 81], ["1.85 MBq) N-succinimidyl [2,3-3 H]propionate", "SIMPLE_CHEMICAL", 121, 165], ["3 H-NSP", "SIMPLE_CHEMICAL", 168, 175], ["H-NSP", "SIMPLE_CHEMICAL", 206, 211], ["mice", "ORGANISM", 332, 336], ["NT3NT3 protein", "PROTEIN", 75, 89], ["mice", "SPECIES", 332, 336], ["mice", "SPECIES", 332, 336], ["image analysis", "TEST", 42, 56], ["Radiolabelling of NT3NT3 protein", "TEST", 57, 89], ["N-succinimidyl", "TREATMENT", 131, 145], ["propionate", "TREATMENT", 155, 165], ["an \u00c4KTAprime purification system", "TREATMENT", 218, 250], ["a previous method", "TREATMENT", 275, 292], ["The same treatment", "TREATMENT", 296, 314], ["stroke", "PROBLEM", 348, 354]]], ["In this set of experiments, 0.074 MBq of 14 C Sucrose (vascular marker) was injected towards the end of the incubation and the brain tissue samples also taken for capillary depletion analysis to distinguish NT3 or albumin in vascular endothelial cells from that in brain parenchyma.", [["vascular", "ANATOMY", 55, 63], ["brain tissue samples", "ANATOMY", 127, 147], ["capillary", "ANATOMY", 163, 172], ["vascular endothelial cells", "ANATOMY", 225, 251], ["brain parenchyma", "ANATOMY", 265, 281], ["Sucrose", "CHEMICAL", 46, 53], ["Sucrose", "CHEMICAL", 46, 53], ["Sucrose", "SIMPLE_CHEMICAL", 46, 53], ["vascular", "MULTI-TISSUE_STRUCTURE", 55, 63], ["brain tissue samples", "TISSUE", 127, 147], ["capillary", "TISSUE", 163, 172], ["NT3", "GENE_OR_GENE_PRODUCT", 207, 210], ["albumin", "GENE_OR_GENE_PRODUCT", 214, 221], ["vascular endothelial cells", "CELL", 225, 251], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 265, 281], ["NT3", "PROTEIN", 207, 210], ["albumin", "PROTEIN", 214, 221], ["vascular endothelial cells", "CELL_TYPE", 225, 251], ["Sucrose (vascular marker)", "TREATMENT", 46, 71], ["the incubation", "TREATMENT", 104, 118], ["the brain tissue samples", "TEST", 123, 147], ["capillary depletion analysis", "TEST", 163, 191], ["NT3", "PROBLEM", 207, 210], ["albumin in vascular endothelial cells", "PROBLEM", 214, 251], ["brain", "ANATOMY", 127, 132], ["albumin", "OBSERVATION", 214, 221], ["vascular endothelial cells", "OBSERVATION", 225, 251], ["brain", "ANATOMY", 265, 270], ["parenchyma", "ANATOMY_MODIFIER", 271, 281]]], ["In brief, brain tissue was homogenized in physiological buffer (30 \u00b5l per mg of tissue) and 26% dextran (40 \u00b5l per mg of tissue) as described previously 48 .", [["brain tissue", "ANATOMY", 10, 22], ["tissue", "ANATOMY", 80, 86], ["tissue", "ANATOMY", 121, 127], ["dextran", "CHEMICAL", 96, 103], ["brain tissue", "TISSUE", 10, 22], ["tissue", "TISSUE", 80, 86], ["dextran", "SIMPLE_CHEMICAL", 96, 103], ["tissue", "TISSUE", 121, 127], ["physiological buffer", "TREATMENT", 42, 62], ["26% dextran", "TREATMENT", 92, 103], ["brain tissue", "ANATOMY", 10, 22]]], ["The homogenate was subjected to density gradient centrifugation (5,400 \u00d7 g for 15 min at 4\u00b0C) to give an endothelial cell-enriched pellet and a supernatant containing the brain parenchyma and interstitial fluid (ISF).", [["homogenate", "ANATOMY", 4, 14], ["endothelial cell", "ANATOMY", 105, 121], ["pellet", "ANATOMY", 131, 137], ["supernatant", "ANATOMY", 144, 155], ["brain parenchyma", "ANATOMY", 171, 187], ["interstitial fluid", "ANATOMY", 192, 210], ["ISF", "ANATOMY", 212, 215], ["endothelial cell", "CELL", 105, 121], ["brain parenchyma", "TISSUE", 171, 187], ["interstitial fluid", "TISSUE", 192, 210], ["density gradient centrifugation", "TREATMENT", 32, 63], ["an endothelial cell-enriched pellet", "TREATMENT", 102, 137], ["interstitial fluid", "PROBLEM", 192, 210], ["density", "OBSERVATION_MODIFIER", 32, 39], ["gradient centrifugation", "OBSERVATION", 40, 63], ["endothelial", "ANATOMY", 105, 116], ["enriched pellet", "OBSERVATION", 122, 137], ["brain", "ANATOMY", 171, 176], ["parenchyma", "ANATOMY_MODIFIER", 177, 187], ["interstitial", "ANATOMY_MODIFIER", 192, 204], ["fluid", "OBSERVATION", 205, 210]]], ["The homogenate, pellet and supernatant samples were solubilized and counted as described above.", [["homogenate", "ANATOMY", 4, 14], ["pellet", "ANATOMY", 16, 22], ["supernatant samples", "ANATOMY", 27, 46], ["supernatant samples", "TEST", 27, 46]]], ["Distribution volume, VD, was calculated for all samples, including the endothelial pellet and brain parenchyma (ISF).", [["samples", "ANATOMY", 48, 55], ["endothelial pellet", "ANATOMY", 71, 89], ["brain parenchyma", "ANATOMY", 94, 110], ["ISF", "ANATOMY", 112, 115], ["endothelial pellet", "TISSUE", 71, 89], ["brain parenchyma", "TISSUE", 94, 110], ["Distribution volume", "TEST", 0, 19], ["all samples", "TEST", 44, 55], ["the endothelial pellet", "TEST", 67, 89], ["endothelial", "ANATOMY", 71, 82], ["brain", "ANATOMY", 94, 99], ["parenchyma", "ANATOMY_MODIFIER", 100, 110]]], ["The values were corrected for 14 C Sucrose.", [["Sucrose", "CHEMICAL", 35, 42], ["Sucrose", "CHEMICAL", 35, 42], ["14 C Sucrose", "SIMPLE_CHEMICAL", 30, 42], ["The values", "TEST", 0, 10]]], ["Data was analysed for capillary fraction, parenchyma and whole brain using one way ANOVA and post hoc (Bonferroni) t-tests.Proteomic analysis10 ug of protein was subjected to denaturing or non-denaturing SDS PAGE and visualised using Colloidal Coomassie brilliant blue staining.", [["capillary", "ANATOMY", 22, 31], ["parenchyma", "ANATOMY", 42, 52], ["whole brain", "ANATOMY", 57, 68], ["Coomassie brilliant blue", "CHEMICAL", 244, 268], ["capillary", "TISSUE", 22, 31], ["parenchyma", "TISSUE", 42, 52], ["brain", "ORGAN", 63, 68], ["Coomassie", "SIMPLE_CHEMICAL", 244, 253], ["capillary fraction", "TEST", 22, 40], ["parenchyma", "ANATOMY", 42, 52], ["brain", "ANATOMY", 63, 68]]], ["Each band was excised separately, digested enzymatically (with trypsin) and subjected to LC/MS/MS analysis (Dr. Steve Lynham, Proteomics Facility, KCL).", [["trypsin", "GENE_OR_GENE_PRODUCT", 63, 70], ["trypsin", "PROTEIN", 63, 70], ["LC", "TEST", 89, 91], ["MS analysis", "TEST", 95, 106], ["KCL", "TREATMENT", 147, 150]]], ["In-gel reduction, alkylation and digestion with trypsin were performed prior to subsequent analysis by mass spectrometry.", [["trypsin", "GENE_OR_GENE_PRODUCT", 48, 55], ["trypsin", "PROTEIN", 48, 55], ["In-gel reduction", "TREATMENT", 0, 16], ["alkylation", "TREATMENT", 18, 28], ["digestion", "PROBLEM", 33, 42], ["trypsin", "TREATMENT", 48, 55], ["subsequent analysis", "TEST", 80, 99], ["mass spectrometry", "PROBLEM", 103, 120], ["alkylation", "OBSERVATION", 18, 28]]], ["Cysteine residues were reduced with dithiothreitol and derivatised by treatment with iodoacetamide to form stable carbamidomethyl derivatives.", [["Cysteine", "CHEMICAL", 0, 8], ["dithiothreitol", "CHEMICAL", 36, 50], ["iodoacetamide", "CHEMICAL", 85, 98], ["carbamidomethyl", "CHEMICAL", 114, 129], ["Cysteine", "CHEMICAL", 0, 8], ["dithiothreitol", "CHEMICAL", 36, 50], ["iodoacetamide", "CHEMICAL", 85, 98], ["carbamidomethyl", "CHEMICAL", 114, 129], ["Cysteine", "AMINO_ACID", 0, 8], ["dithiothreitol", "SIMPLE_CHEMICAL", 36, 50], ["iodoacetamide", "SIMPLE_CHEMICAL", 85, 98], ["carbamidomethyl derivatives", "SIMPLE_CHEMICAL", 114, 141], ["Cysteine residues", "PROBLEM", 0, 17], ["dithiothreitol", "TREATMENT", 36, 50], ["iodoacetamide", "TREATMENT", 85, 98], ["stable carbamidomethyl derivatives", "TREATMENT", 107, 141], ["reduced", "OBSERVATION_MODIFIER", 23, 30], ["stable", "OBSERVATION_MODIFIER", 107, 113], ["carbamidomethyl derivatives", "OBSERVATION", 114, 141]]], ["Trypsin digestion was carried out overnight at room temperature after initial incubation at 37 o C for 2 hours.", [["Trypsin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Trypsin digestion", "PROBLEM", 0, 17]]], ["LC/MS/MS: Peptides were extracted from the gel pieces by a series of acetonitrile and aqueous washes.", [["acetonitrile", "CHEMICAL", 69, 81], ["acetonitrile", "CHEMICAL", 69, 81], ["acetonitrile", "SIMPLE_CHEMICAL", 69, 81], ["Peptides", "PROBLEM", 10, 18], ["the gel pieces", "TREATMENT", 39, 53], ["acetonitrile", "TREATMENT", 69, 81], ["aqueous washes", "TREATMENT", 86, 100]]], ["The extract was pooled with the initial supernatant and lyophilised.", [["extract", "ANATOMY", 4, 11], ["supernatant", "ANATOMY", 40, 51]]], ["Each sample was then resuspended in 23\uf06dL of 50mM ammonium bicarbonate and analysed by LC/MS/MS. Chromatographic separations were performed using an Ultimate LC system (Dionex, UK).", [["sample", "ANATOMY", 5, 11], ["ammonium bicarbonate", "CHEMICAL", 49, 69], ["ammonium bicarbonate", "CHEMICAL", 49, 69], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 49, 69], ["50mM ammonium bicarbonate", "TREATMENT", 44, 69], ["Chromatographic separations", "TEST", 96, 123]]], ["Peptides were resolved by reversed phase chromatography on a 75 \uf06dm C18 PepMap column using a three step linear gradient of acetonitrile in 0.1% formic acid.", [["acetonitrile", "CHEMICAL", 123, 135], ["formic acid", "CHEMICAL", 144, 155], ["acetonitrile", "CHEMICAL", 123, 135], ["formic acid", "CHEMICAL", 144, 155], ["acetonitrile", "SIMPLE_CHEMICAL", 123, 135], ["formic acid", "SIMPLE_CHEMICAL", 144, 155], ["a 75 \uf06dm C18 PepMap column", "TREATMENT", 59, 84], ["acetonitrile", "TREATMENT", 123, 135], ["formic acid", "TREATMENT", 144, 155]]], ["The gradient was delivered to elute the peptides at a flow rate of 200 nL/min over 60 min.", [["a flow rate", "TEST", 52, 63], ["gradient", "OBSERVATION_MODIFIER", 4, 12]]], ["The eluate was ionised by electrospray ionisation using a Z-spray source fitted to a QTof-micro (Waters Corp.) operating under MassLynx v4.0.", [["electrospray ionisation", "TREATMENT", 26, 49], ["a Z-spray source", "TREATMENT", 56, 72]]], ["The instrument was run in automated data-dependent switching mode, selecting precursor ions based on their intensity for sequencing by collision-induced fragmentation.", [["automated data", "TEST", 26, 40], ["selecting precursor ions", "TREATMENT", 67, 91], ["induced fragmentation", "PROBLEM", 145, 166], ["fragmentation", "OBSERVATION", 153, 166]]], ["The MS/MS analyses were conducted using collision energy profiles that were chosen based on the mass-to-charge ratio (m/z) and the charge state of the peptide.Proteomic analysisDatabase Searching: The mass spectral data was processed into peak lists using ProteinLynx Global Server v2.2.5 with the following parameters: (MS survey -No background subtraction, SG smoothing 2 iterations 3 channels, peaks centroided (top 80%) no de-isotoping; MS/MS -No background subtraction, SG smoothing 2 iterations 4 channels, peak centroiding (top 80%) no de-isotoping).", [["The MS/MS analyses", "TEST", 0, 18], ["collision energy profiles", "TEST", 40, 65], ["the mass", "TEST", 92, 100], ["The mass spectral data", "PROBLEM", 197, 219], ["MS survey", "TEST", 321, 330], ["background subtraction", "TEST", 335, 357], ["de-isotoping", "PROBLEM", 427, 439], ["MS", "PROBLEM", 441, 443], ["MS", "PROBLEM", 444, 446], ["background subtraction", "PROBLEM", 451, 473], ["peak centroiding", "TEST", 513, 529], ["de-isotoping", "PROBLEM", 543, 555], ["mass", "OBSERVATION", 96, 100]]], ["The peak list was searched against the Uniprot database using Mascot software v2.2 using the following parameter specifications (Precursor ion mass tolerance 1.2 Da; Fragment ion mass tolerance 0.6 Da; Tryptic digest with up to three missed cleavages; Variable modifications: Acetyl (Protein N-term), Carbamidomethylation (C), Gln->pyro-glu (N-term Q) and Oxidation (M).Proteomic analysisLC/MS/MS analysis and interrogation of the data against the Uniprot database identified NT3 from the excised and digested 1D gel bands.", [["Acetyl", "CHEMICAL", 276, 282], ["Gln", "CHEMICAL", 327, 330], ["Acetyl", "CHEMICAL", 276, 282], ["Gln", "CHEMICAL", 327, 330], ["pyro-glu", "CHEMICAL", 332, 340], ["Acetyl", "SIMPLE_CHEMICAL", 276, 282], ["Carbamidomethylation", "SIMPLE_CHEMICAL", 301, 321], ["C", "SIMPLE_CHEMICAL", 323, 324], ["Gln", "SIMPLE_CHEMICAL", 327, 330], ["pyro-glu", "SIMPLE_CHEMICAL", 332, 340], ["NT3", "GENE_OR_GENE_PRODUCT", 476, 479], ["NT3", "PROTEIN", 476, 479], ["Mascot software", "TEST", 62, 77], ["the following parameter specifications", "TREATMENT", 89, 127], ["Precursor ion mass tolerance", "TREATMENT", 129, 157], ["Fragment ion mass tolerance", "TREATMENT", 166, 193], ["Tryptic digest", "TREATMENT", 202, 216], ["Acetyl (Protein N-term)", "TREATMENT", 276, 299], ["Carbamidomethylation (C", "TREATMENT", 301, 324], ["Gln", "TEST", 327, 330], ["Proteomic analysisLC", "TEST", 370, 390], ["MS", "PROBLEM", 391, 393], ["MS analysis", "TEST", 394, 405], ["the data", "TEST", 427, 435], ["the Uniprot database", "TEST", 444, 464], ["NT3", "PROBLEM", 476, 479], ["1D gel bands", "TREATMENT", 510, 522]]], ["The results of the analysis and database searches are given in Supplementary Figure 8 .", [["the analysis", "TEST", 15, 27], ["database searches", "TEST", 32, 49]]], ["All samples were aligned in this software for easier interpretation and used to validate MS/MS based peptide assignments and protein identifications.", [["samples", "ANATOMY", 4, 11], ["protein identifications", "TEST", 125, 148]]], ["Peptide assignments were accepted if they contained at least two unique peptide assignments and were established at 100% identification probability by the Protein Prophet algorithm 49 .", [["the Protein Prophet algorithm", "TEST", 151, 180]]], ["The result table includes probability scores (Mowse) for each peptide identified from the protein sequence.", [["each peptide", "PROBLEM", 57, 69], ["the protein sequence", "TEST", 86, 106]]], ["Peptides identified below these probabilities were accepted following manual inspection of the raw data to ensure that fragment ions correctly match the assigned sequence.", [["manual inspection", "TEST", 70, 87], ["the raw data", "TEST", 91, 103], ["fragment ions", "PROBLEM", 119, 132]]], ["The sequence coverage for each identified protein is represented in Supplementary Figure 8 in yellow highlights.StatisticsStatistical analyses were conducted using SPSS (version 18.0).", [["The sequence coverage", "TREATMENT", 0, 21], ["StatisticsStatistical analyses", "TEST", 112, 142], ["SPSS (version", "TEST", 164, 177]]], ["Graphs show means \u00b1 SEMs (except where otherwise stated) and 'n' denotes number of rats.", [["rats", "ORGANISM", 83, 87], ["rats", "SPECIES", 83, 87], ["\u00b1 SEMs", "OBSERVATION", 18, 24]]], ["Threshold for significance was 0.05.", [["Threshold", "TEST", 0, 9]]], ["Histology and molecular biology data were assessed using Kruskal-Wallis and Mann-Whitney tests (due to small sample sizes).", [["Histology", "TEST", 0, 9], ["molecular biology data", "TEST", 14, 36], ["Whitney tests", "TEST", 81, 94], ["small sample sizes", "PROBLEM", 103, 121]]], ["Serotonergic fibre lengths was analysed by region using one way ANOVA and post hoc (Bonferroni) t-tests.", [["Serotonergic fibre", "ANATOMY", 0, 18], ["Serotonergic fibre", "TISSUE", 0, 18], ["Serotonergic fibre lengths", "PROBLEM", 0, 26], ["t-tests", "TEST", 96, 103], ["fibre lengths", "OBSERVATION", 13, 26]]], ["PKC\u03b3 data was analysed using Kruskal Wallis and Mann Whitney tests.", [["PKC\u03b3", "GENE_OR_GENE_PRODUCT", 0, 4], ["PKC\u03b3", "PROTEIN", 0, 4], ["PKC\u03b3 data", "TEST", 0, 9], ["Whitney tests", "TEST", 53, 66]]], ["Behavioural and MRI data were analysed using linear models and Restricted Maximum Likelihood estimation to accommodate data from rats with occasional missing values 50 .", [["rats", "ORGANISM", 129, 133], ["rats", "SPECIES", 129, 133], ["Behavioural and MRI data", "TEST", 0, 24], ["linear models", "TEST", 45, 58]]], ["Akaike's Information Criterion showed that the model with best fit for the horizontal ladder data had a compound symmetric covariance matrix, whereas for the sensory test and MRI data an unstructured covariance matrix was used.", [["the horizontal ladder data", "TEST", 71, 97], ["a compound symmetric covariance matrix", "PROBLEM", 102, 140], ["the sensory test", "TEST", 154, 170], ["MRI data", "TEST", 175, 183], ["an unstructured covariance matrix", "TREATMENT", 184, 217]]], ["The model with best fit for the vertical cylinder had a compound symmetric covariance matrix, according to the -2 restricted log likelihood information criterion.", [["a compound symmetric covariance matrix", "PROBLEM", 54, 92]]], ["Baseline scores were used as covariates.", [["Baseline scores", "PROBLEM", 0, 15]]], ["Degrees of freedom are reported to nearest integer.", [["freedom", "OBSERVATION", 11, 18]]], ["Normality was assessed using histograms. t-tests were two-tailed unless otherwise specified.", [["histograms", "TEST", 29, 39], ["t-tests", "TEST", 41, 48]]], ["Sample size calculations were presented previously 38 .MRI confirmed equivalent infarct volumes between stroke groupsMagnetic resonance imaging (MRI) confirmed that infarcts included the forelimb and hindlimb areas in sensorimotor cortex (Fig 1c) .", [["infarct", "ANATOMY", 80, 87], ["infarcts", "ANATOMY", 165, 173], ["forelimb", "ANATOMY", 187, 195], ["hindlimb areas", "ANATOMY", 200, 214], ["sensorimotor cortex", "ANATOMY", 218, 237], ["infarct", "DISEASE", 80, 87], ["stroke", "DISEASE", 104, 110], ["infarcts", "DISEASE", 165, 173], ["forelimb", "ORGANISM_SUBDIVISION", 187, 195], ["hindlimb", "ORGANISM_SUBDIVISION", 200, 208], ["sensorimotor cortex", "MULTI-TISSUE_STRUCTURE", 218, 237], ["Sample size calculations", "TEST", 0, 24], ["MRI", "TEST", 55, 58], ["equivalent infarct volumes between stroke groups", "PROBLEM", 69, 117], ["Magnetic resonance imaging", "TEST", 117, 143], ["MRI", "TEST", 145, 148], ["infarcts", "PROBLEM", 165, 173], ["the forelimb and hindlimb areas in sensorimotor cortex", "PROBLEM", 183, 237], ["size", "OBSERVATION_MODIFIER", 7, 11], ["equivalent", "OBSERVATION_MODIFIER", 69, 79], ["infarct", "OBSERVATION", 80, 87], ["volumes", "OBSERVATION_MODIFIER", 88, 95], ["infarcts", "OBSERVATION", 165, 173], ["forelimb", "ANATOMY_MODIFIER", 187, 195], ["hindlimb", "ANATOMY", 200, 208], ["areas", "ANATOMY_MODIFIER", 209, 214], ["sensorimotor cortex", "ANATOMY", 218, 237]]], ["There was no difference in the mean infarct volume between stroke groups at 24 h, one or eight weeks after stroke (Fig. 1d) .", [["infarct", "ANATOMY", 36, 43], ["infarct", "DISEASE", 36, 43], ["stroke", "DISEASE", 59, 65], ["stroke", "DISEASE", 107, 113], ["the mean infarct volume", "PROBLEM", 27, 50], ["stroke", "PROBLEM", 107, 113], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["Loss of CST axons was assessed at 8 weeks in the upper cervical spinal cord using protein kinase C gamma (PKC\u03b3) immunofluorescence 38, 51 (Fig. 1e) .", [["CST axons", "ANATOMY", 8, 17], ["upper cervical spinal cord", "ANATOMY", 49, 75], ["CST axons", "MULTI-TISSUE_STRUCTURE", 8, 17], ["upper cervical spinal cord", "ORGAN", 49, 75], ["protein kinase C gamma", "GENE_OR_GENE_PRODUCT", 82, 104], ["PKC\u03b3", "GENE_OR_GENE_PRODUCT", 106, 110], ["CST", "PROTEIN", 8, 11], ["protein kinase C gamma", "PROTEIN", 82, 104], ["PKC\u03b3", "PROTEIN", 106, 110], ["Loss of CST axons", "PROBLEM", 0, 17], ["protein kinase C gamma (PKC\u03b3) immunofluorescence", "TEST", 82, 130], ["CST axons", "OBSERVATION", 8, 17], ["upper", "ANATOMY_MODIFIER", 49, 54], ["cervical spinal cord", "ANATOMY", 55, 75]]], ["Stroke caused a 24% loss of CST axons in the dorsal columns relative to shams (Fig. 1f) with no difference between vehicle and NT3 treated rats.", [["CST axons", "ANATOMY", 28, 37], ["dorsal columns", "ANATOMY", 45, 59], ["Stroke", "DISEASE", 0, 6], ["loss of CST axons", "DISEASE", 20, 37], ["NT3", "CHEMICAL", 127, 130], ["CST axons", "MULTI-TISSUE_STRUCTURE", 28, 37], ["dorsal columns", "MULTI-TISSUE_STRUCTURE", 45, 59], ["NT3", "GENE_OR_GENE_PRODUCT", 127, 130], ["rats", "ORGANISM", 139, 143], ["NT3", "PROTEIN", 127, 130], ["rats", "SPECIES", 139, 143], ["Stroke", "PROBLEM", 0, 6], ["a 24% loss of CST axons", "PROBLEM", 14, 37], ["24%", "OBSERVATION_MODIFIER", 16, 19], ["loss", "OBSERVATION_MODIFIER", 20, 24], ["CST axons", "OBSERVATION", 28, 37], ["dorsal", "ANATOMY_MODIFIER", 45, 51], ["columns", "ANATOMY_MODIFIER", 52, 59], ["no", "UNCERTAINTY", 93, 95]]], ["Together, the MRI and PKC\u03b3 histology data indicate that there were no confounding pre-treatment differences in mean infarct volumes and that NT3 did not act as a neuroprotective agent, as expected, based on our previous results 19 and given that treatment was initiated after the majority of cell death will have occurred.Delayed NT3 improved forelimb sensory and motor function after strokeWe used the \"adhesive patch\" test to assess forepaw somatosensory function.", [["cell", "ANATOMY", 292, 296], ["forelimb sensory", "ANATOMY", 343, 359], ["forepaw somatosensory", "ANATOMY", 435, 456], ["infarct", "DISEASE", 116, 123], ["death", "DISEASE", 297, 302], ["PKC", "GENE_OR_GENE_PRODUCT", 22, 25], ["NT3", "GENE_OR_GENE_PRODUCT", 141, 144], ["cell", "CELL", 292, 296], ["NT3", "GENE_OR_GENE_PRODUCT", 330, 333], ["forelimb sensory", "MULTI-TISSUE_STRUCTURE", 343, 359], ["PKC", "PROTEIN", 22, 25], ["NT3", "PROTEIN", 141, 144], ["NT3", "PROTEIN", 330, 333], ["the MRI", "TEST", 10, 17], ["PKC\u03b3 histology data", "TEST", 22, 41], ["confounding pre-treatment differences", "PROBLEM", 70, 107], ["mean infarct volumes", "PROBLEM", 111, 131], ["NT3", "PROBLEM", 141, 144], ["treatment", "TREATMENT", 246, 255], ["cell death", "PROBLEM", 292, 302], ["the \"adhesive patch", "TREATMENT", 399, 418], ["no", "UNCERTAINTY", 67, 69]]], ["A Sensory Score was obtained by attaching pairs of adhesive patches to each rat's wrist on the dorsal side (Fig. 2a) : a high score (e.g. 6) denotes that a rat preferentially removed the smaller stimulus from their less-affected wrist (i.e., did not first remove the larger stimulus on their affected wrist).", [["wrist", "ANATOMY", 82, 87], ["dorsal", "ANATOMY", 95, 101], ["wrist", "ANATOMY", 229, 234], ["wrist", "ANATOMY", 301, 306], ["rat", "ORGANISM", 76, 79], ["wrist", "ORGANISM_SUBDIVISION", 82, 87], ["rat", "ORGANISM", 156, 159], ["wrist", "ORGANISM_SUBDIVISION", 229, 234], ["wrist", "ORGANISM_SUBDIVISION", 301, 306], ["rat", "SPECIES", 76, 79], ["rat", "SPECIES", 156, 159], ["A Sensory Score", "TEST", 0, 15], ["adhesive patches", "TREATMENT", 51, 67], ["a high score", "PROBLEM", 119, 131], ["wrist", "ANATOMY", 82, 87], ["dorsal", "ANATOMY_MODIFIER", 95, 101], ["smaller", "OBSERVATION_MODIFIER", 187, 194], ["wrist", "ANATOMY", 229, 234], ["wrist", "ANATOMY", 301, 306]]], ["The two stroke groups exhibited a similar lack of responsiveness to stimuli on their affected wrists after one week (Fig. 2b) .", [["wrists", "ANATOMY", 94, 100], ["stroke", "DISEASE", 8, 14], ["wrists", "ORGANISM_SUBDIVISION", 94, 100], ["The two stroke groups", "PROBLEM", 0, 21], ["two", "OBSERVATION_MODIFIER", 4, 7], ["stroke", "OBSERVATION", 8, 14]]], ["Delayed treatment with NT3 caused recovery compared to vehicle: whereas vehicle-treated stroke rats showed a deficit relative to sham rats which persisted for eight weeks.", [["NT3", "CHEMICAL", 23, 26], ["stroke", "DISEASE", 88, 94], ["NT3", "GENE_OR_GENE_PRODUCT", 23, 26], ["vehicle", "SIMPLE_CHEMICAL", 72, 79], ["rats", "ORGANISM", 95, 99], ["rats", "ORGANISM", 134, 138], ["NT3", "PROTEIN", 23, 26], ["rats", "SPECIES", 95, 99], ["rats", "SPECIES", 134, 138], ["Delayed treatment", "TREATMENT", 0, 17], ["NT3", "TREATMENT", 23, 26], ["stroke rats", "PROBLEM", 88, 99], ["a deficit", "PROBLEM", 107, 116]]], ["Importantly, there were no confounding differences in the time taken to contact or to remove a patch from either their less-affected or affected paw: after stroke, NT3-treated rats and vehicletreated rats took longer to contact an adhesive patch relative to shams, but there was no difference between NT3 and vehicle treated rats (Supplementary Fig. 1a) .", [["paw", "ANATOMY", 145, 148], ["stroke", "DISEASE", 156, 162], ["NT3", "CHEMICAL", 164, 167], ["paw", "ORGANISM_SUBDIVISION", 145, 148], ["NT3", "GENE_OR_GENE_PRODUCT", 164, 167], ["rats", "ORGANISM", 176, 180], ["rats", "ORGANISM", 200, 204], ["NT3", "GENE_OR_GENE_PRODUCT", 301, 304], ["rats", "ORGANISM", 325, 329], ["NT3", "PROTEIN", 164, 167], ["NT3", "PROTEIN", 301, 304], ["rats", "SPECIES", 176, 180], ["rats", "SPECIES", 200, 204], ["rats", "SPECIES", 325, 329], ["a patch", "TREATMENT", 93, 100], ["stroke", "PROBLEM", 156, 162], ["NT3", "TREATMENT", 164, 167], ["an adhesive patch", "TREATMENT", 228, 245], ["no", "UNCERTAINTY", 24, 26], ["paw", "ANATOMY", 145, 148], ["no", "UNCERTAINTY", 279, 281]]], ["Moreover, neither stroke nor NT3 treatment caused any deficit in the additional time taken after contact to remove the patch (Supplementary Figure 1b) .", [["stroke", "DISEASE", 18, 24], ["NT3", "CHEMICAL", 29, 32], ["NT3", "GENE_OR_GENE_PRODUCT", 29, 32], ["NT3", "PROTEIN", 29, 32], ["neither stroke", "PROBLEM", 10, 24], ["NT3 treatment", "TREATMENT", 29, 42], ["any deficit", "PROBLEM", 50, 61], ["the patch", "TREATMENT", 115, 124]]], ["Thus, delayed treatment of disabled forelimb muscles with NT3 improved responsiveness to tactile stimuli after ischemic stroke.Delayed NT3 improved forelimb sensory and motor function after strokeWalking was assessed using a horizontal ladder with irregularly spaced rungs (Fig. 2c) .", [["forelimb muscles", "ANATOMY", 36, 52], ["forelimb sensory", "ANATOMY", 148, 164], ["ischemic stroke", "DISEASE", 111, 126], ["forelimb muscles", "ORGANISM_SUBDIVISION", 36, 52], ["NT3", "GENE_OR_GENE_PRODUCT", 58, 61], ["NT3", "GENE_OR_GENE_PRODUCT", 135, 138], ["forelimb sensory", "MULTI-TISSUE_STRUCTURE", 148, 164], ["NT3", "PROTEIN", 58, 61], ["NT3", "PROTEIN", 135, 138], ["disabled forelimb muscles", "PROBLEM", 27, 52], ["tactile stimuli", "TEST", 89, 104], ["ischemic stroke", "PROBLEM", 111, 126], ["a horizontal ladder", "TREATMENT", 223, 242], ["irregularly spaced rungs", "PROBLEM", 248, 272], ["forelimb muscles", "ANATOMY", 36, 52], ["ischemic", "OBSERVATION_MODIFIER", 111, 119], ["stroke", "OBSERVATION", 120, 126], ["improved", "OBSERVATION_MODIFIER", 139, 147], ["forelimb", "OBSERVATION_MODIFIER", 148, 156], ["sensory", "OBSERVATION_MODIFIER", 157, 164]]], ["Accurate paw placement during crossing requires proprioceptive feedback from muscle spindles 24 .", [["paw", "ANATOMY", 9, 12], ["muscle spindles", "ANATOMY", 77, 92], ["paw", "ORGANISM_SUBDIVISION", 9, 12], ["Accurate paw placement", "TREATMENT", 0, 22], ["paw", "OBSERVATION", 9, 12], ["muscle", "ANATOMY", 77, 83]]], ["After one week, the two stroke groups made a similar number of errors with their affected forelimb when crossing a horizontal ladder (Fig. 2d) .", [["forelimb", "ANATOMY", 90, 98], ["stroke", "DISEASE", 24, 30], ["forelimb", "ORGANISM_SUBDIVISION", 90, 98], ["the two stroke groups", "PROBLEM", 16, 37]]], ["Delayed NT3 treatment caused a progressive recovery after stroke whereas vehicle treated animals remained persistently impaired until the end of the study.", [["stroke", "DISEASE", 58, 64], ["NT3", "GENE_OR_GENE_PRODUCT", 8, 11], ["NT3", "PROTEIN", 8, 11], ["Delayed NT3 treatment", "TREATMENT", 0, 21], ["stroke", "PROBLEM", 58, 64], ["persistently impaired", "PROBLEM", 106, 127], ["the study", "TEST", 145, 154], ["progressive", "OBSERVATION_MODIFIER", 31, 42], ["recovery", "OBSERVATION_MODIFIER", 43, 51]]], ["This is consistent with previous work from our lab 17, 19 .", [["consistent with", "UNCERTAINTY", 8, 23]]], ["Stroke also caused a modest unilateral hindlimb impairment on the ladder; infusion of NT3 into the forelimb triceps brachii did not improve this (Supplementary Figure 2) .Delayed NT3 improved forelimb sensory and motor function after strokeNeurotrophin-3 also restored the use of the affected forelimb for lateral support while rats reared in a vertical cylinder (Fig. 2e) .", [["hindlimb", "ANATOMY", 39, 47], ["forelimb triceps brachii", "ANATOMY", 99, 123], ["forelimb sensory", "ANATOMY", 192, 208], ["forelimb", "ANATOMY", 293, 301], ["Stroke", "DISEASE", 0, 6], ["hindlimb impairment", "DISEASE", 39, 58], ["stroke", "DISEASE", 234, 240], ["hindlimb", "ORGANISM_SUBDIVISION", 39, 47], ["NT3", "GENE_OR_GENE_PRODUCT", 86, 89], ["forelimb", "ORGANISM_SUBDIVISION", 99, 107], ["triceps brachii", "ORGAN", 108, 123], ["NT3", "GENE_OR_GENE_PRODUCT", 179, 182], ["forelimb sensory", "MULTI-TISSUE_STRUCTURE", 192, 208], ["Neurotrophin-3", "GENE_OR_GENE_PRODUCT", 240, 254], ["forelimb", "ORGANISM_SUBDIVISION", 293, 301], ["rats", "ORGANISM", 328, 332], ["NT3", "PROTEIN", 86, 89], ["NT3", "PROTEIN", 179, 182], ["rats", "SPECIES", 328, 332], ["Stroke", "PROBLEM", 0, 6], ["a modest unilateral hindlimb impairment on the ladder", "PROBLEM", 19, 72], ["infusion of NT3 into the forelimb triceps brachii", "TREATMENT", 74, 123], ["Delayed NT3", "PROBLEM", 171, 182], ["stroke", "PROBLEM", 234, 240], ["Neurotrophin", "TREATMENT", 240, 252], ["the affected forelimb", "TREATMENT", 280, 301], ["lateral support", "TREATMENT", 306, 321], ["modest", "OBSERVATION_MODIFIER", 21, 27], ["unilateral", "ANATOMY_MODIFIER", 28, 38], ["hindlimb", "ANATOMY", 39, 47], ["impairment", "OBSERVATION", 48, 58], ["forelimb", "ANATOMY_MODIFIER", 99, 107], ["triceps brachii", "ANATOMY", 108, 123], ["motor function", "OBSERVATION", 213, 227]]], ["After stroke and vehicle treatment, rats used their affected forelimb less often than shams.", [["forelimb", "ANATOMY", 61, 69], ["stroke", "DISEASE", 6, 12], ["rats", "ORGANISM", 36, 40], ["forelimb", "ORGANISM_SUBDIVISION", 61, 69], ["rats", "SPECIES", 36, 40], ["stroke", "PROBLEM", 6, 12], ["vehicle treatment", "TREATMENT", 17, 34], ["stroke", "OBSERVATION", 6, 12]]], ["NT3-treated rats showed more frequent use of the affected forelimb relative to vehicle-treated rats (Fig. 2f) .Delayed NT3 improved forelimb sensory and motor function after strokeWe used force transducers to measure grip strength of each forelimb (Supplementary Fig. 3) .", [["forelimb", "ANATOMY", 58, 66], ["forelimb sensory", "ANATOMY", 132, 148], ["forelimb", "ANATOMY", 239, 247], ["NT3", "CHEMICAL", 0, 3], ["NT3", "GENE_OR_GENE_PRODUCT", 0, 3], ["rats", "ORGANISM", 12, 16], ["forelimb", "ORGANISM_SUBDIVISION", 58, 66], ["rats", "ORGANISM", 95, 99], ["NT3", "GENE_OR_GENE_PRODUCT", 119, 122], ["forelimb sensory", "MULTI-TISSUE_STRUCTURE", 132, 148], ["forelimb", "ORGANISM_SUBDIVISION", 239, 247], ["NT3", "PROTEIN", 0, 3], ["NT3", "PROTEIN", 119, 122], ["rats", "SPECIES", 12, 16], ["rats", "SPECIES", 95, 99], ["NT3", "TREATMENT", 0, 3], ["the affected forelimb", "PROBLEM", 45, 66], ["force transducers", "TREATMENT", 188, 205]]], ["Stroke caused transient weakness in both groups but infusion of NT3 into triceps brachii did not modify grip strength.", [["triceps brachii", "ANATOMY", 73, 88], ["Stroke", "DISEASE", 0, 6], ["weakness", "DISEASE", 24, 32], ["NT3", "GENE_OR_GENE_PRODUCT", 64, 67], ["triceps brachii", "ORGAN", 73, 88], ["grip", "ORGANISM_SUBDIVISION", 104, 108], ["NT3", "PROTEIN", 64, 67], ["Stroke", "PROBLEM", 0, 6], ["transient weakness in both groups", "PROBLEM", 14, 47], ["infusion of NT3 into triceps brachii", "TREATMENT", 52, 88], ["transient", "OBSERVATION_MODIFIER", 14, 23], ["weakness", "OBSERVATION", 24, 32], ["both", "ANATOMY_MODIFIER", 36, 40], ["triceps brachii", "ANATOMY", 73, 88]]], ["We also found no evidence for pain (cold allodynia) on the affected or treated forelimbs, assessed by application of ice-cold acetone to the centre of the forepaw.", [["forelimbs", "ANATOMY", 79, 88], ["pain", "DISEASE", 30, 34], ["allodynia", "DISEASE", 41, 50], ["acetone", "CHEMICAL", 126, 133], ["forelimbs", "ORGANISM_SUBDIVISION", 79, 88], ["forepaw", "ORGANISM_SUBDIVISION", 155, 162], ["pain (cold allodynia", "PROBLEM", 30, 50], ["ice-cold acetone", "TREATMENT", 117, 133], ["no evidence for", "UNCERTAINTY", 14, 29], ["forelimbs", "ANATOMY", 79, 88], ["forepaw", "ANATOMY", 155, 162]]], ["Cold allodynia was induced neither by stroke nor NT3 treatment (Supplementary Fig. 4 ).Delayed NT3 improved forelimb sensory and motor function after strokeIn summary, infusion of NT3 protein into the triceps brachii induced recovery on both sensory and motor tasks that require control of muscles by pathways including corticospinal pathways, serotonergic raphespinal pathways and proprioceptive circuits.", [["forelimb sensory", "ANATOMY", 108, 124], ["triceps brachii", "ANATOMY", 201, 216], ["muscles", "ANATOMY", 290, 297], ["corticospinal", "ANATOMY", 320, 333], ["allodynia", "DISEASE", 5, 14], ["stroke", "DISEASE", 38, 44], ["NT3", "CHEMICAL", 49, 52], ["stroke", "DISEASE", 150, 156], ["NT3", "GENE_OR_GENE_PRODUCT", 49, 52], ["NT3", "GENE_OR_GENE_PRODUCT", 95, 98], ["forelimb sensory", "MULTI-TISSUE_STRUCTURE", 108, 124], ["NT3", "GENE_OR_GENE_PRODUCT", 180, 183], ["triceps brachii", "ORGANISM", 201, 216], ["muscles", "ORGANISM_SUBDIVISION", 290, 297], ["corticospinal", "ANATOMICAL_SYSTEM", 320, 333], ["NT3", "PROTEIN", 49, 52], ["NT3", "PROTEIN", 95, 98], ["NT3 protein", "PROTEIN", 180, 191], ["Cold allodynia", "PROBLEM", 0, 14], ["stroke", "PROBLEM", 38, 44], ["NT3 treatment", "TREATMENT", 49, 62], ["Delayed NT3", "PROBLEM", 87, 98], ["stroke", "PROBLEM", 150, 156], ["infusion of NT3 protein", "TREATMENT", 168, 191], ["corticospinal pathways", "TEST", 320, 342], ["serotonergic raphespinal pathways", "TREATMENT", 344, 377], ["proprioceptive circuits", "TREATMENT", 382, 405], ["allodynia", "OBSERVATION", 5, 14], ["motor function", "OBSERVATION", 129, 143], ["triceps brachii", "ANATOMY", 201, 216], ["muscles", "ANATOMY", 290, 297], ["proprioceptive circuits", "OBSERVATION", 382, 405]]], ["Accordingly, we hypothesised that NT3 would induce neuroplasticity in multiple pathways.NT3 induced neuroplasticity in multiple spinal locomotor pathwaysWe examined anatomical neuroplasticity in the C7 cervical spinal cord because we knew from experiments using adult and elderly rats that the less-affected corticospinal tract sprouts at this level (as well as other levels) after injection of AAV-NT3 into muscles including triceps brachii 19 .", [["spinal", "ANATOMY", 128, 134], ["C7 cervical spinal cord", "ANATOMY", 199, 222], ["corticospinal tract sprouts", "ANATOMY", 308, 335], ["muscles", "ANATOMY", 408, 415], ["triceps brachii", "ANATOMY", 426, 441], ["NT3", "GENE_OR_GENE_PRODUCT", 34, 37], ["NT3", "GENE_OR_GENE_PRODUCT", 88, 91], ["C7 cervical spinal cord", "ORGAN", 199, 222], ["rats", "ORGANISM", 280, 284], ["corticospinal tract sprouts", "TISSUE", 308, 335], ["AAV", "ORGANISM", 395, 398], ["NT3", "GENE_OR_GENE_PRODUCT", 399, 402], ["muscles", "ORGAN", 408, 415], ["triceps brachii 19", "ORGANISM", 426, 444], ["NT3", "PROTEIN", 34, 37], ["NT3", "PROTEIN", 88, 91], ["NT3", "PROTEIN", 399, 402], ["rats", "SPECIES", 280, 284], ["NT3", "TREATMENT", 34, 37], ["NT3 induced neuroplasticity in multiple spinal locomotor pathways", "PROBLEM", 88, 153], ["anatomical neuroplasticity in the C7 cervical spinal cord", "PROBLEM", 165, 222], ["the less-affected corticospinal tract sprouts", "PROBLEM", 290, 335], ["AAV", "TREATMENT", 395, 398], ["neuroplasticity", "OBSERVATION", 100, 115], ["spinal locomotor", "ANATOMY", 128, 144], ["anatomical neuroplasticity", "OBSERVATION", 165, 191], ["C7", "ANATOMY_MODIFIER", 199, 201], ["cervical", "ANATOMY_MODIFIER", 202, 210], ["spinal cord", "ANATOMY", 211, 222], ["corticospinal tract", "ANATOMY", 308, 327], ["muscles", "ANATOMY", 408, 415], ["triceps brachii", "ANATOMY", 426, 441]]], ["Indeed, anterograde tracing from the less-affected hemisphere (Fig. 1b) revealed that infusion of NT3 protein increased sprouting of the CST in the C7 spinal cord (Fig. 3 a,b) across the midline and into the affected side at two more lateral planes, and also from the ventral CST.NT3 induced neuroplasticity in multiple spinal locomotor pathwaysWe assessed neural output in the ulnar nerve on the affected side, whose motor neurons are also found in C7 (range: C4 to C8) that supply muscles in the forearm including the hand 42, 52 .", [["hemisphere", "ANATOMY", 51, 61], ["CST", "ANATOMY", 137, 140], ["C7 spinal cord", "ANATOMY", 148, 162], ["midline", "ANATOMY", 187, 194], ["lateral planes", "ANATOMY", 234, 248], ["ventral CST", "ANATOMY", 268, 279], ["spinal", "ANATOMY", 320, 326], ["neural", "ANATOMY", 357, 363], ["ulnar nerve", "ANATOMY", 378, 389], ["motor neurons", "ANATOMY", 418, 431], ["muscles", "ANATOMY", 483, 490], ["forearm", "ANATOMY", 498, 505], ["hand", "ANATOMY", 520, 524], ["NT3", "GENE_OR_GENE_PRODUCT", 98, 101], ["CST", "GENE_OR_GENE_PRODUCT", 137, 140], ["C7 spinal cord", "TISSUE", 148, 162], ["midline", "ORGAN", 187, 194], ["CST", "GENE_OR_GENE_PRODUCT", 276, 279], ["NT3", "GENE_OR_GENE_PRODUCT", 280, 283], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 378, 389], ["motor neurons", "CELL", 418, 431], ["muscles", "ORGAN", 483, 490], ["forearm", "ORGANISM_SUBDIVISION", 498, 505], ["NT3 protein", "PROTEIN", 98, 109], ["NT3", "PROTEIN", 280, 283], ["motor neurons", "CELL_TYPE", 418, 431], ["C7", "CELL_LINE", 450, 452], ["anterograde tracing", "TEST", 8, 27], ["NT3 protein", "PROBLEM", 98, 109], ["NT3 induced neuroplasticity in multiple spinal locomotor pathways", "PROBLEM", 280, 345], ["neural output", "TEST", 357, 370], ["NT3 protein", "OBSERVATION", 98, 109], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["sprouting", "OBSERVATION_MODIFIER", 120, 129], ["CST", "ANATOMY_MODIFIER", 137, 140], ["C7", "ANATOMY_MODIFIER", 148, 150], ["spinal cord", "ANATOMY", 151, 162], ["midline", "ANATOMY_MODIFIER", 187, 194], ["ventral", "ANATOMY_MODIFIER", 268, 275], ["neuroplasticity", "OBSERVATION", 292, 307], ["spinal locomotor", "ANATOMY", 320, 336], ["neural output", "OBSERVATION", 357, 370], ["ulnar nerve", "ANATOMY", 378, 389], ["motor neurons", "ANATOMY", 418, 431], ["C7", "ANATOMY", 450, 452], ["muscles", "ANATOMY", 483, 490], ["forearm", "ANATOMY", 498, 505]]], ["To do this, we recorded responses during electrical stimulation of either the spared less-affected corticospinal tract (Fig. 3c) or the partially-ablated corticospinal tract (Fig. 3f) in the medullary pyramids.", [["corticospinal tract", "ANATOMY", 99, 118], ["corticospinal tract", "ANATOMY", 154, 173], ["medullary pyramids", "ANATOMY", 191, 209], ["corticospinal tract", "ORGANISM_SUBDIVISION", 99, 118], ["corticospinal tract", "ORGANISM_SUBDIVISION", 154, 173], ["medullary pyramids", "CANCER", 191, 209], ["electrical stimulation", "TREATMENT", 41, 63], ["the spared less-affected corticospinal tract", "PROBLEM", 74, 118], ["the partially-ablated corticospinal tract", "PROBLEM", 132, 173], ["corticospinal tract", "ANATOMY", 99, 118], ["ablated", "OBSERVATION", 146, 153], ["corticospinal tract", "ANATOMY", 154, 173], ["medullary", "ANATOMY", 191, 200], ["pyramids", "ANATOMY_MODIFIER", 201, 209]]], ["NT3 treatment led to enhanced responses in the ulnar nerve during stimulation of the less-affected (Fig. 3 d, e) and more-affected (Fig. 3g, h) pathways.", [["ulnar nerve", "ANATOMY", 47, 58], ["NT3", "CHEMICAL", 0, 3], ["NT3", "GENE_OR_GENE_PRODUCT", 0, 3], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 47, 58], ["NT3", "PROTEIN", 0, 3], ["NT3 treatment", "TREATMENT", 0, 13], ["enhanced responses in the ulnar nerve", "PROBLEM", 21, 58], ["ulnar nerve", "ANATOMY", 47, 58]]], ["This result is consistent with the sprouting of traced CST axons (Fig. 3a,b) and indicates that CST axons from both the stroke hemisphere and the contralesional hemisphere formed new synapses and/or strengthened preexisting connections in the cord on the treated side, most likely on pre-motor interneurons that lie between CST axons and motoneurons 53, 54 .", [["CST axons", "ANATOMY", 55, 64], ["CST axons", "ANATOMY", 96, 105], ["stroke hemisphere", "ANATOMY", 120, 137], ["contralesional hemisphere", "ANATOMY", 146, 171], ["synapses", "ANATOMY", 183, 191], ["cord", "ANATOMY", 243, 247], ["pre-motor interneurons", "ANATOMY", 284, 306], ["CST axons", "ANATOMY", 324, 333], ["motoneurons", "ANATOMY", 338, 349], ["stroke", "DISEASE", 120, 126], ["CST axons", "CELLULAR_COMPONENT", 55, 64], ["CST axons", "MULTI-TISSUE_STRUCTURE", 96, 105], ["cord", "ORGAN", 243, 247], ["pre-motor interneurons", "CELL", 284, 306], ["CST axons", "MULTI-TISSUE_STRUCTURE", 324, 333], ["CST axons", "CELL_TYPE", 55, 64], ["CST axons", "CELL_TYPE", 96, 105], ["CST axons", "PROBLEM", 96, 105], ["new synapses", "PROBLEM", 179, 191], ["strengthened preexisting connections in the cord", "PROBLEM", 199, 247], ["consistent with", "UNCERTAINTY", 15, 30], ["stroke hemisphere", "ANATOMY", 120, 137], ["contralesional hemisphere", "ANATOMY", 146, 171], ["new", "OBSERVATION_MODIFIER", 179, 182], ["synapses", "OBSERVATION", 183, 191], ["cord", "ANATOMY", 243, 247], ["most likely", "UNCERTAINTY", 269, 280], ["motoneurons", "ANATOMY", 338, 349]]], ["However, we did not find any evidence that NT3 strengthened the short-latency reflex from afferents in the median nerve to motor neurons in the ulnar nerve (Fig. 3i-l) .", [["afferents", "ANATOMY", 90, 99], ["nerve", "ANATOMY", 114, 119], ["motor neurons", "ANATOMY", 123, 136], ["ulnar nerve", "ANATOMY", 144, 155], ["NT3", "GENE_OR_GENE_PRODUCT", 43, 46], ["nerve", "MULTI-TISSUE_STRUCTURE", 114, 119], ["motor neurons", "CELL", 123, 136], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 144, 155], ["NT3", "PROTEIN", 43, 46], ["motor neurons", "CELL_TYPE", 123, 136], ["NT3", "PROBLEM", 43, 46], ["the short-latency reflex", "PROBLEM", 60, 84], ["median nerve", "ANATOMY", 107, 119], ["motor neurons", "ANATOMY", 123, 136], ["ulnar nerve", "ANATOMY", 144, 155]]], ["We also found that NT3 treatment caused serotonergic axons to sprout in the ventral C7 spinal cord (Fig. 4a-d) .", [["serotonergic axons", "ANATOMY", 40, 58], ["sprout", "ANATOMY", 62, 68], ["ventral C7 spinal cord", "ANATOMY", 76, 98], ["NT3", "CHEMICAL", 19, 22], ["NT3", "GENE_OR_GENE_PRODUCT", 19, 22], ["serotonergic axons", "CELLULAR_COMPONENT", 40, 58], ["ventral C7 spinal cord", "TISSUE", 76, 98], ["NT3", "PROTEIN", 19, 22], ["NT3 treatment", "TREATMENT", 19, 32], ["serotonergic axons", "PROBLEM", 40, 58], ["NT3 treatment", "OBSERVATION", 19, 32], ["serotonergic axons", "OBSERVATION", 40, 58], ["sprout", "ANATOMY_MODIFIER", 62, 68], ["ventral", "ANATOMY_MODIFIER", 76, 83], ["C7", "ANATOMY_MODIFIER", 84, 86], ["spinal cord", "ANATOMY", 87, 98]]], ["Anatomical and functional plasticity of corticospinal and raphespinal pathways is consistent with their expression of receptors for NT3 3,4,55-57 .NT3 induced neuroplasticity in multiple spinal locomotor pathwaysWe conclude that NT3 caused neuroplasticity in multiple descending locomotor pathways including the raphespinal and the spared corticospinal tracts.", [["corticospinal", "ANATOMY", 40, 53], ["spinal", "ANATOMY", 187, 193], ["raphespinal", "ANATOMY", 312, 323], ["corticospinal tracts", "ANATOMY", 339, 359], ["corticospinal", "MULTI-TISSUE_STRUCTURE", 40, 53], ["NT3 3,4,55-57", "GENE_OR_GENE_PRODUCT", 132, 145], ["NT3", "GENE_OR_GENE_PRODUCT", 147, 150], ["NT3", "GENE_OR_GENE_PRODUCT", 229, 232], ["raphespinal", "CANCER", 312, 323], ["corticospinal tracts", "MULTI-TISSUE_STRUCTURE", 339, 359], ["NT3 3,4,55-57", "PROTEIN", 132, 145], ["NT3", "PROTEIN", 147, 150], ["NT3", "PROTEIN", 229, 232], ["NT3", "TEST", 132, 135], ["NT3 induced neuroplasticity in multiple spinal locomotor pathways", "PROBLEM", 147, 212], ["NT3", "TREATMENT", 229, 232], ["functional plasticity", "OBSERVATION", 15, 36], ["corticospinal", "ANATOMY_MODIFIER", 40, 53], ["consistent with", "UNCERTAINTY", 82, 97], ["neuroplasticity", "OBSERVATION", 159, 174], ["spinal locomotor", "ANATOMY", 187, 203], ["descending", "ANATOMY_MODIFIER", 268, 278], ["raphespinal", "ANATOMY_MODIFIER", 312, 323], ["spared", "ANATOMY_MODIFIER", 332, 338], ["corticospinal tracts", "ANATOMY", 339, 359]]], ["These data are consistent with previous findings from our lab 17,19 that peripherally-administered NT3 can, directly or indirectly, enhance supraspinal plasticity after stroke.", [["supraspinal", "ANATOMY", 140, 151], ["stroke", "DISEASE", 169, 175], ["NT3", "GENE_OR_GENE_PRODUCT", 99, 102], ["NT3", "PROTEIN", 99, 102], ["stroke", "PROBLEM", 169, 175], ["consistent with", "UNCERTAINTY", 15, 30], ["supraspinal plasticity", "OBSERVATION", 140, 162], ["stroke", "OBSERVATION", 169, 175]]], ["Accordingly, next, we assessed the biodistribution of NT3 after peripheral administration.Neurotrophin-3 enters the PNS and CNS after peripheral administrationWe measured the amount of total (rat and human) NT3 in the triceps brachii and C7 spinal cord.", [["PNS", "ANATOMY", 116, 119], ["CNS", "ANATOMY", 124, 127], ["triceps brachii", "ANATOMY", 218, 233], ["C7 spinal cord", "ANATOMY", 238, 252], ["NT3", "GENE_OR_GENE_PRODUCT", 54, 57], ["Neurotrophin-3", "GENE_OR_GENE_PRODUCT", 90, 104], ["PNS", "ANATOMICAL_SYSTEM", 116, 119], ["CNS", "ANATOMICAL_SYSTEM", 124, 127], ["rat", "ORGANISM", 192, 195], ["human", "ORGANISM", 200, 205], ["NT3", "GENE_OR_GENE_PRODUCT", 207, 210], ["triceps brachii", "ORGAN", 218, 233], ["C7 spinal cord", "TISSUE", 238, 252], ["NT3", "PROTEIN", 54, 57], ["Neurotrophin-3", "PROTEIN", 90, 104], ["NT3", "PROTEIN", 207, 210], ["rat", "SPECIES", 192, 195], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 200, 205], ["peripheral administration", "TREATMENT", 64, 89], ["Neurotrophin", "TREATMENT", 90, 102], ["peripheral administrationWe", "TREATMENT", 134, 161], ["CNS", "ANATOMY", 124, 127], ["triceps brachii", "ANATOMY", 218, 233], ["C7", "ANATOMY_MODIFIER", 238, 240], ["spinal cord", "ANATOMY", 241, 252]]], ["ELISA was performed using a subset of five rats per group withdrawn at random from the study at the four-week time point: this revealed an increase in total NT3 protein levels in the triceps brachii on the treated side (Fig. 5a ) and, surprisingly, on the untreated side (perhaps due to NT3 in endothelial cells; see below).", [["triceps brachii", "ANATOMY", 183, 198], ["endothelial cells", "ANATOMY", 294, 311], ["rats", "ORGANISM", 43, 47], ["NT3", "GENE_OR_GENE_PRODUCT", 157, 160], ["triceps brachii", "ORGAN", 183, 198], ["NT3", "GENE_OR_GENE_PRODUCT", 287, 290], ["endothelial cells", "CELL", 294, 311], ["NT3 protein", "PROTEIN", 157, 168], ["NT3", "PROTEIN", 287, 290], ["endothelial cells", "CELL_TYPE", 294, 311], ["rats", "SPECIES", 43, 47], ["ELISA", "TEST", 0, 5], ["the study", "TEST", 83, 92], ["an increase in total NT3 protein levels in the triceps brachii", "PROBLEM", 136, 198], ["NT3 in endothelial cells", "PROBLEM", 287, 311], ["increase", "OBSERVATION_MODIFIER", 139, 147], ["total NT3 protein levels", "OBSERVATION", 151, 175], ["triceps brachii", "ANATOMY", 183, 198], ["endothelial cells", "OBSERVATION", 294, 311]]], ["We were not able to detect any increase in total NT3 in the C7 spinal cords (Supplementary Fig. 5 ).", [["C7 spinal cords", "ANATOMY", 60, 75], ["NT3", "GENE_OR_GENE_PRODUCT", 49, 52], ["C7 spinal cords", "TISSUE", 60, 75], ["NT3", "PROTEIN", 49, 52], ["any increase in total NT3 in the C7 spinal cords", "PROBLEM", 27, 75], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["total NT3", "OBSERVATION", 43, 52], ["C7", "ANATOMY_MODIFIER", 60, 62], ["spinal cords", "ANATOMY", 63, 75]]], ["However, ELISA cannot distinguish exogenous human NT3 from endogenous rat NT3 because the amino acid sequences for mature human and rat NT3 are identical 58,59 .", [["amino acid", "CHEMICAL", 90, 100], ["amino acid", "CHEMICAL", 90, 100], ["human", "ORGANISM", 44, 49], ["NT3", "GENE_OR_GENE_PRODUCT", 50, 53], ["rat", "ORGANISM", 70, 73], ["NT3", "GENE_OR_GENE_PRODUCT", 74, 77], ["amino acid", "AMINO_ACID", 90, 100], ["human", "ORGANISM", 122, 127], ["rat", "ORGANISM", 132, 135], ["NT3", "GENE_OR_GENE_PRODUCT", 136, 139], ["exogenous human NT3", "PROTEIN", 34, 53], ["endogenous rat NT3", "PROTEIN", 59, 77], ["amino acid sequences", "PROTEIN", 90, 110], ["mature human and rat NT3", "PROTEIN", 115, 139], ["human", "SPECIES", 44, 49], ["rat", "SPECIES", 70, 73], ["human", "SPECIES", 122, 127], ["rat", "SPECIES", 132, 135], ["human", "SPECIES", 44, 49], ["rat", "SPECIES", 70, 73], ["human", "SPECIES", 122, 127], ["rat", "SPECIES", 132, 135], ["ELISA", "TEST", 9, 14], ["endogenous rat NT3", "TREATMENT", 59, 77], ["the amino acid sequences", "TEST", 86, 110]]], ["Because ELISA did not allow us to detect any small increases in exogenous human NT3 against the background of endogenous rat NT3 in the CNS, we next used a more sensitive method for measuring trafficking of NT3 across the blood-CNS barrier.Neurotrophin-3 enters the PNS and CNS after peripheral administrationRecombinant NT3 protein was radiolabelled and purified. [ 3 H]NT3 was injected intravenously into adult mice.", [["CNS", "ANATOMY", 136, 139], ["blood", "ANATOMY", 222, 227], ["CNS", "ANATOMY", 228, 231], ["PNS", "ANATOMY", 266, 269], ["CNS", "ANATOMY", 274, 277], ["intravenously", "ANATOMY", 388, 401], ["Neurotrophin-3", "CHEMICAL", 240, 254], ["[ 3 H", "CHEMICAL", 365, 370], ["NT3", "CHEMICAL", 371, 374], ["[ 3 H]NT3", "CHEMICAL", 365, 374], ["human", "ORGANISM", 74, 79], ["NT3", "GENE_OR_GENE_PRODUCT", 80, 83], ["rat", "ORGANISM", 121, 124], ["NT3", "GENE_OR_GENE_PRODUCT", 125, 128], ["CNS", "ANATOMICAL_SYSTEM", 136, 139], ["NT3", "GENE_OR_GENE_PRODUCT", 207, 210], ["blood", "ORGANISM_SUBSTANCE", 222, 227], ["CNS barrier", "TISSUE", 228, 239], ["Neurotrophin-3", "GENE_OR_GENE_PRODUCT", 240, 254], ["PNS", "ANATOMICAL_SYSTEM", 266, 269], ["CNS", "ANATOMICAL_SYSTEM", 274, 277], ["NT3", "GENE_OR_GENE_PRODUCT", 321, 324], ["[ 3 H]NT3", "SIMPLE_CHEMICAL", 365, 374], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 388, 401], ["mice", "ORGANISM", 413, 417], ["exogenous human NT3", "PROTEIN", 64, 83], ["endogenous rat NT3", "PROTEIN", 110, 128], ["NT3", "PROTEIN", 207, 210], ["Neurotrophin-3", "PROTEIN", 240, 254], ["NT3 protein", "PROTEIN", 321, 332], ["[ 3 H]NT3", "PROTEIN", 365, 374], ["human", "SPECIES", 74, 79], ["rat", "SPECIES", 121, 124], ["mice", "SPECIES", 413, 417], ["human", "SPECIES", 74, 79], ["rat", "SPECIES", 121, 124], ["mice", "SPECIES", 413, 417], ["any small increases", "PROBLEM", 41, 60], ["exogenous human NT3", "TREATMENT", 64, 83], ["endogenous rat NT3 in the CNS", "PROBLEM", 110, 139], ["Neurotrophin", "TREATMENT", 240, 252], ["the PNS", "TREATMENT", 262, 269], ["peripheral administrationRecombinant NT3 protein", "TREATMENT", 284, 332], ["NT3", "TREATMENT", 371, 374], ["small", "OBSERVATION_MODIFIER", 45, 50], ["increases", "OBSERVATION", 51, 60], ["CNS", "ANATOMY", 136, 139], ["CNS", "ANATOMY", 228, 231], ["PNS", "ANATOMY", 266, 269], ["CNS", "ANATOMY", 274, 277]]], ["Radiolabelled albumin was used as a control because it does not enter the CNS efficiently from the bloodstream.", [["CNS", "ANATOMY", 74, 77], ["bloodstream", "ANATOMY", 99, 110], ["albumin", "GENE_OR_GENE_PRODUCT", 14, 21], ["CNS", "ANATOMICAL_SYSTEM", 74, 77], ["Radiolabelled albumin", "TREATMENT", 0, 21], ["albumin", "OBSERVATION", 14, 21], ["bloodstream", "ANATOMY", 99, 110]]], ["After 3, 15, 20, 30, 40, 60 or 90 minutes, brain, spinal cord and serum were taken for scintillation counting.", [["brain", "ANATOMY", 43, 48], ["spinal cord", "ANATOMY", 50, 61], ["serum", "ANATOMY", 66, 71], ["brain", "ORGAN", 43, 48], ["spinal cord", "ORGAN", 50, 61], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["scintillation counting", "TEST", 87, 109], ["brain", "ANATOMY", 43, 48], ["spinal cord", "ANATOMY", 50, 61]]], ["NT3 progressively accumulated in the intact brain (Fig. 5b) and cervical spinal cord (Fig. 5c) .", [["brain", "ANATOMY", 44, 49], ["cervical spinal cord", "ANATOMY", 64, 84], ["NT3", "GENE_OR_GENE_PRODUCT", 0, 3], ["brain", "ORGAN", 44, 49], ["cervical spinal cord", "TISSUE", 64, 84], ["NT3", "PROTEIN", 0, 3], ["NT3", "PROBLEM", 0, 3], ["intact", "ANATOMY_MODIFIER", 37, 43], ["brain", "ANATOMY", 44, 49], ["cervical", "ANATOMY", 64, 72], ["spinal cord", "ANATOMY", 73, 84]]], ["In plasma, the half-life of NT3 was short (Fig. 5d) .", [["plasma", "ANATOMY", 3, 9], ["plasma", "ORGANISM_SUBSTANCE", 3, 9], ["NT3", "GENE_OR_GENE_PRODUCT", 28, 31], ["NT3", "PROTEIN", 28, 31]]], ["Our data is consistent with that from others who have shown that radiolabelled NT3 rapidly crosses the barriers between the blood and an intact CNS [26] [27] [28] and that a small amount of intact NT3 accumulates in the brain and cervical spinal cord (although the majority of NT3 is cleared rapidly from the bloodstream) [26] [27] [28] .", [["blood", "ANATOMY", 124, 129], ["CNS", "ANATOMY", 144, 147], ["brain", "ANATOMY", 220, 225], ["cervical spinal cord", "ANATOMY", 230, 250], ["NT3", "GENE_OR_GENE_PRODUCT", 79, 82], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["NT3", "GENE_OR_GENE_PRODUCT", 197, 200], ["brain", "ORGAN", 220, 225], ["cervical", "ORGAN", 230, 238], ["spinal cord", "ORGAN", 239, 250], ["NT3", "GENE_OR_GENE_PRODUCT", 277, 280], ["NT3", "PROTEIN", 79, 82], ["NT3", "PROTEIN", 197, 200], ["NT3", "PROTEIN", 277, 280], ["Our data", "TEST", 0, 8], ["radiolabelled NT3", "TREATMENT", 65, 82], ["the blood", "TEST", 120, 129], ["consistent with", "UNCERTAINTY", 12, 27], ["small", "OBSERVATION_MODIFIER", 174, 179], ["amount", "OBSERVATION_MODIFIER", 180, 186], ["intact", "OBSERVATION", 190, 196], ["NT3 accumulates", "OBSERVATION", 197, 212], ["brain", "ANATOMY", 220, 225], ["cervical", "ANATOMY_MODIFIER", 230, 238], ["spinal cord", "ANATOMY", 239, 250]]], ["For example, after injection of NT3 into the brachial vein (which provides drainage from the triceps brachii), NT3 accumulates in the cortex, striatum, brainstem, cerebellum, sciatic nerve (and other regions of the nervous system involved with locomotion) 27 .Next, [ 3 H]NT3 or [ 3 H]albumin was injected intravenously into adult mice 24 hours after corticalischemia.", [["brachial vein", "ANATOMY", 45, 58], ["triceps brachii", "ANATOMY", 93, 108], ["cortex", "ANATOMY", 134, 140], ["striatum", "ANATOMY", 142, 150], ["brainstem", "ANATOMY", 152, 161], ["cerebellum", "ANATOMY", 163, 173], ["sciatic nerve", "ANATOMY", 175, 188], ["nervous system", "ANATOMY", 215, 229], ["intravenously", "ANATOMY", 306, 319], ["[ 3 H", "CHEMICAL", 279, 284], ["corticalischemia", "DISEASE", 351, 367], ["[ 3 H]NT3", "CHEMICAL", 266, 275], ["NT3", "GENE_OR_GENE_PRODUCT", 32, 35], ["brachial vein", "MULTI-TISSUE_STRUCTURE", 45, 58], ["triceps brachii", "ORGAN", 93, 108], ["NT3", "GENE_OR_GENE_PRODUCT", 111, 114], ["cortex", "CANCER", 134, 140], ["striatum", "MULTI-TISSUE_STRUCTURE", 142, 150], ["brainstem", "MULTI-TISSUE_STRUCTURE", 152, 161], ["cerebellum", "ORGAN", 163, 173], ["sciatic nerve", "MULTI-TISSUE_STRUCTURE", 175, 188], ["nervous system", "ANATOMICAL_SYSTEM", 215, 229], ["[ 3 H]NT3", "SIMPLE_CHEMICAL", 266, 275], ["[ 3 H]albumin", "SIMPLE_CHEMICAL", 279, 292], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 306, 319], ["mice", "ORGANISM", 331, 335], ["NT3", "PROTEIN", 32, 35], ["NT3", "PROTEIN", 111, 114], ["mice", "SPECIES", 331, 335], ["mice", "SPECIES", 331, 335], ["injection of NT3", "TREATMENT", 19, 35], ["drainage from the triceps brachii)", "TREATMENT", 75, 109], ["NT3 accumulates in the cortex, striatum, brainstem, cerebellum, sciatic nerve", "PROBLEM", 111, 188], ["albumin", "TREATMENT", 285, 292], ["corticalischemia", "PROBLEM", 351, 367], ["brachial vein", "ANATOMY", 45, 58], ["drainage", "OBSERVATION", 75, 83], ["triceps brachii", "ANATOMY", 93, 108], ["cortex", "ANATOMY_MODIFIER", 134, 140], ["striatum", "ANATOMY_MODIFIER", 142, 150], ["brainstem", "ANATOMY", 152, 161], ["cerebellum", "ANATOMY", 163, 173], ["sciatic nerve", "ANATOMY", 175, 188], ["nervous", "ANATOMY", 215, 222]]], ["40 minutes later, tissues were taken for scintillation counting.", [["tissues", "ANATOMY", 18, 25], ["tissues", "TISSUE", 18, 25], ["scintillation counting", "TEST", 41, 63]]], ["In contrast to [ 3 H]albumin, [ 3 H]NT3 accumulated in the brain (Fig 5e) .", [["brain", "ANATOMY", 59, 64], ["[ 3 H", "CHEMICAL", 30, 35], ["[ 3 H]NT3", "CHEMICAL", 30, 39], ["[ 3 H]albumin", "SIMPLE_CHEMICAL", 15, 28], ["[ 3 H]NT3", "SIMPLE_CHEMICAL", 30, 39], ["brain", "ORGAN", 59, 64], ["[ 3 H]albumin", "PROTEIN", 15, 28], ["[ 3 H]NT3", "PROTEIN", 30, 39], ["albumin", "TEST", 21, 28], ["NT3 accumulated in the brain", "PROBLEM", 36, 64], ["brain", "ANATOMY", 59, 64]]], ["To confirm entry of [ 3 H]NT3 into brain parenchyma beyond endothelial cells, capillaries were depleted by gradient centrifugation to yield a supernatant containing brain parenchyma and an endothelial cell-enriched pellet 60 . [ 3 H]NT3 entered parenchyma (depleted of endothelial cells) at a level above that seen for [ 3 H]albumin (Fig. 5f ).", [["brain parenchyma", "ANATOMY", 35, 51], ["endothelial cells", "ANATOMY", 59, 76], ["capillaries", "ANATOMY", 78, 89], ["supernatant", "ANATOMY", 142, 153], ["brain parenchyma", "ANATOMY", 165, 181], ["endothelial cell", "ANATOMY", 189, 205], ["parenchyma", "ANATOMY", 245, 255], ["endothelial cells", "ANATOMY", 269, 286], ["[ 3 H]albumin", "CHEMICAL", 319, 332], ["[ 3 H]NT3", "GENE_OR_GENE_PRODUCT", 20, 29], ["brain parenchyma", "CELL", 35, 51], ["endothelial cells", "CELL", 59, 76], ["capillaries", "TISSUE", 78, 89], ["brain parenchyma", "TISSUE", 165, 181], ["endothelial cell", "CELL", 189, 205], ["NT3", "GENE_OR_GENE_PRODUCT", 233, 236], ["parenchyma", "TISSUE", 245, 255], ["endothelial cells", "CELL", 269, 286], ["[ 3 H]albumin", "SIMPLE_CHEMICAL", 319, 332], ["[ 3 H]NT3", "PROTEIN", 20, 29], ["endothelial cells", "CELL_TYPE", 59, 76], ["endothelial cell", "CELL_TYPE", 189, 205], ["NT3", "PROTEIN", 233, 236], ["endothelial cells", "CELL_TYPE", 269, 286], ["entry of [ 3 H]NT3 into brain parenchyma", "TEST", 11, 51], ["gradient centrifugation", "TEST", 107, 130], ["a supernatant containing brain parenchyma", "PROBLEM", 140, 181], ["an endothelial cell", "TEST", 186, 205], ["NT3 entered parenchyma", "TEST", 233, 255], ["endothelial cells", "PROBLEM", 269, 286], ["albumin (Fig.", "TREATMENT", 325, 338], ["brain", "ANATOMY", 35, 40], ["parenchyma", "ANATOMY_MODIFIER", 41, 51], ["endothelial cells", "ANATOMY", 59, 76], ["brain", "ANATOMY", 165, 170], ["parenchyma", "ANATOMY_MODIFIER", 171, 181], ["endothelial cell", "OBSERVATION", 189, 205], ["parenchyma", "ANATOMY", 245, 255], ["endothelial cells", "OBSERVATION", 269, 286]]], ["Transport of NT3 into the CNS is apparently a receptor-mediated process 61 as shown by 1) the expression of NT3 receptors in rodent and human CNS capillaries 62, 63 and 2) the ability of non-radiolabelled NT3 to compete for uptake of radiolabelled NT3 into the CNS 12, 13, 44 .Next, [ 3 H]NT3 or [ 3 H]albumin was injected intravenously into adult mice 24 hours after corticalIn addition, we and others have shown that NT3 enters the PNS after peripheral administration: after intramuscular overexpression of AAV encoding NT3, NT3 levels are elevated in the blood stream and NT3 accumulates in the ipsilateral DRG 17, 19 .", [["CNS", "ANATOMY", 26, 29], ["CNS capillaries", "ANATOMY", 142, 157], ["CNS", "ANATOMY", 261, 264], ["intravenously", "ANATOMY", 323, 336], ["cortical", "ANATOMY", 368, 376], ["PNS", "ANATOMY", 434, 437], ["intramuscular", "ANATOMY", 477, 490], ["blood stream", "ANATOMY", 558, 570], ["ipsilateral DRG", "ANATOMY", 598, 613], ["[ 3 H", "CHEMICAL", 296, 301], ["[ 3 H]NT3", "CHEMICAL", 283, 292], ["NT3", "GENE_OR_GENE_PRODUCT", 13, 16], ["CNS", "ANATOMICAL_SYSTEM", 26, 29], ["NT3", "GENE_OR_GENE_PRODUCT", 108, 111], ["human", "ORGANISM", 136, 141], ["CNS capillaries", "TISSUE", 142, 157], ["NT3", "GENE_OR_GENE_PRODUCT", 205, 208], ["NT3", "GENE_OR_GENE_PRODUCT", 248, 251], ["[ 3 H]NT3", "SIMPLE_CHEMICAL", 283, 292], ["[ 3 H]albumin", "SIMPLE_CHEMICAL", 296, 309], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 323, 336], ["mice", "ORGANISM", 348, 352], ["cortical", "MULTI-TISSUE_STRUCTURE", 368, 376], ["NT3", "GENE_OR_GENE_PRODUCT", 419, 422], ["PNS", "ANATOMICAL_SYSTEM", 434, 437], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 477, 490], ["AAV", "GENE_OR_GENE_PRODUCT", 509, 512], ["NT3", "GENE_OR_GENE_PRODUCT", 522, 525], ["NT3", "GENE_OR_GENE_PRODUCT", 527, 530], ["blood", "ORGANISM_SUBSTANCE", 558, 563], ["NT3", "GENE_OR_GENE_PRODUCT", 575, 578], ["NT3", "PROTEIN", 13, 16], ["NT3 receptors", "PROTEIN", 108, 121], ["NT3", "PROTEIN", 205, 208], ["NT3", "PROTEIN", 248, 251], ["[ 3 H]NT3", "PROTEIN", 283, 292], ["NT3", "PROTEIN", 419, 422], ["NT3", "PROTEIN", 522, 525], ["NT3", "PROTEIN", 527, 530], ["NT3", "PROTEIN", 575, 578], ["rodent", "SPECIES", 125, 131], ["human", "SPECIES", 136, 141], ["mice", "SPECIES", 348, 352], ["human", "SPECIES", 136, 141], ["mice", "SPECIES", 348, 352], ["NT3 receptors", "TEST", 108, 121], ["human CNS capillaries", "TEST", 136, 157], ["non-radiolabelled NT3", "TREATMENT", 187, 208], ["radiolabelled NT3 into the CNS", "TEST", 234, 264], ["albumin", "TREATMENT", 302, 309], ["NT3", "TREATMENT", 419, 422], ["peripheral administration", "TREATMENT", 444, 469], ["AAV encoding NT3", "TREATMENT", 509, 525], ["NT3 levels", "TEST", 527, 537], ["elevated", "PROBLEM", 542, 550], ["the blood stream", "TEST", 554, 570], ["the ipsilateral DRG", "TEST", 594, 613], ["CNS", "ANATOMY", 26, 29], ["CNS", "ANATOMY", 261, 264], ["PNS", "ANATOMY", 434, 437], ["AAV", "OBSERVATION", 509, 512], ["elevated", "OBSERVATION_MODIFIER", 542, 550], ["blood", "ANATOMY", 558, 563], ["stream", "ANATOMY_MODIFIER", 564, 570], ["NT3 accumulates", "OBSERVATION", 575, 590], ["ipsilateral", "ANATOMY_MODIFIER", 598, 609], ["DRG", "ANATOMY", 610, 613]]], ["We also found some evidence that NT3 is retrogradely transported from muscle to ipsilateral motor neurons 17 .", [["muscle", "ANATOMY", 70, 76], ["ipsilateral motor neurons", "ANATOMY", 80, 105], ["NT3", "GENE_OR_GENE_PRODUCT", 33, 36], ["muscle", "ORGAN", 70, 76], ["NT3", "PROTEIN", 33, 36], ["NT3", "PROBLEM", 33, 36], ["NT3", "OBSERVATION", 33, 36], ["muscle", "ANATOMY", 70, 76], ["ipsilateral", "ANATOMY_MODIFIER", 80, 91], ["motor neurons", "ANATOMY", 92, 105]]], ["This is consistent with data showing that 1) the blood-nerve barrier in DRGs is permeable to proteins like NT3 64 , 2) that after intravenous injection, radiolabelled NT3 accumulates in the sciatic nerve 27 and 3) that NT3 is retrogradely transported from muscle to the spinal cord or DRG in nerves 5, 7, 65, 66 .", [["blood-nerve barrier", "ANATOMY", 49, 68], ["DRGs", "ANATOMY", 72, 76], ["intravenous", "ANATOMY", 130, 141], ["sciatic nerve", "ANATOMY", 190, 203], ["muscle", "ANATOMY", 256, 262], ["spinal cord", "ANATOMY", 270, 281], ["DRG", "ANATOMY", 285, 288], ["nerves", "ANATOMY", 292, 298], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["nerve barrier", "MULTI-TISSUE_STRUCTURE", 55, 68], ["NT3", "GENE_OR_GENE_PRODUCT", 107, 110], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 130, 141], ["NT3", "GENE_OR_GENE_PRODUCT", 167, 170], ["sciatic nerve", "MULTI-TISSUE_STRUCTURE", 190, 203], ["NT3", "GENE_OR_GENE_PRODUCT", 219, 222], ["muscle", "ORGAN", 256, 262], ["spinal cord", "ORGAN", 270, 281], ["DRG", "MULTI-TISSUE_STRUCTURE", 285, 288], ["nerves", "MULTI-TISSUE_STRUCTURE", 292, 298], ["NT3 64", "PROTEIN", 107, 113], ["NT3", "PROTEIN", 167, 170], ["NT3", "PROTEIN", 219, 222], ["the blood-nerve barrier in DRGs", "PROBLEM", 45, 76], ["NT3", "TEST", 107, 110], ["intravenous injection", "TREATMENT", 130, 151], ["radiolabelled NT3", "TREATMENT", 153, 170], ["consistent with", "UNCERTAINTY", 8, 23], ["nerve", "ANATOMY", 55, 60], ["sciatic nerve", "ANATOMY", 190, 203], ["muscle", "ANATOMY", 256, 262], ["spinal cord", "ANATOMY", 270, 281], ["DRG", "OBSERVATION", 285, 288], ["nerves", "ANATOMY", 292, 298]]], ["We conclude that neuroplasticity occurred in multiple locomotor pathways because peripherally-administered NT3 bound to receptors in the PNS and CNS.BOLD signal in perilesional somatosensory cortex evoked by stimulation of the affected wrist recovers with time after stroke and is not further enhanced by NT3To explore the mechanism whereby NT3 improved responsiveness to stimuli attached to the affected wrist (Fig. 2b) , we performed functional brain imaging (BOLD-fMRI) during low threshold (non-noxious) intensity electrical stimulation of the affected wrist ( Supplementary Fig. 6 ).", [["PNS", "ANATOMY", 137, 140], ["CNS", "ANATOMY", 145, 148], ["perilesional somatosensory cortex", "ANATOMY", 164, 197], ["wrist", "ANATOMY", 236, 241], ["wrist", "ANATOMY", 405, 410], ["brain", "ANATOMY", 447, 452], ["wrist", "ANATOMY", 557, 562], ["stroke", "DISEASE", 267, 273], ["NT3", "GENE_OR_GENE_PRODUCT", 107, 110], ["PNS", "ANATOMICAL_SYSTEM", 137, 140], ["CNS", "ANATOMICAL_SYSTEM", 145, 148], ["perilesional somatosensory cortex", "CANCER", 164, 197], ["wrist", "ORGANISM_SUBDIVISION", 236, 241], ["NT3To", "SIMPLE_CHEMICAL", 305, 310], ["NT3", "GENE_OR_GENE_PRODUCT", 341, 344], ["wrist", "ORGANISM_SUBDIVISION", 405, 410], ["brain", "ORGAN", 447, 452], ["wrist", "ORGANISM_SUBDIVISION", 557, 562], ["NT3", "PROTEIN", 107, 110], ["NT3To", "PROTEIN", 305, 310], ["NT3", "PROTEIN", 341, 344], ["BOLD signal", "TEST", 149, 160], ["stroke", "PROBLEM", 267, 273], ["functional brain imaging", "TEST", 436, 460], ["BOLD-fMRI", "TEST", 462, 471], ["low threshold (non-noxious) intensity electrical stimulation of the affected wrist", "TREATMENT", 480, 562], ["PNS", "ANATOMY", 137, 140], ["CNS", "ANATOMY", 145, 148], ["perilesional", "ANATOMY_MODIFIER", 164, 176], ["somatosensory cortex", "ANATOMY", 177, 197], ["wrist", "ANATOMY", 236, 241], ["wrist", "ANATOMY", 405, 410], ["wrist", "ANATOMY", 557, 562]]], ["As expected, prior to stroke, stimulation of the wrist resulted in a higher probability of activation of the opposite somatosensory cortex (Supplementary Fig. 6a ). fMRI performed one week after stroke confirmed that somatosensory cortex was not active when the affected paw was stimulated in either vehicle or NT3 treated rats (p>0.05, Supplementary Fig. 6b ).", [["wrist", "ANATOMY", 49, 54], ["somatosensory cortex", "ANATOMY", 118, 138], ["somatosensory cortex", "ANATOMY", 217, 237], ["paw", "ANATOMY", 271, 274], ["stroke", "DISEASE", 22, 28], ["stroke", "DISEASE", 195, 201], ["wrist", "ORGANISM_SUBDIVISION", 49, 54], ["somatosensory cortex", "MULTI-TISSUE_STRUCTURE", 118, 138], ["somatosensory cortex", "CANCER", 217, 237], ["paw", "ORGANISM_SUBDIVISION", 271, 274], ["NT3", "GENE_OR_GENE_PRODUCT", 311, 314], ["rats", "ORGANISM", 323, 327], ["rats", "SPECIES", 323, 327], ["stroke", "PROBLEM", 22, 28], ["stimulation of the wrist", "TREATMENT", 30, 54], ["fMRI", "TEST", 165, 169], ["stroke", "PROBLEM", 195, 201], ["somatosensory cortex", "PROBLEM", 217, 237], ["the affected paw", "PROBLEM", 258, 274], ["stroke", "OBSERVATION", 22, 28], ["wrist", "ANATOMY", 49, 54], ["somatosensory cortex", "OBSERVATION", 217, 237], ["not", "UNCERTAINTY", 242, 245], ["active", "OBSERVATION_MODIFIER", 246, 252]]], ["This supports our claim above that there were no early differences between groups that could be explained by neuroprotection. fMRI performed eight weeks after stroke revealed a trend towards perilesional re-activation of somatosensory cortex in both vehicle and NT3 treated groups (p<0.05, Supplementary Fig. 6c ).", [["perilesional", "ANATOMY", 191, 203], ["somatosensory cortex", "ANATOMY", 221, 241], ["stroke", "DISEASE", 159, 165], ["perilesional", "PATHOLOGICAL_FORMATION", 191, 203], ["somatosensory cortex", "MULTI-TISSUE_STRUCTURE", 221, 241], ["NT3", "GENE_OR_GENE_PRODUCT", 262, 265], ["fMRI", "TEST", 126, 130], ["stroke", "PROBLEM", 159, 165], ["a trend towards perilesional re-activation of somatosensory cortex", "PROBLEM", 175, 241], ["somatosensory cortex", "OBSERVATION", 221, 241], ["both", "ANATOMY_MODIFIER", 245, 249], ["vehicle", "ANATOMY", 250, 257]]], ["This is in line with human brain imaging studies showing that spontaneous sensory recovery is increased after stroke when more-normal activity patterns are observed on the affected side of the brain 67 .", [["brain", "ANATOMY", 27, 32], ["brain", "ANATOMY", 193, 198], ["stroke", "DISEASE", 110, 116], ["human", "ORGANISM", 21, 26], ["brain", "ORGAN", 27, 32], ["brain", "ORGAN", 193, 198], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["human brain imaging studies", "TEST", 21, 48], ["spontaneous sensory recovery", "PROBLEM", 62, 90], ["stroke", "PROBLEM", 110, 116], ["spontaneous", "OBSERVATION_MODIFIER", 62, 73], ["sensory recovery", "OBSERVATION", 74, 90], ["increased", "OBSERVATION_MODIFIER", 94, 103], ["brain", "ANATOMY", 193, 198]]], ["However, these probabilities of re-activation were not big enough to survive correction for testing of multiple voxels (p-values>0.01) although clearly they are in a location that might mediate recovery of somatosensation.BOLD signal in perilesional somatosensory cortex evoked by stimulation of the affected wrist recovers with time after stroke and is not further enhanced by NT3A longitudinal analysis showed that at 8 weeks (relative to pre-stroke baseline), there was some evidence that rats treated with Neurotrophin-3 showed increased probability of activation of perilesional cortex (Supplementary Fig. 6d, p<0 .05) and showed decreased probability of activation of somatosensory cortex on the less-affected hemisphere (p<0.05) relative to vehicletreated stroke rats.", [["perilesional somatosensory cortex", "ANATOMY", 237, 270], ["wrist", "ANATOMY", 309, 314], ["perilesional cortex", "ANATOMY", 571, 590], ["somatosensory cortex", "ANATOMY", 674, 694], ["hemisphere", "ANATOMY", 716, 726], ["somatosensation", "DISEASE", 206, 221], ["stroke", "DISEASE", 340, 346], ["stroke", "DISEASE", 763, 769], ["perilesional somatosensory cortex", "CANCER", 237, 270], ["wrist", "ORGANISM_SUBDIVISION", 309, 314], ["rats", "ORGANISM", 492, 496], ["Neurotrophin-3", "GENE_OR_GENE_PRODUCT", 510, 524], ["perilesional cortex", "MULTI-TISSUE_STRUCTURE", 571, 590], ["somatosensory cortex", "MULTI-TISSUE_STRUCTURE", 674, 694], ["rats", "ORGANISM", 770, 774], ["rats", "SPECIES", 492, 496], ["rats", "SPECIES", 770, 774], ["testing", "TEST", 92, 99], ["multiple voxels", "TEST", 103, 118], ["p-values", "TEST", 120, 128], ["somatosensation", "PROBLEM", 206, 221], ["BOLD signal", "TEST", 222, 233], ["stroke", "PROBLEM", 340, 346], ["NT3A longitudinal analysis", "TEST", 378, 404], ["Neurotrophin", "TEST", 510, 522], ["activation of perilesional cortex", "PROBLEM", 557, 590], ["activation of somatosensory cortex", "PROBLEM", 660, 694], ["vehicletreated stroke rats", "PROBLEM", 748, 774], ["perilesional", "ANATOMY_MODIFIER", 237, 249], ["somatosensory cortex", "ANATOMY", 250, 270], ["wrist", "ANATOMY", 309, 314], ["perilesional cortex", "ANATOMY", 571, 590], ["decreased", "OBSERVATION_MODIFIER", 635, 644], ["somatosensory cortex", "OBSERVATION", 674, 694], ["stroke", "OBSERVATION", 763, 769]]], ["However, these apparent differences did not survive correction for testing of multiple voxels (p<0.01).", [["testing", "TEST", 67, 74], ["multiple voxels", "TEST", 78, 93]]], ["We conclude that both groups showed partial, spontaneous restoration of more-normal patterns of somatosensory cortex activation 68,69 but, conservatively, that NT3 did not further increase probability of activation of any supraspinal areas.", [["somatosensory cortex", "ANATOMY", 96, 116], ["supraspinal areas", "ANATOMY", 222, 239], ["somatosensory cortex", "MULTI-TISSUE_STRUCTURE", 96, 116], ["NT3", "GENE_OR_GENE_PRODUCT", 160, 163], ["NT3", "PROTEIN", 160, 163], ["somatosensory cortex activation", "PROBLEM", 96, 127], ["NT3", "TREATMENT", 160, 163], ["activation of any supraspinal areas", "PROBLEM", 204, 239], ["partial", "OBSERVATION_MODIFIER", 36, 43], ["somatosensory cortex", "OBSERVATION", 96, 116], ["supraspinal", "ANATOMY", 222, 233]]], ["These conclusions are consistent with previous fMRI data from our laboratory 19 ; we propose that the additional recovery of somatosensory function after NT3 treatment (Fig. 2b) is due to changes in the spinal cord rather than in supraspinal areas.Proteomic analysis of NT3The batch of neurotrophin-3 protein that we used was produced more than a decade ago by Genentech.", [["somatosensory", "ANATOMY", 125, 138], ["spinal cord", "ANATOMY", 203, 214], ["supraspinal areas", "ANATOMY", 230, 247], ["NT3", "GENE_OR_GENE_PRODUCT", 154, 157], ["spinal cord", "ORGAN", 203, 214], ["NT3", "GENE_OR_GENE_PRODUCT", 270, 273], ["neurotrophin-3", "GENE_OR_GENE_PRODUCT", 286, 300], ["NT3", "PROTEIN", 154, 157], ["NT3", "PROTEIN", 270, 273], ["neurotrophin-3 protein", "PROTEIN", 286, 308], ["previous fMRI data", "TEST", 38, 56], ["somatosensory function", "PROBLEM", 125, 147], ["NT3 treatment", "TREATMENT", 154, 167], ["changes in the spinal cord", "PROBLEM", 188, 214], ["Proteomic analysis", "TEST", 248, 266], ["neurotrophin-3 protein", "TREATMENT", 286, 308], ["consistent with", "UNCERTAINTY", 22, 37], ["spinal cord", "ANATOMY", 203, 214], ["supraspinal", "ANATOMY", 230, 241], ["NT3", "OBSERVATION", 270, 273]]], ["We sought to determine whether any degradation had occurred and to confirm its amino acid sequence so that identical preparations of neurotrophin-3 could be made for future experiments.", [["amino acid", "CHEMICAL", 79, 89], ["amino acid", "CHEMICAL", 79, 89], ["amino acid", "AMINO_ACID", 79, 89], ["neurotrophin-3", "GENE_OR_GENE_PRODUCT", 133, 147], ["neurotrophin-3", "PROTEIN", 133, 147], ["any degradation", "PROBLEM", 31, 46], ["its amino acid sequence", "PROBLEM", 75, 98], ["neurotrophin-3", "TREATMENT", 133, 147]]], ["Supplementary Figure 7 depicts results from a non-denaturing gel showing a higher molecular weight band (30 kDa) and a lower molecular weight band (14 kDa) consistent, respectively, with dimeric mature NT3 and monomeric mature NT3.", [["NT3", "GENE_OR_GENE_PRODUCT", 202, 205], ["NT3", "GENE_OR_GENE_PRODUCT", 227, 230], ["dimeric mature NT3", "PROTEIN", 187, 205], ["monomeric mature NT3", "PROTEIN", 210, 230], ["a non-denaturing gel", "TEST", 44, 64], ["a higher molecular weight band", "PROBLEM", 73, 103], ["a lower molecular weight band", "TEST", 117, 146], ["monomeric mature NT3", "OBSERVATION", 210, 230]]], ["There was no evidence of degradation or aggregation.", [["degradation", "PROBLEM", 25, 36], ["aggregation", "PROBLEM", 40, 51], ["no evidence of", "UNCERTAINTY", 10, 24], ["degradation", "OBSERVATION", 25, 36], ["aggregation", "OBSERVATION", 40, 51]]], ["Each band was excised separately, digested enzymatically (with trypsin) and subjected to LC/MS/MS analysis.", [["trypsin", "GENE_OR_GENE_PRODUCT", 63, 70], ["trypsin", "PROTEIN", 63, 70], ["LC/MS/MS analysis", "TEST", 89, 106]]], ["Proteomic analysis was consistent with both bands being mature NT3 with no evidence of residual prepro sequences (Supplementary Figure 8) .", [["NT3", "GENE_OR_GENE_PRODUCT", 63, 66], ["NT3", "PROTEIN", 63, 66], ["prepro sequences", "DNA", 96, 112], ["Proteomic analysis", "TEST", 0, 18], ["both bands", "PROBLEM", 39, 49], ["residual prepro sequences", "PROBLEM", 87, 112], ["consistent with", "UNCERTAINTY", 23, 38], ["no evidence of", "UNCERTAINTY", 72, 86], ["residual", "OBSERVATION_MODIFIER", 87, 95]]], ["We conclude that the higher molecular weight band is not preproNT3 (~30 kDa) but rather corresponds to dimeric mature NT3.", [["NT3", "GENE_OR_GENE_PRODUCT", 63, 66], ["NT3", "GENE_OR_GENE_PRODUCT", 118, 121], ["preproNT3", "PROTEIN", 57, 66], ["dimeric mature NT3", "PROTEIN", 103, 121], ["preproNT3", "TREATMENT", 57, 66]]], ["This facilitated our ongoing experiments to evaluate NT3 as a therapy for stroke because most commercial preparations of NT3 consist of mature NT3 rather than preproNT3.DiscussionTreatment of disabled arm muscles with NT3 protein, initiated 24 hours after stroke, caused changes in multiple locomotor circuits, and promoted a progressive recovery of sensory and motor function in rats.", [["arm muscles", "ANATOMY", 201, 212], ["stroke", "DISEASE", 74, 80], ["stroke", "DISEASE", 256, 262], ["NT3", "GENE_OR_GENE_PRODUCT", 53, 56], ["NT3", "GENE_OR_GENE_PRODUCT", 121, 124], ["NT3", "GENE_OR_GENE_PRODUCT", 143, 146], ["preproNT3", "GENE_OR_GENE_PRODUCT", 159, 168], ["arm muscles", "ORGANISM_SUBDIVISION", 201, 212], ["NT3", "GENE_OR_GENE_PRODUCT", 218, 221], ["rats", "ORGANISM", 380, 384], ["NT3", "PROTEIN", 53, 56], ["NT3", "PROTEIN", 121, 124], ["NT3", "PROTEIN", 143, 146], ["preproNT3", "PROTEIN", 159, 168], ["NT3 protein", "PROTEIN", 218, 229], ["rats", "SPECIES", 380, 384], ["NT3", "TREATMENT", 53, 56], ["a therapy", "TREATMENT", 60, 69], ["stroke", "PROBLEM", 74, 80], ["NT3", "TREATMENT", 121, 124], ["disabled arm muscles", "PROBLEM", 192, 212], ["NT3 protein", "TREATMENT", 218, 229], ["stroke", "PROBLEM", 256, 262], ["multiple locomotor circuits", "TREATMENT", 282, 309], ["arm muscles", "ANATOMY", 201, 212], ["multiple", "OBSERVATION_MODIFIER", 282, 290], ["locomotor circuits", "OBSERVATION", 291, 309], ["progressive", "OBSERVATION_MODIFIER", 326, 337], ["motor function", "OBSERVATION", 362, 376]]], ["The fact that NT3 can reverse disability when treatment is initiated 24 hours after stroke is exciting because the vast majority of stroke victims are diagnosed within this time frame 2 .", [["disability", "DISEASE", 30, 40], ["stroke", "DISEASE", 84, 90], ["stroke", "DISEASE", 132, 138], ["NT3", "GENE_OR_GENE_PRODUCT", 14, 17], ["NT3", "PROTEIN", 14, 17], ["NT3", "TREATMENT", 14, 17], ["treatment", "TREATMENT", 46, 55], ["stroke", "PROBLEM", 84, 90], ["stroke victims", "PROBLEM", 132, 146], ["stroke", "OBSERVATION", 132, 138]]], ["In contrast, the gold-standard drug for ischemic stroke, tPA, needs to be given within a few hours and is only administered to a minority.", [["ischemic stroke", "DISEASE", 40, 55], ["tPA", "GENE_OR_GENE_PRODUCT", 57, 60], ["ischemic stroke", "PROBLEM", 40, 55], ["tPA", "TREATMENT", 57, 60], ["ischemic", "OBSERVATION_MODIFIER", 40, 48], ["stroke", "OBSERVATION", 49, 55]]], ["Thus, NT3 could potentially be used to treat an enormous number of victims.DiscussionNT3 has good clinical potential.", [["DiscussionNT3", "CHEMICAL", 75, 88], ["NT3", "GENE_OR_GENE_PRODUCT", 6, 9], ["NT3", "PROTEIN", 6, 9], ["NT3", "TREATMENT", 6, 9], ["enormous", "OBSERVATION_MODIFIER", 48, 56], ["number", "OBSERVATION_MODIFIER", 57, 63]]], ["Firstly, Phase II clinical trials show that doses up to 150 \u00b5g/kg/day are well tolerated and safe in healthy humans and in humans with other conditions 29,31-33 .", [["humans", "ORGANISM", 109, 115], ["humans", "ORGANISM", 123, 129], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 123, 129], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 123, 129]]], ["We used a threefold lower dose (48 \u00b5g/kg/day) in this study: in future experiments we will optimize the dose and duration of treatment because it is possible that a higher dose of NT3 would promote additional recovery after stroke.", [["NT3", "CHEMICAL", 180, 183], ["stroke", "DISEASE", 224, 230], ["NT3", "GENE_OR_GENE_PRODUCT", 180, 183], ["NT3", "PROTEIN", 180, 183], ["a threefold lower dose", "TREATMENT", 8, 30], ["this study", "TEST", 49, 59], ["treatment", "TREATMENT", 125, 134], ["a higher dose of NT3", "TREATMENT", 163, 183], ["stroke", "PROBLEM", 224, 230]]], ["Secondly, there is good conservation from rodents to primates including humans in the expression of receptors for NT3 in the locomotor system 3, 4, [70] [71] [72] .", [["primates", "ORGANISM", 53, 61], ["humans", "ORGANISM", 72, 78], ["NT3", "GENE_OR_GENE_PRODUCT", 114, 117], ["NT3", "PROTEIN", 114, 117], ["humans", "SPECIES", 72, 78], ["humans", "SPECIES", 72, 78], ["NT3 in the locomotor system", "TEST", 114, 141], ["good", "OBSERVATION_MODIFIER", 19, 23], ["conservation", "OBSERVATION", 24, 36]]], ["Thirdly, in none of our rodent experiments has NT3 treatment caused any detectable pain, spasticity or muscle weakness (in line with the human trials); rather, after bilateral corticospinal tract injury in rats, intramuscular delivery of AAV-NT3 reduced spasticity, slightly improved grip strength and showed a trend towards reducing mechanical hyperalgesia 17 .DiscussionIn this study and in a previous study we used functional MRI combined with electrical stimulation of the wrist in an effort to discover what neuroplasticity underlies recovery of somatosensory responsiveness to adhesive patches attached to the wrist.", [["muscle", "ANATOMY", 103, 109], ["corticospinal tract", "ANATOMY", 176, 195], ["intramuscular", "ANATOMY", 212, 225], ["wrist", "ANATOMY", 477, 482], ["somatosensory", "ANATOMY", 551, 564], ["wrist", "ANATOMY", 616, 621], ["NT3", "CHEMICAL", 47, 50], ["pain", "DISEASE", 83, 87], ["spasticity", "DISEASE", 89, 99], ["muscle weakness", "DISEASE", 103, 118], ["corticospinal tract injury", "DISEASE", 176, 202], ["spasticity", "DISEASE", 254, 264], ["hyperalgesia", "DISEASE", 345, 357], ["NT3", "GENE_OR_GENE_PRODUCT", 47, 50], ["muscle", "ORGAN", 103, 109], ["human", "ORGANISM", 137, 142], ["corticospinal tract", "ORGANISM_SUBDIVISION", 176, 195], ["rats", "ORGANISM", 206, 210], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 212, 225], ["AAV", "ORGANISM", 238, 241], ["NT3", "GENE_OR_GENE_PRODUCT", 242, 245], ["wrist", "ORGANISM_SUBDIVISION", 477, 482], ["wrist", "ORGANISM_SUBDIVISION", 616, 621], ["NT3", "PROTEIN", 47, 50], ["NT3", "PROTEIN", 242, 245], ["human", "SPECIES", 137, 142], ["rats", "SPECIES", 206, 210], ["human", "SPECIES", 137, 142], ["NT3 treatment", "TREATMENT", 47, 60], ["any detectable pain", "PROBLEM", 68, 87], ["spasticity", "PROBLEM", 89, 99], ["muscle weakness", "PROBLEM", 103, 118], ["the human trials", "TREATMENT", 133, 149], ["bilateral corticospinal tract injury in rats", "PROBLEM", 166, 210], ["intramuscular delivery", "TREATMENT", 212, 234], ["AAV", "TREATMENT", 238, 241], ["NT3 reduced spasticity", "PROBLEM", 242, 264], ["slightly improved grip strength", "PROBLEM", 266, 297], ["reducing mechanical hyperalgesia", "PROBLEM", 325, 357], ["this study", "TEST", 375, 385], ["a previous study", "TEST", 393, 409], ["functional MRI", "TEST", 418, 432], ["electrical stimulation of the wrist", "TREATMENT", 447, 482], ["somatosensory responsiveness", "PROBLEM", 551, 579], ["adhesive patches", "TREATMENT", 583, 599], ["muscle", "ANATOMY", 103, 109], ["weakness", "OBSERVATION", 110, 118], ["bilateral", "ANATOMY_MODIFIER", 166, 175], ["corticospinal tract", "ANATOMY", 176, 195], ["injury", "OBSERVATION", 196, 202], ["wrist", "ANATOMY", 477, 482], ["wrist", "ANATOMY", 616, 621]]], ["We confirmed work by others that recovery correlated well with more-normal patterns of increased BOLD signal surrounding the infarct (potentially in spared somatosensory cortex) 68,69,73,74 but we did not find strong evidence that NT3 further increased peri-lesional (or other) activation (either in this study or in our previous study 19 ).", [["somatosensory cortex", "ANATOMY", 156, 176], ["infarct", "DISEASE", 125, 132], ["somatosensory cortex", "CANCER", 156, 176], ["NT3", "GENE_OR_GENE_PRODUCT", 231, 234], ["NT3", "PROTEIN", 231, 234], ["increased BOLD signal", "PROBLEM", 87, 108], ["the infarct", "PROBLEM", 121, 132], ["NT3 further increased peri-lesional (or other) activation", "PROBLEM", 231, 288], ["this study", "TEST", 300, 310], ["our previous study", "TEST", 317, 335], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["BOLD signal", "OBSERVATION", 97, 108], ["infarct", "OBSERVATION", 125, 132], ["increased", "OBSERVATION_MODIFIER", 243, 252], ["peri-lesional", "OBSERVATION_MODIFIER", 253, 266]]], ["Instead, we now propose that NT3 increased somatosensory recovery by inducing neuroplasticity in spinal circuits involving cutaneous afferents.", [["somatosensory", "ANATOMY", 43, 56], ["spinal", "ANATOMY", 97, 103], ["cutaneous afferents", "ANATOMY", 123, 142], ["NT3", "GENE_OR_GENE_PRODUCT", 29, 32], ["spinal circuits", "MULTI-TISSUE_STRUCTURE", 97, 112], ["cutaneous afferents", "MULTI-TISSUE_STRUCTURE", 123, 142], ["NT3", "PROTEIN", 29, 32], ["NT3 increased somatosensory recovery", "TREATMENT", 29, 65], ["neuroplasticity in spinal circuits", "TREATMENT", 78, 112], ["somatosensory recovery", "OBSERVATION", 43, 65], ["spinal circuits", "ANATOMY", 97, 112], ["cutaneous afferents", "OBSERVATION", 123, 142]]], ["This is plausible because cutaneous afferents which mediate tactile sensitivity express TrkC receptors 6 .", [["cutaneous afferents", "ANATOMY", 26, 45], ["cutaneous afferents", "MULTI-TISSUE_STRUCTURE", 26, 45], ["TrkC", "GENE_OR_GENE_PRODUCT", 88, 92], ["TrkC receptors 6", "PROTEIN", 88, 104], ["cutaneous afferents", "PROBLEM", 26, 45]]], ["Moreover, others have shown that dl3 spinal interneurons can gate cutaneous transmission 75 .", [["dl3 spinal interneurons", "ANATOMY", 33, 56], ["cutaneous", "ANATOMY", 66, 75], ["dl3", "GENE_OR_GENE_PRODUCT", 33, 36], ["dl3", "PROTEIN", 33, 36], ["dl3 spinal interneurons", "PROBLEM", 33, 56], ["spinal", "ANATOMY", 37, 43]]], ["We have previously shown that NT3 normalises post-activation depression of output from spinal circuits evoked by stimulation of low threshold afferents from the treated wrist 17 (which might include cutaneous afferents as well as proprioceptive afferents) although in those experiments we measured motor output rather than sensory transmission.", [["spinal", "ANATOMY", 87, 93], ["wrist", "ANATOMY", 169, 174], ["cutaneous afferents", "ANATOMY", 199, 218], ["proprioceptive afferents", "ANATOMY", 230, 254], ["depression", "DISEASE", 61, 71], ["NT3", "GENE_OR_GENE_PRODUCT", 30, 33], ["NT3", "PROTEIN", 30, 33], ["NT3", "PROBLEM", 30, 33], ["depression of output from spinal circuits", "PROBLEM", 61, 102], ["low threshold afferents", "PROBLEM", 128, 151], ["motor output", "TEST", 298, 310], ["spinal circuits", "ANATOMY", 87, 102], ["low threshold", "OBSERVATION_MODIFIER", 128, 141], ["wrist", "ANATOMY", 169, 174], ["motor output", "OBSERVATION", 298, 310]]], ["In the future one might examine whether NT3 modulates gating of somatosensory inputs from the wrist to spinal interneurons 75 .", [["somatosensory inputs", "ANATOMY", 64, 84], ["wrist", "ANATOMY", 94, 99], ["spinal interneurons", "ANATOMY", 103, 122], ["NT3", "GENE_OR_GENE_PRODUCT", 40, 43], ["somatosensory inputs", "MULTI-TISSUE_STRUCTURE", 64, 84], ["wrist", "ORGANISM_SUBDIVISION", 94, 99], ["NT3", "PROTEIN", 40, 43], ["NT3 modulates gating of somatosensory inputs", "PROBLEM", 40, 84], ["wrist", "ANATOMY", 94, 99], ["spinal interneurons", "ANATOMY", 103, 122]]], ["However, in the present work, the deficits in somatosensory responses were modest and might be difficult to dissect.DiscussionWith regard to corticospinal neuroplasticity, we have shown twice previously (in adult and elderly rats) that the less-affected corticospinal tract sprouts across the cervical midline after injection of AAV-NT3 into affected forelimb muscles 19 .", [["somatosensory", "ANATOMY", 46, 59], ["corticospinal", "ANATOMY", 141, 154], ["corticospinal tract sprouts", "ANATOMY", 254, 281], ["cervical midline", "ANATOMY", 293, 309], ["forelimb muscles", "ANATOMY", 351, 367], ["corticospinal", "ANATOMICAL_SYSTEM", 141, 154], ["rats", "ORGANISM", 225, 229], ["corticospinal tract sprouts", "TISSUE", 254, 281], ["cervical midline", "MULTI-TISSUE_STRUCTURE", 293, 309], ["AAV", "ORGANISM", 329, 332], ["NT3", "GENE_OR_GENE_PRODUCT", 333, 336], ["forelimb muscles", "ORGAN", 351, 367], ["NT3", "PROTEIN", 333, 336], ["rats", "SPECIES", 225, 229], ["the deficits in somatosensory responses", "PROBLEM", 30, 69], ["corticospinal neuroplasticity", "PROBLEM", 141, 170], ["the less-affected corticospinal tract", "PROBLEM", 236, 273], ["AAV-NT3 into affected forelimb muscles", "TREATMENT", 329, 367], ["corticospinal tract", "ANATOMY", 254, 273], ["cervical midline", "ANATOMY", 293, 309], ["forelimb muscles", "ANATOMY", 351, 367]]], ["Others have shown that intrathecal infusion of NT3 induces sprouting of the corticospinal tracts 16 and that injection of vectors encoding NT3 into muscles 10 or nerve 11 can induce corticospinal tract sprouting.", [["corticospinal tracts", "ANATOMY", 76, 96], ["muscles", "ANATOMY", 148, 155], ["corticospinal tract", "ANATOMY", 182, 201], ["NT3", "CHEMICAL", 47, 50], ["intrathecal", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 34], ["NT3", "GENE_OR_GENE_PRODUCT", 47, 50], ["NT3", "GENE_OR_GENE_PRODUCT", 139, 142], ["corticospinal tract", "MULTI-TISSUE_STRUCTURE", 182, 201], ["NT3", "PROTEIN", 47, 50], ["NT3", "PROTEIN", 139, 142], ["intrathecal infusion of NT3", "TREATMENT", 23, 50], ["sprouting of the corticospinal tracts", "PROBLEM", 59, 96], ["corticospinal tract sprouting", "PROBLEM", 182, 211], ["corticospinal tracts", "ANATOMY", 76, 96], ["muscles", "ANATOMY", 148, 155], ["nerve", "ANATOMY", 162, 167], ["corticospinal tract", "ANATOMY", 182, 201]]], ["Here, our anatomical tracing confirmed that the less-affected corticospinal tract sprouted after infusion of NT3 protein into triceps and in future we will trace both tracts.", [["corticospinal tract", "ANATOMY", 62, 81], ["triceps", "ANATOMY", 126, 133], ["corticospinal tract", "ORGANISM_SUBDIVISION", 62, 81], ["NT3", "GENE_OR_GENE_PRODUCT", 109, 112], ["triceps", "ORGANISM_SUBDIVISION", 126, 133], ["NT3 protein", "PROTEIN", 109, 120], ["our anatomical tracing", "TEST", 6, 28], ["the less-affected corticospinal tract", "PROBLEM", 44, 81], ["infusion of NT3 protein into triceps", "TREATMENT", 97, 133], ["corticospinal tract", "ANATOMY", 62, 81], ["triceps", "ANATOMY", 126, 133]]], ["This is because, in the present study, neurophysiology revealed that both corticospinal tracts underwent plasticity after unilateral infusion of NT3 protein.", [["corticospinal tracts", "ANATOMY", 74, 94], ["corticospinal tracts", "MULTI-TISSUE_STRUCTURE", 74, 94], ["NT3", "GENE_OR_GENE_PRODUCT", 145, 148], ["NT3 protein", "PROTEIN", 145, 156], ["the present study", "TEST", 20, 37], ["unilateral infusion of NT3 protein", "TREATMENT", 122, 156], ["corticospinal tracts", "ANATOMY", 74, 94]]], ["We propose that spared CST axons sprouted after NT3 entered the CNS from the systemic circulation.", [["CST axons", "ANATOMY", 23, 32], ["CNS", "ANATOMY", 64, 67], ["CST axons", "MULTI-TISSUE_STRUCTURE", 23, 32], ["NT3", "GENE_OR_GENE_PRODUCT", 48, 51], ["CNS", "ANATOMICAL_SYSTEM", 64, 67], ["CST axons", "CELL_TYPE", 23, 32], ["NT3", "PROTEIN", 48, 51], ["NT3", "TREATMENT", 48, 51], ["CNS", "ANATOMY", 64, 67], ["systemic circulation", "ANATOMY", 77, 97]]], ["This is consistent with data from us and others showing that radiolabelled NT3 entered the brain and spinal cord after intravenous injection [26] [27] [28] .", [["brain", "ANATOMY", 91, 96], ["spinal cord", "ANATOMY", 101, 112], ["intravenous", "ANATOMY", 119, 130], ["NT3", "GENE_OR_GENE_PRODUCT", 75, 78], ["brain", "ORGAN", 91, 96], ["spinal cord", "ORGAN", 101, 112], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 119, 130], ["NT3", "PROTEIN", 75, 78], ["radiolabelled NT3", "TEST", 61, 78], ["intravenous injection", "TREATMENT", 119, 140], ["consistent with", "UNCERTAINTY", 8, 23], ["brain", "ANATOMY", 91, 96], ["spinal cord", "ANATOMY", 101, 112]]], ["Moreover, it has been shown that endogenous muscle spindle-derived cues induce sprouting of descending pathways after spinal cord injury in adult mice 24 ; given that muscle spindles make NT3 endogenously 25 , it is plausible that infusion of supplementary NT3 to muscle might enhance corticospinal sprouting after stroke.DiscussionIt is also notable that infusion of NT3 into a proximal forelimb extensor improved the accuracy of use of the affected forelimb when walking on a horizontal ladder but did not improve the accuracy of use of the affected hindlimb; this implies that circulating NT3 is not sufficient to improve hindlimb movements.", [["muscle spindle", "ANATOMY", 44, 58], ["spinal cord", "ANATOMY", 118, 129], ["muscle spindles", "ANATOMY", 167, 182], ["muscle", "ANATOMY", 264, 270], ["corticospinal", "ANATOMY", 285, 298], ["forelimb extensor", "ANATOMY", 388, 405], ["forelimb", "ANATOMY", 451, 459], ["hindlimb", "ANATOMY", 552, 560], ["hindlimb", "ANATOMY", 625, 633], ["cord injury", "DISEASE", 125, 136], ["stroke", "DISEASE", 315, 321], ["muscle spindle", "CELL", 44, 58], ["spinal cord", "ORGAN", 118, 129], ["mice", "ORGANISM", 146, 150], ["muscle spindles", "MULTI-TISSUE_STRUCTURE", 167, 182], ["NT3", "GENE_OR_GENE_PRODUCT", 188, 191], ["NT3", "GENE_OR_GENE_PRODUCT", 257, 260], ["muscle", "ORGAN", 264, 270], ["corticospinal", "MULTI-TISSUE_STRUCTURE", 285, 298], ["NT3", "GENE_OR_GENE_PRODUCT", 368, 371], ["forelimb extensor", "ORGANISM_SUBDIVISION", 388, 405], ["forelimb", "ORGANISM_SUBDIVISION", 451, 459], ["hindlimb", "ORGANISM_SUBDIVISION", 552, 560], ["NT3", "GENE_OR_GENE_PRODUCT", 592, 595], ["hindlimb", "ORGANISM_SUBDIVISION", 625, 633], ["NT3", "PROTEIN", 188, 191], ["NT3", "PROTEIN", 257, 260], ["NT3", "PROTEIN", 368, 371], ["NT3", "PROTEIN", 592, 595], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 146, 150], ["endogenous muscle spindle", "PROBLEM", 33, 58], ["sprouting of descending pathways", "PROBLEM", 79, 111], ["spinal cord injury", "PROBLEM", 118, 136], ["muscle spindles", "PROBLEM", 167, 182], ["infusion of supplementary NT3", "TREATMENT", 231, 260], ["stroke", "PROBLEM", 315, 321], ["infusion of NT3", "TREATMENT", 356, 371], ["the affected forelimb", "PROBLEM", 438, 459], ["the affected hindlimb", "PROBLEM", 539, 560], ["circulating NT3", "TREATMENT", 580, 595], ["endogenous muscle spindle", "OBSERVATION", 33, 58], ["descending", "ANATOMY_MODIFIER", 92, 102], ["spinal cord", "ANATOMY", 118, 129], ["injury", "OBSERVATION", 130, 136], ["muscle", "ANATOMY", 167, 173], ["muscle", "ANATOMY", 264, 270], ["corticospinal sprouting", "OBSERVATION", 285, 308], ["stroke", "OBSERVATION", 315, 321], ["proximal", "ANATOMY_MODIFIER", 379, 387], ["forelimb extensor", "ANATOMY", 388, 405], ["hindlimb", "ANATOMY", 552, 560]]], ["Moreover, we did not find any evidence that NT3 strengthened the short-latency reflex between afferents in the median nerve and motor neurons in the ulnar nerve; this may be because we infused NT3 into the triceps brachii whose afferents do not run in the median or ulnar nerve.", [["afferents", "ANATOMY", 94, 103], ["median nerve", "ANATOMY", 111, 123], ["motor neurons", "ANATOMY", 128, 141], ["ulnar nerve", "ANATOMY", 149, 160], ["triceps brachii", "ANATOMY", 206, 221], ["afferents", "ANATOMY", 228, 237], ["ulnar nerve", "ANATOMY", 266, 277], ["NT3", "GENE_OR_GENE_PRODUCT", 44, 47], ["nerve", "MULTI-TISSUE_STRUCTURE", 118, 123], ["motor neurons", "CELL", 128, 141], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 149, 160], ["NT3", "GENE_OR_GENE_PRODUCT", 193, 196], ["triceps brachii", "ORGAN", 206, 221], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 266, 277], ["NT3", "PROTEIN", 44, 47], ["motor neurons", "CELL_TYPE", 128, 141], ["NT3", "PROTEIN", 193, 196], ["NT3", "PROBLEM", 44, 47], ["the short-latency reflex", "PROBLEM", 61, 85], ["median nerve", "ANATOMY", 111, 123], ["motor neurons", "ANATOMY", 128, 141], ["ulnar nerve", "ANATOMY", 149, 160], ["triceps brachii", "ANATOMY", 206, 221], ["median", "ANATOMY_MODIFIER", 256, 262], ["ulnar nerve", "ANATOMY", 266, 277]]], ["This is consistent with previous work of ours showing that a reflex may be strengthened when its afferent comes from a muscle expressing higher levels of NT3 but not when its afferent comes from a muscle lacking transgenic expression of NT3 17 .", [["muscle", "ANATOMY", 119, 125], ["muscle", "ANATOMY", 197, 203], ["muscle", "ORGAN", 119, 125], ["NT3", "GENE_OR_GENE_PRODUCT", 154, 157], ["muscle", "ORGAN", 197, 203], ["NT3", "GENE_OR_GENE_PRODUCT", 237, 240], ["NT3", "PROTEIN", 154, 157], ["NT3 17", "PROTEIN", 237, 243], ["consistent with", "UNCERTAINTY", 8, 23], ["muscle", "ANATOMY", 119, 125], ["muscle", "ANATOMY", 197, 203]]], ["Finally, infusion of NT3 protein into triceps brachii did not improve forelimb grip strength: however, the grip strength task probably depends more on strength in hand and digit flexor muscles (into which NT3 was not infused) than on triceps brachii (elbow extensors).", [["triceps brachii", "ANATOMY", 38, 53], ["forelimb", "ANATOMY", 70, 78], ["hand", "ANATOMY", 163, 167], ["digit flexor muscles", "ANATOMY", 172, 192], ["triceps brachii", "ANATOMY", 234, 249], ["elbow", "ANATOMY", 251, 256], ["NT3", "GENE_OR_GENE_PRODUCT", 21, 24], ["triceps brachii", "ORGAN", 38, 53], ["forelimb", "ORGANISM_SUBDIVISION", 70, 78], ["grip", "ORGANISM_SUBDIVISION", 79, 83], ["hand", "ORGANISM_SUBDIVISION", 163, 167], ["digit flexor", "ORGANISM_SUBDIVISION", 172, 184], ["muscles", "ORGAN", 185, 192], ["NT3", "GENE_OR_GENE_PRODUCT", 205, 208], ["triceps brachii", "ORGAN", 234, 249], ["elbow", "ORGANISM_SUBDIVISION", 251, 256], ["extensors", "ORGANISM_SUBDIVISION", 257, 266], ["NT3 protein", "PROTEIN", 21, 32], ["NT3", "PROTEIN", 205, 208], ["infusion of NT3 protein into triceps brachii", "TREATMENT", 9, 53], ["the grip strength task", "TEST", 103, 125], ["NT3", "TEST", 205, 208], ["triceps brachii", "ANATOMY", 38, 53], ["hand", "ANATOMY", 163, 167], ["digit", "ANATOMY_MODIFIER", 172, 177], ["flexor muscles", "ANATOMY", 178, 192], ["triceps brachii", "ANATOMY", 234, 249], ["elbow extensors", "ANATOMY", 251, 266]]], ["Indeed, in previous work, injection of AAV-NT3 into proximal and distal flexor muscles did modestly improve grip strength 17 .", [["distal flexor muscles", "ANATOMY", 65, 86], ["AAV", "ORGANISM", 39, 42], ["NT3", "GENE_OR_GENE_PRODUCT", 43, 46], ["proximal", "MULTI-TISSUE_STRUCTURE", 52, 60], ["flexor muscles", "ORGAN", 72, 86], ["NT3", "PROTEIN", 43, 46], ["AAV-NT3 into proximal and distal flexor muscles", "TREATMENT", 39, 86], ["proximal", "ANATOMY_MODIFIER", 52, 60], ["distal", "ANATOMY_MODIFIER", 65, 71], ["flexor muscles", "ANATOMY", 72, 86], ["grip strength", "OBSERVATION", 108, 121]]], ["Taken together, these results indicate that it may be important to target NT3 to multiple muscles.DiscussionHowever, it is not straightforward to reconcile all our findings with a single mechanistic explanation.", [["muscles", "ANATOMY", 90, 97], ["NT3", "GENE_OR_GENE_PRODUCT", 74, 77], ["muscles", "ORGAN", 90, 97], ["NT3", "PROTEIN", 74, 77], ["muscles", "ANATOMY", 90, 97]]], ["It is possible that, additionally, NT3 was trafficked from triceps brachii in axons to motor neurons and/or by DRG neurons where it induced expression of a molecule that was secreted and induced CST sprouting (e.g., BDNF or IGF1 76,77 ).", [["triceps brachii", "ANATOMY", 59, 74], ["axons", "ANATOMY", 78, 83], ["motor neurons", "ANATOMY", 87, 100], ["DRG neurons", "ANATOMY", 111, 122], ["CST", "ANATOMY", 195, 198], ["NT3", "GENE_OR_GENE_PRODUCT", 35, 38], ["triceps brachii", "ORGAN", 59, 74], ["axons", "CELL", 78, 83], ["motor neurons", "CELL", 87, 100], ["DRG neurons", "CELL", 111, 122], ["CST", "GENE_OR_GENE_PRODUCT", 195, 198], ["BDNF", "GENE_OR_GENE_PRODUCT", 216, 220], ["IGF1", "GENE_OR_GENE_PRODUCT", 224, 228], ["NT3", "PROTEIN", 35, 38], ["motor neurons", "CELL_TYPE", 87, 100], ["DRG neurons", "CELL_TYPE", 111, 122], ["BDNF", "PROTEIN", 216, 220], ["IGF1 76,77", "PROTEIN", 224, 234], ["a molecule", "PROBLEM", 154, 164], ["IGF1", "TEST", 224, 228], ["triceps brachii", "ANATOMY", 59, 74], ["motor neurons", "ANATOMY", 87, 100], ["DRG neurons", "ANATOMY", 111, 122]]], ["NT3 is certainly trafficked to ipsilateral motor neurons and DRG after intramuscular delivery 5, 7, 17, 19, 65 and in this study we also showed, unexpectedly, a small increase in contralateral triceps (perhaps from NT3 in endothelial cells).", [["ipsilateral motor neurons", "ANATOMY", 31, 56], ["DRG", "ANATOMY", 61, 64], ["intramuscular", "ANATOMY", 71, 84], ["triceps", "ANATOMY", 193, 200], ["endothelial cells", "ANATOMY", 222, 239], ["NT3", "GENE_OR_GENE_PRODUCT", 0, 3], ["motor neurons", "CELL", 43, 56], ["DRG", "MULTI-TISSUE_STRUCTURE", 61, 64], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 71, 84], ["triceps", "ORGANISM_SUBDIVISION", 193, 200], ["NT3", "GENE_OR_GENE_PRODUCT", 215, 218], ["endothelial cells", "CELL", 222, 239], ["NT3", "PROTEIN", 0, 3], ["ipsilateral motor neurons", "CELL_TYPE", 31, 56], ["NT3", "PROTEIN", 215, 218], ["endothelial cells", "CELL_TYPE", 222, 239], ["NT3", "TREATMENT", 0, 3], ["intramuscular delivery", "TEST", 71, 93], ["this study", "TEST", 118, 128], ["a small increase in contralateral triceps", "PROBLEM", 159, 200], ["NT3 in endothelial cells", "TREATMENT", 215, 239], ["ipsilateral", "ANATOMY_MODIFIER", 31, 42], ["motor neurons", "ANATOMY", 43, 56], ["DRG", "ANATOMY", 61, 64], ["small", "OBSERVATION_MODIFIER", 161, 166], ["increase", "OBSERVATION_MODIFIER", 167, 175], ["contralateral", "ANATOMY_MODIFIER", 179, 192], ["triceps", "ANATOMY", 193, 200], ["endothelial cells", "OBSERVATION", 222, 239]]], ["Diffusion of NT3 within neuropil is inefficient 78 but spinal motor neuron dendritic arbors can be very large; some even extend across the midline 79 and these might provide a widespread source of cues for supraspinal axonal plasticity (e.g., across the midline).", [["neuropil", "ANATOMY", 24, 32], ["spinal motor neuron dendritic arbors", "ANATOMY", 55, 91], ["supraspinal axonal", "ANATOMY", 206, 224], ["midline", "ANATOMY", 254, 261], ["NT3", "GENE_OR_GENE_PRODUCT", 13, 16], ["neuropil", "CELLULAR_COMPONENT", 24, 32], ["dendritic arbors", "MULTI-TISSUE_STRUCTURE", 75, 91], ["axonal", "MULTI-TISSUE_STRUCTURE", 218, 224], ["NT3", "PROTEIN", 13, 16], ["Diffusion of NT3 within neuropil", "TEST", 0, 32], ["supraspinal axonal plasticity", "PROBLEM", 206, 235], ["spinal", "ANATOMY", 55, 61], ["motor neuron", "ANATOMY", 62, 74], ["dendritic arbors", "OBSERVATION", 75, 91], ["very", "OBSERVATION_MODIFIER", 99, 103], ["large", "OBSERVATION", 104, 109], ["midline", "ANATOMY_MODIFIER", 139, 146], ["supraspinal", "ANATOMY_MODIFIER", 206, 217], ["axonal plasticity", "OBSERVATION", 218, 235], ["midline", "ANATOMY", 254, 261]]], ["To seek DRG-secreted factors, we have performed RNAseq of cervical DRG after injection of AAV-NT3 into forelimb flexors 17, 80 .", [["cervical DRG", "ANATOMY", 58, 70], ["forelimb flexors", "ANATOMY", 103, 119], ["cervical DRG", "MULTI-TISSUE_STRUCTURE", 58, 70], ["AAV", "ORGANISM", 90, 93], ["NT3", "GENE_OR_GENE_PRODUCT", 94, 97], ["DRG-secreted factors", "PROTEIN", 8, 28], ["NT3", "PROTEIN", 94, 97], ["cervical DRG", "PROBLEM", 58, 70], ["AAV-NT3 into forelimb flexors", "TREATMENT", 90, 119], ["cervical", "ANATOMY", 58, 66], ["forelimb flexors", "ANATOMY", 103, 119]]], ["In the future we will also seek motor neuron-derived cues.DiscussionFinally, it is interesting that the recovery continues even after infusion of NT3 is discontinued at four weeks.", [["motor neuron", "ANATOMY", 32, 44], ["NT3", "CHEMICAL", 146, 149], ["NT3", "GENE_OR_GENE_PRODUCT", 146, 149], ["NT3", "PROTEIN", 146, 149], ["infusion of NT3", "TREATMENT", 134, 149]]], ["We propose that the four-week long NT3 treatment induces changes in target neurons that persist (e.g., due to sustained modifications in gene expression).", [["neurons", "ANATOMY", 75, 82], ["NT3", "CHEMICAL", 35, 38], ["NT3", "GENE_OR_GENE_PRODUCT", 35, 38], ["neurons", "CELL", 75, 82], ["NT3", "PROTEIN", 35, 38], ["target neurons", "CELL_TYPE", 68, 82], ["long NT3 treatment", "TREATMENT", 30, 48], ["changes in target neurons", "PROBLEM", 57, 82]]], ["Indeed, longer treatment with NT3 induces different intracellular signalling events in sensory axons than does brief treatment, thereby enhancing terminal branching 81 .", [["intracellular", "ANATOMY", 52, 65], ["sensory axons", "ANATOMY", 87, 100], ["NT3", "CHEMICAL", 30, 33], ["NT3", "GENE_OR_GENE_PRODUCT", 30, 33], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 65], ["sensory axons", "MULTI-TISSUE_STRUCTURE", 87, 100], ["NT3", "PROTEIN", 30, 33], ["NT3", "TREATMENT", 30, 33], ["different intracellular signalling events", "PROBLEM", 42, 83], ["brief treatment", "TREATMENT", 111, 126], ["thereby enhancing terminal branching", "PROBLEM", 128, 164], ["intracellular signalling", "OBSERVATION", 52, 76], ["sensory axons", "OBSERVATION", 87, 100], ["enhancing", "OBSERVATION_MODIFIER", 136, 145], ["terminal", "OBSERVATION_MODIFIER", 146, 154], ["branching", "OBSERVATION_MODIFIER", 155, 164]]], ["In the future, we will seek factors that are persistently increased in target neurons after NT3 treatment is discontinued.", [["neurons", "ANATOMY", 78, 85], ["NT3", "CHEMICAL", 92, 95], ["neurons", "CELL", 78, 85], ["NT3", "GENE_OR_GENE_PRODUCT", 92, 95], ["target neurons", "CELL_TYPE", 71, 85], ["NT3", "PROTEIN", 92, 95], ["NT3 treatment", "TREATMENT", 92, 105]]], ["Additionally, it may be that NT3 induces sprouting of CST axons that (after cessation of treatment) is followed by selection of synapses (e.g., strengthening or pruning) by a mechanism that is independent of NT3.", [["CST axons", "ANATOMY", 54, 63], ["synapses", "ANATOMY", 128, 136], ["NT3", "GENE_OR_GENE_PRODUCT", 29, 32], ["CST axons", "CELLULAR_COMPONENT", 54, 63], ["NT3", "GENE_OR_GENE_PRODUCT", 208, 211], ["NT3", "PROTEIN", 29, 32], ["NT3", "PROTEIN", 208, 211], ["NT3", "PROBLEM", 29, 32], ["treatment", "TREATMENT", 89, 98], ["synapses", "PROBLEM", 128, 136], ["may be", "UNCERTAINTY", 17, 23], ["sprouting", "OBSERVATION_MODIFIER", 41, 50], ["CST axons", "OBSERVATION", 54, 63]]], ["For example, it is known that corticomotoneuronal axon synapses are pruned by repulsive PlexinA1-Sema6D interactions 82 .", [["corticomotoneuronal axon synapses", "ANATOMY", 30, 63], ["corticomotoneuronal axon synapses", "CELLULAR_COMPONENT", 30, 63], ["PlexinA1", "GENE_OR_GENE_PRODUCT", 88, 96], ["Sema6D", "GENE_OR_GENE_PRODUCT", 97, 103], ["PlexinA1", "PROTEIN", 88, 96], ["Sema6D", "PROTEIN", 97, 103], ["corticomotoneuronal axon synapses", "PROBLEM", 30, 63], ["axon synapses", "OBSERVATION", 50, 63], ["repulsive", "OBSERVATION_MODIFIER", 78, 87]]], ["To begin to dissect the mechanisms whereby NT3 promotes neuroplasticity and recovery after peripheral delivery, we are setting up a mouse model of stroke.DiscussionIn summary, treatment of disabled arm muscles with NT3 (initiated in a clinically-feasible timeframe) induces multilevel spinal and supraspinal neuroplasticity, improves walking and reverses a tactile sensory impairment. and 24 hours later infusion of NT3 or vehicle into the disabled triceps brachii was initiated for one month.", [["arm muscles", "ANATOMY", 198, 209], ["spinal", "ANATOMY", 285, 291], ["triceps brachii", "ANATOMY", 449, 464], ["stroke", "DISEASE", 147, 153], ["tactile sensory impairment", "DISEASE", 357, 383], ["NT3", "CHEMICAL", 416, 419], ["NT3", "GENE_OR_GENE_PRODUCT", 43, 46], ["mouse", "ORGANISM", 132, 137], ["arm muscles", "ORGANISM_SUBDIVISION", 198, 209], ["NT3", "GENE_OR_GENE_PRODUCT", 215, 218], ["spinal", "MULTI-TISSUE_STRUCTURE", 285, 291], ["NT3", "GENE_OR_GENE_PRODUCT", 416, 419], ["triceps brachii", "ORGAN", 449, 464], ["NT3", "PROTEIN", 43, 46], ["NT3", "PROTEIN", 215, 218], ["NT3", "PROTEIN", 416, 419], ["mouse", "SPECIES", 132, 137], ["mouse", "SPECIES", 132, 137], ["peripheral delivery", "TREATMENT", 91, 110], ["stroke", "PROBLEM", 147, 153], ["disabled arm muscles", "PROBLEM", 189, 209], ["NT3", "TREATMENT", 215, 218], ["multilevel spinal and supraspinal neuroplasticity", "PROBLEM", 274, 323], ["a tactile sensory impairment", "PROBLEM", 355, 383], ["infusion of NT3 or vehicle into the disabled triceps brachii", "TREATMENT", 404, 464], ["stroke", "OBSERVATION", 147, 153], ["arm muscles", "ANATOMY", 198, 209], ["spinal", "ANATOMY", 285, 291], ["supraspinal neuroplasticity", "ANATOMY", 296, 323], ["triceps brachii", "ANATOMY", 449, 464]]], ["Six weeks after stroke, anterograde tracer was injected into the contralesional hemisphere (blue).", [["contralesional hemisphere", "ANATOMY", 65, 90], ["stroke", "DISEASE", 16, 22], ["stroke", "PROBLEM", 16, 22], ["anterograde tracer", "TREATMENT", 24, 42], ["contralesional hemisphere", "ANATOMY", 65, 90]]], ["Rats underwent 8 weeks of behavioural testing.", [["Rats", "ORGANISM", 0, 4], ["Rats", "SPECIES", 0, 4], ["behavioural testing", "TEST", 26, 45]]], ["Structural MRI was conducted on all rats at 24 hours, 1 week and 8 weeks after stroke and fMRI was conducted in a subset of rats at baseline, week 1 and week 8.", [["stroke", "DISEASE", 79, 85], ["rats", "ORGANISM", 36, 40], ["rats", "ORGANISM", 124, 128], ["rats", "SPECIES", 36, 40], ["rats", "SPECIES", 124, 128], ["Structural MRI", "TEST", 0, 14], ["stroke", "PROBLEM", 79, 85], ["fMRI", "TEST", 90, 94]]], ["Electrophysiology was performed in the subset of rats which did not receive BDA tracing.", [["BDA", "CHEMICAL", 76, 79], ["BDA", "CHEMICAL", 76, 79], ["rats", "ORGANISM", 49, 53], ["BDA", "SIMPLE_CHEMICAL", 76, 79], ["rats", "SPECIES", 49, 53], ["BDA tracing", "TEST", 76, 87]]], ["All surgeries, treatments and behavioural testing were performed using a randomized block design and the study was completed blinded to treatment allocation. c) T2 MRI scans 24 hours after stroke, immediately prior to treatment, showing infarct in coronal sections rostral (mm) to bregma. d) There were no differences between stroke groups in mean lesion volume at 24 hours (Mann Whitney p values = 0.86). e) Photomicrographs showing loss of Figure 2 : Delayed NT3 treatment improved responsiveness to somatosensory stimulation, improved walking and partially restored use of the affected forelimb for lateral support during rearing. a-c) Somatosensory deficits were assessed using pairs of adhesive patches attached to the rat's wrists. b) Treatment with NT3 caused improvement compared to vehicle (linear model; F2,126=32.5, p<0.001; post hoc p=0.003): whereas vehicle-treated stroke rats showed a deficit relative to sham rats which persisted for eight weeks (linear model; F14,263=4.1,Figure 3: Delayed neurotrophin-3 treatment caused corticospinal tract sprouting and increased output in forelimb motor nerves during corticospinal tract stimulation. a)Corticospinal axons were anterogradely traced from the less-affected cortex and were counted at the midline (M), at two more lateral planes (D1 and D2) and crossing into grey matter from the ipsilateral, ventral tract (Ipsi). b) NT3 treatment caused an increase in the number of axons crossing at the midline (F2,28=6.1, p=0.007; post hoc p value=0.003), at two lateral planes denoted as D1 (F2,28=20.3, p<0.001, post hoc p value<0.001) and D2 (F2,28=13.8,p<0.001, post hoc p value<0.001) and from the ventral CST on the treated side (F2,28=5.2, p=0.013, post hoc p value=0.005).", [["coronal sections", "ANATOMY", 248, 264], ["lesion", "ANATOMY", 348, 354], ["forelimb", "ANATOMY", 589, 597], ["wrists", "ANATOMY", 730, 736], ["corticospinal tract", "ANATOMY", 1039, 1058], ["forelimb motor nerves", "ANATOMY", 1093, 1114], ["corticospinal tract", "ANATOMY", 1122, 1141], ["Corticospinal axons", "ANATOMY", 1157, 1176], ["cortex", "ANATOMY", 1226, 1232], ["midline", "ANATOMY", 1257, 1264], ["lateral planes", "ANATOMY", 1282, 1296], ["grey matter", "ANATOMY", 1327, 1338], ["ipsilateral", "ANATOMY", 1348, 1359], ["ventral tract", "ANATOMY", 1361, 1374], ["axons", "ANATOMY", 1436, 1441], ["midline", "ANATOMY", 1458, 1465], ["ventral CST", "ANATOMY", 1659, 1670], ["stroke", "DISEASE", 189, 195], ["infarct", "DISEASE", 237, 244], ["stroke", "DISEASE", 326, 332], ["Somatosensory deficits", "DISEASE", 639, 661], ["NT3", "CHEMICAL", 756, 759], ["stroke", "DISEASE", 879, 885], ["NT3", "CHEMICAL", 1386, 1389], ["NT3", "GENE_OR_GENE_PRODUCT", 461, 464], ["forelimb", "ORGANISM_SUBDIVISION", 589, 597], ["rat", "ORGANISM", 724, 727], ["wrists", "ORGANISM_SUBDIVISION", 730, 736], ["NT3", "GENE_OR_GENE_PRODUCT", 756, 759], ["rats", "ORGANISM", 886, 890], ["rats", "ORGANISM", 925, 929], ["neurotrophin-3", "GENE_OR_GENE_PRODUCT", 1007, 1021], ["corticospinal tract", "MULTI-TISSUE_STRUCTURE", 1039, 1058], ["forelimb motor nerves", "MULTI-TISSUE_STRUCTURE", 1093, 1114], ["corticospinal tract", "ORGANISM_SUBDIVISION", 1122, 1141], ["Corticospinal axons", "MULTI-TISSUE_STRUCTURE", 1157, 1176], ["cortex", "CANCER", 1226, 1232], ["ventral tract", "ORGANISM_SUBDIVISION", 1361, 1374], ["Ipsi", "CANCER", 1376, 1380], ["NT3", "GENE_OR_GENE_PRODUCT", 1386, 1389], ["axons", "CELLULAR_COMPONENT", 1436, 1441], ["ventral CST", "MULTI-TISSUE_STRUCTURE", 1659, 1670], ["NT3", "PROTEIN", 461, 464], ["NT3", "PROTEIN", 756, 759], ["NT3", "PROTEIN", 1386, 1389], ["D1", "PROTEIN", 1545, 1547], ["D2", "PROTEIN", 1598, 1600], ["rat", "SPECIES", 724, 727], ["rats", "SPECIES", 886, 890], ["rats", "SPECIES", 925, 929], ["All surgeries", "TREATMENT", 0, 13], ["treatments", "TREATMENT", 15, 25], ["behavioural testing", "TEST", 30, 49], ["a randomized block design", "TREATMENT", 71, 96], ["the study", "TEST", 101, 110], ["T2 MRI scans", "TEST", 161, 173], ["stroke", "PROBLEM", 189, 195], ["treatment", "TREATMENT", 218, 227], ["infarct", "PROBLEM", 237, 244], ["differences between stroke groups", "PROBLEM", 306, 339], ["mean lesion volume", "PROBLEM", 343, 361], ["Mann Whitney p values", "TEST", 375, 396], ["Photomicrographs", "TEST", 409, 425], ["loss of Figure 2", "PROBLEM", 434, 450], ["Delayed NT3 treatment", "TREATMENT", 453, 474], ["somatosensory stimulation", "TREATMENT", 502, 527], ["the affected forelimb", "TREATMENT", 576, 597], ["lateral support", "TREATMENT", 602, 617], ["Somatosensory deficits", "PROBLEM", 639, 661], ["adhesive patches", "TREATMENT", 691, 707], ["NT3", "TREATMENT", 756, 759], ["linear model", "TEST", 800, 812], ["treated stroke rats", "PROBLEM", 871, 890], ["a deficit", "PROBLEM", 898, 907], ["sham rats", "TEST", 920, 929], ["linear model", "TEST", 963, 975], ["Delayed neurotrophin-3 treatment", "TREATMENT", 999, 1031], ["corticospinal tract sprouting", "PROBLEM", 1039, 1068], ["increased output in forelimb motor nerves", "PROBLEM", 1073, 1114], ["corticospinal tract stimulation", "TREATMENT", 1122, 1153], ["a)Corticospinal axons", "PROBLEM", 1155, 1176], ["NT3 treatment", "TREATMENT", 1386, 1399], ["an increase", "PROBLEM", 1407, 1418], ["p", "TEST", 1478, 1479], ["post hoc p value", "TEST", 1487, 1503], ["D1", "TEST", 1545, 1547], ["p", "TEST", 1561, 1562], ["hoc p value", "TEST", 1575, 1586], ["D2", "TEST", 1598, 1600], ["F2,28", "TEST", 1602, 1607], ["hoc p value", "TEST", 1627, 1638], ["the ventral CST", "TEST", 1655, 1670], ["p", "TEST", 1703, 1704], ["post hoc p value", "TEST", 1712, 1728], ["infarct", "OBSERVATION", 237, 244], ["no", "UNCERTAINTY", 303, 305], ["loss", "OBSERVATION_MODIFIER", 434, 438], ["wrists", "ANATOMY", 730, 736], ["corticospinal tract", "ANATOMY", 1039, 1058], ["increased", "OBSERVATION_MODIFIER", 1073, 1082], ["output", "OBSERVATION_MODIFIER", 1083, 1089], ["forelimb", "ANATOMY_MODIFIER", 1093, 1101], ["motor nerves", "ANATOMY", 1102, 1114], ["corticospinal tract", "ANATOMY", 1122, 1141], ["Corticospinal axons", "ANATOMY", 1157, 1176], ["less", "OBSERVATION_MODIFIER", 1212, 1216], ["affected", "OBSERVATION_MODIFIER", 1217, 1225], ["cortex", "ANATOMY_MODIFIER", 1226, 1232], ["midline", "ANATOMY_MODIFIER", 1257, 1264], ["grey matter", "OBSERVATION", 1327, 1338], ["ipsilateral", "ANATOMY_MODIFIER", 1348, 1359], ["ventral tract", "ANATOMY", 1361, 1374], ["increase", "OBSERVATION_MODIFIER", 1410, 1418], ["midline", "ANATOMY_MODIFIER", 1458, 1465], ["ventral", "ANATOMY_MODIFIER", 1659, 1666]]], ["Although stroke by itself caused sprouting at the midline at C1 (planned comparison p=0.031), NT3 did not promote additional sprouting at C1. n=10/group were used for tract tracing. c-e) The CST from the less-affected hemisphere or f-h) lesioned hemisphere was stimulated in the medullary pyramids (before the decussation) and the motor output was recorded from the ulnar nerve on the treated side. d, g) The majority of spikes were detected between 17 ms and 45 ms, latencies consistent with polysynaptic transmission, in both vehicle-treated rats (grey) and NT3 treated rats (blue) when the less-affected or affected CST was stimulated. e, h) Stimulus intensity was increased incrementally from 50 \u00b5A to 400 \u00b5A and the area under the curve were measured (between 17 and 45 ms) after stimulation of the affected or less-affected hemisphere.", [["midline", "ANATOMY", 50, 57], ["tract", "ANATOMY", 167, 172], ["hemisphere", "ANATOMY", 218, 228], ["hemisphere", "ANATOMY", 246, 256], ["medullary pyramids", "ANATOMY", 279, 297], ["ulnar nerve", "ANATOMY", 366, 377], ["CST", "ANATOMY", 619, 622], ["hemisphere", "ANATOMY", 830, 840], ["stroke", "DISEASE", 9, 15], ["NT3", "GENE_OR_GENE_PRODUCT", 94, 97], ["tract", "ORGANISM_SUBDIVISION", 167, 172], ["c-e)", "GENE_OR_GENE_PRODUCT", 182, 186], ["CST", "CANCER", 191, 194], ["hemisphere", "CANCER", 218, 228], ["hemisphere", "MULTI-TISSUE_STRUCTURE", 246, 256], ["medullary pyramids", "MULTI-TISSUE_STRUCTURE", 279, 297], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 366, 377], ["rats", "ORGANISM", 544, 548], ["NT3", "GENE_OR_GENE_PRODUCT", 560, 563], ["rats", "ORGANISM", 572, 576], ["CST", "MULTI-TISSUE_STRUCTURE", 619, 622], ["NT3", "PROTEIN", 94, 97], ["CST", "PROTEIN", 619, 622], ["rats", "SPECIES", 544, 548], ["rats", "SPECIES", 572, 576], ["stroke", "PROBLEM", 9, 15], ["NT3", "TREATMENT", 94, 97], ["tract tracing", "TEST", 167, 180], ["The CST", "TEST", 187, 194], ["lesioned hemisphere", "PROBLEM", 237, 256], ["the motor output", "TEST", 327, 343], ["spikes", "PROBLEM", 421, 427], ["latencies", "TEST", 467, 476], ["polysynaptic transmission", "PROBLEM", 493, 518], ["Stimulus intensity", "PROBLEM", 645, 663], ["the curve", "TEST", 732, 741], ["stroke", "OBSERVATION", 9, 15], ["midline", "ANATOMY_MODIFIER", 50, 57], ["C1", "ANATOMY", 61, 63], ["sprouting", "OBSERVATION", 125, 134], ["C1", "ANATOMY", 138, 140], ["medullary pyramids", "ANATOMY", 279, 297], ["motor output", "OBSERVATION", 331, 343], ["ulnar nerve", "ANATOMY", 366, 377], ["consistent with", "UNCERTAINTY", 477, 492], ["polysynaptic transmission", "OBSERVATION", 493, 518]]], ["NT3 treatment caused increased output in the ulnar nerve during stimulation of either the affected CST (two-way RM ANOVA intensity* group interaction F1,14=7.9, p=0.008, n=6 Vehicle, 6 NT3) or less affected CST (F2,17=9.8, p=0.01, n=4 Vehicle, n=6 NT3). i, j) The heteronymous reflex from median afferents to ulnar motor neurons was recorded in the axilla. k) The monosynaptic component was measured. l) NT3 did not increase the strength of the monosynaptic component.", [["ulnar nerve", "ANATOMY", 45, 56], ["CST", "ANATOMY", 99, 102], ["afferents", "ANATOMY", 296, 305], ["ulnar motor neurons", "ANATOMY", 309, 328], ["axilla", "ANATOMY", 349, 355], ["NT3", "CHEMICAL", 0, 3], ["NT3", "GENE_OR_GENE_PRODUCT", 0, 3], ["ulnar nerve", "MULTI-TISSUE_STRUCTURE", 45, 56], ["ulnar motor neurons", "CELL", 309, 328], ["NT3", "GENE_OR_GENE_PRODUCT", 404, 407], ["NT3", "PROTEIN", 0, 3], ["NT3", "PROTEIN", 185, 188], ["ulnar motor neurons", "CELL_TYPE", 309, 328], ["NT3", "PROTEIN", 404, 407], ["NT3 treatment", "TREATMENT", 0, 13], ["increased output in the ulnar nerve", "PROBLEM", 21, 56], ["the affected CST", "PROBLEM", 86, 102], ["group interaction", "TEST", 132, 149], ["p", "TEST", 161, 162], ["n", "TEST", 170, 171], ["Vehicle", "TEST", 174, 181], ["less affected CST", "PROBLEM", 193, 210], ["p", "TEST", 223, 224], ["n", "TEST", 231, 232], ["Vehicle", "TEST", 235, 242], ["The heteronymous reflex", "PROBLEM", 260, 283], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["output", "OBSERVATION_MODIFIER", 31, 37], ["ulnar nerve", "ANATOMY", 45, 56], ["ulnar", "ANATOMY_MODIFIER", 309, 314], ["motor neurons", "ANATOMY", 315, 328], ["axilla", "ANATOMY", 349, 355], ["monosynaptic", "OBSERVATION_MODIFIER", 364, 376], ["component", "OBSERVATION_MODIFIER", 377, 386], ["increase", "OBSERVATION_MODIFIER", 416, 424], ["strength", "OBSERVATION_MODIFIER", 429, 437], ["monosynaptic component", "OBSERVATION", 445, 467]]], ["The rats held bilaterally on to the pair of force transducers (top left) and the rat was pulled away horizontally and perpendicularly (towards the right) until the bilateral grip was broken.", [["rats", "ORGANISM", 4, 8], ["rat", "ORGANISM", 81, 84], ["grip", "ORGANISM_SUBDIVISION", 174, 178], ["rats", "SPECIES", 4, 8], ["rat", "SPECIES", 81, 84], ["bilaterally", "ANATOMY_MODIFIER", 14, 25], ["left", "ANATOMY_MODIFIER", 67, 71], ["right", "ANATOMY_MODIFIER", 147, 152], ["bilateral", "ANATOMY_MODIFIER", 164, 173], ["grip", "ANATOMY", 174, 178], ["broken", "OBSERVATION", 183, 189]]], ["The force transducers provide a measure of strength (grams) for each upper limb.", [["upper limb", "ANATOMY", 69, 79], ["upper limb", "ORGANISM_SUBDIVISION", 69, 79], ["The force transducers", "TEST", 0, 21], ["upper limb", "ANATOMY", 69, 79]]], ["An average of three trials was taken per rat per week.", [["rat", "ORGANISM", 41, 44], ["rat", "SPECIES", 41, 44], ["average", "OBSERVATION_MODIFIER", 3, 10]]], ["Grip strength (grams) are presented as group means \u00b1 SEMs. b) Grip strength of the affected limb was subtracted from the unaffected limb strength, as an internal control (e.g., to control for differences in motivation, etc.). c) Grip strength for the affected limb. d) Grip strength for the less-affected limb.", [["limb", "ANATOMY", 92, 96], ["limb", "ANATOMY", 132, 136], ["limb", "ANATOMY", 260, 264], ["limb", "ANATOMY", 305, 309], ["limb", "ORGANISM_SUBDIVISION", 92, 96], ["limb", "ORGANISM_SUBDIVISION", 132, 136], ["limb", "ORGANISM_SUBDIVISION", 260, 264], ["limb", "ORGANISM_SUBDIVISION", 305, 309], ["the affected limb", "PROBLEM", 247, 264], ["Grip strength", "TEST", 269, 282], ["affected limb", "ANATOMY", 83, 96], ["limb", "ANATOMY", 260, 264], ["limb", "ANATOMY", 305, 309]]], ["Stroke caused a weak trend towards a transient decrease in strength on the limb affected by stroke (relative to shams; time F7,349=1.8, p=0.09; p-values p=0.121 and 0.124, respectively) but multiple pairwise comparisons did not show significant differences at any timepoint (all p>0.05).", [["limb", "ANATOMY", 75, 79], ["Stroke", "DISEASE", 0, 6], ["stroke", "DISEASE", 92, 98], ["limb", "ORGANISM_SUBDIVISION", 75, 79], ["Stroke", "PROBLEM", 0, 6], ["a weak trend", "PROBLEM", 14, 26], ["a transient decrease in strength", "PROBLEM", 35, 67], ["stroke", "PROBLEM", 92, 98], ["p", "TEST", 136, 137], ["p-values p", "TEST", 144, 154], ["multiple pairwise comparisons", "TEST", 190, 219], ["significant differences", "PROBLEM", 233, 256], ["weak", "OBSERVATION_MODIFIER", 16, 20], ["transient", "OBSERVATION_MODIFIER", 37, 46], ["decrease", "OBSERVATION_MODIFIER", 47, 55], ["limb", "ANATOMY", 75, 79], ["stroke", "OBSERVATION", 92, 98]]], ["There was no difference between NT3 and vehicle treated rats overall (group F2,51=1.", [["NT3", "GENE_OR_GENE_PRODUCT", 32, 35], ["rats", "ORGANISM", 56, 60], ["NT3", "PROTEIN", 32, 35], ["rats", "SPECIES", 56, 60], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]]], "bcea326da7ffbd034aa531671d14f0b907e561cc": [["INTRODUCTIONAMPHIBIANS are frequently parasitized by various protozoans present in body fluids and tissues and in some cases the parasites cause serious and debilitating diseases (Abrams, 1969; Roudabush & Coatney, 1937) .", [["body fluids", "ANATOMY", 83, 94], ["tissues", "ANATOMY", 99, 106], ["body fluids", "TISSUE", 83, 94], ["tissues", "TISSUE", 99, 106], ["serious and debilitating diseases", "PROBLEM", 145, 178], ["tissues", "ANATOMY", 99, 106], ["serious", "OBSERVATION_MODIFIER", 145, 152], ["debilitating", "OBSERVATION_MODIFIER", 157, 169]]], ["Trypanosomatid flagellates, in particular trypanosomes, have been reported in and isolated from the blood of frogs, toads and newts (Bardsley & Harmsen, 1973; Woo & Bogart 1986) .INTRODUCTIONThroughout the investigations into trypanosomatid infection in humans and mammals, sera have been examined for both anti-parasite antibodies and parasite antigens using various immunodiagnostic techniques (Strickland & Hunter, 1982; Tiru & Hennessen, 1985) .", [["blood", "ANATOMY", 100, 105], ["sera", "ANATOMY", 274, 278], ["trypanosomatid infection", "DISEASE", 226, 250], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["frogs", "ORGANISM_SUBDIVISION", 109, 114], ["toads", "ORGANISM_SUBDIVISION", 116, 121], ["newts", "DEVELOPING_ANATOMICAL_STRUCTURE", 126, 131], ["humans", "ORGANISM", 254, 260], ["sera", "ORGANISM_SUBSTANCE", 274, 278], ["anti-parasite antibodies", "PROTEIN", 307, 331], ["parasite antigens", "PROTEIN", 336, 353], ["humans", "SPECIES", 254, 260], ["Bardsley & Harmsen, 1973; Woo & Bogart 1986)", "SPECIES", 133, 177], ["humans", "SPECIES", 254, 260], ["Strickland & Hunter, 1982; Tiru & Hennessen, 1985)", "SPECIES", 397, 447], ["Trypanosomatid flagellates", "PROBLEM", 0, 26], ["the investigations", "TEST", 202, 220], ["trypanosomatid infection", "PROBLEM", 226, 250], ["both anti-parasite antibodies", "TREATMENT", 302, 331], ["infection", "OBSERVATION", 241, 250]]], ["However there is a dearth of information pertaining to the use of serodiagnostic methods to detect kinetoplastid infections and resultant antibody production in poikilothermic vertebrates with only reptiles having been studied (Dollahon, Hager & Hua, 1983; Ingram & Molyneux, 1983a , b.", [["kinetoplastid infections", "DISEASE", 99, 123], ["serodiagnostic methods", "TEST", 66, 88], ["kinetoplastid infections", "PROBLEM", 99, 123], ["resultant antibody production in poikilothermic vertebrates", "PROBLEM", 128, 187], ["infections", "OBSERVATION", 113, 123], ["antibody production", "OBSERVATION", 138, 157], ["Hua", "ANATOMY", 246, 249]]], ["1984a .INTRODUCTIONIn this paper we present the results of acomparative assessment of four serological tests (direct agglutination, indirect haemagglutination, complement-fixation test and ELISA) used to detect and to determine the levels of antibodies in the sera of green toads (B. viridis), used as experimental models.", [["sera", "ANATOMY", 260, 264], ["sera", "ORGANISM_SUBSTANCE", 260, 264], ["green toads", "ORGANISM", 268, 279], ["B. viridis", "ORGANISM", 281, 291], ["antibodies", "PROTEIN", 242, 252], ["B. viridis", "SPECIES", 281, 291], ["green toads", "SPECIES", 268, 279], ["B. viridis", "SPECIES", 281, 291], ["acomparative assessment", "TEST", 59, 82], ["four serological tests", "TEST", 86, 108], ["direct agglutination", "TEST", 110, 130], ["indirect haemagglutination", "TEST", 132, 158], ["complement-fixation test", "TEST", 160, 184], ["ELISA", "TEST", 189, 194], ["the levels of antibodies", "PROBLEM", 228, 252], ["green toads", "PROBLEM", 268, 279]]], ["These amphibians had been injected with the choanomastigotes of C. fusciculutu, a trypanosomatid flagellate.", [["amphibians", "ORGANISM", 6, 16], ["C. fusciculutu", "ORGANISM", 64, 78], ["C. fusciculutu", "SPECIES", 64, 78], ["C. fusciculutu", "SPECIES", 64, 78], ["C. fusciculutu", "PROBLEM", 64, 78], ["a trypanosomatid flagellate", "PROBLEM", 80, 107]]], ["The parasites were chosen because of their ease of culture under laboratory conditions and more importantly because of their presence in the blood and alimentary canal of ranid anurans under natural conditions (Smyth & Smyth, 1980) .", [["blood", "ANATOMY", 141, 146], ["alimentary canal", "ANATOMY", 151, 167], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["alimentary canal", "MULTI-TISSUE_STRUCTURE", 151, 167], ["The parasites", "TREATMENT", 0, 13], ["culture", "TEST", 51, 58], ["the blood", "TEST", 137, 146], ["ranid anurans", "PROBLEM", 171, 184], ["parasites", "OBSERVATION", 4, 13], ["alimentary canal", "ANATOMY", 151, 167], ["natural conditions", "OBSERVATION", 191, 209]]], ["To the authors' knowledge, this is the first report of the use of an immunoenzyme method to detect antibodies in amphibians.", [["antibodies", "PROTEIN", 99, 109], ["an immunoenzyme method", "TREATMENT", 66, 88], ["antibodies in amphibians", "PROBLEM", 99, 123]]], ["Furthermore, there are no previous data concerning anti-parasite antibody detection in amphibian serum.", [["serum", "ANATOMY", 97, 102], ["amphibian", "ORGANISM", 87, 96], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["anti-parasite antibody", "PROTEIN", 51, 73], ["previous data", "TEST", 26, 39], ["anti-parasite antibody detection", "TEST", 51, 83], ["amphibian serum", "TEST", 87, 102], ["no", "UNCERTAINTY", 23, 25]]], ["Before injection of the parasites. a small sample of blood was taken by cardiac puncture from each of the toads and inspected for any current infection (with naturally-occurring trypanosomatid flagellates) by smear, wet mount preparation and slope culture as described elsewhere (Ingram & Molyneux, 1983a. b ).", [["sample", "ANATOMY", 43, 49], ["blood", "ANATOMY", 53, 58], ["cardiac", "ANATOMY", 72, 79], ["infection", "DISEASE", 142, 151], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["cardiac puncture", "MULTI-TISSUE_STRUCTURE", 72, 88], ["toads", "ORGANISM", 106, 111], ["a small sample of blood", "PROBLEM", 35, 58], ["cardiac puncture", "TEST", 72, 88], ["any current infection", "PROBLEM", 130, 151], ["trypanosomatid flagellates", "PROBLEM", 178, 204], ["smear", "TEST", 209, 214], ["slope culture", "TEST", 242, 255], ["parasites", "OBSERVATION", 24, 33], ["small", "OBSERVATION_MODIFIER", 37, 42], ["cardiac", "ANATOMY", 72, 79], ["puncture", "OBSERVATION", 80, 88], ["infection", "OBSERVATION", 142, 151]]], ["In addition. blood smears were also examined by an immunoenzyme method reported previously by Ingram and Molyneux (1 Y84b, c) but using a rabbit anti-C., firscic~tkctcr serum/swine anti-rabbit immunoglobulins antiserum/ peroxidase-rabbit antiperoxidase/amino-ethylcarbazole substrate system.", [["blood", "ANATOMY", 13, 18], ["amino-ethylcarbazole", "CHEMICAL", 253, 273], ["amino-ethylcarbazole", "CHEMICAL", 253, 273], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["smears", "ORGANISM_SUBSTANCE", 19, 25], ["rabbit", "ORGANISM", 138, 144], ["tkctcr", "ORGANISM", 162, 168], ["serum", "ORGANISM_SUBSTANCE", 169, 174], ["swine", "ORGANISM", 175, 180], ["peroxidase", "GENE_OR_GENE_PRODUCT", 220, 230], ["rabbit", "ORGANISM", 231, 237], ["antiperoxidase", "SIMPLE_CHEMICAL", 238, 252], ["amino-ethylcarbazole", "SIMPLE_CHEMICAL", 253, 273], ["rabbit anti-C., firscic~tkctcr serum/swine anti-rabbit immunoglobulins antiserum/ peroxidase", "PROTEIN", 138, 230], ["rabbit", "SPECIES", 138, 144], ["swine", "SPECIES", 175, 180], ["anti-rabbit", "SPECIES", 181, 192], ["rabbit", "SPECIES", 231, 237], ["rabbit", "SPECIES", 138, 144], ["swine", "SPECIES", 175, 180], ["anti-rabbit", "SPECIES", 181, 192], ["rabbit", "SPECIES", 231, 237], ["blood smears", "TEST", 13, 25], ["an immunoenzyme method", "TEST", 48, 70], ["a rabbit anti-C.", "TEST", 136, 152], ["firscic", "TEST", 154, 161], ["serum", "TEST", 169, 174], ["swine anti-rabbit immunoglobulins antiserum", "TREATMENT", 175, 218], ["peroxidase", "TREATMENT", 220, 230], ["rabbit antiperoxidase", "TREATMENT", 231, 252], ["amino-ethylcarbazole substrate system", "TREATMENT", 253, 290]]], ["Furthermore, the gut contents and PBS extracts of randomly selected insects and worms respectively were also examined microscopically and by culture for the presence of trypanosomatids.AmphibiunsThe choanomastigotes in culture overlay were centrifuged at 250 X g for 5 min.", [["gut", "ANATOMY", 17, 20], ["extracts", "ANATOMY", 38, 46], ["worms", "ANATOMY", 80, 85], ["choanomastigotes", "ANATOMY", 199, 215], ["gut", "ORGANISM_SUBDIVISION", 17, 20], ["PBS extracts", "ORGANISM_SUBSTANCE", 34, 46], ["worms", "ORGANISM", 80, 85], ["Amphibiuns", "SIMPLE_CHEMICAL", 185, 195], ["worms", "SPECIES", 80, 85], ["PBS extracts", "TREATMENT", 34, 46], ["culture", "TEST", 141, 148], ["trypanosomatids", "PROBLEM", 169, 184], ["Amphibiuns", "TREATMENT", 185, 195], ["The choanomastigotes in culture overlay", "TREATMENT", 195, 234], ["gut", "ANATOMY", 17, 20], ["contents", "OBSERVATION", 21, 29]]], ["The overlay was removed and the parasites were washed three times in phosphate buffered saline-PBS. pH 7.3 (I 45 mM-NaCI; 7.53 mM-Na?HPO, and I 30 mM-NaH,PO,.Amphibiuns2H,O in de-ionized water).", [["phosphate", "CHEMICAL", 69, 78], ["Na", "CHEMICAL", 130, 132], ["Amphibiuns2H", "CHEMICAL", 158, 170], ["phosphate", "CHEMICAL", 69, 78], ["NaCI", "CHEMICAL", 116, 120], ["Na", "CHEMICAL", 130, 132], ["NaH", "CHEMICAL", 150, 153], ["Amphibiuns2H", "CHEMICAL", 158, 170], ["O", "CHEMICAL", 171, 172], ["phosphate buffered saline-PBS", "SIMPLE_CHEMICAL", 69, 98], ["HPO", "SIMPLE_CHEMICAL", 133, 136], ["mM-NaH", "SIMPLE_CHEMICAL", 147, 153], ["PO", "SIMPLE_CHEMICAL", 154, 156], ["Amphibiuns2H", "SIMPLE_CHEMICAL", 158, 170], ["the parasites", "TREATMENT", 28, 41], ["phosphate buffered saline", "TREATMENT", 69, 94], ["pH", "TEST", 100, 102], ["I", "TEST", 108, 109], ["mM", "TEST", 113, 115], ["NaCI", "TEST", 116, 120], ["mM", "TEST", 127, 129], ["Na", "TEST", 130, 132], ["Amphibiuns2H", "TREATMENT", 158, 170], ["parasites", "OBSERVATION_MODIFIER", 32, 41]]], ["The number of parasites was counted and the suspension adjusted with PBS to give the required dose for injection purposes.Toads were given a single intraperitoneal (IP) injection of 16 X IO\" choanomastigotes in PBS.", [["intraperitoneal", "ANATOMY", 148, 163], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 148, 163], ["the suspension", "TREATMENT", 40, 54], ["PBS", "TREATMENT", 69, 72], ["injection purposes", "TREATMENT", 103, 121], ["a single intraperitoneal (IP) injection", "TREATMENT", 139, 178], ["16 X IO\" choanomastigotes in PBS", "TREATMENT", 182, 214], ["number", "OBSERVATION_MODIFIER", 4, 10], ["parasites", "OBSERVATION", 14, 23]]], ["Control animals consisted of those given PBS IP and normal, uninjected toads.", [["toads", "ORGANISM", 71, 76], ["PBS IP", "TREATMENT", 41, 47], ["normal", "OBSERVATION", 52, 58]]], ["The toads were anaesthetized.Amphibiunsbled, killed and their weights and lengths noted.", [["toads", "ORGANISM", 4, 9]]], ["The parasite-and PBS-injected animals were bled at 7-day intervals.AmphibiunsThe uninjected controls were sampled at random intervals throughout the duration of the experiment.", [["PBS", "SIMPLE_CHEMICAL", 17, 20], ["animals", "ORGANISM", 30, 37], ["Amphibiuns", "SIMPLE_CHEMICAL", 67, 77], ["The parasite", "TEST", 0, 12], ["PBS", "TREATMENT", 17, 20], ["Amphibiuns", "TREATMENT", 67, 77], ["The uninjected controls", "TREATMENT", 77, 100], ["parasite", "OBSERVATION_MODIFIER", 4, 12]]], ["In order to detect parasite infection. blood was examined in a similar manner to that obtained from prrinjected animals and the uninjected controls.", [["blood", "ANATOMY", 39, 44], ["parasite infection", "DISEASE", 19, 37], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["parasite infection", "PROBLEM", 19, 37], ["blood", "TEST", 39, 44], ["parasite", "OBSERVATION_MODIFIER", 19, 27], ["infection", "OBSERVATION", 28, 37]]], ["The sera were isolated and stored at -20\u00b0C.AmphibiunsSpecificifv.", [["sera", "ANATOMY", 4, 8], ["AmphibiunsSpecificifv", "CHEMICAL", 43, 64], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["The sera", "TEST", 0, 8], ["AmphibiunsSpecificifv", "TREATMENT", 43, 64]]], ["The promastigotes and procyclics of Lershmania herfigi her@ and Trpanosoma brucei brucei respectively, both kinetoplastid flagellate species related to c'. ulrtu, were used in the antibody assays to examine for possible non-specific reactions in the toad sera.AmphibiunsAntisera preparation.", [["sera", "ANATOMY", 255, 259], ["promastigotes", "CELL", 4, 17], ["Lershmania herfigi her@", "ORGANISM", 36, 59], ["Trpanosoma brucei brucei", "ORGANISM", 64, 88], ["c'. ulrtu", "ORGANISM", 152, 161], ["toad", "ORGANISM", 250, 254], ["sera", "ORGANISM_SUBSTANCE", 255, 259], ["Lershmania herfigi", "SPECIES", 36, 54], ["Trpanosoma brucei", "SPECIES", 64, 81], ["brucei", "SPECIES", 82, 88], ["Lershmania herfigi", "SPECIES", 36, 54], ["Trpanosoma brucei brucei", "SPECIES", 64, 88], ["c'. ulrtu", "SPECIES", 152, 161], ["The promastigotes", "PROBLEM", 0, 17], ["Lershmania herfigi her@", "PROBLEM", 36, 59], ["Trpanosoma brucei brucei", "PROBLEM", 64, 88], ["both kinetoplastid flagellate species", "PROBLEM", 103, 140], ["c'. ulrtu", "TREATMENT", 152, 161], ["the antibody assays", "TEST", 176, 195], ["non-specific reactions in the toad sera", "PROBLEM", 220, 259], ["AmphibiunsAntisera preparation", "TREATMENT", 260, 290], ["brucei brucei", "OBSERVATION", 75, 88]]], ["Rabbit anti-toad serum was produced by an immunization schedule as described previously (Ingram & Alexander.", [["serum", "ANATOMY", 17, 22], ["Rabbit", "ORGANISM", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit anti-toad serum", "TEST", 0, 22], ["an immunization schedule", "TREATMENT", 39, 63]]], ["1976 ) and the immunoglobulin tttres of the antisera obtained were estimated by either countercurrent electrophoresis or ELISA (Ingram & Molyneux, 1983a).AmphibiunsAntigen extract.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 15, 29], ["immunoglobulin tttres", "PROTEIN", 15, 36], ["the immunoglobulin tttres", "TEST", 11, 36], ["the antisera", "TEST", 40, 52], ["ELISA", "TEST", 121, 126]]], ["Parasite antigen extracts were produced in two ways for use in the immunological techniques.", [["extracts", "ANATOMY", 17, 25], ["extracts", "ORGANISM_SUBSTANCE", 17, 25], ["Parasite antigen extracts", "TEST", 0, 25]]], ["The choanomastigotes were centrifuged at 1700 X g for IO min in cold PBS. pH 7.3.", [["choanomastigotes", "ANATOMY", 4, 20], ["choanomastigotes", "CANCER", 4, 20], ["pH", "TEST", 74, 76]]], ["The pellet formed was resuspended in PBS and then washed and centrifuged a further three times.", [["pellet", "ANATOMY", 4, 10], ["PBS", "TREATMENT", 37, 40], ["pellet", "OBSERVATION_MODIFIER", 4, 10], ["formed", "OBSERVATION", 11, 17]]], ["Prior to use, the cells were subjected to either freezing and thawing (F&T) or sonication (Son) treatments.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["the cells", "PROBLEM", 14, 23]]], ["The material wsas then centrifuged to remove cell debris and the supernatant protein concentration measured by the Lowry method.", [["cell", "ANATOMY", 45, 49], ["supernatant", "ANATOMY", 65, 76], ["cell", "CELL", 45, 49], ["The material", "TREATMENT", 0, 12], ["cell debris", "PROBLEM", 45, 56], ["the supernatant protein concentration", "TEST", 61, 98], ["cell debris", "OBSERVATION", 45, 56], ["supernatant protein concentration", "OBSERVATION", 65, 98]]], ["Alternatively, after addition of cold buffer, the pellet was disrupted by ultrasonication for three 4-min intervals whilst the mixture was kept chilled.", [["cold buffer", "TREATMENT", 33, 44], ["the pellet", "TREATMENT", 46, 56], ["the mixture", "TREATMENT", 123, 134]]], ["The sonicated material was then left overnight at 5 \"C to further remove any protein.", [["The sonicated material", "TREATMENT", 0, 22], ["any protein", "PROBLEM", 73, 84]]], ["It was then centrifuged at 2900 X g for I5 min and the amount of soluble protein in the supernatant determined.AmphibiunsAgglutination assay Two-fold serial dilutions of toad sera. inactivated by heating at 3X\"C for 20 min to destroy naturally-occurring complement activity, were preparcd with PBS. pH 7.3 (containing 24X mr+NaCI).", [["supernatant", "ANATOMY", 88, 99], ["sera", "ANATOMY", 175, 179], ["NaCI", "CHEMICAL", 325, 329], ["toad", "ORGANISM", 170, 174], ["sera", "ORGANISM_SUBSTANCE", 175, 179], ["soluble protein", "PROTEIN", 65, 80], ["soluble protein", "TREATMENT", 65, 80], ["AmphibiunsAgglutination assay", "TEST", 111, 140], ["toad sera", "TREATMENT", 170, 179], ["PBS", "TREATMENT", 294, 297], ["pH", "TEST", 299, 301], ["soluble protein", "OBSERVATION", 65, 80]]], ["To each dilution wsas added an equal volume of choanomastigotes (I 5 X IO cells ml-') and the mixtures incubated at 30\u00b0C for 45 min.", [["cells", "ANATOMY", 74, 79], ["an equal volume of choanomastigotes (I 5 X IO cells ml", "TREATMENT", 28, 82]]], ["The direct agglutination (DA) end point titre was regarded as that dilution in which visible agglutination was observed when compared to the PBS/parasite controls.", [["DA", "CHEMICAL", 26, 28], ["DA", "SIMPLE_CHEMICAL", 26, 28], ["The direct agglutination (DA)", "TREATMENT", 0, 29], ["visible agglutination", "PROBLEM", 85, 106], ["the PBS/parasite controls", "TREATMENT", 137, 162], ["parasite", "OBSERVATION", 145, 153]]], ["Normal toad sera were examined for the presence of natural haemagglutinins against sheep crythrocytes (ShE) before commencing the IHA test as described by Weir (IY7X).PBS-washedShE were tanned with 3.3 X It)-' mg ml-' tannic acid and coated with either F&T or Son ant&n extract containing 0.Y mg ml-' protein.", [["sera", "ANATOMY", 12, 16], ["crythrocytes", "ANATOMY", 89, 101], ["ShE", "CHEMICAL", 177, 180], ["tannic acid", "CHEMICAL", 218, 229], ["F&T", "CHEMICAL", 253, 256], ["Son ant&n extract", "CHEMICAL", 260, 277], ["ml-' tannic acid", "CHEMICAL", 213, 229], ["toad", "ORGANISM", 7, 11], ["sera", "ORGANISM_SUBSTANCE", 12, 16], ["haemagglutinins", "SIMPLE_CHEMICAL", 59, 74], ["sheep", "ORGANISM", 83, 88], ["crythrocytes", "CELL", 89, 101], ["PBS", "SIMPLE_CHEMICAL", 167, 170], ["ShE", "SIMPLE_CHEMICAL", 177, 180], ["ml-' tannic acid", "SIMPLE_CHEMICAL", 213, 229], ["F&T", "SIMPLE_CHEMICAL", 253, 256], ["sheep crythrocytes", "CELL_TYPE", 83, 101], ["Weir", "PROTEIN", 155, 159], ["sheep", "SPECIES", 83, 88], ["sheep", "SPECIES", 83, 88], ["sheep crythrocytes", "PROBLEM", 83, 101], ["the IHA test", "TEST", 126, 138], ["PBS", "TEST", 167, 170], ["' tannic acid", "TREATMENT", 216, 229]]], ["Doubling dilutionr of inactivated sera were made and to each was added the same volume of 2% tanned and coated ShE.The test samples were incubated at 37\u00b0C for 45 min followed by{ overnight at 4C.", [["sera", "ANATOMY", 34, 38], ["samples", "ANATOMY", 124, 131], ["sera", "ORGANISM_SUBSTANCE", 34, 38], ["Doubling dilutionr of inactivated sera", "TREATMENT", 0, 38], ["The test samples", "TEST", 115, 131]]], ["The samples were then examined and the degree of haemapglutination assessed.", [["samples", "ANATOMY", 4, 11], ["haemapglutination", "DISEASE", 49, 66], ["The samples", "TEST", 0, 11], ["haemapglutination", "PROBLEM", 49, 66]]], ["Untanned, tanned and antigencoated ShE were used as controls.", [["ShE", "CHEMICAL", 35, 38], ["ShE", "SIMPLE_CHEMICAL", 35, 38], ["tanned and antigencoated ShE", "CELL_LINE", 10, 38], ["tanned", "OBSERVATION", 10, 16]]], ["Antigen. toad antisera and either BVS or GPC were mixed together and fixation allowed to occur overnight at 5 \"C. Sensitized ShE were then added and the mixtures incubated at 37\u00b0C for 60 min after which the end-points were scored.", [["BVS", "CHEMICAL", 34, 37], ["ShE", "CHEMICAL", 125, 128], ["toad", "ORGANISM", 9, 13], ["GPC", "SIMPLE_CHEMICAL", 41, 44], ["ShE", "SIMPLE_CHEMICAL", 125, 128], ["toad antisera", "TREATMENT", 9, 22], ["GPC", "PROBLEM", 41, 44], ["fixation", "TREATMENT", 69, 77]]], ["Following further incubation for 12 h at SC, the samples under test were re-examined.Cv~plemenr fixurion test (CFTThe complement-fixing antibody (CFA) titre was taken as that dilution which gave 50% hacmolysis.Cv~plemenr fixurion test (CFTELlSA.", [["samples", "ANATOMY", 49, 56], ["complement-fixing antibody", "GENE_OR_GENE_PRODUCT", 118, 144], ["CFA", "SIMPLE_CHEMICAL", 146, 149], ["CFTThe complement-fixing antibody", "PROTEIN", 111, 144], ["CFA", "PROTEIN", 146, 149], ["further incubation", "TREATMENT", 10, 28], ["the samples under test", "TEST", 45, 67], ["Cv~plemenr fixurion test", "TEST", 85, 109], ["CFTThe complement", "TEST", 111, 128], ["fixing antibody (CFA) titre", "TREATMENT", 129, 156], ["Cv~plemenr fixurion test", "TEST", 210, 234]]], ["MacGregor,Premier & Hurrell (I YX2) was used.", [["MacGregor", "TREATMENT", 0, 9], ["Premier & Hurrell (I YX2)", "TREATMENT", 10, 35]]], ["The concentrations of antigen. rabbit anti-toad antiserum and enzyme-conjugate used for the ELISA were determined by chequerboard titration.", [["rabbit", "ORGANISM", 31, 37], ["enzyme-conjugate", "PROTEIN", 62, 78], ["rabbit", "SPECIES", 31, 37], ["rabbit", "SPECIES", 31, 37], ["rabbit anti-toad antiserum", "TREATMENT", 31, 57], ["enzyme", "TEST", 62, 68], ["the ELISA", "TEST", 88, 97], ["concentrations", "OBSERVATION_MODIFIER", 4, 18]]], ["The F&T and Son antigen extracts (containing I mg ml-' protein) were prepared in 0.053 M-carbonate/bicarbonate coating buffer pH Y.6: C'. fi~scicrtlartr was adjusted to 2.5 X 10\" cells ml-' in coating buffer and the three antigen preparations were separately dried onto the plates by overnight incubation at 30\u00b0C. After washing with PBS (containing O.OS% Tween 20) pH 7.3, a range of two-fold serial dilutions of control and immune sera were added to the appropriate wells and the plates were reincubated at 37\u00b0C for 30 min.", [["extracts", "ANATOMY", 24, 32], ["cells", "ANATOMY", 179, 184], ["sera", "ANATOMY", 432, 436], ["M-carbonate", "CHEMICAL", 87, 98], ["bicarbonate", "CHEMICAL", 99, 110], ["carbonate", "CHEMICAL", 89, 98], ["bicarbonate", "CHEMICAL", 99, 110], ["Tween 20", "CHEMICAL", 355, 363], ["F&T", "SIMPLE_CHEMICAL", 4, 7], ["extracts", "ORGANISM_SUBSTANCE", 24, 32], ["0.053 M-carbonate", "SIMPLE_CHEMICAL", 81, 98], ["bicarbonate", "SIMPLE_CHEMICAL", 99, 110], ["C'. fi~scicrtlartr", "SIMPLE_CHEMICAL", 134, 152], ["cells", "CELL", 179, 184], ["sera", "ORGANISM_SUBSTANCE", 432, 436], ["F&T", "PROTEIN", 4, 7], ["The F&T and Son antigen extracts (containing I mg ml-' protein)", "TREATMENT", 0, 63], ["M-carbonate/bicarbonate coating buffer pH", "TREATMENT", 87, 128], ["C'. fi~scicrtlartr", "TREATMENT", 134, 152], ["' in coating buffer", "TREATMENT", 188, 207], ["the three antigen preparations", "TREATMENT", 212, 242], ["PBS", "TREATMENT", 333, 336], ["pH", "TEST", 365, 367], ["two-fold serial dilutions of control", "TREATMENT", 384, 420], ["immune sera", "TREATMENT", 425, 436], ["the plates", "TEST", 477, 487]]], ["MacGregor,rabbit anti-toad antiserum (ELISA titre I : 1024) at a dilution of 1 :7S was added and the plates were incubated as before.", [["rabbit", "ORGANISM", 10, 16], ["rabbit", "SPECIES", 10, 16], ["rabbit", "SPECIES", 10, 16], ["MacGregor", "TREATMENT", 0, 9], ["rabbit anti-toad antiserum", "TREATMENT", 10, 36]]], ["After re-washing, sheep anti-rabbit I@ immunoglobulin comugated to urease. diluted I in 120. was dispensed into the wells and the plates were similarly incubated.", [["sheep", "ORGANISM", 18, 23], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 39, 53], ["urease", "GENE_OR_GENE_PRODUCT", 67, 73], ["I@ immunoglobulin", "PROTEIN", 36, 53], ["urease", "PROTEIN", 67, 73], ["sheep", "SPECIES", 18, 23], ["anti-rabbit", "SPECIES", 24, 35], ["sheep", "SPECIES", 18, 23], ["anti-rabbit", "SPECIES", 24, 35], ["immunoglobulin", "TREATMENT", 39, 53]]], ["After a final three washes with PBS/Tween followed by four washes with distilled water, urease substrate (Sera-I.ab, Crawley.", [["Tween", "CHEMICAL", 36, 41], ["urease", "SIMPLE_CHEMICAL", 88, 94], ["PBS/Tween", "TREATMENT", 32, 41], ["distilled water", "TREATMENT", 71, 86]]], ["The plate\u00a0were subjected to a final incubation at 37\u00b0C for 30~40 min and the reaction halted by the addition of I % thiomersal solution (v/v).", [["I % thiomersal solution", "TREATMENT", 112, 135], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["The end point antibody titre was considered to be that dilution which was visually different from the appropriate reference controls included with each experimental run.RESULTSThe mean toad serum antibody titres, S.E.M. and ranges in the control and C. fasciculuta -injected groups, together with the number of sera-containing detectable antibodies, are given in Table 1 .", [["serum", "ANATOMY", 190, 195], ["sera", "ANATOMY", 311, 315], ["toad", "ORGANISM", 185, 189], ["serum", "ORGANISM_SUBSTANCE", 190, 195], ["C. fasciculuta", "ORGANISM", 250, 264], ["sera", "ORGANISM_SUBSTANCE", 311, 315], ["antibodies", "PROTEIN", 338, 348], ["C. fasciculuta", "SPECIES", 250, 264], ["C. fasciculuta", "SPECIES", 250, 264], ["The end point antibody titre", "TEST", 0, 28], ["mean toad serum antibody titres", "TEST", 180, 211], ["S.E.M.", "TEST", 213, 219], ["ranges", "TEST", 224, 230], ["sera", "TEST", 311, 315], ["detectable antibodies", "PROBLEM", 327, 348]]], ["The mean value, range in titres and number of animals in which antibodies were detected were lowest for the CFT and highest by ELISA.", [["antibodies", "PROTEIN", 63, 73], ["The mean value", "TEST", 0, 14], ["titres", "TEST", 25, 31], ["the CFT", "TEST", 104, 111], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Of the 29 control and 38 parasiteinjected toads, 93 and 92%, respectively contained antibodies detectable by ELISA.", [["toads", "ORGANISM", 42, 47], ["antibodies", "PROTEIN", 84, 94], ["38 parasiteinjected toads", "TEST", 22, 47]]], ["When all four immunological assays were applied to each individual serum, in all cases antibodies were detected by at least two or more of the methods used.", [["serum", "ANATOMY", 67, 72], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["antibodies", "PROTEIN", 87, 97], ["all four immunological assays", "TEST", 5, 34], ["individual serum", "TEST", 56, 72], ["all cases antibodies", "TEST", 77, 97], ["the methods", "TREATMENT", 139, 150]]], ["However the background 'positive antibody' titres in the control animals ranged from 0 to 2-j depending on the technique employed.", [["the background 'positive antibody' titres", "PROBLEM", 8, 49]]], ["Therefore values higher than 2-' were considered to be positive for the parasiteinjected toads.", [["toads", "ORGANISM", 89, 94], ["the parasiteinjected toads", "PROBLEM", 68, 94]]], ["Furthermore comparisons between control and immune sera for each method revealed significant differences in antibody titres (P< 0.01; Student's t-test).", [["immune sera", "ANATOMY", 44, 55], ["sera", "ORGANISM_SUBSTANCE", 51, 55], ["immune sera", "TEST", 44, 55], ["each method", "TEST", 60, 71], ["significant differences", "PROBLEM", 81, 104], ["antibody titres", "TEST", 108, 123], ["Student's t-test", "TEST", 134, 150], ["significant", "OBSERVATION_MODIFIER", 81, 92]]], ["Moreover, 'antibody' levels were not significantly different between the two control groups (P> 0.05).RESULTSThe titres against L. hertigi and T. brucei varied from 0 to 2-j and from 0 to 2-1 in the control and immune sera, respectively.RESULTSThe results for each technique were compared in turn with those for the other methods and the half matrix of the Pearson product-moment correlation coefficients (r) calculated for all experimental animals ( Table 2 ).", [["sera", "ANATOMY", 218, 222], ["L. hertigi", "ORGANISM", 128, 138], ["T. brucei", "ORGANISM", 143, 152], ["sera", "ORGANISM_SUBSTANCE", 218, 222], ["L. hertigi", "SPECIES", 128, 138], ["T. brucei", "SPECIES", 143, 152], ["L. hertigi", "SPECIES", 128, 138], ["T. brucei", "SPECIES", 143, 152], ["'antibody' levels", "TEST", 10, 27], ["P", "TEST", 93, 94], ["RESULTSThe titres", "TEST", 102, 119], ["L. hertigi", "TEST", 128, 138], ["T. brucei", "TEST", 143, 152], ["each technique", "TEST", 260, 274], ["significantly different", "OBSERVATION_MODIFIER", 37, 60]]], ["The significance of each r value was tested by the t-test.", [["each r value", "TEST", 20, 32]]], ["In the case of the control sera, r values ranging from 49 to SY% (P< 0.01) were calculated whilst overall higher correlations were determined for sera from immune animals which varied from 82 to 99% (all I'< 0.00 1).RESULTSIn order that the results of the present study can be used by other investigators for comparative purposes with different experimental models, regression formulae to convert the antibody titres as determined for each technique to those of another are given in Table 3 .", [["sera", "ANATOMY", 27, 31], ["sera", "ANATOMY", 146, 150], ["sera", "ORGANISM_SUBSTANCE", 27, 31], ["sera", "ORGANISM_SUBSTANCE", 146, 150], ["the control sera", "TEST", 15, 31], ["r values", "TEST", 33, 41], ["sera", "TEST", 146, 150], ["immune animals", "TEST", 156, 170], ["the present study", "TEST", 252, 269], ["comparative purposes", "TEST", 309, 329], ["the antibody titres", "TEST", 397, 416]]], ["The regression equations, based on the rectilinear relationship Y = mX + c, were only calculated for the highest mean titre found for each of the four immunological methods.DISCUSSIONThe mean antibody titres against C. fasciculata and the number of control and immune sera containing detectable antibodies were the lowest for DA and CFT, intermediate for IHA and highest for the ELISA method (Table 1) .", [["fasciculata", "ANATOMY", 219, 230], ["sera", "ANATOMY", 268, 272], ["DA", "CHEMICAL", 326, 328], ["mX + c", "GENE_OR_GENE_PRODUCT", 68, 74], ["C. fasciculata", "ORGANISM", 216, 230], ["sera", "ORGANISM_SUBSTANCE", 268, 272], ["DA", "SIMPLE_CHEMICAL", 326, 328], ["antibodies", "PROTEIN", 295, 305], ["C. fasciculata", "SPECIES", 216, 230], ["C. fasciculata", "SPECIES", 216, 230], ["The regression equations", "PROBLEM", 0, 24], ["The mean antibody titres", "TEST", 183, 207], ["C. fasciculata", "PROBLEM", 216, 230], ["immune sera", "TEST", 261, 272], ["detectable antibodies", "TEST", 284, 305], ["DA", "TEST", 326, 328], ["CFT", "TEST", 333, 336], ["IHA", "TEST", 355, 358], ["the ELISA method", "TEST", 375, 391]]], ["These findings may reflect the different sensitivities of the immunological techniques used (Voller & De Savigny, 1 Y8 1).DISCUSSIONThe classical agglutination test has often been used for antibody titration in amphibian immunobiological studies (Cooper, 1976 ).", [["The classical agglutination test", "TEST", 132, 164], ["antibody titration", "TREATMENT", 189, 207], ["amphibian immunobiological studies", "TEST", 211, 245], ["may reflect", "UNCERTAINTY", 15, 26]]], ["Significant correlations (P < 0.0 1) were obtained for both control (range 4Y-76%) and immune sera (83-Y2%) when the DA titres were compared to the values found for the other methods.", [["sera", "ANATOMY", 94, 98], ["DA", "CHEMICAL", 117, 119], ["sera", "ORGANISM_SUBSTANCE", 94, 98], ["DA", "SIMPLE_CHEMICAL", 117, 119], ["immune sera", "TEST", 87, 98], ["the DA titres", "TEST", 113, 126]]], ["Although DA is simple to perform, preconditions of the test include antigen-type specificity, the non-immobilization and non-autoagglutination of parasites and usually the use of living cells.", [["cells", "ANATOMY", 186, 191], ["DA", "CHEMICAL", 9, 11], ["DA", "SIMPLE_CHEMICAL", 9, 11], ["cells", "CELL", 186, 191], ["living cells", "CELL_TYPE", 179, 191], ["the test", "TEST", 51, 59], ["the non-immobilization and non-autoagglutination of parasites", "PROBLEM", 94, 155], ["living cells", "TREATMENT", 179, 191]]], ["In the current study, loss of cell motility was observed in some instances and the possibility of inclusion of nonviable cells in others cannot be ruled out.", [["cell", "ANATOMY", 30, 34], ["cells", "ANATOMY", 121, 126], ["cell", "CELL", 30, 34], ["cells", "CELL", 121, 126], ["nonviable cells", "CELL_TYPE", 111, 126], ["the current study", "TEST", 3, 20], ["loss of cell motility", "PROBLEM", 22, 43], ["nonviable cells", "PROBLEM", 111, 126], ["cell motility", "OBSERVATION", 30, 43], ["nonviable cells", "OBSERVATION", 111, 126], ["cannot be ruled", "UNCERTAINTY", 137, 152]]], ["Nevertheless caution must be taken in the interpretation of natural 'antibody' levels in view of the detection of 'antibodies' in normal BVS against L. hertigi and T. brucei with titres within the range found for C. fuscicdata.", [["BVS", "GENE_OR_GENE_PRODUCT", 137, 140], ["L. hertigi", "ORGANISM", 149, 159], ["T. brucei", "ORGANISM", 164, 173], ["C. fuscicdata", "ORGANISM", 213, 226], ["L. hertigi", "SPECIES", 149, 159], ["T. brucei", "SPECIES", 164, 173], ["C. fuscicdata", "SPECIES", 213, 226], ["L. hertigi", "SPECIES", 149, 159], ["T. brucei", "SPECIES", 164, 173], ["C. fuscicdata", "SPECIES", 213, 226], ["natural 'antibody' levels", "TEST", 60, 85], ["the detection", "TEST", 97, 110], ["'antibodies'", "PROBLEM", 114, 126], ["T. brucei", "PROBLEM", 164, 173], ["C. fuscicdata", "PROBLEM", 213, 226]]], ["Positive results for normal BVS would suggest the presence of low amounts of specific immunoglobulins induced by a current infection with or previous exposure to C. fasciculata parasites.", [["infection", "DISEASE", 123, 132], ["C. fasciculata parasites", "DISEASE", 162, 186], ["BVS", "CANCER", 28, 31], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 86, 101], ["C. fasciculata parasites", "ORGANISM", 162, 186], ["immunoglobulins", "PROTEIN", 86, 101], ["C. fasciculata", "SPECIES", 162, 176], ["C. fasciculata", "SPECIES", 162, 176], ["low amounts of specific immunoglobulins", "PROBLEM", 62, 101], ["a current infection", "PROBLEM", 113, 132], ["C. fasciculata parasites", "PROBLEM", 162, 186], ["normal BVS", "OBSERVATION", 21, 31], ["low amounts", "OBSERVATION_MODIFIER", 62, 73], ["infection", "OBSERVATION", 123, 132], ["fasciculata parasites", "OBSERVATION", 165, 186]]], ["However, the low levels of naturally-occurring 'antibodies' in normal BVS may also have been stimulated by the environmental presence of micro-organisms or other trypanosomatid flagellates which non-specifically cross react with shared cell wall carbohydrate antigenic determinants (Andrews, Reilly, Ferris & Hanson, 1965; Schnaidman, Yoshida, Gorin & Travassos, 1986; Sharabi & Gilboa-Garber, 1980 ).", [["BVS", "ANATOMY", 70, 73], ["cell wall", "ANATOMY", 236, 245], ["carbohydrate", "CHEMICAL", 246, 258], ["BVS", "GENE_OR_GENE_PRODUCT", 70, 73], ["cell", "CELL", 236, 240], ["Ferris & Hanson, 1965; Schnaidman, Yoshida, Gorin & Travassos, 1986; Sharabi & Gilboa-Garber, 1980 )", "SPECIES", 300, 400], ["micro-organisms", "PROBLEM", 137, 152], ["other trypanosomatid flagellates", "PROBLEM", 156, 188], ["low levels", "OBSERVATION_MODIFIER", 13, 23], ["normal BVS", "OBSERVATION", 63, 73], ["wall", "ANATOMY_MODIFIER", 241, 245], ["carbohydrate antigenic", "OBSERVATION", 246, 268]]], ["In the present study, the low levels of 'antibody' in sera from the control groups are not likely to be caused by a current infection because no increase in titres were found throughout the 1 O-week duration of the experiment.DISCUSSIONThe lack of detection of C. fasciculata in blood microscopically or by culture coupled with the finding of parasite antigen(s) in blood up to 2 weeks postinjection by the immunoenzyme method suggests that 8.", [["sera", "ANATOMY", 54, 58], ["fasciculata", "ANATOMY", 264, 275], ["blood", "ANATOMY", 279, 284], ["blood", "ANATOMY", 366, 371], ["infection", "DISEASE", 124, 133], ["sera", "ORGANISM_SUBSTANCE", 54, 58], ["C. fasciculata", "ORGANISM", 261, 275], ["blood", "ORGANISM_SUBSTANCE", 279, 284], ["parasite antigen", "GENE_OR_GENE_PRODUCT", 343, 359], ["blood", "ORGANISM_SUBSTANCE", 366, 371], ["parasite antigen", "PROTEIN", 343, 359], ["C. fasciculata", "SPECIES", 261, 275], ["C. fasciculata", "SPECIES", 261, 275], ["the present study", "TEST", 3, 20], ["the low levels of 'antibody' in sera", "PROBLEM", 22, 58], ["a current infection", "PROBLEM", 114, 133], ["increase in titres", "PROBLEM", 145, 163], ["C. fasciculata in blood microscopically", "PROBLEM", 261, 300], ["culture", "TEST", 307, 314], ["parasite antigen", "PROBLEM", 343, 359], ["blood", "TEST", 366, 371], ["the immunoenzyme method", "TEST", 403, 426], ["low levels", "OBSERVATION_MODIFIER", 26, 36], ["not likely to be", "UNCERTAINTY", 87, 103], ["infection", "OBSERVATION", 124, 133], ["increase", "OBSERVATION_MODIFIER", 145, 153], ["titres", "OBSERVATION", 157, 163]]], ["Grids possesses an efficient immune system responsible for the rapid elimination of antigen.", [["immune system", "ANATOMY", 29, 42], ["Grids", "CHEMICAL", 0, 5], ["the rapid elimination of antigen", "PROBLEM", 59, 91]]], ["Therefore it was not possible in the work reported here to correlate the level of parasitaemia and antibody titres.", [["parasitaemia", "DISEASE", 82, 94], ["parasitaemia", "PROBLEM", 82, 94], ["antibody titres", "TEST", 99, 114], ["not possible", "UNCERTAINTY", 17, 29], ["parasitaemia", "OBSERVATION", 82, 94]]], ["However the exposure of B. Grids to C. fasciculata evoked a specific immune response and resulted in significantly increased levels of serum antibody.", [["fasciculata", "ANATOMY", 39, 50], ["serum", "ANATOMY", 135, 140], ["B. Grids", "ORGANISM", 24, 32], ["C. fasciculata", "ORGANISM", 36, 50], ["serum", "ORGANISM_SUBSTANCE", 135, 140], ["serum antibody", "PROTEIN", 135, 149], ["C. fasciculata", "SPECIES", 36, 50], ["B. Grids", "SPECIES", 24, 32], ["C. fasciculata", "SPECIES", 36, 50], ["C. fasciculata", "PROBLEM", 36, 50], ["significantly increased levels of serum antibody", "PROBLEM", 101, 149], ["significantly", "OBSERVATION_MODIFIER", 101, 114], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["serum antibody", "OBSERVATION", 135, 149]]], ["Under normal environmental situations, it is feasible that naturally-occurring immunoglobulins in BVS restrict parasite numbers to below a potential infectious threshold.", [["immunoglobulins", "GENE_OR_GENE_PRODUCT", 79, 94], ["BVS", "SIMPLE_CHEMICAL", 98, 101], ["immunoglobulins", "PROTEIN", 79, 94], ["immunoglobulins in BVS", "TREATMENT", 79, 101], ["normal", "OBSERVATION", 6, 12], ["environmental situations", "OBSERVATION", 13, 37], ["infectious", "OBSERVATION", 149, 159]]], ["The finding of serum antibody titres above those of normal background levels in amphibians or other animal hosts in similar habitats or areas endemic for certain diseases would indicate current infection with parasites, other infectious agents or pathogens within a population.DISCUSSIONNo haemolytic anti-complementary activities were detected in normal BVS against the antigen extracts unlike previous reports for amphibians (Gigli & Austen, 197 1) .", [["serum", "ANATOMY", 15, 20], ["extracts", "ANATOMY", 379, 387], ["infection", "DISEASE", 194, 203], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["extracts", "ORGANISM_SUBSTANCE", 379, 387], ["serum antibody", "PROTEIN", 15, 29], ["serum antibody titres", "TEST", 15, 36], ["areas endemic", "PROBLEM", 136, 149], ["certain diseases", "PROBLEM", 154, 170], ["current infection", "PROBLEM", 186, 203], ["parasites", "PROBLEM", 209, 218], ["pathogens", "PROBLEM", 247, 256], ["haemolytic anti-complementary activities", "PROBLEM", 290, 330], ["infection", "OBSERVATION", 194, 203]]], ["Whereas the CFT is frequently nonspecific and inconvenient for handling many samples, it can utilize crude, soluble parasite antigen extracts.", [["samples", "ANATOMY", 77, 84], ["extracts", "ANATOMY", 133, 141], ["extracts", "ORGANISM_SUBSTANCE", 133, 141], ["the CFT", "TEST", 8, 15], ["frequently", "OBSERVATION_MODIFIER", 19, 29], ["nonspecific", "OBSERVATION", 30, 41]]], ["As with DA cross reactivity can often lead to false positive results.", [["DA", "CHEMICAL", 8, 10], ["DA", "SIMPLE_CHEMICAL", 8, 10], ["false positive results", "PROBLEM", 46, 68]]], ["When the results obtained by CFT were compared with each other and with IHA and ELISA, the lowest range of correlations, although significant and similar to those determined for the DA comparisons, were found for control BVS (50-77%; IgM which is an efficient complement fixer and also a good agglutinin (Atwell & Marchalonis, 1976; Yamaguchi.", [["DA", "CHEMICAL", 182, 184], ["IgM", "GENE_OR_GENE_PRODUCT", 234, 237], ["BVS", "PROTEIN", 221, 224], ["IgM", "PROTEIN", 234, 237], ["CFT", "TEST", 29, 32], ["IHA", "TEST", 72, 75], ["ELISA", "TEST", 80, 85], ["BVS", "TEST", 221, 224], ["IgM", "TEST", 234, 237], ["significant", "OBSERVATION_MODIFIER", 130, 141]]], ["However, the 'antibodies' in normal BVS would be present in limited amounts, fix complement less effectively and hence result in low background CFA values.", [["BVS", "ANATOMY", 36, 39], ["BVS", "CANCER", 36, 39], ["CFA", "SIMPLE_CHEMICAL", 144, 147], ["the 'antibodies", "TEST", 9, 24], ["low background CFA values", "PROBLEM", 129, 154], ["normal BVS", "OBSERVATION", 29, 39], ["low", "OBSERVATION_MODIFIER", 129, 132]]], ["This could also account for the lowest correlations found when the CFA titres were compared to those of the other methods for the controls.DISCUSSIONThe source of complement seems to be important for the efficient fixation of toad antibodies.", [["toad", "ORGANISM", 226, 230], ["toad antibodies", "PROTEIN", 226, 241], ["the CFA titres", "TEST", 63, 77], ["the efficient fixation of toad antibodies", "TREATMENT", 200, 241], ["could also account for", "UNCERTAINTY", 5, 27]]], ["The use of toad serum as homologous complement source gave a higher mean value and usually slightly higher individual endpoint titres in both control and immunized animals compared to the antibody levels obtained with heterologous GPC.", [["toad serum", "ANATOMY", 11, 21], ["toad", "ORGANISM", 11, 15], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["toad serum", "TEST", 11, 21], ["immunized animals", "PROBLEM", 154, 171], ["the antibody levels", "TEST", 184, 203], ["heterologous GPC", "PROBLEM", 218, 234]]], ["Homologous serum has proved a reliable source of complement for the fixation of immunoglobulins in other anurans (Alexander & Steiner, 1980; Sekizawa, Fujii & Katagiri, 1984) .", [["serum", "ANATOMY", 11, 16], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 80, 95], ["immunoglobulins", "PROTEIN", 80, 95], ["Homologous serum", "TEST", 0, 16], ["the fixation of immunoglobulins", "TREATMENT", 64, 95]]], ["However the use of commercially available GPC is also known to initiate good fixation in amphibian species (Lallone, Chambers & Horton, 1984 : Romano, Geczy & Steiner, 1973 ).", [["GPC", "TEST", 42, 45], ["fixation", "OBSERVATION", 77, 85], ["amphibian species", "OBSERVATION", 89, 106]]], ["In the current study, 50% correlation (P < 0.0 1) and 92\"/,, (P< 0.00 1) were found for control and immune sera. respectively when the different complement sources were compared.", [["immune sera", "ANATOMY", 100, 111], ["sera", "ORGANISM_SUBSTANCE", 107, 111], ["the current study", "TEST", 3, 20], ["P", "TEST", 39, 40]]], ["Low (SO-77%, controls) and high (86-94X, immunized) but significant (I'< 0.01) r values were determined in comparisons between IHA and CFT.", [["IHA", "TEST", 127, 130], ["CFT", "TEST", 135, 138]]], ["IHA is prone to lack specificity in some cases and, in contrast to the CFT, usually requires highly purified antigen preparations but is easier to perform.DISCUSSIONELISA gave the highest percentage positive titres in all the samples examined and appears to be the most sensitive of the techniques used to detect anticrithidial antibodies in toad sera.", [["samples", "ANATOMY", 226, 233], ["sera", "ANATOMY", 347, 351], ["anticrithidial antibodies", "GENE_OR_GENE_PRODUCT", 313, 338], ["toad", "ORGANISM", 342, 346], ["sera", "ORGANISM_SUBSTANCE", 347, 351], ["anticrithidial antibodies", "PROTEIN", 313, 338], ["the techniques", "TEST", 283, 297], ["anticrithidial antibodies in toad sera", "PROBLEM", 313, 351]]], ["ELISA was easy to peform, specific, An important factor which affects the values of the antibody titrcs is the preparation of the antigen extract (Crouch & Raybould, 1983; Pappas.", [["the antibody titrcs", "TREATMENT", 84, 103]]], ["Son antigen preparations gave higher titres than F&T antigen extracts.", [["extracts", "ANATOMY", 61, 69], ["Son antigen", "GENE_OR_GENE_PRODUCT", 0, 11], ["F&T antigen", "GENE_OR_GENE_PRODUCT", 49, 60], ["extracts", "ORGANISM_SUBSTANCE", 61, 69], ["Son antigen preparations", "TREATMENT", 0, 24]]], ["However, the coating of ELISA plates with whole cells produced the highest values.", [["whole cells", "ANATOMY", 42, 53], ["cells", "CELL", 48, 53], ["ELISA plates", "TEST", 24, 36], ["coating", "OBSERVATION_MODIFIER", 13, 20]]], ["In the work reported here, similar batches of antigen were used thus reducing potential variations due to different preparations.DISCUSSIONIt is of interest to note that a comparison between IHA and ELISA control titres revealed 79-89% (P < 0.00 I ) significant correlations and similar numbers of positive animals.", [["different preparations", "TREATMENT", 106, 128], ["IHA", "TEST", 191, 194], ["ELISA control titres", "TEST", 199, 219], ["positive", "OBSERVATION", 298, 306]]], ["This implies that the above two techniques have similar sensitivities in the screening of normal BVS for anti-parasite antibodies.", [["BVS", "CANCER", 97, 100], ["anti-parasite antibodies", "GENE_OR_GENE_PRODUCT", 105, 129], ["BVS", "PROTEIN", 97, 100], ["anti-parasite antibodies", "PROTEIN", 105, 129], ["the screening", "TEST", 73, 86], ["anti-parasite antibodies", "TREATMENT", 105, 129], ["normal BVS", "OBSERVATION", 90, 100]]], ["Nevertheless the method of antigen preparation ma> not be a salient criterion for antibody estimation in immune sera because correlation values of over 89% (f'< 0.001) were found when IHA titres were compared to those of ELISA.DISCUSSIONELISA seems appropriate for use in serodiagnostic surveillance programmes. applied to different amphibian species or other aquatic and semi-aquatic lower vertebrates, to detect antibodies stimulated against diverse parasite environmental pathogens.", [["immune sera", "ANATOMY", 105, 116], ["sera", "ORGANISM_SUBSTANCE", 112, 116], ["antibodies", "PROTEIN", 414, 424], ["antigen preparation ma", "TREATMENT", 27, 49], ["antibody estimation", "TEST", 82, 101], ["immune sera", "TEST", 105, 116], ["correlation values", "TEST", 125, 143], ["IHA titres", "TEST", 184, 194], ["ELISA", "TEST", 221, 226], ["different amphibian species", "PROBLEM", 323, 350], ["semi-aquatic lower vertebrates", "TREATMENT", 372, 402], ["antibodies", "TREATMENT", 414, 424], ["diverse parasite environmental pathogens", "PROBLEM", 444, 484], ["amphibian species", "OBSERVATION", 333, 350]]], ["Furthermore this technique would be of value in screening lower vertebrates for potential carriers or reservoirs of infective kinetoplastid tlagellates or indeed other pathogenic micro-organisms.", [["this technique", "TREATMENT", 12, 26], ["screening lower vertebrates", "TEST", 48, 75], ["potential carriers", "PROBLEM", 80, 98], ["infective kinetoplastid tlagellates", "PROBLEM", 116, 151], ["indeed other pathogenic micro-organisms", "PROBLEM", 155, 194]]], ["Such information may reflect the health status of animals within a population and aid in the determination of specific epidemiological and aetiological features of zoonoses and epizootics prevalence.", [["zoonoses", "DISEASE", 164, 172], ["epizootics", "DISEASE", 177, 187], ["zoonoses", "PROBLEM", 164, 172]]], ["Acf~~*,left,s-'I'his work was undertaken whilst one of us (GAI) was on an EEC Funded Project contracted to the British Council. in part subcontracted to the University of Salford, for the development of the Faculty of Science at Yarmouk University.", [["Acf", "PROBLEM", 0, 3], ["left", "ANATOMY_MODIFIER", 7, 11]]], ["GA1 would like to thank Dr S. K. Abdul-Hafez for the use of his laboratory facilities for part of the work, Dr N. Ishmail for assistance with the bleeding of the animals and Dr Ellen Lee of the University of Salford ComputingDISCUSSIONCentre for advice on the use of the computer for statistical analysis of the results.", [["bleeding", "DISEASE", 146, 154], ["the bleeding", "PROBLEM", 142, 154], ["statistical analysis", "TEST", 284, 304]]]], "9efc9721f93124956c6bc58cd11f33caf2224ec7": [["approach is crucial because these diseases' effects transcend their original and current host species, affecting the wellbeing of animals, people, and the environment in multiple ways.", [["people", "ORGANISM", 139, 145], ["people", "SPECIES", 139, 145], ["these diseases' effects", "PROBLEM", 28, 51], ["diseases", "OBSERVATION", 34, 42], ["host species", "OBSERVATION", 89, 101]]], ["Therefore, calls to adopt OH approaches in dealing with these pandemics (Amuasi et al., 2020) must transcend reductionist, pathogencentric approaches and focus on holistic outcomes, embracing the intricate interactions within a system and confronting the problems that beset it (Zinsstag, Schelling, Waltner-Toews, Whittaker, & Tanner, 2015) .", [["OH", "CHEMICAL", 26, 28], ["pathogencentric approaches", "TREATMENT", 123, 149], ["the problems", "PROBLEM", 251, 263]]]]}